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ABSTRACT 
The applications of nanoparticles are growing, but little is known about their interactions with 
the immune system as most studies did not use suitable in vivo test systems. The purpose of these 
studies was to investigate the utility of chicken growing feathers as an in vivo test site for iron 
oxide nanoparticle (IONP) interactions with the immune system. The first objective of this study 
was to monitor leukocyte infiltration into the growing feather pulp upon the administration of 
IONP and IO-mIgG preparations. The second objective was to test the utility of IONPs as 
vaccine adjuvants by monitoring primary and memory immune responses in the growing feathers 
upon intramuscular injection of treatment preparations. For the first objective, three feather 
injection studies were conducted. The IONP treatment alone elicited similar responses as the IO-
mIgG treatment, suggesting that IONPs can elicit immune responses without the presence of an 
antigen. The IO-mIgG treatment elicited a significantly higher heterophil response, p = 0.009, 
and MHCII+ macrophage response, p = 0.0027, compared to the Alum-mIgG group. However, 
Alum-mIgG elicited significantly higher adaptive immune responses compared to IO-mIgG. It is 
possible that IONPs were taken up by the innate immune cells before they could activate the 
adaptive immune cells, but the analyses of organ tissue is an ongoing study that will further 
clarify this finding. For the second objective, four intramuscular injection studies were conducted 
using IONPs, Alum-mIgG, and mIgG treatments. The mIgG concentration in Study A was 20-
fold lower in the IONP group compared to the other groups. IO-mIgG elicited significantly 
higher MHCII+ B cell+,  T cell+ CD8+, and  T cell+ CD8- feather pulp infiltration 
compared to the other groups. When the mIgG concentration for all treatment groups was 
matched in Study B, the IO-mIgG group elicited similar or significantly lower responses 
compared to the other groups. These findings suggest that growing feathers in chickens can be 
used to monitor immune responses to treatments periodically in one subject. The clinical utility 
of IONPs as vaccine adjuvants is promising, but further research is necessary to improve the 
knowledge of IONP biointeractions and toxicity. 
Keywords: adaptive immunity, growing feather, innate immunity, IONP, primary 
immune response, memory immune response 
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INTRODUCTION 
 The development of in vivo test systems for testing bioactivities and toxicity of 
nanoparticles (NPs) is required to ensure that they are safe and effective in healthcare, but 
current animal models are invasive and do not allow monitoring bioactivities periodically in one 
individual. The aim of this study is to develop an avian test-system that would allow repeat 
access to tissue from the test-site and would enable researchers to utilize minimally invasive 
tissue collection methods. 
 Biological interactions and toxic effects of NPs are still being investigated, but NPs are 
often used in consumer products. Consequently, the safety of nanostructures to the health of 
individuals, as well as the environmental risks associated with NP manufacturing byproducts and 
NP waste disposal, are a major concern (Roco, 2005). In the biomedical field, previous studies 
found that the toxicity of NPs mostly depends on the type of NP core material (Chen, Zhen, 
Todd, Chu, & Xie, 2013). Although no long term adverse events have been reported, the 
degradation of the NPs metal cores can leave traces of toxic metals in the body. 
 Quantum dots show the highest toxicity because cadmium residue can be found in the 
organs (i.e., liver, spleen, and kidneys) up to 90 days after administration (Chen et al., 2013). 
Metal NPs are also a potential hazard due to toxic effects, but their toxicity is mostly regulated 
because it is affected by size, solubility, and level of targeted cellular uptake (Johnston et al., 
2010). The lowest levels of toxicity are reported for iron oxide NPs (IONPs), which increase the 
risk of oxidative tissue damage by increasing cytoplasmic ferric iron levels (Zhao et al., 2011). 
Although some degree of oxidative stress has been reported due to IONP administration in mice 
and non-human primates, no long-term effects were observed upon histological analyses of 
organ tissues (Jain et al., 2008; Pusic et al., 2013).  
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 The numerous potential medical applications of NPs include improved diagnosis via 
contrast imaging, targeted drug delivery, tissue engineering, and the use of NPs as adjuvants in 
vaccine preparation (Salata, 2004). Depending on the purpose of the NP in the organism, 
different surface modifications can be applied. For example, manufacturing NPs to deliver drugs 
to cancer cells needs to improve the longevity of the NPs in the blood, which is achieved by 
avoiding complement activation and modifying the size and surface of the particles to avoid 
premature elimination (Kievit & Zhang, 2011; Sim & Wallis, 2011). However, when NPs are 
used as vaccine adjuvants, they must be able to elicit a high immune response. 
 At the moment, the most common adjuvant found in the vaccines produced in the United 
States is aluminum, which is used in form of gels or salts in small doses to elicit an immune 
response so that the body can build better immunity when exposed to the antigen in the vaccine. 
The U.S. Food and Drug Administration (FDA) recommend an upper limit of 0.85-1.25 mg for 
aluminum used in vaccines, but the exact dose depends on age and bodyweight, so aluminum 
contents in vaccines can be as low as 0.25 mg for infants (Keith, Jones, & Chou, 2002). 
 Compared to aluminum, monophosphoryl lipid A (MPL-A) is a less common adjuvant in 
vaccines, but its effectiveness and safety have been established (Casella & Mitchell, 2008; 
Drachenberg, Wheeler, Stuebner, & Horak, 2001). MPL-A is derived from the Salmonella 
minnesota lipopolysaccharide (LPS). LPS induces a higher proinflammatory cytokine response 
compared to MPL-A, but MPL-A is safer for use in humans because it attenuates the toxic 
effects of LPS (Ulrich & Myers, 1995).  
 The key difference among adjuvants is their mode of action because they can work as 
antigen delivery systems or immunopotentiators, but the balance between efficacy and safety is 
also a major concern for healthcare practitioners and clinical researchers (Batista-Duharte, 
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Lindblad, & Oviedo-Orta, 2011). Depending on the patient’s medical history and current 
situation, the administration of adjuvants in vaccines can trade off efficacy for safety when 
patients are at high risk for adverse events. Trading off safety for efficacy is also an option for 
patients with severe disease (e.g., human immunodeficiency virus, cancer patients), who need 
stronger adjuvants to elicit an adequate immune response compared to the general healthy 
population. The necessity of redistributing the efficacy and safety of adjuvants is the key issue 
with contemporary adjuvants, so novel adjuvants are continuously developed to address the 
needs of specific vulnerable populations (Grzegorzewska, 2014).  
 Although NPs proved to be efficient adjuvants with little or no toxic effects (Alaamri, 
Byrne, Falcon, & Erf, 2014; Pusic et al., 2011), the understanding of NP-immune interactions in 
vivo is still limited. The efficacy and safety of NPs as vaccination adjuvants needs to be further 
investigated in animal models before their utility is investigated in human clinical trials. 
However, the choice of animal models affects the outcomes of studies that monitor NP in vivo 
interactions as each model has certain strengths and limitations regarding procedural advantages 
and reliability of results. 
 Based on previous studies (Erf, Trejo-Skalli, & Smyth, 1995; Erf, 2010; Wang & Erf, 
2004), the chicken model was identified as the least invasive model that has several immune 
system features similar to mammalian organisms because growing feather (GF) pulp can be used 
as a test-site for biological interactions. It is important to note that the use of GF as a test site is 
not limited to specific agents or poultry species. All young feathered birds have GF, and the only 
difference between the species is the age at which they develop and lose the ability to regenerate 
feathers (Erf, U.S. Patent No. 8,216,551, 2012). The use of GFs as a test site in chickens is 
common because they are immunologically well-defined and easy to obtain for research. 
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Specifically, the Long Brown Leghorn (LBL) chicken line (see Figure 1) is immunologically 
well-defined and is not susceptible to autoimmune vitiligo (Erf, 2010; Sreekumar, Smyth, 
Ambady, & de Leon, 2000). These advantages of the LBL line make it a suitable in vivo test 
system for monitoring the effects of NPs on cellular, molecular, and physiological events. 
 GFs are present in chickens between 2 and 22 weeks of age. The GF consists of the barbs 
and the living portion, which is ensheathed (see Figure 1). The living portion size depends on the 
chicken line and age, so its size varies between 8 and 10 mm in length and between 2 and 3 mm 
in diameter. The inner pulp arises from the dermal papilla and makes up the majority of the 
living portion. It consists mostly of mesenchymal reticulum, which is a loose and pliable tissue, 
but the pulp also has a central axial artery and a network of vascular structures, including 
arterioles, capillaries, lymphatic capillaries and vessels, small sinuses, venules, and veins (Lucas 
& Stettenheim, 1971). The nervous system in the pulp is comprised of three sets of nerves, which 
include the autonomic ganglion cells, short fibers that follow a sinusoidal course, and long fibers 
positioned along the peripheral part of the pulp. The pulp is immunologically active with a low 
mononuclear cell presence similar to the dermis and the ability to recruit leukocytes from the 
circulation (Abdul-Careem et al., 2008; Erf et al., 1995). The pulp of the feather is surrounded by 
an epidermal layer and an outer sheath comprised of connective tissue (see Figure 1). 
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Figure 1. The chicken model and growing feather anatomy. 
 
Left panel: The chicken model used in the current studies, showing a) one male LBL at 7 weeks 
of age and b) a plucked 2-3 week old GF, approximately 8-10 mm long and 2-3 mm in diameter 
of living tissue from bottom (newest growth) to epidermal cap. 
 
Right panel: H/E stained sections showing the feather’s a) top, b) part of the middle, and c) 
bottom .The red arrow in a) point to the cap portion of the epidermis. The red arrows in c) point 
to the sheath (A), pulp epithelium epidermis (B), and the pulp (dermis)(C). 
 
Source: Erf (U.S. Patent No. 8,216,551, 2012) 
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 The presence of GFs can be confirmed by plucking a feather, which should subsequently 
regenerate. The regenerating feathers allow researchers to periodically monitor the biological 
activities associated with NPs in one subject, and the procedures used are minimally invasive 
(Erf, U.S. Patent No. 8,216,551, 2012). The results obtained from tissue analyses of GF are more 
reliable than those obtained from the skin because GF injections restrict the testing area to the 
inner pulp, whereas the distribution of particles after skin injections cannot be controlled. As 
these features are specific to the chicken model, it has several advantages over other animal 
models that can be used to study NPs in vivo. 
 The purpose of the current studies is to demonstrate the feasibility of the chicken model 
and the GF as a test site for in vivo monitoring of immune responses to injections of antigen-
conjugated IONPs. Although Furthermore, the current studies aim to determine how the effects 
of NPs on immune system responses compare to traditional aluminum adjuvants because it was 
suggested that NPs could improve targeted vaccine delivery and elicit high immune responses 
(Aguilar et al., 2010; Singh, Chakrapani, & O'Hagan, 2007). Two research objectives were 
established: 
 Objective 1: Monitor and assess local leukocytes infiltration into the pulp that occurs 
after the administration of antigen-conjugated NPs and NPs via GF injections. Upon the 
administration of treatments in the GF pulp, the NPs are exposed to the soluble and cellular 
components of the innate immune system. Using GFs as a test site allows for periodical 
collection of tissue samples from the same bird, and the evaluation of innate immune responses 
can be conducted by analyzing the pulp of the injected feathers and the peripheral blood. The 
immunomodulatory activity of NPs will be compared to the activity of other treatments, 
including antigen, antigen-conjugated NPs, antigen-conjugated Alum, and Alum. It was 
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hypothesized that the nature and extent of leukocyte infiltration would depend on the treatment 
used. Specifically, it was expected that NPs alone would achieve no inflammatory activity or 
moderate activity compared to other treatment preparations. 
 Objective 2: Monitor and assess the adaptive immune system’s primary and memory 
responses to the intramuscular injections of antigen-conjugated NPs. This objective addresses the 
necessity of improving vaccine adjuvants because an efficient adjuvant should be able to achieve 
both humoral and cell-mediated immune responses. Just like the first objective, the goal of this 
of this objective was to demonstrate the feasibility of using the chicken model as a minimally 
invasive alternative to other in vivo test systems. Whereas the first objective focused on the 
innate immune response to NPs, this objective focuses on monitoring the humoral and cell-
mediated immune activities of the adaptive system. Therefore, the goal of this objective was to 
demonstrate that the chicken model is suitable for simultaneously monitoring both humoral and 
cell-mediated immune responses periodically in each chicken. That feature makes it more 
versatile and cost-effective compared to conventional animal models used for in vivo research. 
 The second goal was to determine whether NPs are an effective and safe adjuvant. It was 
hypothesized that the primary and memory response would be higher in chickens that had 
received antigen-conjugated NPs compared to chickens that had received antigen-conjugated 
Alum or antigen injections alone. 
 By addressing these two objectives, it is expected that this research will make various 
contributions to future studies investigating the in vivo effects of NPs. Specifically, this study 
contributes to the development of an avian in vivo test system using GF as a test site in the LBL 
line of chickens. This will address the need for the development of less invasive in vivo test 
systems compared to conventional models, such as non-human primates or mice (National 
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Research Council, 2012). The injection of NPs and antigen-conjugated NPs into the GF pulp 
tissue allows for periodical monitoring of local inflammatory responses, thus creating an 
opportunity to develop indexes for determining in vivo NP toxicity and bioactivity. 
 In addition to enhancing the avian test system for monitoring NPs in vivo, these studies 
also assess the utility of NPs as a vaccine adjuvant. As new adjuvants need to be developed to 
address the problem of balancing their safety and efficacy depending on each patient’s situation, 
NPs could prove to be a more effective vaccine platform compared to conventional adjuvants. 
Specifically, IONPs are used as they have not been associated with adverse events because of 
toxicity risks. If antigen-conjugated NPs can improve the efficiency of immune responses 
compared to aluminum adjuvants without displaying toxic effects, future studies can refine the 
use of NPs as vaccine platforms to enhance the quality of healthcare delivery. 
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CHAPTER 1—LITERATURE REVIEW 
 Nanoparticles (NPs) are a promising diagnosis and treatment tool in healthcare because 
of their ability to transport materials, such as pharmacological agents, and target specified 
structures on an atomic or molecular level. However, safety is still a major barrier to the use of 
NPs because the materials used to develop them are inorganic and diverse. Although some NPs 
are approved for commercial use, some materials can increase the risk for toxicity-related 
adverse events that are difficult to establish for each type of NP. At the moment, there is no 
consensus for lower and upper NP toxicity levels despite the numerous in vitro and in vivo 
studies. Even though no short-term adverse events have been reported in studies using mice and 
non-human primate animal models, long-term follow-ups revealed residual doses of toxic 
materials in various tissues (Chen, Zhen, Todd, Chu, & Xie, 2013). The interactions between 
NPs and biological systems, as well as their potential toxicity threats and immunological 
responses, require further investigation before NPs are implemented in biomedical practice. 
NP Overview 
NP Types and Properties 
 NPs are classified based on their size, shape, and construction materials. Fine particles 
(diameter: 100-2,500 nm) and coarse particles (diameter: 2,500-10,000 nm) are classified as 
nanoparticles, but ultrafine particles (diameter: <100 nm) show the most effective results for in 
vivo application (Dobrovolskaia & McNeil, 2007; Müller et al., 2007; Xiang et al., 2006). 
However, it is important to note that shape also determines how size affects rate of uptake in 
cells. For example, when fine particles are used to bind to the target, rod-shaped NPs show 
higher cellular uptake compared to other shapes (Gratton et al., 2008), but spheres outperform 
rods when ultrafine particles are used (Albanese, Tang, & Chan, 2012). The optimal size for 
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maximizing rate of uptake in mammalian cells and intracellular concentrations was established at 
50 nm (Albanese et al., 2012). Therefore, spherical ultrafine particles appear to be the most 
promising NPs for biomedical applications.  
 Several materials can be used to build NPs, and some examples include iron oxides 
(IONP), gold (AuNP), dendrimers, quantum dots, polymers, and nanotubes (Llevot & Astruc, 
2012). Each type of material has specific properties that determine its biomedical applications 
and efficiency, but also risk for toxicity. 
 Quantum dots (QDs) produce different emissions depending on their size and 
composition, so one group of QDs can produce a wide emission spectrum even when they are 
excited with a single light source. Because of that property, QDs were considered ideal tags for 
multiplex optical fluorescence imaging (Chen et al., 2013). However, the main issue with QDs is 
the high level of toxicity because they release cadmium during deterioration. Cadmium residue 
was detected in various organs, such as the liver and kidneys, of rhesus macaques monkeys 90 
days after the administration (Chen et al., 2013). 
 IONPs improve the visibility of anatomical structures in magnetic resonance imaging 
(MRI) results because of their property to work as contrast agents. For example, conventional 
MRI can reveal tumor size and location, but IONPs in conjunction with MRI can also reveal 
metastases, which are too small for conventional MRI to detect (Harisinghani et al., 2003). The 
ability to enhance MRI images is only one feature of IONPs. Like other NPs, they can also be 
used for targeted drug delivery, and they are efficient vaccine adjuvants (Alaamri, Byrne, Falcon, 
& Erf, 2014; Kievit & Zhang, 2011). 
 AuNPs have multiple potential applications in healthcare because of their scattering and 
absorption properties. These properties vary based on their shape and size, so large AuNPs can 
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be used for diagnostic tests (e.g., optical coherence tomography) because they scatter light better 
than small AuNPs. However, small AuNPs have a higher absorption efficiency compared to 
large AuNPs, which makes them efficient for hyperthermal therapy (Chen et al., 2013). When 
both large and small AuNPs are combined, their absorption and scattering properties make them 
a superior contrast agent compared to fluorescein molecules and other nanoparticles based on the 
strength of their emissions and photostability (Gobin et al., 2007; Huang & El-Sayed, 2010). 
 Various other materials have also been tested, including carbon black NPs and metal 
oxide NPs (e.g., zinc, nickel, copper). Carbon black NPs were associated with inflammatory and 
genotoxic events in the primary exposed tissue, as well as secondary tissues (Bourdon et al., 
2012). Zinc, nickel, and copper metallic oxide NPs were all associated with cytotoxic effects 
(Cho et al., 2011). However, IONPs are considered safe because no long-term or significant toxic 
events have been reported in previous studies (Jain, Reddy, Morales, Leslie-Pelecky, & 
Labhasetwar, 2008; Pusic et al., 2013). 
NP Modifications 
 NP surface modifications are essential for overcoming barriers to the effective 
biomedical implementation of NPs, most notably the challenges of preventing the destruction of 
NPs by the immune system. The purpose of modifications is to ensure that the NPs do not 
activate the complement immune system while remaining hydrophilic so that they are compatible 
with biological fluids. Current research shows that polymers with repetitive recognition patterns 
can avoid complement activation by altering their conformation, thus resulting in improved NP 
longevity and allowing them to reach targeted cells (Sim & Wallis, 2011). Another strategy is to 
use evasion strategies observed in bacteria and parasites adapted to human tissue, such as 
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borrowing complement-regulating proteins (e.g., Factor H) to limit complement activity (Sim, & 
Wallis, 2011). 
 Surface modifications are also used for targeted drug delivery and diagnosis. For targeted 
drug delivery, NPs need to reach their target without interference from macrophages, so 
macrophage evasion techniques are currently being developed to ensure that the NPs stay in the 
blood long enough to reach the targeted cells. Surface modifications are currently the most 
effective method for improving targeted drug delivery, but methods like red blood cell 
hitchhiking and alternative shapes are also possible solutions for avoiding macrophages (Yoo, 
Chambers, & Mitragotri, 2010).  
 The biocompatible coating that surrounds the metal core of the particle contains 
therapeutic agents. For example, NPs that deliver drugs to tumor cells can contain gene therapy 
agents, therapeutic proteins, and chemotherapy drugs (Kievit & Zhang, 2011). In order to deliver 
those drugs to the target cells, the NPs need to be functionalized by attaching targeting agents to 
their coating. NP-antibody conjugates and membrane-permeating molecules are often used in 
experiments to diagnose or treat specific types of cancer based on their expression of antigens 
(Llevot & Astruc, 2012). 
NP Potential Applications 
 Cancer therapy is currently one of the most promising fields because NPs allow for 
targeted drug delivery. Other examples of the potential applications of NPs in biomedical science 
that can improve human quality of life and well-being also include pathogen detection, protein 
detection, and tissue engineering. 
 Cancer therapy. Because of their properties and the ability to perform passive and active 
targeting via various targeting moieties (e.g., antibodies and aptamers), NPs could improve the 
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diagnosis and treatment of cancer. The use of NPs for cancer treatment using in vivo animal 
models found that drug delivery efficiency and survival rates improve significantly when NPs 
are used (Yu, Park, & Jon, 2012). In addition to targeting moieties, other effective methods for 
targeted cancer drug delivery include drug-encapsulated IONPs (Yigit, Moore, & Medarova, 
2012) and adjusting responsiveness to pH differences between malignant and non-malignant 
cells (Lim et al., 2011). 
 AuNPs are currently the most promising type of NPs for cancer treatment in human 
subjects because of their ability to attach to cancer cells and induce intracellular hyperthermia 
once stimulated with radio frequency radiation or other stimuli (Glazer et al., 2010). Some 
clinical trials in palliative care patients with AuNPs have already been conducted. Biopsies were 
used to evaluate the targeting efficiency of AuNPs, and it was found that AuNPs were present 
only in tumors, but not in the healthy tissues (Libutti et al., 2009 as cited in Jain, Hirst, & 
O'Sullivan, 2012). However, the toxicity of AuNPs is still contradictory. While Pan et al. (2007) 
reported that small AuNPs (1-2 nm) are toxic, larger AuNPs (>15 nm) proved to be safe even in 
larger doses. However, those findings are contradictory to the findings by Vecchio et al. (2012), 
which indicate that AuNP-related toxicity is exclusively dose-dependent, regardless of the 
particles’ sizes.  
 Pathogen detection. Biosensors using NPs that bind to DNA samples can measure 
concentrations and identities of pathogens. The Bead Array Counter (BARC) is an example of a 
biosensor that injects magnetic fine NPs (1,000 nm) into the sample placed in the instrument. 
Once the magnetic field removes excessive particles, the giant magnetoresistive sensor detects 
the intensity and location of the signal received from the remaining beads (Edelstein et al., 2000). 
Depending on the signal’s intensity and location, the concentration and the identity of the 
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pathogens analyzed are determined. Although the primary purpose of developing this technology 
was to improve the identification process of biological warfare agents, it is possible that this 
technology will prove useful in healthcare diagnostics. 
 Protein detection. As a key variable in cellular functions and inter-cellular 
communication, understanding protein-protein interactions can improve the understanding of 
physiological mechanisms on cellular levels. Using 10 nm AuNPs, Cognet et al. (2003) 
demonstrated the application of photothermal interference contrast for 3D imaging of low levels 
of intracellular proteins. Therefore, this method can be used to detect low-expression proteins as 
an alternative to manipulating induction conditions or examining codon usage.  
 Protein detection techniques can also have therapeutic applications if they are used to 
detect small concentrations of protein targets that are biomarkers for disease. For example, the 
bio-bar-code method can detect prostate-specific antigen (PSA), which is often found in small 
concentrations during early stages of relapse in former prostate cancer patients, and it is also 
present in even smaller amounts among female breast cancer patients. The high sensitivity of the 
method allows it to detect PSA concentrations at 30 attomolar concentration using a 10 µL 
sample (Nam, Thaxton, & Mirkin, 2003). The potential application of this method is facilitating 
the therapeutic response to cancer relapse so that early adjuvant therapies could increase 
treatment success rates. 
 Tissue engineering. While polymer NPs are not suitable for therapeutic interventions, 
they have the potential to improve tissue engineering by forming natural structures 
corresponding to the body’s native structures. For example, natural bone surfaces do not have a 
smooth surface, which is characterized by pores of 100 nm in diameter (Salata, 2004). Using 
polymer nanoparticles makes it possible to replicate these structures for bone and dental repairs. 
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Those nanostructures are uniform and strong so that the body can transport nutrients through the 
porous surface without compromising adhesion, mechanical strength, and rejecting the foreign 
substance (Salata, 2004). 
 Even if biomaterial tissue is used for implants, the use of NPs could prevent the 
formation of biofilm, which is recognized as a cause of bacterial adhesion and infections. 
Antibiotics and immune cells cannot penetrate the biofilm to cure biomaterial-associated 
infections, but IONPs with a polymer brush coating can significantly reduce biofilm formation to 
prevent bacterial adhesion or expose the pathogens to antibiotics and immune cells (Thukkaram, 
Sitaram, Kannaiyan, & Subbiahdoss, 2014).  
 Vaccine platform. The effectiveness of peptide vaccines depends on whether the 
adjuvant can induce an immune response, but adjuvants that prove effective in animal models are 
not necessarily effective in human clinical trials. For example, malaria vaccine with anti-
Merozoite Surface Protein 1-42 (anti-MSP1-42) with oil-water emulsion adjuvants proved to be 
safe and immunogenic in animal models. However, human trials using adjuvants with anti-
MSP1-42 did not demonstrate the same immunogenic efficacy (Ogutu et al., 2009). Therefore, 
alternative strategies need to be investigated to improve the immunological efficacy of agents in 
vaccine. 
 The use of NPs as a delivery platform to increase the immunogenic effect of vaccines is 
one of the promising strategies. The proof-of-concept study by Pusic et al. (2011) found that 
small (< 15 nm), water-soluble, inorganic QDs can be used to stimulate an immune response that 
could enhance the activation of T-cells or antigen presentation. The IONP-mouse IgG conjugate 
also proved to increase lymphocyte infiltration in Light Brown Leghorn (LBL) significantly 
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higher compared to other adjuvants (Alaamri et al., 2014). Aluminum gels or salts are typically 
used as vaccine adjuvants, but they are outperformed by NPs. 
IONP Overview 
 IONPs are well-known for their intrinsic superparamagnetism that allows minimally-
invasive, highly reliable tumor detection with MRI. These particles also have several potential 
applications as cancer treatment delivery agents and adjuvants for vaccine. The base of each 
IONP is the iron oxide core that serves as a contrast agent for diagnostic purposes and an agent 
carrier for therapeutic purposes. IONPs are biodegradable, which is suitable for in vivo 
applications, but the particles need to be designed to evade physiological barriers (i.e., blood, 
liver, kidneys, spleen, and blood-organ barriers) and cellular barriers so that their longevity 
inside the organism allows them to perform the intended function. This is achieved using suitable 
coating materials to protect the core from early interactions with native systems and increase 
their biocompatibility (see Figure 2). For example, lauric acid coating can increase cellular 
uptake and cellular interactions of IONPs in vivo compared to dextran coating (Pradhan, Giri, 
Banerjee, Bellare, & Bahadur, 2007). 
 The level of cellular uptake and interactions does not necessarily improve the longevity 
of the particles, which cannot be used for diagnostic or therapeutic purposes if they are 
eliminated before they reach their targets. The IONP coating usually consists of polyethylene 
glycol (PEG) because it protects the core from quick degradation in the blood as well as the 
adsorption of blood components (Kievit & Zhang, 2011). Another common threat in the blood 
includes the complement immune system proteins, which can trigger an immune response to 
eliminate the IONP if they are recognized as threats. These threats are usually evaded using 
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various strategies, such as modifying the shape of the particles to minimize complement 
activation (Sim & Wallis, 2011).  
 Besides blood components, elimination by the kidney, liver, and spleen is another 
significant concern for the longevity of IONPs. However, consistent with the size of materials 
taken by the reticuloendothelial system (> 100 nm) and the pore size on the kidney’s basal 
lamina (approx. 10 nm), IONPs sized between 10 and 100 nm show reduced uptake by clearance 
organs (Longmire, Choyke, & Kobayashi, 2008). Therefore, coating and size are key 
determinants for IONP longevity and reaching the targeted cells (see Figure 2). 
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Left panel: Biocompatibility is achieved by coating the particles with polymers to increase their 
blood circulation longevity; specific targeting is achieved by attaching ligands or antibodies to 
the surface; organic fluorophores are conjugated to the surface for imaging purposes; drug 
release of attached therapeutic agents is achieved by setting up a stimuli-responsive release, so 
that the drugs are delivered due to enzymatic action or changes in pH value. Reproduced from 
Figuerola, Di Corato, Manna, and Pellegrino (2010). 
 
Right panel: IONP design used by Hadjipanayis et al. (2010) to demonstrate how the particles 
can enhance glioblastoma multiforme MRI visibility and induce apoptosis in tumor cells without 
causing toxic effects to human tissue. The core is 10 nm in diameter and is coated using PEG, 
which improves the IONPs blood circulation longevity and enables them to reach the target. The 
surface is modified using epidermal growth factor receptor (EGFRvIII) so that the particles can 
bind to the tumor cells without binding to healthy brain cells. Reproduced from Hadjipanayis et 
al. (2010). 
 
 If the particles can reach the targeted cells after bypassing barriers, they will also need to 
enter the cells and identify the targeted intracellular components to perform their functions. This 
is achieved by using targeting agents that are placed on the coating of the particle, but various 
other factors determine the efficacy of cell penetration. Those factors include size, charge, and 
coating materials. Using tumor cells as an example, the best cellular uptake occurs with particles 
above 60 nm in diameter (Kievit & Zhang, 2011). Cationic particles have high cell penetration, 
but their distribution in the tumor is poor, so charge-reversal can be used to change anionic 
Figure 2. Overview of possible IONP modifications that could be used in clinical practice. 
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particles to cationic particles at low pH levels once they distribute throughout the tumor (Mok et 
al., 2010). This approach enhances both particle distribution and cell penetration. Finally, coating 
is critical for penetrating the endosome membrane before the cell’s enzymes target it for 
degradation. 
 The effects of IONPs on immune responses and their toxicity have been tested 
extensively. The immune response depends on various factors, such as NP charge, particle 
purity, particle size, and surface properties. Most studies agree that cationic IONPs induce higher 
inflammatory response compared to anionic and neutral IONPs (Dobrovolskaia & McNeil, 
2007). IONPs should also be purified to reduce inflammatory responses associated with impurity 
because there are better ways to stimulate the immune system if the particles are used as 
vaccination adjuvants (Müller et al., 2007). 
 In order to activate the cell-mediated immune system, small particles (< 100 nm) should 
be used because they were associated with higher levels of antibodies compared to large particles 
(Xiang et al., 2006). However, it is important to note that both small and large IONPs are capable 
of activating T helper cells, which consequently activate and regulate the B cells, T cells, and 
macrophages (van Zijverden & Granum, 2000). Furthermore, surface modifications are essential 
for stimulating the immune system because the particles can be engineered to mimic pathogens. 
For example, Toll-like receptor (TLR) modifications with antigens are used to deliver antigens to 
the dendritic cells (DCs), which activate T cell proliferation (Diwan, Elamanchili, Lane, Gainer, 
& Samuel, 2003).  
 The toxicity of IONPs is still a significant concern and a barrier to their practical 
implications in biomedicine. Upon the degradation of the iron core, the divalent metal transport 
channel moves the ferric iron into the cytoplasm, thus causing an increase in cytoplasmic iron 
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levels (Zhao et al., 2011). This release of ferric iron into the cytoplasm results in the 
development of reactive oxygen species, which damage cell functionality. The level of oxidative 
stress is tissue-dependent, and it peaks at approximately 3 days after the injection in rats, but the 
effects of oxidative damage does not cause long-term abnormal changes in liver, spleen, and 
kidney tissues of small animals (Jain et al., 2008). The short-term increase of oxidative stress 
upon IONP administration could be attributed to immune responses, but the lack of long-term 
oxidative damage suggests that IONPs are safe for in vivo use. Furthermore, the size of the 
particles can affect clearance speed and reduce their toxic effects. Mice and non-human primates 
did not display signs of kidney or liver damage after high doses of IONP administration, so the 
use of IONPs in vivo is considered safe (Pusic et al., 2013).  
 Based on the current body of research concerning IONPs, those particles are safe and 
effective when used as contrasting agents for diagnosis, targeted drug delivery, or vaccine 
adjuvants. Teeguarden et al. (2014) measured the inflammogenic cellular doses of IONPs in 
mice, and the calculated adjustments for humans suggest that the acceptable exposure limit is 10 
mg/m3 of iron oxide. However, the lungs were the targeted tissue, so it is important to investigate 
the toxic effects of iron oxide on other tissues as well.  
 The applications and toxicity of IONPs are still observed using a variety of animal 
models to completely understand their effects on the immune system and their biological 
interactions with various tissues. In order to ensure the results obtained from in vivo studies, it is 
important to consider the advantages and disadvantages of each model that can be used for 
measuring and evaluating NPs in vivo. 
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Animal Models 
 Various animal models have been utilized to test NPs in vivo, and some of the most 
common ones include the mouse and non-human primate models. Other models (e.g., porcine) 
are also sometimes used, but they are less common. Compared to the human immune system, the 
mouse model appears to be one of the most reliable models for in vivo studies, but the avian 
model is responsible for various insights in immunology, especially in vaccination studies 
(Schat, Kaspers, & Kaiser, 2014). Using the avian model, specifically chicken, to study the 
interactions between NPs and the immune system is a promising alternative to other models in 
terms of financial advantages, procedural advantages, and reliability of results. 
Mouse Models 
 Although the mouse model is well-known for studying NP-associated biological 
interactions and immune responses in vivo, it is an invasive model. According to the mapping of 
lymphatic drainage basins in mice, the hindfoot and the tail are the best injection sites for 
stimulating and monitoring local immune responses (Harrell, Iritani, & Ruddell, 2008). 
Therefore, a typical research procedure involves tail vein injections, followed by periodical 
blood collection from the periorbital vein for plasma analysis. The mice have to be sacrificed in 
order to obtain tissues from organs (e.g., liver and spleen) for histological analysis (Karmali et 
al., 2012).  
 Complex procedures are also available to study cell-mediated immunity in mice. 
Studying T cells is difficult because their functionality depends on the type of T cell, and it is 
difficult to monitor their migration and cell-to-cell communication. Technologies such as 
intravital microscopy (IVM) are required to visualize T cell functions and interactions in vivo. 
IVM techniques are invasive because the microscope has to be positioned above an incision 
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made on the animal’s tail. Although IVM does not require sacrificing the animal once the 
experiment is completed, those techniques have other limitations. Observing antigen-experienced 
lymphocytes using IVM techniques does not require large numbers of purified cells, but the 
visibility of cells is determined by blood flow rate. The attempt to produce a 3D image and 
visualize the T cell migration and cell-to-cell communication can be disrupted by tissue 
movements of a few micrometers (Mempel, Scimone, Mora, & von Andrian, 2004). Finally, 
observing local immune responses in mice is not reliable because particles injected in the skin 
can disperse and expand the area of inflammation (Gopee et al., 2009).  
 There is no alternative to using invasive procedures when mice are used in NP research. 
Even in studies that investigated skin permeability of NPs, skin penetration in mice was not 
possible unless the skin was dermabraded (Smijs & Bouwstra, 2010). In order to study cell-
mediated immunity in mice, the animal usually needs to be sacrificed in order to obtain tissue for 
histological analysis. Unless IVM is used to monitor T cell recruitment and trafficking in real 
time, there is no feasible method for observing cell-mediated responses multiple times in a single 
animal. 
 For NP applications in immunization, the mouse model is not always a suitable choice 
because of the differences in immune responses between mice and humans. For example, 
antitumor T-cell responses in mice are different from those that occur in humans (Lévy, & 
Colombetti, 2006). Furthermore, activation of antigen-specific T-cells was achieved with 
peptide-pulsed DCs (Degl'Innocenti et al., 2005), but not with peptide/adjuvant immunization 
(Grossmann, Davila, & Celis, 2001). Pusic et al. (2013) reported that IONP as an adjuvant 
resulted in 100% immune responsiveness for non-human primates whereas mice exhibited a high 
immune response only when their DCs were significantly activated. 
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 These characteristics of the mouse immune system could also explain why studies using 
the mouse model often report contradictory findings. Shen, Liang, Wang, Liao, and Jan (2012) 
reported that IONPs suppress the infiltration and functions of T helper 1 cells and macrophages 
in response to the antigen. The treatments were injected in the tail veins. However, Mulens-
Arias, Rojas, Pérez-Yagüe, Morales, and Barber (2015) reported that IONPs modulated 
macrophage formation through TLR-4 and reactive oxygen species signaling after treatment 
administration in the peritoneal region. The differences in findings could be attributed to the 
differences in IONP coatings used, but different injection sites could also account for the 
differences in findings. 
 The mouse model requires invasive procedures and the differences between mice and 
humans could affect the transferability of findings, so the mouse model is not the best model to 
study in vivo NP interactions and their effects on the immune system. The use of other animal 
models for investigating NP biointeractions could produce more reliable and transferable results 
compared to the mouse model. 
Non-human Primate Model 
 The non-human primate model in NP research is often used to determine whether the in 
vitro results and small animal models can be generalized to humans, especially concerning the 
toxicity of NPs. Using the non-human primate model, researchers concluded that small water-
soluble IONPs can deteriorate quickly, but their dispersion and exact deterioration need to be 
monitored using dyes (Pusic et al., 2013). In contrast, the breakdown of QDs is much slower and 
cadmium doses can remain stored in the liver for up to 90 days (Ye et al., 2012). 
 For determining the toxicity and acceptable doses, the non-human primate model is often 
used for measuring immune system responses because of the physiological similarities between 
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the human and non-human primate adaptive immunity (Messaoudi, Estep, Robinson, & Wong, 
2011). Another significant advantage of the primate model is that small animals are not 
susceptible to infections from pathogens that affect primates only, such as the hepatitis C virus 
(HCV) or the human immunodeficiency virus. Although the accumulation of NPs in the 
hepatocytes and Kupffer cells of small animals indicates that targeted NP therapy has potential 
for HCV treatment, reliable results can be obtained only through primate models (Ryoo et al., 
2012). 
 However, this model also has several disadvantages. Physical or chemical restraints are 
often required when handling research subjects, even though the animals can be trained to 
cooperate during various procedures, including vaccinations and examinations. The long life-
span of non-human primates is beneficial for conducting longitudinal studies, but not for 
researching intervention effects throughout multiple stages of development. Finally, the 
restrictions and regulations for using non-human primates are constantly increasing, and the cost 
of those studies often exceeds the potential benefits. Therefore, the biological interactions of NPs 
are often studied in small animal models whereas the non-human primate model is often used to 
verify in vivo findings prior to the transition of research to human clinical trials (Ye et al., 2012). 
Other Models  
 The Drosophilia melanogaster (i.e., common fruit fly) model was reported for testing the 
toxicity of AuNPs (Vecchio et al., 2012). Using the fruit fly model is common in biomedical 
research because the experiment requires little equipment and their short life span makes it easy 
to study inheritance. However, for the purpose of studying acute toxicity, insect models may not 
be the best option. It is estimated that 77% of human disease genes match to the fruit fly genome, 
so the fruit fly model can be useful for studying the genetics of progressive disease (Reiter, 
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Potocki, Chien, Gribskov, & Bier, 2001). However, that does not allow researchers to identify 
relevant biological processes specific to mammals, such as inflammation response pathway 
activation caused by NP interactions. 
 The porcine model is rarely used for NP research, but it is feasible because the human 
and pig skin show similar lipid organization. The only significant difference between the two is 
that the lipid organization in the pig skin stratum corneum has less crystalline packing compared 
to the stratum corneum in humans. That difference does not affect the permeability 
characteristics of the skin when exposed to NPs, so the porcine model can be used to test 
penetration and localization of NPs (Smijs & Bouwstra, 2010). Although this model can 
investigate how skin characteristics and NP characteristics affect penetration and localization, it 
cannot provide valuable insight into the immunological responses caused by NPs that would be 
relevant to humans. 
 These models can meet a variety of research objectives, but they are not suitable for 
investigating immune reactions to NPs. Most researchers prefer mice because their immune 
system has a similar structure to the human immune system. Even though several discrepancies 
in innate and adaptive immune responses between these two species have been identified (e.g., T 
cell signaling pathway components, Th1/Th2 differentiation), the two systems are comparable if 
those discrepancies are considered when interpreting results (Mestas & Hughes, 2004). Non-
human primates can offer important insights into the toxicity of NPs given their weight similarity 
with humans, as well as the genetic and immune system similarities between the two species. 
However, both of those models lack a suitable test site where immune reactions can be localized 
and observed repeatedly. That is why using the chicken model can provide more valuable insight 
into the effects of NPs on immune responses compared to other models. 
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Chicken Model  
 The avian model can be used to study immunity because of the similarities birds share 
with mammals. Both birds and mammals produce their antibody repertoire using somatic gene 
conversion, and the avian major histocompatibility complex (MHC) performs cell-mediated 
immune functions similar to the mammalian MHC (Schat et al., 2014). Improvements in the 
chicken model made it possible to quantify immune system responses via various pathways. For 
example, Mannan-binding lectin (MBL) is produced in hepatocytes during acute infections as the 
first-line of immune response, and chicken share a similar MBL production and regulation 
pathways as mammals. Norup and Juul-Madsen (2007) established an assay for quantitatively 
measuring the complement activation capacity of the MBL pathway in chicken by depositing the 
human complement factor 4 (C4), and the high correlation between chicken MBL (cMBL) 
concentration and C4 deposition (r = 0.85, p < 0.0001) indicates that the assay is reliable. 
 The chicken model is also suitable for investigating diseases that occur in both humans 
and chicken, such as autoimmune disease, cancer, infectious disease, dermatitis, and various 
others. The avian immune system features and common disease with humans make chicken good 
subjects for investigating immune system responses. Besides comparable immune systems with 
mammals, the chicken genome was published in 2004, allowing researchers to explore the 
genetic factors associated with immunity in depth (Schat et al., 2014).  
 However, the biggest advantage of chicken compared to other models is the ability to 
monitor in vivo immune responses using the growing feather (GF) as a test site. Feather injection 
is a minimally-invasive procedure and feathers are easy to access as samples for histological 
analyses. Unlike the mouse model, which usually requires sacrificing the animals to obtain tissue 
samples, the test material in the chicken model can be monitored periodically for one test 
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subject. The use of the avian model for administering agents and measuring immune responses to 
determine vaccine efficiency was patented by Erf (U.S. Patent No. 8,216,551, 2012). 
 The procedure introduces an agent locally or systemically, followed by plucking the 
feather and analyzing the tissue responses in the tip of the feather. Approximately 10 µl of the 
agent studied can be injected directly into the feather tip as they are 1 cm long on average, 
depending on the age of the chickens. As a general rule, chickens between 2 and 22 weeks of age 
have GF, but the exact age depends on the line studied. Directly injecting an agent into the pulp 
of the feather does not affect the regeneration of the GF. The administration of agents does not 
cause bleeding or tissue damage, which usually occurs when more sensitive test sites are used, 
such as the wing web or wattle.  
 Multiple agents can be administered into the GF to monitor their effects in vivo. 
According to Erf (U.S. Patent No. 8,216,551, 2012), most agents can be tested using this 
procedure, including NPs, microbes, polypeptides, lipids, pharmaceuticals, polynucleotides, 
carbohydrates, and various others. In addition to direct injection, responses associated with 
exposure to environmental factors (e.g., pollutants) can also be monitored using the feather tip. 
Multiple tests on one subject can be conducted by administering tested agents into multiple GF 
test sites in one subject, so that each feather tip can be plucked and analyzed at different time 
points during the experiment. 
 In contrast with previous methods that required injecting agents into the birds’ sensitive 
tissues, plucking the feather does not require euthanization and does not limit the selection of 
appropriate assays that can be used to analyze the tissue. The feather tips can be analyzed using a 
variety of tests, including histological analyses, flow cytometry, tissue culture, enzyme activity 
assessment, various analyses (i.e., transcriptome, protein, and lipid), and immunohistochemistry 
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(Erf, Trejo-Skalli, & Smyth, 1995; Lockhart & Erf, 2004; Shrestaa, Smyth, & Erf, 1997; 
Stepicheva, Liyanage, Lay, Dienglewicz, & Erf, 2010; Wang & Erf, 2004). The scope of agents 
and analyses that can be used does not depend on the chicken line because all birds have GF 
before reaching adulthood. However, the selection of different lines needs to be consistent with 
the purpose of the study. 
 The Smyth-Line (SL) chicken has been used extensively in autoimmune vitiligo research. 
Normally, the SL chickens are the intervention group whereas the Light Brown Leghorn (LBL) 
chickens are used as controls (Erf, 2004; Sreekumar et al., 2000; Wang & Erf, 2004). SL chicken 
are naturally susceptible to autoimmune vitiligo, but the LBL line appears to be vitiligo resistant, 
even after the attempts to induce it with 5-azacytidine (Erf, 2004). 
 Therefore, for the purpose of investigating immune responses, the LBL line could be a 
better choice compared to the SL chickens. Because SL chickens are susceptible to autoimmune 
disease, a spontaneous onset of vitiligo could interfere with immune responses and alter the 
results of analyses aimed at investigating the effects of injected agents. The resistance of the 
LBL line to autoimmune disease means that less random interference is expected during 
experiments, so the LBL could be a better option for studying immune responses to external 
agents. 
 The diversity of chicken lines that can be used in research is another advantage of this 
model because each line has specific genetic characteristics. The LBL line, SL line, and Brown 
line (BL) are examples of lines that are well-defined in terms of disease susceptibility whereas 
random bred lines can also be used. This enables researchers to use multiple different lines of 
chicken and analyze the differences in immune reactions or disease susceptibility between them. 
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 The chicken model is a minimally invasive procedure that provides reliable results when 
assessing immunological responses based on various immune system activities, such as 
lymphocyte infiltration or antibody production (Alaamri et al., 2014). The ability to monitor 
immune responses over time is a specific feature of the chicken model because GF can be used 
as a test site whereas skin has to be used when working with other animals. Therefore, the avian 
model requires less complicated and less invasive procedures compared to other models for 
monitoring the activities of NPs in vivo and the outcomes of those activities. 
Immune System Overview 
 The immune system protects the body from infections by identifying and evaluating 
threats, coordinating the elimination of pathogens, and preventing or limiting damage to the 
native tissue. The immune system can be divided into the innate and the adaptive immune 
systems, which are distinguished by two characteristics. First, each system has a different 
method it uses to recognize antigens. The innate immune system recognizes pathogens using 
germ-line encoded pattern recognition receptors (PRRs), which induce signals for activating 
adaptive immunity. The receptors used by adaptive immunity are diverse because they 
consistently mutate and recombine so that they can identify and eliminate specific pathogens. 
Second, only the adaptive immune system can develop immunological memory, which allows it 
to become more efficient after each exposure to pathogens with the same antigen. 
 The innate immune system is comprised of several immune cell subsets, which are 
responsible for detecting pathogen-associated molecular patterns (PAMPs). They include 
macrophages, natural killer (NK) cells, neutrophils (heterophils in chickens), DCs, 
inflammasomes, complement proteins, acute-phase proteins and various other subsets 
(Medzhitov, 2007). The recognition of pathogens occurs via three general mechanisms, which 
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include (1) microbial non-self recognition, (2) missing self recognition, and (3) altered self 
recognition (Medzhitov & Janeway, 2002). Non-self molecules that are specific to microbes are 
the easiest to recognize via the immune cells’ PRRs, but most pathogens adapted to infecting 
humans can reduce immune system activation by binding regulating proteins (Sim, & Wallis, 
2011). In those cases, the presence of pathogens is detected based on the cell surface alterations 
in infected cells. Infected cells usually display MHC on their surface, which triggers an immune 
response. However, the NK cells are able to recognize infected cells even when no obvious 
infection markers are present, which is referred to as the “missing self” (Vivier et al., 2011). The 
surface structure of the apoptotic cells can change by developing apoptotic cell-associated 
molecular patterns (ACAMPs) so that phagocytes recognize the pattern as “altered self” and 
trigger an immune response (Nakanishi, Henson, & Shiratsuchi, 2009). 
 Innate immunity is often referred to as the first line of defense because it is responsible 
for identifying threats and activating the production of antimicrobial cells that inhibit pathogen 
replication (Messaoudi et al., 2011). The innate immune system is also responsible for activating 
the adaptive immune system by associating PAMPs with the lymphocytes abilities to recognize 
specific antigens. The T cells of the adaptive immune systems are activated by DCs, which 
process the pathogens’ protein constituents into antigenic peptides. The DCs also produce 
cytokines as a response to PRR-induced signaling. Once the DCs reach the lymph nodes, their 
antigenic peptides and PRR-induced signals serve as triggers for T cell activation (Medzhitov, 
2007). B cell activation uses a different pathway, which involves physically linking an antigen 
and a specific PAMP through the coordinated effort of PRRs and B-cell receptors (Medzhitov, 
2007). 
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 Two aspects of the adaptive immune system can be distinguished, and they include 
humoral immunity and cell-mediated immunity. Humoral immunity is also referred to as 
antibody-mediated immunity because a humoral immune response leads to the production of 
soluble antibodies that bind to antigens. When triggered, the humoral immune system’s B cells 
produce immunoglobulin M (IgM), a molecule that has a total of ten antigen binding sites. 
Because of its ability to bind many antigens and activate the complement system to assist in the 
elimination of the bound antigens, IgM is the first antibody produced in response to an infection 
(Racine et al., 2011). IgM is also used as a first response and is generally of low affinity to an 
infection because the B cells need to mature by mutations that increase affinity to the pathogen’s 
antigen while they simultaneously switch to producing IgG antibodies, and those mutations are 
induced by T cells. The production of IgG antibodies increases the efficiency of the immune 
system because those antibodies have better antigen affinity compared to IgM antibodies and can 
also bind on leukocytes to enhance their efficiency. Because of the adaptive immune system’s 
memory, the B cells can produce IgG antibodies immediately on secondary infection without 
producing IgM antibodies if the immune system recognizes the antigen. 
 Cell-mediated immunity protects the body by activating cells that eliminate pathogens or 
by activating cytokines that regulate the functions of other systems involved in the immune 
response. The pathogens can be eliminated directly by activating phagocytes and NK cells as 
long as the antigens are extracellular. Once a cell is infected, a different mechanism has to be 
used.  In that case, antigen-specific cytotoxic T cells can be activated to induce apoptosis in 
infected cells with altered surfaces that display non-classical MHC molecules (Medzhitov, 
2007). 
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 Both humoral and cell-mediated immunity are monitored to examine the effects of 
vaccination adjuvants on the immune responses. The effects of adjuvants on the humoral 
immune response are easier to measure and monitor compared to the cell-mediated response. The 
humoral response can be replicated in vitro and the antibodies are easy to obtain when using in 
vivo studies. The humoral immune response usually occurs 48 hours after primary exposure to 
antigen or sooner for repeat exposures (Kelsoe, 2000). Depending on the purpose of the study, 
non-invasive procedures are available to researchers observing humoral immune responses in 
vivo. For example, MRI with positive contrasting can be used to observe the migration of DCs to 
activate the T cells in the lymph nodes (Tavaré et al., 2011). Because the humoral immune 
system’s antibodies are found in extracellular fluids, blood samples and tear collection are 
minimally invasive procedures that can be used to obtain samples for testing humoral response 
levels. The assessment of serum antibodies can be performed using a variety of immunoassays, 
such as the enzyme-linked immunosorbent assay (ELISA), complement fixation, 
immunodiffusion, and serum neutralization (Koller, 1982).  
 Cell-mediated immunity is more difficult to study because live antigen-specific T cells 
need to be measured. Those T cells can identify only antigen-peptides associated with self-MHC 
on antigen-presenting cells (Ignatowicz, Kappler, & Marrack, 1996). Therefore, observing and 
measuring immune responses requires having MHC-matched target cells. Satisfying that 
criterion using random-bred population for in vivo studies is difficult.  
 Although both in vitro and in vivo methods can be used, the assays used to measure cell-
mediated immunity have several disadvantages compared to humoral immunoassays, including 
susceptibility to biological variability and technical complexity (Limaye, 2010). This is 
especially true for studies investigating the effects of NPs on immune responses because the 
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presence of NPs can interfere with the assays’ readout parameters (Oostingh et al., 2011). 
Different cell populations and population subsets can be identified using flow cytometry, but 
even with a precise quantification of T cells, it is difficult to determine their functional capacity 
and distinguish between naïve, effector, or memory T cells. 
 Furthermore, cell-mediated immunity is tissue-specific. Effector T cells produce 
cytokines or kill affected host cells at the infection site, so invasive methods of obtaining tissue 
for histological analyses are required, such as skin biopsy. Skin is often used as a test site for in 
vivo studies because it produces a visible response to the test material (Abbas, Lichtman, & 
Pillai, 2015). Although the reaction is characterized by the presence of immune response 
indicators (e.g., edema, redness, induration), repeat assessments in one test subject are not 
possible because molecular interactions can be observed only after biopsy. 
 Skin is a suitable and reliable test site for investigating cell-mediated immunity triggered 
by NPs because the small size of the NPs allows them to penetrate the stratum corneum, which is 
the upper layer of the skin. However, there are two key issues with using skin as a test site for 
NP bioactivity and immunological responses. First, damaged skin has reduced permeability due 
to structural changes or lipid organizations, so the effectiveness of permeability is dependent on 
the size of NPs and skin condition (Mortensen, Oberdörster, Pentland, & DeLouise, 2008). 
Second, the accumulation of NPs in hair follicles depends on NP size (< 50 nm) and the hair 
growth cycle (Smijs & Bouwstra, 2010). 
 Given the invasive nature of skin biopsy, the use of feathers as test sites for the effects of 
NPs on the immune response is preferred as a less invasive and simpler procedure. Both sites are 
similar in terms of mononuclear cell presence during an inactive immune response, and both 
sites recruit leukocytes from circulation (Erf et al., 1995). However, upon skin penetration in 
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vivo, NPs can also interact with other organs, such as the liver, so it is difficult to control the 
behavior of NPs after they penetrate the skin (Gopee et al., 2009). The antigen distribution and 
immune response locations cannot be reliably predefined when skin is used as a test site whereas 
using the inner pulp of the growing feather as a test site limits the immune response to a 
predefined area. That means multiple agents or antigens can be tested using one subject by 
injecting several feathers simultaneously because there is no interference between the test 
materials. 
 In terms of procedural advantages, feather collection does not require euthanization or 
sacrificing the animal. Even though skin biopsy is an option for tissue collection, animals can 
often be sacrificed for tissue harvesting (Mortensen et al., 2008). The skin also needs to be sliced 
to assess and analyze each layer whereas plucked feather tips are easy to remove and can be 
analyzed for lymphocyte infiltration using a variety of procedures, including histological 
analysis, immunohistochemistry, flow cytometry, and various other methods. Most importantly, 
there are currently no procedures that would allow researchers to analyze tissue samples from the 
same subject more than once when skin is used as a test site. That makes growing feathers the 
only test site that is both minimally invasive and allows researchers to repeatedly monitor the 
immune response in one animal. 
Findings and Gaps in the Current Literature 
 Cho et al. (2011) demonstrated that in vitro data cannot be used to reliably predict the 
effect of NPs on the immune system or their toxicity because NPs tend to behave differently 
when in vivo test systems are used. However, the selection of the animal model used is critical so 
that in vivo results are reliable. The advantages of the chicken model over other models (e.g., 
mouse, porcine) have been discussed. The majority of studies on chicken have been conducted 
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using the SL line as the primary purpose of those studies was to investigate autoimmune disease 
(Erf et al., 1995; Lockhart & Erf, 2004; Shrestaa et al., 1997; Stepicheva et al., 2010; Wang & 
Erf, 2004).  
 Most studies that investigated immune responses and NP interactions focused on the 
mouse model, so more studies are required to investigate the effects of NPs on avian immune 
systems and tissue. Specifically, those studies should focus on Leghorn lines because they are 
more resistant to disease compared to other breeds, and their specific immunity is more efficient 
compared to other breeds (Parmentier et al., 2004). These advantages of Leghorn breeds make 
LBL chicken an excellent model for investigating biological interactions and pro-inflammatory 
effects of NPs. The cell-mediated immune response in chickens can be monitored with various 
instruments. Flow cytometry proved to be a reliable and repeatable procedure for monitoring, 
regardless of their environmental background and line (Fair, Taylor-McCabe, Shou, & Marrone, 
2008). 
 The core and coating materials appear to be critical determinants of immune responses 
when NPs are used as adjuvants. Various types of NPs proved to be suitable vaccine adjuvants. 
Lipid-enveloped NPs with a polylactide-co-glycolide acid (PLGA) core can mimic the structural 
characteristics of pathogens to enhance a humoral immunity response (Moon et al., 2012). Using 
IONPs as an adjuvant results in higher immune response activities compared to mouse IgG and 
Alum adjuvant & mIgG (Alaamri et al., 2014). 
 It is important to note that the immune system responses can depend on various factors, 
including charge, size, and particle purity (Dobrovolskaia & McNeil, 2007; Müller et al., 2007). 
Current studies suggest that small particles (< 100 nm) are more efficient than larger particles for 
activating the cell-mediated immune system (Xiang et al., 2006). Surface modifications also 
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need to be documented because they influence T cell proliferation (Diwan et al., 2003). For 
example, protein antigens enhance the NPs ability to interact with DCs and activate antigen-
presentation to T cells (Pusic et al., 2011; Tavaré et al., 2011). 
 The selection of appropriate materials is also critical for reducing the toxic effects of NPs 
in vivo. Hussain, Vanoirbeek, & Hoet (2012) reported that some nanomaterials can induce a pro-
inflammatory response whereas other nanomaterials reduce the efficiency of the immune system. 
This is an important consideration for vaccinology because only materials that incude a pro-
inflammatory response can be used to improve vaccination efficiency. 
 IONPs are considered safe because no adverse events or abnormal tissue alterations were 
reported in mice or non-human primates (Pusic et al., 2013). AuNP toxicity leads to DNA 
fragmentation and alterations in gene expressions that regulate apoptosis, DNA damage 
recognition, and stress response (Vecchio et al., 2012). QDs are generally considered safe, but 
cadmium retention in the tissue upon QD degradation is a potential issue that needs to be 
addressed (Chen et al., 2013). Based on the currently available evidence, it appears that IONPs 
could be the safest material as they have not been associated with deposition of toxic materials or 
increased levels of reactive oxygen species (Shen, Liang, Wang, Liao, & Jan, 2011). The exact 
level of oxidative stress depends on the type of tissue and peaks after approximately 3 days, but 
no long-term abnormal tissue changes were reported (Jain et al., 2008). Nevertheless, further 
investigations of IONP interactions in vivo are warranted to ensure their degradation does not 
cause significant oxidative damage to tissue. 
 In addition to safety, IONPs used as adjuvants have high stability and elicit high immune 
responses. Pusic et al. (2013) reported that IONPs conjugated with merozoite surface protein 1, 
elicit high immune responses in non-human primates (100%) as well as parasite inhibitory 
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antibodies. However, the reported immune response in mice was not as high as the one observed 
in primates, and the existing activation of DCs was associated with a higher immune response. 
 Based on the current body of knowledge, future research in the area of NPs should focus 
on testing IONPs as vaccine platforms because they do not show significant toxic effects. The 
use of IONP-antigen adjuvants was found to stimulate higher humoral and cell-mediated 
responses compared to Alum-antigen (Alaamri et al., 2014; Yue et al., 2012). Because most 
studies used mice to investigate immune responses to NPs, more studies using the chicken model 
are required to obtain results that explain how immune responses to NPs change over time in a 
single animal. The chicken model proved to be a suitable model for testing NP bioactivities and 
toxicity in vivo, so those studies will create a foundation for establishing clinical implications of 
NPs as vaccine adjuvants. Given the similarities between the avian and the mammalian immune 
systems, future studies can use the chicken model as a minimally-invasive in vivo test system to 
explore all other medical applications of NPs as well. 
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CHAPTER 2—MATERIALS AND METHODS FOR FEATHER AND INTRAMUSCULAR 
INJECTION STUDIES 
 A total of seven studies were conducted. Three studies monitored the innate immune 
response (i.e., feather injection studies). Four studies monitored the in vivo cell-mediated 
immune response (i.e., intramuscular injection studies). Two intramuscular injection studies 
monitored the primary response, and two studies monitored the memory response. 
 The majority of materials and methods used in all studies were similar. All studies used 
the same chicken breed (LBL line) and treatment preparations. The chicken, IONPs, and 
materials used to make the preparations were obtained from the same manufacturers, and the 
tissue collection and analysis procedures were similar for all studies. Therefore, the general 
materials and methods used in all studies are discussed before the specific characteristics of each 
study are presented. 
Animals 
 The LBL line was used in this study. The University of Arkansas Experiment Station has 
been maintaining the LBL line since 1995. The animals are maintained as a closed population 
and frequently monitored for pathogens. The levels of biosecurity are high, and the chickens’ 
fertile eggs, blood samples, and tissue samples meet the import requirements of Canada and 
European countries. The procedures used involving animals (e.g., feather sampling) have been 
approved by the University of Arkansas Institutional Animal Care and Use Committee (IACUC; 
protocol exp. Date 11/03/2014). The letter of approval is included in Appendix A. 
 The sample was randomly selected at hatch from different nests with one male per 
family, and the chicks were banded with an identification tag. Marek’s disease vaccine (HVT) 
was not administered at hatch. The sample was raised in floor pens covered in wood shavings 
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where they had free access to food and water. The studies were conducted in a bio secured room 
at the Poultry Health Laboratory, University of Arkansas (Fayetteville, AR) where the birds 
reached 7 weeks of age. The birds were randomly divided into 4 groups with matching age-lines-
MHC101/101 (i.e., one bird from each nest per group). The number of birds in each group was 
determined based on previous experience in working with the LBL line model (Erf, personal 
communication) and the Power Analysis conducted using cell population data and quantitative 
real time reverse transcription polymerase chain reaction (RT-PCR) data (SYSTAT Power 
Analysis Program; Systat Software, Inc., Chicago, IL). Each group had to consist of minimum 4 
and maximum 7 birds. 
Nanoparticles 
 IONPs are approved for use in humans by the Federal Drug Administration (FDA). The 
IONPs for this study (10 nm Fe2O3 with carboxylic acid groups; IO catalog # SHP-10- 01) were 
obtained via Ocean NanoTech, LLC (Springdale, AR). 
Treatment Preparation 
 The preparation of treatment materials was conducted under sterile conditions in the 
poultry science building’s tissue culture room at the University of Arkansas (Fayetteville, AR). 
The treatments prepared for the birds included mIgG + IO, mIgG + Alu, mIgG, Sterile 
Dulbecco’s phosphate-buffered saline (1X ST PBS), and endotoxin-free PBS (EF PBS). 
 ST PBS was used for injection and dilution. 1 ml of 2X ST PBS was made to dilute mIgG 
by adding 10X ST PBS (100 μl) to 1X ST PBS (900μl). ST PBS was used in two feather 
injection studies (Study 2 and 3, Chapter 3) and two intramuscular injection studies (Study A, 
Chapter 4). 1X EF PBS was used in two intramuscular injection studies (Study 1 and 3, Chapter 
3) and two intramuscular injection studies (Study B, Chapter 4). 
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 The final concentration of IO-mIgG used for intramuscular injection was 1mg/ml (i.e., 
0.1 ml/dose). The stock concentration was 5mg/ml, and sterile Dulbecco’s phosphate-buffered 
saline (1X PBS) was added to the final concentration used in the treatment. The calculation for 
the final concentration was dependent on the number of sampling units used. The diluted mIgG 
was mixed using the pipet, and each 1mg/ml IO contained 2 mIgG per one nanoparticle (0.26 
mg/ml of mIgG). 
 The mIgG + Alu was prepared using 2% Alhydrogel, which was provided as a sterile 
aluminum hydroxide wet gel suspension (Cat. # vac-alu-50; InvivoGen, San Diego, CA 9212). 
Based on the manufacturer’s instructions, a 1:1 dilution has to be made (i.e., 400 µl Alhydrogel 
2% for 400 µl of Ag). The Alhydrogel was shaken before mixing it with mIgG (10 mg/ml). 
Pipetting up and down was used for 5 minutes so that the Alum can effectively absorb the mIgG. 
The final concentration used for intramuscular injections was 5mg/ml. 
 The mIgG was obtained as an antigen (Ag) from Rockland Antibody and Assays (Cat. # 
010-0102; Gilbertsville, PA 19525). The stock concentration was 25 mg/ml, and the dilution was 
performed based on the manufacturer’s instructions – 2.5 ml of sterile de-ionized water was 
added to 25 mg mIgG to obtain a concentration of 10mg/ml. 1X ST PBS was added to make the 
final concentration (5 mg/ml mIgG using 1:1 dilution). 10mg/ml of unused mIgG was divided 
into micro tubes (100 µl/aliquot) and placed in extended storage at -20 degrees. 80 μl of 10 
mg/ml mIgG was added to 80 μl 2X PBS and 640 μl 1X ST PBS so that the feather injections 
can be performed using 800 μl of 1 mg/ml mIgG. 
Immunization 
 Immunizations were conducted using sterile 3ml 25G  x 1 (0.5mm x 25mm) syringes, two 
syringes per treatment (BD, Franklin Lakes, NJ 0717). The syringes were filled with treatment 
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preparations at specific concentrations that were different for all studies. The syringes were 
inverted before each administration, and the immunization was performed in the health 
laboratory of the Poultry Science Department (Fayetteville, AR) in sterile conditions.  
 Regardless of the treatment, the intramuscular injection amount was 0.1 ml/chicken. The 
dose of mIgG was 20-fold higher for mIgG-Alum and mIgG compared to IO-mIgG. The 
treatments were administered using the breast muscles. Studies monitoring the primary response 
used the left breast muscle whereas studies monitoring the memory response used the left muscle 
for the first immunization and the right muscle for the second immunization. 
Feather Injections 
 The barbs emerging from the sheath were cut off with scissor before the birds were 
injected so that the epidermal cap would be left intact (see Figure 3). Sterile-disposable insulin 
syringes that are 8mm in length with 31G needles (BD, Franklin Lakes, NJ 07417) were used, one 
syringe per bird.  
 The syringes were filled in the culture room at poultry science department (Fayetteville, 
AR) under the hood in sterile conditions. The syringes were filled with the treatment 
preparations using the same amount of 240µl for each treatment, but the treatment concentrations 
varied depending on the study. The concentrations used for the feather injection studies are 
shown in Table 5 whereas the concentrations used for the intramuscular injection studies are 
shown in Table 6 (Overview of Studies section). A total of 20 feathers were injected (10 on each 
side of the breast). The feathers were selected on both sides of the breast to be in a row next to 
each other (see Figure 3). The injection amount was 10 µl for each feather. The syringes were 
inverted before each administration. The syringe was inserted into the center of the pulp and 10 
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µl was injected to deliver the mIgG into the lower half of the pulp (see Figure 3). This procedure 
did not affect the tissue barrier because the pulp is surrounded by the epidermis. 
 In Study A, the mIgG injected into the GF test site was at 5-fold lower concentration 
compared to the intramuscular injection of mIgG alone (control group) and mIgG-Alum. In 
Study B, the mIgG concentrations were matched for all treatments. The feather injection studies 
used a concentration of mIgG with IO that was more than 20-fold lower compared to mIgG alone 
and mIgG with Alum. 
  
Images show: a) injected feathers (10 on each side of the breast) were selected to be in a row 
next to each other for easier identification during collection, b) cutting the emerging barbs above 
the epidermal cap, and c) injecting feathers with 10 µl of treatment for each feather. 
 
Source: Erf (U.S. Patent No. 8,216,551, 2012) 
 
Figure 3. Preparation of growing feathers for injection. 
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Tissue Collection 
Growing Feathers Preparation and Collection 
 Injected feathers were plucked 3 weeks before the feather injection. On the days of each 
study, the feathers were collected just before the injection and 4-6 hours after the injection, 
followed by feather collection at 24 hour intervals after feather injection. The number of days 
used to collect feathers depended on the immune response studied. Three injected feather tips 
were plucked from each bird, and each of the three tips were placed in separate tubes. The 
formalin tube was used for feathers designated for conventional histology processing at the 
University of Arkansas Histology Service Laboratory. The optimum cutting temperature (OCT) 
medium cups were used for immunohistochemistry and RNA extraction. Finally, the 1 ml cold 
1X PBS tubes were used for feathers that were analyzed using flow cytometry. The tubes used 
for storage are shown in Figure 4.  
 Flow cytometry feathers were not trimmed, and the cold 1X PBS tubes were placed in 
ice. The procedure was conducted on the same day as the feather collection. The feathers for 
immunohistochemistry and RNA extraction were plucked and cut just above the epidermal cap. 
The feathers were stored in the bottom of aluminum cups containing Tissue-Tek® O.C.T freezing 
medium (SaKura Finetek Inc., Torrance, CA) and snap frozen with liquid nitrogen (see Figure 4) 
and stored at -80º C until used. The feathers stored in formalin were cut under the epidermal cap 
and placed in micro tubes filled with 1ml 10% buffered formalin to remain fixed. The tubes were 
stored at room temperature in biohazard place. 
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Figure 4. Feathers storage after collection at various times post-injection for ex vivo analysis. 
 
Images show: a) formalin tubes, b) OCT medium cups, c) 1 ml cold 1X PBS tubes, and d) snap 
freezing feathers in aluminum cups for storage. 
 
Source: Erf (U.S. Patent No. 8,216,551, 2012) 
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Blood 
 The blood (2.2 – 2.5 ml) was collected periodically from each bird in the treatment 
groups before and after immunization. The intervals and the duration of blood collection varied 
depending on the study. 1 ml of blood was stored into micro tubes, one for each chicken, and 
placed on ice to be used for plasma isolation. The remaining amount of blood was split into 2 
microtubes with 500 µl of blood in each. Those samples were used on the same day of collection 
for automated hematology analysis using the CELL-DYN (Abbott Diagnostics, Abbott Park, IL) 
7500 calibration for avian blood and blood smear. 
 The collected blood samples assigned for plasma isolation were placed in cold centrifuge 
at 4°C and centrifuged for 7 minutes at 750 x g so that the plasma layer could be distinctly 
identified above the blood cells. After the separation, the plasma was collected and placed into 
two separate micro tubes for each chicken. The micro tubes contained approximately 250 μL of 
plasma and were kept at -80°C. 
Organs  
 Organs were collected once the birds were euthanized after blood and feather collection. 
The organs (liver, kidney, lung, and muscles) were collected and placed on the bottom of 
aluminum cups with Tissue-Tek® O.C.T freezing medium (SaKura Finetek Inc., Torrance, CA). 
They were snap frozen and preserved at -80ºC. 
Procedures 
Cell Isolation 
 The collected GFs (1 feather per bird) were cut longitudinally. The pulp of the feathers 
was pulled out for an hour enzymatic digestion with collagenase/dispase (Life Technologies, 
Carlsbad, CA) at 37 C° (see Figure 5). The feathers were subsequently filtered using a 60µm 
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pore size nylon mesh (monofilament screening fabric; Tekto Inc., Elmsford, NY) so that the 
single cell suspensions can be obtained (see Figure 5). The cells were washed twice with cold 
PBS (VWR International, Radnor, PA) and PBS+ (BSA 1% [Sigma] and 0.1% NAN3), 
respectively in order to prevent non-specific antibody binding and marker internalization. The 
samples were centrifuged at 1200 rpm for 10 minutes at 4°C in centrifuge tubes with 
polypropylene (Cat. # 89004-368; VWR international, Radnor, PA). The pellets obtained were 
re-suspended in 500µl cold PBS+. 
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Figure 5. Cell isolation preparation. 
 
Images show: a) removal of the pulp from the sheath, b) 
filtering the feather pulp for single cell suspension. 
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Antibodies 
 Antibodies (mAb) were purchased from Sothern Biotechnology (Birmingham, AL), AbD 
Serotec (Raleigh, NC), and Sigma (St. Louis, MO). The antibodies used are listed in Table 1. 
The Dual-Tag from Sigma was used as an isotype control (IC). The IC is a mix of mouse IgG1 
conjugated with fluorescein isothiocyanate (FITC) and phycoerythrin (PE), and it was used to 
detect non-specific binding of fluorescent labeled antibodies, as well as decide the cut-off 
between fluorescence positive and florescence negative populations. 
 
Table 1. List of antibodies used with corresponding isotype, specificity, and dilution 
Antibodies Isotype Specificity Dilution 
Dual-Tag IC  no specifity to chicken molecules 1:100 
Mouse anti-chicken CT-8 Ig mouse IgG1k α chain 34kDa of chicken CD8 1:100 
TCR1 Ig mouse IgG1k γδTCR 1:100 
CT-4 Ig mouse IgG1k chicken CD4 (Mr 64 kDa) 1:200 
TCR2 Ig mouse IgG1k αβ1TCR/Vb1 1:100 
TCR3 Ig mouse IgG1 αβ2TCR/Vb2 1:100 
EP42 Ig mouse IgG2a chicken CD8β 1:100 
Cla Ig mouse IgMk chicken Ia 1:100 
LT40 Ig mouse IgMk chicken CD45 (Mr 190-215k Da) 1:200 
21-1A4 Ig mouse IgG1k chicken Bu-1 1:100 
AV6 Ig mouse IgG1k chicken CD44 1:200 
CT-3 Ig mouse IgG1k chicken CD3 1:200 
KUL01 Ig mouse IgG1k 
Monocyte/Macrophage early T- cell 
marker 1:100 
AV142 Ig mouse IgG1k chicken CD3 1:200 
Mouse anti-chicken MHC 
Class II* mouse IgG1 chicken MHC Class II 1:200 
M-1 Ig** mouse IgG2bk chicken IgM 1:100 
G-1 Ig** mouse IgG1k   chicken IgG 1:100 
* Antibody used for feather injection studies only 
** Antibodies used for 2014 studies only 
 
Direct Immunofluorescent Staining  
 Cells were stained with a panel of fluorescently labeled chicken leukocyte specific 
monoclonal antibodies using single, dual, and triple staining. The antibody dilutions and 
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conditions were provided by Sothern Biotechnology (Birmingham, AL) and AbD Serotec 
(Raleigh, NC). The antibodies used have been listed in Table 1. 
 50 µl of diluted mAb was added to 50µl of cells (approximately 2 x 106) in labeled 96-
well round-bottom microtiter plates. The contents were mixed gently and incubated in the dark at 
4°C for 30 minutes. The cells were then washed twice using cold PBS+ and centrifuged at 1200 
rpm for 5 minutes at 4°C. The final pellets were re-suspended using 250µl PBS+ and transferred 
into 5 ml sterile Falcon round bottom tubes manufactured by VWR International, after which 
they were analyzed using flow cytometry. 
Flow Cytometry 
 The FACScan with Consort 30 software package (Becton Dickinson 
Immunocytochemistry System, Mountain View, CA) was used for cell population analyses. The 
FL1 channel (530/30 nm band pass filter) and FL2 channel (585/42 nm band pass filter) were 
used to detect green fluorescence (from FITC) and orange fluorescence (from R-PE), 
respectively. Gating was used to exclude red cells, debris, and dead cells from the analyses. Cell 
acquisition and analysis was performed in list mode at 10,000 events per sample.  
 The antibody combinations used for flow cytometry were different in each study. Table 2 
shows the antibody combinations used in the feather injection studies whereas Table 3 and Table 
4 show the antibody combinations used in the intramuscular injection studies. 
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Table 2. Antibody combinations for feather injection studies 
Study/Combination FITC PE Red (SR) 
Feather injection Study 1 and 2    
A CD44 FITC Macro PE - 
B CD45 FITC CD8 PE - 
C Bu-1 FITC Ia PE - 
D CD8 FITC TCR1 PE - 
E TCR2 FITC TCR3 PE - 
F CD44 FITC CD4 PE - 
Feather injection Study 3    
A CD44 FITC Macro PE CD45 SR 
B CD4 FITC CD8 PE CD45 SR 
C Bu1 FITC Ia PE CD45 SR 
D TCR1 FITC CD8a PE CD45 SR 
E TCR2 FITC TCR3 PE CD45 SR 
F CD8b FITC CD8a PE CD3 SR 
G CD25 FITC CD4 PE CD3 SR 
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Table 3. Antibody combinations for Study A 
Study/Combination FITC PE Red (SR) IC used for control 
Primary response     
A CD45 FITC Macrophages PE - - 
B CD4 FITC CD8 PE - - 
C Bu-1 FITC Ia PE - - 
D CD8 FITC TCR1 PE - - 
E TCR2 FITC TCR3 PE - - 
F CD25 FITC CD4 PE - - 
G CD44 FITC CD4 PE - Yes 
Memory response     
A CD44 FITC Macro PE CD45 SR - 
B CD4 FITC CD8 PE CD45 SR - 
C Bu1 FITC Ia PE CD45 SR - 
D TCR1 FITC CD8a PE CD45 SR - 
E TCR2 FITC TCR3 PE CD45 SR - 
F CD8b FITC CD8a PE CD3 SR - 
G CD25 FITC CD4 PE CD3 SR - 
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Table 4. Antibody combinations for Study B 
Combinations FITC PE Red (SR) 
A MHCII FITC KUL01 PE CD45 SR 
B CD4 FITC TCR1 PE CD8 Red 
C CD4 FITC TCR2 PE CD8 Red 
D CD4 FITC TCR3 PE CD8 Red 
E Bu-1 FITC IgM CD44 Red 
F Bu-1 FITC IgG CD3 Red 
 
 The data were expressed in percentages for the following populations: live cells, 
lymphocytes, CD45, macrophages, CD4+, CD8+, TCR1+, TCR2+, TCR3+, CD25, MHC class 
II, and B cells. The percent of CD4+ cells was divided by the percent CD8+ cells for sampling 
unit to obtain the CD4:CD8 ratio. 
Statistical Analysis 
 Dependent variables. A total of 13 response factors were monitored to achieve the first 
research objective, which was to monitor and assess the local leukocytes infiltration into the pulp 
after the administration of IONPs. A total of (n) response factors were monitored to achieve the 
second research objective, which was to examine the immune response to IONP administration. 
Three gating regions were created around live pulp cells, lymphocytes, and heterophils. All types 
of lymphocyte cells were calculated as the percent total of the lymphocyte region. Each study 
monitored a different number of response factors, and the complete list of response factors by 
study is presented in Appendix B. 
 Independent variables. The analyses aimed to determine the differences in the 
percentage of pulp leukocyte populations depending on the type of treatment used, time of 
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sample collection, and their interaction. Those three variables were used as fixed effects in the 
analyses. 
 Statistical tests. The data were analyzed using SAS (SAS Inst., Inc.; Cary, NC) to 
conduct repeat measures procedures. The type III test of fixed effects was used to determine 
whether collection days, treatment, and their interaction had a significant effect on each response 
factor measured. Further analyses were not conducted for response factors that were not 
significantly affected by the fixed effects (p > 0.05). The differences of least square means were 
calculated for response factors that were significantly affected by day, treatment, or both 
variables. Response factors that showed a significant main effect of the interaction between 
treatment type and days were further analyzed using the test of simple main effects, which 
analyzes the mean differences in the response factor over time for each treatment and differences 
between treatment groups by day. It was determined that there were 4,753 possible pairs of 
means of treatment/day combinations, so mean separations were not performed. 
Overview of Studies 
 The general methods and materials are the same for all studies whereas the differences 
included sample size, treatments, treatment concentrations, and tissue collection protocols. The 
treatment amounts administered to the chickens were consistent in all studies. The feather 
injection amount was 10 µl/GF for 10 feathers on each side of the breast, and the injection 
amount in the intramuscular injection studies was 0.1 ml/chicken.  
 All studies followed the same feather collection protocol. The feathers were collected just 
before the injections and 0.25 days after the injections, followed by periodical collection every 
24 hours after the injection for 7 days. One feather injection study (12/02/2013) skipped feather 
collection on the third and fourth day. 
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 Table 5 shows the GF injection date, total number of chickens, treatments used, and 
treatment concentrations in each of the three feather injection studies. Blood was collected for 
plasma only just before the injections, 0.25 days after the injection, and 7 days after the injection. 
 
Table 5. Sample size, treatment, and treatment concentrations for feather injection studies 
Study GF Injection Date Sample Size Treatment Treatment concentration 
Study 1 08/09/2013 12 IO (n = 4) 0.2 mg/ml 
 IOEF (n = 4) 0.2 mg/ml 
 IO-mIgG (n = 4) 0.2 mg/ml 
Study 2 12/02/2013 16 Alum (n = 4) 15% 
 IO (n = 4) 0.2 mg/ml 
 IO-mIgG (n = 4) 0.2 mg/ml 
 Alum-mIgG (n = 4) 15%-0.5 mg/ml 
Study 3 06/27/2014 12 Alum-mIgG (n = 4) 15%-0.26 mg/ml 
 IO-mIgG (n = 4) 1 mg/ml 
 mIgG (n = 4) 0.26 mg/ml 
 
 
 Table 6 shows the total number of chickens, treatments used, and treatment 
concentrations for injections in each intramuscular injection study. The GFs were injected, at the 
height of immune response, with mIgG (recall Ag) 10 days after the first immunization in the 
intramuscular injection studies and 5 days after the second immunization in studies that 
monitored the memory immune response.  
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Table 6. Sample size, treatment, and treatment concentrations for intramuscular injection studies 
Response 
(Study) 
Intramuscular Injection 
Dates 
Sample 
Size 
Treatment 
Treatment 
Concentration 
Primary (A) 06/28/2013 – treatment 18 mIgG (n = 6) 5 mg/ml 
Alum-mIgG (n = 6) 15%-5 mg/ml 
IO-mIgG (n = 6) 1 mg/ml-0.26 mg/ml 
Memory (A) 10/18/2013 – first 
11/15/2013 – booster 
20 mIgG (n = 5) 5 mg/ml 
Alum-mIgG (n = 6) 15%-5 mg/ml 
IO-mIgG (n = 6) 1 mg/ml-0.26 mg/ml 
EF PBS (n = 3) 1X 
Primary (B) 05/17/2014 12 mIgG (n = 4) 0.26 mg/ml 
Alum-mIgG (n = 4) 15%-0.26 mg/ml 
IO-mIgG (n = 4) 1 mg/ml-0.26 mg/ml 
Memory (B) 05/15/2014 – first 
06/18/14 - booster 
16 mIgG (n = 4) 0.26 mg/ml 
Alum-mIgG (n = 4) 15%-5 mg/ml 
IO-mIgG (n = 4) 1 mg/ml-0.26 mg/ml 
EF PBS (n = 4) 1X 
 
 Blood was collected for plasma only, and the collection protocols were different for all 
intramuscular injection studies (see Table 7). Organs were collected only in Study A upon 
completing feather and blood collection for measuring the primary response (Wednesday, 
8/7/2013) and the memory response (Wednesday 11/27/2013). The birds were euthanized, and 
their organs (liver, kidney, lung, and muscles) were collected. 
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Table 7. Blood collection time points for intramuscular injection studies 
Time points (days) Primary A Memory A Primary B Memory B 
0 (before immunization) + + + + 
0.25 + + - - 
3 - - + + 
7 + + + + 
10 (before GF injection) + - + + 
14 + - + + 
21 - . + + 
28 + . + + 
0 (before 2nd immunization) - + - + 
3 - - - + 
5 (before GF injection) - + - + 
7 - + - + 
10 - - - + 
14 - - - + 
21 - - - + 
28 - - - + 
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CHAPTER 3—THE EFFECTS OF IONP GROWING FEATHER INJECTIONS ON 
LEUKOCYTE INFILTRATION 
Abstract 
The growing feather pulp in chickens is a minimally invasive in vivo test site that allows periodic 
monitoring of biological reactions to injected treatments in one subject. However, the majority of 
studies that observe iron oxide nanoparticle (IONP) interactions in vivo primarily use other 
animal models, such as the mouse and non-human primate models. The purpose of these three 
studies was to investigate the utility of growing feathers in light brown leghorn (LBL) chickens 
as a test site for the effects of IONPs on immune responses. In Study 1, a sample of 12 chickens 
was divided into three groups with 4 subjects in each group, and the following treatments were 
administered to each group: IO, IO-mIgG, and IOEF. The treatment concentration was 0.2 
mg/ml for all treatment preparations. In Study 2, a sample of 16 chickens was divided into four 
groups with 4 subjects in each group. The following treatment preparations were administed to 
each group: IO (0.2 mg/ml), IO-mIgG (0.2 mg/ml), Alum (15%), and Alum-mIgG (15%-0.5 
mg/ml). In Study 3, a sample of 12 chickens was divided into three groups with 4 subjects in 
each group. The following treatment preparations were administered to each group: IO-mIgG (1 
mg/ml), Alum-mIgG (15%-0.26 mg/ml), and mIgG (0.26 mg/ml). The feather injection amount 
was 10 µl/feather for 10 feathers on each side of the breast in all studies. The results of Study 1 
showed significantly higher immune responses to IO and IO-mIgG treatments compared to the 
responses observed for the IOEF treatment for the following response factors: lymphocytes, 
CD45+, CD4- CD8+, CD4+ CD8+, CD4+ CD8-,  T cell+ CD8-, 2 T cell+, 1 T cell+, and 
MHCII+ B cell+. The complete blood cell count analysis in Study 2 found heterophil 
concentration was significantly higher in the IO-mIgG group compared to the Alum-mIgG 
58 
 
 
 
group, p = 0.0188. In Study 3, the IO-mIgG treatment elicited a significantly higher heterophil 
response, p = 0.009, and MHCII+ macrophage response, p = 0.0027, compared to the Alum-
mIgG group. However, Alum-mIgG elicited significantly higher adaptive immune responses 
compared to IO-mIgG, including B cell+ IgM-,  T cells, and  T cells. These findings 
suggest that the chicken growing feather is a suitable in vivo test site because the immune cells 
infiltrated the feather pulp, making longitudinal and minimally invasive observations of immune 
responses in each individual subject possible. The IO-mIgG conjugate elicited a stronger innate 
response compared to the other treatments, but it did not elicit a strong adaptive immune 
response. The results suggested that the nanoparticles were taken up by the innate immune cells 
before they could elicit an adaptive immune response. It is not clear which cells took up the 
IONPs, but the organ tissue analysis is an ongoing study that will further clarify the interactions 
between the IONPs and the immune system. 
 Keywords: aluminum, growing feather, IONP, leukocyte infiltration, mIgG 
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Introduction 
 The current in vivo test systems for monitoring the effects of NPs on cellular, molecular, 
and physiological processes have significant limitations. The two most popular animal models 
include the non-human primate and the mouse model, with the mouse model being preferred 
because the animals are easier to obtain and require fewer resources to maintain the animals 
compared to non-human primates. However, the current strategy for investigating nanomaterials 
calls for the development of a minimally invasive animal model that does not require terminal 
procedures. The mouse model does not satisfy those criteria as the assessment of NP tissue 
activities are usually conducted using skin tests, which require invasive procedures (e.g., skin 
biopsy) or post-mortem collection of tissue.  
 Furthermore, using skin as a test site does not ensure accurate results because it is 
difficult to control the behavior of NPs because they can spread unpredictably across a wide area, 
as well as interact with organs (Gopee et al., 2009). Therefore, the location used to monitor 
responses to the administration of NPs cannot be reliably predetermined. The invasive nature of 
the procedures used to collect tissue also does not allow for monitoring tissue responses at 
multiple time points in one sample subject, so it is not possible to reliably determine how 
responses to NPs change over time. 
 These limitations of current models can be addressed by introducing the avian model as a 
minimally invasive in vivo test system for monitoring events associated with NP administration. 
The GF in birds has similar immunological properties as the skin because it has a low 
mononuclear presence and can recruit leukocytes from the circulation (Erf et al., 1995). Using 
the pulp of GFs in chickens as a test site restricts the responses to administered agents within a 
predefined location, and it is possible to inject multiple agents or a single agent into multiple 
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feathers. This allows testing multiple agents simultaneously and periodical response monitoring 
within an individual subject. 
 The purpose of the current feather injection studies was to monitor and assess local 
leukocytes infiltration into the pulp upon the administration of antigen-conjugated IONPs and 
IONPs using GF as a test site. In addition to IONP treatments, the other treatments used included 
antigen, antigen-conjugated Alum, and Alum. The treatments are exposed to the soluble and 
cellular components of the immune system in the pulp, which makes it possible to assess and 
evaluate their immunomodulatory activities. It was hypothesized that the nature and extent of 
leukocyte infiltration would depend on the treatment used. Specifically, it was expected that 
IONPs alone would display little or moderate inflammatory activity compared to antigen-
conjugated NPs and other treatment preparations. 
Results 
Blood Cell Responses 
 The fixed effect variables were the time of sample collection and treatment type. Time of 
collection was defined as a class with three levels in all studies and contained the following 
values: 0, 0.25, and 7 days. In Study 1, treatment type was defined as a class with three levels 
that contained the following values: IO, IOEF, and IO-mIgG. In Study 2, the treatment type was 
a class with four levels and contained the following values: Alum, Alum-mIgG, IO, and IO-
mIgG. The treatment values in Study 3 were as follows: Alum-mIgG, IO-mIgG, and mIgG. The 
concentration of mIgG in Study 1 and Study 2 was more than 20-fold lower in the IO-mIgG 
group compared to the other groups in which mIgG was used, whereas the mIgG concentrations 
were matched in Study 3 for all treatment groups. 
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 The results of the type III test of fixed effects are included in Appendix C. In Study 1, 
time of collection had a significant effect on heterophil concentration and percentage, 
lymphocyte concentration and percentage, and monocyte percentage, and thrombocyte 
percentage (p < 0.05). 
 In Study 2, significant changes by day were observed for total WBC concentration, 
heterophil concentration and percentage, lymphocyte percentage, monocyte concentration and 
percentage, basophil concentration and percentage, and RBC concentration. Treatment type had 
a significant effect on lymphocyte concentration, and the interaction between collection time and 
type of treatment was significant only for heterophil concentration (p < 0.05). 
 In Study 3, significant changes by day were observed for heterophil concentration and 
percentage, lymphocyte concentration and percentage, monocyte concentration and percentage, 
eosinophil percentage, basophil concentration, and thrombocyte concentration. Treatment type 
had a significant effect only on thrombocyte concentration (p < 0.05). 
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Table 8. Blood cell responses by day, Study 1 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
Heterophils (K/uL) 0 5.17 ± 0.35 a 
 0.25 8.84 ± 0.33 b 
 7 6.40 ± 0.28 c 
Heterophils (%) 0 18.66 ± 1.72 a 
 0.25 35.92 ± 1.17 b 
 7 29.47 ± 3.74 b 
Lymphocytes (K/uL) 0 20.05 ± 1.02 a 
 0.25 11.91 ± 0.54 b 
 7 15.28 ± 1.50 c 
Lymphocytes (%) 0 70.53 ± 1.61 a 
 0.25 46.13 ± 3.15 b 
 7 59.44 ± 4.17 c 
Monocytes (%) 0 5.66 ± 0.40 a 
 0.25 9.49 ± 0.91 b 
 7 5.62 ± 0.54 a 
Thrombocytes (K/uL) 0 21.51 ± 0.89 a 
 0.25 29.44 ± 1.27 b 
 7 23.97 ± 0.86 c 
Note: different letters (a-c) represent significant differences (p < 0.05) between days for each 
response factor. 
 
 The results of the analysis of least squares means differences for response factors with 
significant changes in Study 1 by day are shown in Table 8. Heterophil concentration and 
percentage increased significantly 0.25 days after the injections, and their estimates remained 
significantly elevated on day 7 compared to baseline estimates. The same pattern was observed 
for thrombocyte concentration, which increased significantly by day 0.25 and remained 
significantly higher than baseline estimates by day 7.  
 Monocyte concentration increased significantly by day 0.25, but monocytes were the 
only cells that did not remain significantly elevated on day 7 compared to estimates before the 
injections. Lymphocyte concentration reduced significantly by day 0.25 and remained reduced 
by day 7 compared to baseline estimates. The same was true for lymphocyte percentage, which 
reduced by day 0.25 and remained lower on day 7 compared to baseline. 
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Table 9. Blood cell responses by day, Study 2 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
WBCs (K/uL) 0 28.77 ± 1.17 a 
 0.25 33.19 ± 1.38 b 
 7 29.36 ± 2.16 ab 
Heterophils (%) 0 19.37 ± 1.12 a 
 0.25 30.98 ± 2.11 b 
 7 18.18 ± 1.38 a 
Lymphocytes (%) 0 67.11 ± 2.31 a 
 0.25 53.88 ± 3.38 b 
 7 61.88 ± 2.91 ab 
Monocytes (K/uL) 0 2.30 ± 0.39 a 
 0.25 3.54 ± 0.29 b 
 7 3.10 ± 0.41 ab 
Monocytes (%) 0 7.82 ± 1.60 a 
 0.25 10.73 ± 1.46 b 
 7 10.24 ± 1.65 ab 
Basophils (K/uL) 0 1.72 ± 0.14 a 
 0.25 1.52 ± 0.06 a 
 7 2.93 ± 0.28 b 
Basophils (%) 0 5.70 ± 0.55 a 
 0.25 4.39 ± 0.20 b 
 7 9.55 ± 1.11 c 
RBC (K/uL) 0 2.31 ± 0.05 a 
 0.25 2.22 ± 0.03 b 
 7 2.29 ± 0.04 a 
Note: different letters (a-c) represent significant differences (p < 0.05) between days for each 
response factor. 
 
 The results of the analysis of least squares means differences for response factors with 
significant changes by day in Study 2 are shown in Table 9. WBC concentration, heterophil 
percentage, monocyte concentration, and monocyte percentage increased significantly by day 
0.25, but returned to baseline estimates by day 7. Lymphocyte percentage significantly decreased 
by day 0.25 and returned to estimates similar to those observed at baseline on day 7. 
 Basophil concentration did not change significantly by day 0.25 compared to baseline, 
but it did increase significantly on day 7 compared to previous measures. Basophil percentage 
showed a significant decrease by day 0.25 compared to baseline measures, but the estimates on 
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day 7 were significantly higher compared to both previous measurements. RBC concentration 
decreased significantly by day 0.25, but it returned to baseline measures by day 7. 
 
Table 10. Blood cell responses by day, Study 3 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
Heterophils (K/uL) 0 8.19 ± 0.8602 a 
 0.25 12.81 ± 1.5286 b 
 7 6.83 ± 0.3912 a 
Heterophils (%) 0 26.34 ± 1.67 a 
 0.25 47.35 ± 3.46 b 
 7 26.08 ± 2.04 a 
Lymphocytes (K/uL) 0 18.38 ±  0.83 a 
 0.25 9.41 ±  0.97 b 
 7 17.15 ±  1.54 a 
Lymphocytes (%) 0 59.51 ± 1.51 a 
 0.25 35.21 ± 4.01 b 
 7 62.32 ± 2.39 a 
Monocytes (K/uL) 0 2.48 ±  0.16 a 
 0.25 3.06 ±  0.42 a 
 7 1.54 ±  0.13 b 
Monocytes (%) 0 8.07 ± 0.49 a 
 0.25 11.81 ± 1.71 a 
 7 5.87 ± 0.50 b 
Eosinophils (%) 0 0.06 ± 0.02 a 
 0.25 0.15 ± 0.03 b 
 7 0.16 ± 0.03 b 
Basophils (K/uL) 0 1.85 ± 0.10 a 
 0.25 1.44 ± 0.20 ab 
 7 1.47 ± 0.12 b 
Thrombocytes (K/uL) 0 31.05 ± 0.90 a 
 0.25 26.69 ± 1.32 b 
 7 27.68 ± 1.08 ab 
Note: different letters (a-b) represent significant differences (p < 0.05) between days for each 
response factor. 
 
 Table 10 shows the results of the difference of least squares means for blood cell 
responses in Study 3. Heterophil concentration and percentage increased significantly from 
baseline by day 0.25 and returned to values similar to those observed at baseline by day 7. The 
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same pattern of response was observed for lymphocyte concentration and lymphocyte 
percentage. 
 Monocyte concentration and percentage increased by day 0.25, but the increase was not 
significant compared to baseline estimates. After the slight initial increase, monocyte estimates 
reduced and were significantly lower on day 7 compared to baseline. Eosinophil percentage 
increased significantly by day 0.25, and it remained significantly elevated on day 7 compared to 
baseline. Basophil concentration slightly decreased by day 0.25, but the decrease was statistically 
significant only on day 7 compared to baseline. Thrombocyte concentration decreased 
significantly by day 0.25. Although the estimates on day 7 did not return to baseline estimates, 
the difference compared to baseline was no longer statistically significant. 
 Treatment type had a significant effect on lymphocyte concentration in Study 2, as well 
as on thrombocyte concentration in Study 3 (see Table 11). The lowest estimate of lymphocyte 
concentration in the 2013 study was observed in the IO treatment group, which showed a 
significantly lower lymphocyte concentration compared to the Alum group and the Alum-mIgG 
group, but not compared to the IO-mIgG group. In Study 3, thrombocyte concentration was 
significantly higher in the Alum-mIgG group compared to the IO-mIgG group, but not compared 
to the mIgG group.  
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Table 11. Lymphocyte and thrombocyte concentration by treatment group, Study 2 and Study 3 
Response Treatment Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
Lymphocytes (K/uL) Alum 23.84 ± 1.87 a 
(2013 IO vs. Alum) Alum-mIgG 22.54 ± 1.87 a 
 IO 16.20 ± 1.87 b 
 IO-mIgG 18.70 ± 1.87 ab 
Thrombocytes (K/uL) Alum-mIgG 31.00 ± 1.06 a 
(2014) IO-mIgG 26.76 ± 1.06 b 
 mIgG 27.66 ± 1.06 ab 
Note: different letters (a-b) represent significant differences (p < 0.05) between treatment groups 
for each response factor. 
 
Table 12. Treatment and day interaction effect estimates and main effects p-values of heterophil 
concentration, Study 2 
 Treatment  
Day 
Alum 
(K/uL ± SE,  
n = 4) 
Alum-mIgG 
(K/uL ± SE,  
n = 4) 
IO 
(K/uL ± SEM, 
n = 4) 
IO-mIgG 
(K/uL ± SEM, 
n = 4) 
Day main 
effect P-
value 
0 5.69 ± 0.53 5.75 ± 0.53 6.30 ± 0.53 5.47 ± 0.53 0.7240 
0.25 10.00 ± 0.91 9.03 ± 0.91 10.37 ± 0.91 12.53 ± 0.91 0.0986 
7 5.60 ± 0.76 5.86 ± 0.76 5.50 ± 0.76 5.91 ± 0.76 0.9759 
Treatment 
main effect 
P-value 
< 0.0001 0.0001 < 0.0001 < 0.0001 
 
 
 The interaction between treatment type and time of sample collection had a significant on 
heterophil concentration in Study 2 (see Table 12). The simple effects comparison of heterophil 
concentration by treatment showed that all types of treatment increased heterophil concentration 
significantly 0.25 days after the injection. Seven days after the injections, the observed heterophil 
concentration returned to similar levels as measured before the injections in all groups. The 
simple effects comparison by day showed that a significant difference was observed on day 0.25 
between the Alum-mIgG group and the IO-mIgG group (see Figure 6). 
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 Most blood cell response factors measured in all three studies were affected significantly 
by time of collection, but no significant differences were observed in the responses between 
treatment groups. Significant differences by treatment group were observed only for lymphocyte 
concentration in Study 2 and thrombocyte concentration in Study 3. Lymphocyte mean 
concentration was significantly higher in the Alum-mIgG and Alum groups compared to the IO 
group, but not compared to the IO-mIgG group. Thrombocyte mean concentration was 
significantly higher in the Alum-mIgG group compared to the IO-mIgG group. The interaction 
between treatment and time of collection was a significant fixed effect only for heterophil 
Figure 6. Heterophil concentration by day and treatment group, Study 2. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. 
Heterophil concentration increased by day 0.25 in all groups, but the increase was 
significantly higher in the IO-mIgG group compared to the Alum-mIgG group. Different 
lowercase letters (a-b) within one time point represent significant differences (p < 0.05) 
between treatment groups. Different uppercase letters (A-B) represent significant changes 
between days for each treatment group. 
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concentration in Study 2 (see Figure 6). Differences between the groups were observed on day 
0.25 as the IO-mIgG group elicited a higher heterophil response compared to the Alum-mIgG 
group. The difference of least squares means results and simple effect comparison results for 
significant responses are included in Appendix D. 
Pulp Cell Responses 
 Time of collection was defined as a class with eight levels in Study 1 and Study 3 (0, 
0.25, 1, 2, 3, 4, 5, and 7 days) and with six levels in Study 2 (0, 0.25, 1, 2, 5, and 7 days). Type 
of treatment was a class with three levels in Study 1 (IO, IOEF, and IO-mIgG) and in Study 3 
(Alum-mIgG, IO-mIgG, and mIgG). Study 2 defined type of treatment as a class with four levels 
(Alum, Alum-mIGg, IO, and IO-mIgG). The concentration of mIgG in Study 1 and Study 2 was 
more than 20-fold lower in the IO-mIgG group compared to the other groups in which mIgG was 
used, whereas the mIgG concentrations were matched in Study 3 for all treatment groups. The 
results of the type III test of fixed effects for innate immune response factors are presented in 
Appendix E. 
 Live cells. Live cells were significantly affected by the interaction between treatment and 
time of sample collection in Study 1, whereas no significant changes in live cells were observed 
in Study 3. Significant changes in live cell estimates by day were observed in the IO and IO-
mIgG groups, but not in the IOEF group (see Table 13).  
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Table 13. Treatment and day interaction effect estimates and main effects p-values of live cells, 
Study 1 
 Treatment  
Day IO (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
IOEF  
(࢞ഥ േ ࡿࡱ, n = 4) 
Day main effect 
P-value 
0 37.47 ± 1.79 28.63 ± 1.79 30.34 ± 2.00 0.0124 
0.25 35.90 ± 2.55 27.71 ± 2.55 28.21 ± 2.85 0.0833 
1 44.89 ± 2.21 40.83 ± 2.21 45.61 ± 2.48 0.3162 
2 38.94 ± 2.95 33.11 ± 2.95 38.51 ± 3.29 0.3430 
3 35.73 ± 2.31 35.93 ± 2.31 35.57 ± 2.59 0.9945 
4 32.90 ± 2.78 34.46 ± 2.78 29.28 ± 3.11 0.4769 
5 32.65 ± 1.55 35.53 ± 1.55 32.72 ± 1.74 0.3717 
7 32.82 ± 2.18 31.77 ± 2.18 28.62 ± 2.44 0.4459 
Treatment 
main effect 
P-value 
0.0027 0.0150 0.0730 
 
 
 
 The only significant difference between the treatment groups was observed just before 
the injections. The IO treatment group had a higher baseline of live cells compared to other 
groups, and no further differences were observed between the treatment groups by day (see 
Figure 7). 
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 All leukocytes. All fixed effects had a significant effect on CD45+ estimates in Study 2 
and Study 3, but only treatment type had a significant effect on those cells in Study 1. The 
CD45+ cells were significantly different by treatment group in Study 1, with the IOEF group 
showing the lowest response (see Table 14). The response in the IO group was significantly 
higher compared to the IOEF group, and the response in the IOEF group was significantly lower 
Figure 7. Live cells by day and treatment group, 2013 IO. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. Live pulp 
cells are measured by excluding dead and red cells. The only significant difference between 
treatment groups was observed prior to the injections as the IO group had an elevated live cell 
count compared to the other groups. Different lowercase letters (a-b) within one time point 
represent significant differences (p < 0.05) between treatment groups. A significant increase of 
live pulp cells occurred on day 1 and continued decreasing by day 7 in all treatment groups. 
Different uppercase letters (A-D) represent significant changes between days for each treatment 
group. 
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compared to the IO-mIgG group. There were no significant differences in CD45+ responses 
between the IO and the IO-mIgG group. 
 
Table 14. All leukocytes by treatment group, Study 1 
Response Treatment Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD45+ IO 17.58 ± 1.06 a 
 IOEF 12.43 ± 1.19 b 
 IO-mIgG 16.82 ± 1.06 a 
Note: Different letters (a-b) represent significant differences between treatment groups. 
 
 In Study 2, the interaction between treatment type and time of collection significantly 
affected CD45+ estimates. The interaction effect estimates showed that CD45+ varied 
significantly each day for all treatment groups, and the differences between the treatment groups 
were significant from day 1 until day 7 (see Table 15). The highest estimates were observed in 
the Alum-mIgG group, which showed a significantly higher CD45+ response compared to other 
groups between days 1 and 5. On day 7, only the Alum group had  significantly lower CD45+ 
estimates compared to the other groups (see Figure 8, top). 
 The test of interaction effect results for CD45+ estimates in Study 3 are shown in Table 
16. There were no significant differences between Alum-mIgG and IO-mIgG groups by day. 
Compared to the mIgG treatment, the Alum-mIgG treatment and the IO-mIgG treatment elicited 
a significantly higher CD45+ response on day 0.25. However, only the response in the Alum-
mIgG group was still significantly higher compared to the mIgG group on days 2 and 3 (see 
Figure 8, bottom). 
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Table 15. Treatment and day interaction effect estimates and main effects p-values of CD45+, 
Study 2 
 Treatment  
Day 
Alum 
(࢞ഥ	േ ࡿࡱ, 
n = 4) 
Alum-mIgG 
(࢞ഥ േ ࡿࡱ, 
n = 4) 
IO 
(࢞ഥ േ ࡿࡱ, 
n = 4) 
IO-mIgG 
(࢞ഥ	േ ࡿࡱ, 
n = 4) 
Day main 
effect P-
value 
0 9.41 ± 2.59 6.87 ± 2.59 8.62 ± 2.59 9.51 ± 2.59 0.8783 
0.25 39.50 ± 7.41 50.36 ± 7.41 31.03 ± 7.41 39.59 ± 7.41 0.3717 
1 35.26 ± 6.09 60.45 ± 6.09 25.31 ± 6.09 29.95 ± 6.09 0.0068 
2 27.24 ± 5.35 55.31 ± 5.35 16.63 ± 5.35 23.64 ± 5.35 0.0013 
5 34.47 ± 5.15 64.42 ± 5.15 45.41 ± 5.15 44.93 ± 5.15 0.0106 
7 19.06 ± 4.15 41.29 ± 4.15 34.51 ± 4.15 32.68 ± 4.15 0.0174 
Treatment 
main effect 
P-value 
0.0023 < 0.0001 0.0005 0.0006 
 
 
  
Table 16. Treatment and day interaction effect estimates and main effects p-values of CD45+, 
Study 3 
 Treatment  
Day Alum-mIgG (࢞ഥ	േࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) 
Day main effect 
P-value 
0 10.54 ± 1.74 11.36 ± 1.74 7.76 ± 1.74 0.3531 
0.25 37.76 ± 2.79 41.19 ± 2.79 16.02 ± 2.79 0.0003 
1 53.15 ± 8.68 37.42 ± 8.68 25.47 ± 8.68 0.1317 
2 50.24 ± 5.20 35.42 ± 5.20 21.19 ± 5.20 0.0109 
3 60.83 ± 7.24 43.15 ± 7.24 26.16 ± 7.24 0.0248 
4 40.46 ± 12.03 35.67 ± 12.03 31.39 ± 12.03 0.8695 
5 58.91 ± 9.49 39.77 ± 9.49 30.63 ± 9.49 0.1547 
7 31.85 ± 8.05 37.50 ± 8.05 16.97 ± 8.05 0.2652 
Treatment 
main effect 
P-value 
< 0.0001 < 0.0001 0.0218 
 
 
 
 
 
73 
 
 
 
 
 
 
Figure 8. All leukocytes by day and treatment group. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. Different 
lowercase letters (a-b) within one time point represent significant differences (p < 0.05) between 
treatment groups. Different uppercase letters (A-D) represent significant changes between days 
for each treatment group. 
  
Top: The highest increase of CD45+ estimates Study 2 was observed in the Alum-mIgG group. 
The response was significantly higher compared to other groups from day 1 until day 5. 
 
Bottom: The highest increase of CD45+ estimates in Study 3 was observed in the Alum-mIgG 
group. The response was significantly higher compared to the mIgG group, but not compared to 
the IO-mIgG group. 
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 Macrophages. Macrophages measured in Study 1 and Study 2 varied significantly only 
by day (see Table 17). In Study 1, the level of macrophages decreased significantly on day 2 
compared to baseline estimates. Macrophage continued to increase until day 5. The next 
significant decrease in macrophages occurred on day 5, and the values remained significantly 
elevated until day 7. All treatment groups showed similar trends in macrophage estimates by day. 
The macrophage response in Study 2 showed a significant increase by day 0.25. Although the 
response reduced over the 7 days of taking measurements, the macrophage levels were still 
significantly higher on day 7 compared to baseline measures.  
 
Table 17. Macrophage estimates by day, Study 1 and Study 2 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
Macrophages 0 1.87 ± 0.13 a 
(Study 1) 0.25 1.85 ± 0.18 ac 
 1 1.57 ± 0.14 ab 
 2 1.03 ± 0.23 bc 
 3 1.36 ± 0.12 bc 
 4 1.63 ± 0.45 ab 
 5 1.07 ± 0.20 b 
 7 1.22 ± 0.12 b 
Macrophages 0 1.31 ± 0.09 a 
(Study 2) 0.25 3.79 ± 0.39 b 
 1 3.01 ± 0.38 bc 
 2 1.94 ± 0.28 d 
 5 2.55 ± 0.15 c 
 7 2.02 ± 0.13 d 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
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 Heterophils. All fixed effects were associated with changes in heterophil estimates in 
Study 3, but changes in heterophil estimates in Study 2 were associated only with collection 
time. Heterophils increased increased in Study 2 significantly by day 0.25 compared to baseline 
estimates. As collection time increased, heterophil estimates consistently decreased, and their 
levels returned to those observed at baseline on day 5 (see Table 18). 
 
Table 18. Heterophil estimates by day, Study 2 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
Heterophils 0 0.3838 ± 0.05 a 
 0.25 15.5662 ± 1.94 b 
 1 7.6544 ± 1.32 c 
 2 1.8488 ± 0.42 d 
 5 0.6787 ± 0.13 a 
 7 0.4906 ± 0.12 a 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days. 
 
 In Study 3, the effect of the interaction between treatment type and collection time on 
heterophil estimates was significant. The treatment main effect was significant for the Alum-
mIgG and IO-mIgG groups (see Table 19). No significant changes by day were observed in the 
mIgG group. Differences between treatment groups were observed only on day 0.25 and day 1. 
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Table 19. Treatment and day interaction effect estimates and main effects p-values of 
heterophils, 2014 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 2.55 ± 0.63 2.33 ± 0.63 2.61 ± 0.63 0.9502 
0.25 7.97 ± 1.66 19.25 ± 1.66 4.80 ± 1.66 0.0004 
1 4.00 ± 1.83 15.34 ± 1.83 4.58 ± 1.83 0.0029 
2 1.47 ± 0.25 1.87 ± 0.25 1.69 ± 0.25 0.5398 
3 1.44 ± 0.38 1.98 ± 0.38 1.88 ± 0.38 0.5842 
4 1.85 ± 0.39 1.46 ± 0.39 1.21 ± 0.39 0.5190 
5 1.19 ± 0.30 2.12 ± 0.30 1.34 ± 0.30 0.1265 
7 2.12 ± 0.54 2.19 ± 0.54 2.12 ± 0.54 0.9957 
Treatment main 
effect P-value 0.0329 < 0.0001 0.2289 
 
 
 
 There were no significant differences in heterophil baseline estimates among the 
treatment groups, and by day 0.25, the IO-mIgG group elicited a significantly stronger response 
than the Alum-mIgG group and the mIgG group (see Figure 9). Heterophil levels on day 1 were 
still significantly higher than those observed in the Alum-mIgG group and the mIgG group. No 
significant differences in heterophils were observed between the treatment groups on subsequent 
collection times. 
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 Lymphocytes. Lymphocyte estimates varied significantly by day and treatment group in 
Study 1. Lymphocyte estimates in Study 1 increased significantly within 0.25 days after the 
injections (see Table 20). The estimates continued to increase until they peaked on day 2, after 
which they continued to decrease. On day 7, the lymphocyte estimates were no longer 
significantly different compared to baseline. The differences between treatment groups were 
significant as the IOEF group had a significantly lower lymphocyte response compared to the IO 
group and the IO-mIgG group. 
 
Figure 9. Heterophil estimates by day and treatment group, Study 3. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The highest 
response was observed in the IO-mIgG group. After day 2, estimates in all groups returned to 
values similar to those observed at baseline. Different lowercase letters (a-b) within one time 
point represent significant differences (p < 0.05) between treatment groups. Different uppercase 
letters (A-B) represent significant changes between days for each treatment group. 
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Table 20. Lymphocyte estimates by day and treatment group, Study 1 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
Lymphocytes Days   
 0 2.55 ± 0.16 a 
 0.25 4.65 ± 0.68 b 
 1 6.70 ± 0.84 bc 
 2 9.42 ± 1.14 cd 
 3 8.78 ± 1.25 cd 
 4 8.64 ± 0.93 d 
 5 7.90 ± 1.35 cd 
 7 2.90 ± 0.77 ab 
 Treatment   
 IO 8.13 ± 0.76 a 
 IO-mIgG 7.45 ± 0.76 a 
 IOEF 3.74 ± 0.85 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups 
 
 
 Major histocompatibility complex. In Study 1, the MHCII+ macrophage estimates were 
significantly affected by time of collection only (see Table 21). A significant decrease was 
observed on day 0.25 compared to baseline, followed by a significant decrease on day 1 
compared to day 0.25. No significant changes were observed after day 1, but the estimates were 
significantly higher on day 7 compared to baseline estimates. 
 For MHCII+ macrophages in Study 2, the effect of collection time was the only 
significant fixed effect (see Table 22). Total MHCII+ estimates increased significantly by day 1 
compared to baseline, after which they continued declining each day. Compared to baseline 
estimates, MHCII+ macrophage estimates were still significantly higher on day 5, but not on day 
7. 
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Table 21. MHCII+ macrophage estimates by day, Study 1 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
MHCII+  0 0.54 ± 0.07 a 
Macrophages+ 0.25 0.32 ± 0.04 b 
 1 0.72 ± 0.08 ac 
 2 0.52 ± 0.13 abc 
 3 0.74 ± 0.09 ac 
 4 0.66 ± 0.15 ac 
 5 0.71 ± 0.13 ac 
 7 0.79 ± 0.06 c 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days. 
 
Table 22. MHCII+ macrophage estimates by day, Study 2 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
MHCII+  0 0.6537 ± 0.03 a 
Macrophages+ 0.25 0.6950 ± 0.03 ac 
 1 1.4669 ± 0.18 b 
 2 0.9750 ± 0.12 d 
 5 0.9381 ± 0.12 cd 
 7 0.6325 ± 0.11 ad 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days. 
 
Table 23. MHCII+ macrophage estimates by day and treatment group, Study 3 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
MHCII+ Days   
Macrophages+ 0 2.29 ± 0.29 a 
 0.25 4.95 ± 0.31 b 
 1 4.70 ± 0.31 b 
 2 1.55 ± 0.19 ac 
 3 1.72 ± 0.24 ac 
 4 1.38 ± 0.20 c 
 5 1.75 ± 0.12 ac 
 7 2.37 ± 0.16 a 
 Treatment   
 Alum-mIgG 2.77 ± 0.14 a 
 IO-mIgG 3.02 ± 0.14 a 
 mIgG 1.99 ± 0.14 b 
Note: Different letters (a-c) represent significant differences (p < 0.05) between days and 
between treatment groups. 
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 In Study 3, the MHCII+ macrophage estimates were significantly affected by time of 
collection and treatment type, but not by their interaction (see Table 23). Estimates peaked on 
days 0.25 and 1, and the increase was significantly higher compared to the baseline measure. 
After day 1, the estimates decreased and were significantly lower compared to baseline values 
only on day 4. On day 7, MHCII+ macrophage estimates returned to values similar to those 
observed at baseline. 
 The MHCII+ B cell+ response was significant in Study 1 and Study 2 by day only, 
whereas no significant fixed effects for the MHCII+ B cell+ response were observed in Study 3. 
In Study 1, the estimates of MHCII+ B cell+ increased by day 0.25 compared to baseline and 
peaked on day 2 (see Table 24). The observed response was still significant on day 7 compared 
to baseline estimates. In Study 2, the estimates of the MHCII+ B cell+ response showed that a 
decreased by day 0.25, after which the estimates continued to increase (see Table 25). The 
estimates on day 2 were significantly higher compared to baseline estimates, and they peaked on 
day 5. The estimates on day 7 were still statistically significant compared to values observed at 
baseline. 
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Table 24. MHCII+ B cell+ estimates by day, Study 1 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
MHCII+ B cell+ 0 0.15 ± 0.04 a 
 0.25 0.42 ± 0.05 b 
 1 0.67 ± 0.08 c 
 2 1.09 ± 0.11 d 
 3 0.74 ± 0.06 c 
 4 0.77 ± 0.07 c 
 5 0.44 ± 0.17 abc 
 7 0.45 ± 0.10 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days. 
 
Table 25. MHCII+ B cell+ estimates by day, Study 2 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
MHCII+ B cell+ 0 0.18 ± 0.03 ac 
 0.25 0.14 ± 0.02 a 
 1 0.31 ± 0.07 cd 
 2 0.43 ± 0.04 d 
 5 0.85 ± 0.14 b 
 7 0.65 ± 0.07 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days. 
 
 T cells.CD4- CD8+ T cell estimates increased significantly by day 0.25 in Study 1, and 
the highest estimates were observed on days 2 and 4 (see Table 26). The estimates were still 
elevated on day 7 compared to baseline, but the difference was not statistically significant. The 
highest response was observed in the IO treatment group. The difference between the IO and the 
IO-mIgG group was not significant, but the elicited response in both groups was significantly 
higher compared to the response observed in the IOEF group. 
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Table 26. CD4- CD8+ estimates by day and treatment group, Study 1 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4- CD8+ Days   
 0 0.17 ± 0.03 a 
 0.25 0.57 ± 0.07 b 
 1 0.70 ± 0.12 bc 
 2 1.05 ± 0.16 cd 
 3 0.82 ± 0.12 bcd 
 4 1.06 ± 0.12 d 
 5 0.99 ± 0.20 bcd 
 7 0.33 ± 0.09 a 
 Treatment   
 IO 0.96 ± 0.11 a 
 IO-mIgG 0.81 ± 0.11 a 
 IOEF 0.37 ± 0.13 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 
 In Study 2, CD4- CD8+ T cell estimates increased significantly by day 0.25, and the 
highest value was observed on day 5. Despite the significant decrease from day 5 to day 7, the 
CD4- CD8+ T cell estimates were still significantly elevated on day 7 compared to baseline 
estimates (see Table 27). In Study 3, CD4- CD8+ T cell estimates increased by day 0.25, and 
continued increasing until they peaked on day 3 (see Table 28). Although the estimates were still 
elevated on day 7, they were no longer significantly higher compared to baseline. The highest 
response was observed in the Alum-mIgG group, and it was significantly higher compared to the 
other groups. 
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Table 27. CD4- CD8+ estimates by day, Study 2 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4- CD8+ 0 0.65 ± 0.11 a 
 0.25 1.21 ± 0.16 b 
 1 2.13 ± 0.37 cd 
 2 1.72 ± 0.20 c 
 5 2.51 ± 0.18 d 
 7 1.65 ± 0.19 bc 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days. 
 
Table 28. CD4- CD8+ estimates by day and treatment group, Study 3 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4- CD8+ Days   
 0 0.69 ± 0.07 a 
 0.25 1.28 ± 0.18 b 
 1 2.74 ± 0.42 c 
 2 3.50 ± 0.57 c 
 3 6.34 ± 0.87 d 
 4 4.95 ± 1.19 cd 
 5 4.34 ± 0.64 cd 
 7 1.42 ± 0.60 ab 
 Treatment   
 Alum-mIgG 4.62 ± 0.56 a 
 IO-mIgG 2.55 ± 0.57 b 
 mIgG 2.30 ± 0.59 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 CD4+ CD8+ cells changed significantly by day and treatment group in Study 1 (see 
Table 29). The estimates increased significantly by day 1 compared to baseline and peaked on 
day 2, after which they continued decreasing. No significant differences were observed after day 
5 compared to baseline. The response observed in the IO-mIgG group was significantly higher 
compared to the IOEF group.  In Study 2, significant changes in CD4+ CD8+ cells estimates 
were observed by day 0.25, and the estimates continued increasing until they peaked on day 5. 
On day 7, the CD4+ CD8+ estimates decreased significantly compared to day 5, but they were 
still significantly higher compared to baseline (see Table 30). 
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Table 29. CD4+ CD8+ estimates by day and treatment group, Study 1 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4+ CD8+ Days   
 0 0.13 ± 0.03 a 
 0.25 0.32 ± 0.10 abc 
 1 0.24 ± 0.04 b 
 2 0.40 ± 0.04 c 
 3 0.33 ± 0.03 bc 
 4 0.26 ± 0.04 b 
 5 0.16 ± 0.04 ab 
 7 0.11 ± 0.02 a 
 Treatment   
 IO 0.25 ± 0.02 ab 
 IO-mIgG 0.30 ± 0.02 a 
 IOEF 0.19 ± 0.03 b 
Note: Different letters (a-c) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
Table 30. CD4+ CD8+ estimates by day and treatment group, Study 2 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4+ CD8+ 0 0.14 ± 0.03 a 
 0.25 0.22 ± 0.04 b 
 1 0.39 ± 0.11 be 
 2 0.64 ± 0.16 c 
 5 1.01 ± 0.17 d 
 7 0.46 ± 0.07 e 
Note: Different letters (a-e) represent significant differences (p < 0.05) between days. 
 
 CD4+ CD8- cells varied significantly by day and treatment group in Study 1 (see Table 
31). A significant increase compared to baseline was observed by day 0.25. The values increased 
until day 2 and remained significantly elevated until day 5. A significant decrease was observed 
between day 5 and day 7. The estimates on day 7 were still higher compared to baseline, but the 
difference was not significant. The response was significantly higher in the IO and IO-mIgG 
groups compared to the IOEF group. 
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Table 31. CD4+ CD8- estimates by day and treatment group, Study 1 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4+ CD8- Days   
 0 0.82 ± 0.08 a 
 0.25 1.60 ± 0.13 b 
 1 2.23 ± 0.38 bd 
 2 3.61 ± 0.49 c 
 3 3.90 ± 0.60 c 
 4 3.91 ± 0.41 c 
 5 3.85 ± 0.82 cd 
 7 1.40 ± 0.42 ab 
 Treatment   
 IO 3.51 ± 0.40 a 
 IO-mIgG 3.12 ± 0.45 a 
 IOEF 1.36 ± 0.40 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 
 In Study 2, CD4+ CD8- cell estimates increased significantly by day 0.25, and they 
continued to increase until day 5 (see Table 32). A significant decrease was observed from day 5 
to day 7, but the values were still significantly higher on day 7 compared to baseline estimates. 
The highest response was observed in the IO group, but the response was not significantly higher 
compared to the Alum-mIgG and IO groups. The weakest response was observed in the Alum 
group, and it was significantly lower compared to the other groups. In Study 3, CD4+ CD8- cells 
increased significantly on day 2, and the highest estimate was observed on day 3, after which the 
values continued to decline. The estimates on day 7 were no longer significantly higher 
compared to initial estimates (see Table 33). 
 
 
 
 
86 
 
 
 
Table 32. CD4+ CD8- estimates by day and treatment group, Study 2 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4+ CD8- Days   
 0 1.71 ± 0.42 a 
 0.25 3.27 ± 0.47 b 
 1 5.04 ± 0.64 c 
 2 5.44 ± 0.68 ce 
 5 11.99 ± 0.89 d 
 7 6.98 ± 0.51 e 
 Treatment   
 Alum 3.72 ± 0.47 a 
 Alum-mIgG 6.59 ± 0.47 b 
 IO 7.04 ± 0.47 b 
 IO-mIgG 5.61 ± 0.47 b 
Note: Different letters (a-e) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
Table 33. CD4+ CD8- estimates by day, Study 3 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4+ CD8- 0.25 3.90 ± 0.39 a 
 1 5.75 ± 1.04 a 
 2 8.69 ± 1.10 b 
 3 15.74 ± 2.33 c 
 4 10.85 ± 2.35 bc 
 5 11.59 ± 1.63 bc 
 7 5.58 ± 1.05 a 
Note: Different letters (a-c) represent significant differences (p < 0.05) between days. 
 
 The CD3+ response factor was observed only in Study 3, and the effect of the interaction 
between treatment and time of collection. Estimates changed significantly by day in all three 
groups, and differences between the groups were observed from day 0.25 until day 3 (see Table 
34). The highest response was observed in the Alum-mIgG group, but the treatment main effect 
was significant for all groups. Significant differences between the groups were observed between 
days 0.25 and 3 as the Alum-mIgG group elicited a stronger response compared to the other 
groups (see Figure 10). 
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Table 34. Treatment and day interaction effect estimates and main effects p-values of CD3+, 
Study 3 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 2.83 ± 1.00 4.83 ± 1.00 2.70 ± 1.00 0.2892 
0.25 16.29 ± 1.12 6.31 ± 1.12 5.68 ± 1.12 0.0001 
1 27.23 ± 5.12 7.95 ± 5.12 12.53 ± 5.12 0.0613 
2 30.88 ± 3.14 16.54 ± 3.14 12.67 ± 3.14 0.0063 
3 37.91 ± 4.24 23.95 ± 4.24 15.89 ± 4.24 0.0153 
4 22.67 ± 6.60 17.49 ± 6.60 15.24 ± 6.60 0.7247 
5 24.52 ± 4.63 14.91 ± 4.63 15.95 ± 4.63 0.3358 
7 8.13 ± 3.41 16.67 ± 3.94 6.76 ± 3.41 0.1934 
Treatment main 
effect P-value < 0.0001 0.0012 0.0128 
 
 
 
 
Figure 10. CD3+ estimates by day and treatment group, Study 3. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The 
highest response was observed in the Alum-mIgG group, and it was significantly higher 
compared to other groups No significant differences were observed between the IO-mIgG and 
mIgG treatments. Different lowercase letters (a-b) within one time point represent significant 
differences (p < 0.05) between the treatment groups. Different uppercase letters (A-C) 
represent significant changes between days for each treatment group. 
88 
 
 
 
 The CD4/CD8 ratio was measured in all studies, and the effect of sample collection time 
was significant in all studies, but the interaction between time of collection and treatment type 
was significant only in Study 3. In Study 1, the CD4/CD8 ratio decreased significantly by day 
0.25, but the difference was no longer significant on day 2, after which the ratio reduced 
significantly compared to baseline once on day 5 (see Table 35). In Study 2, a significant 
increase of the CD4/CD8 ratio compared to baseline was observed on day 2, and the ratio 
remained significantly higher compared to baseline on day 7 (see Table 35). 
 
Table 35. CD4/CD8 ratio estimates by day, Study 1 and Study 2 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4/CD8 ratio 0 6.35 ± 1.31 a 
(Study 1) 0.25 3.10 ± 0.28 b 
 1 3.27 ± 0.21 b 
 2 3.69 ± 0.39 ab 
 3 4.87 ± 0.29 a 
 4 4.26 ± 0.43 ab 
 5 3.69 ± 0.42 bc 
 7 4.43 ± 0.31 ac 
CD4/CD8 ratio 0 2.41 ± 0.24 a 
(Study 2) 0.25 2.77 ± 0.26 a 
 1 2.66 ± 0.26 ab 
 2 3.44 ± 0.31 b 
 5 5.02 ± 0.42 c 
 7 4.45 ± 0.47 c 
Note: Different letters (a-c) represent significant differences (p < 0.05) between days for each 
response factor. 
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 In Study 3, significant changes in the CD4/CD8 ratio by day were observed in the Alum-
mIgG group and the IO-mIgG group, but not in the mIgG group (see Table 36). The ratio 
increased non-significantly in the mIgG group. In the Alum-mIgG group, the ratio decreased 
significantly by day 1 and remained significantly lower compared to day 0.25 on day 7. The ratio 
also decreased significantly in the IO-mIgG group, but it increased on days 5 and 7, on which it 
was no longer significantly lower compared to day 0.25. The ratio was significantly higher in the 
IO-mIgG group compared to the Alum-mIgG group on days 0.25, 5, and 7 (see Figure 11). 
 
Table 36. Treatment and day interaction effect estimates and main effects p-values of CD4/CD8 
ratio, Study 3 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0.25 3.39 ± 0.54 4.49 ± 0.54 2.11 ± 0.54 0.0372 
1 2.01 ± 0.43 2.15 ± 0.43 2.26 ± 0.43 0.9225 
2 2.57 ± 0.52 3.11 ± 0.52 2.91 ± 0.52 0.7664 
3 2.33 ± 0.47 2.84 ± 0.47 3.25 ± 0.47 0.4225 
4 1.92 ± 0.33 1.94 ± 0.33 2.96 ± 0.33 0.0806 
5 2.08 ± 0.29 3.59 ± 0.29 2.79 ± 0.29 0.0164 
7 2.01 ± 0.60 3.72 ± 0.60 2.37 ± 0.60 0.1570 
Treatment main 
effect P-value 0.0200 0.0044 0.5944 
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 T cell receptors. Time of collection had a significant effect on theT cell+ CD8+ 
response in Study 2, whereas the interaction between collection time and treatment type was 
significant in Study 1. In Study 2, the increase inT cell+ CD8+ estimates was significant by 
day 0.25, and the estimates continued increasing until day 5 (see Table 37). On day 7, the 
estimates were still significantly higher compared to baseline estimates. 
 
 
Figure 11. CD4/CD8 ratio by day and treatment group, Study 3. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The 
CD4/CD8 ration was significantly higher in the IO-mIgG group compared to the Alum-mIgG 
group on days 0.25, 5, and 7. Different lowercase letters (a-b) within one time point represent 
significant differences (p < 0.05) between the treatment groups. Different uppercase letters (A-
C) represent significant changes between days for each treatment group. 
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Table 37.   cell+ CD8+ estimates by day, Study 2 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
T cell+ CD8+ 0 0.17 ± 0.03 a 
 0.25 0.37 ± 0.05 bc 
 1 0.56 ± 0.08 c 
 2 0.58 ± 0.17 bd 
 5 0.66 ± 0.05 d 
 7 0.41 ± 0.05 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
Table 38. Treatment and day interaction effect estimates and main effects p-values of  T cell+ 
CD8+, Study 1 
 Treatment  
Day IO (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
IOEF 
(࢞ഥ േ ࡿࡱ, n = 4) 
Day main effect 
P-value 
0 0.20 ± 0.09 0.26 ± 0.09 0.13 ± 0.10 0.6158 
0.25 1.88 ± 0.78 1.17 ± 0.78 1.83 ± 0.87 0.7838 
1 1.18 ± 0.40 1.34 ± 0.40 0.67 ± 0.44 0.5269 
2 1.52 ± 0.34 1.66 ± 0.34 0.59 ± 0.38 0.1202 
3 1.45 ± 0.27 0.99 ± 0.27 0.54 ± 0.30 0.1184 
4 1.11 ± 0.20 1.31 ± 0.20 0.27 ± 0.22 0.0132 
5 1.48 ± 0.26 0.62 ± 0.26 0.23 ± 0.29 0.0215 
7 0.77 ± 0.20 0.22 ± 0.20 0.26 ± 0.22 0.1330 
Treatment main 
effect P-value 0.0089 0.0749 0.2241 
 
 
 
 T cell+ CD8+ in Study 1 did not change significantly by day in the IO-mIgG group 
and the IOEF group (see Table 38). The differences between the groups were observed only on 
days 4 and 5. The response was significantly higher in the IO and IO-mIgG group compared to 
the IOEF group on day 4, but only the IO group had significantly higher estimates on day 5 
compared to the other groups (see Figure 12). 
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 The treatment main effect for the T cell+ CD8+ response factor in Study 3 was 
significant for all groups (see Table 39). Significant differences between the groups were 
observed only on day 0.25 as Alum-mIgG elicited a higher response compared to other 
treatments. However, no further differences between the groups were observed as the response in 
other groups started increasing significantly after day 1 (see Figure 13). 
  
 
 
Figure 12.  T cell+ CD8+ estimates by day and treatment group, Study 1. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The 
initial response was similar in all groups. The longest duration of the response was observed 
in the IO group. Different lowercase letters (a-b) within one time point represent significant 
differences (p < 0.05) between the treatment groups. Different uppercase letters (A-C) 
represent significant changes between days for each treatment group. 
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Table 39. Treatment and day interaction effect estimates and main effects p-values of  T cell+ 
CD8+, Study 3 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.28 ± 0.08 0.36 ± 0.08 0.26 ± 0.08 0.6990 
0.25 0.81 ± 0.10 0.29 ± 0.10 0.48 ± 0.10 0.0172 
1 1.43 ± 0.25 0.67 ± 0.25 0.96 ± 0.25 0.1384 
2 1.01 ± 0.21 0.82 ± 0.21 0.91 ± 0.21 0.8123 
3 1.33 ± 0.20 0.81 ± 0.20 0.74 ± 0.20 0.1172 
4 0.72 ± 0.28 0.96 ± 0.28 1.00 ± 0.28 0.7558 
5 0.76 ± 0.19 0.82 ± 0.19 1.02 ± 0.19 0.6032 
7 0.45 ± 0.22 0.92 ± 0.24 0.66 ± 0.22 0.4052 
Treatment main 
effect P-value < 0.0001 0.0402 0.0104 
 
 
 
 
 
Figure 13.  T cell+ CD8+ estimates by day and treatment group, Study 3. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The highest 
response was observed in the Alum-mIgG group, and it was significantly higher compared to 
other groups, but only on day 0.25. No significant differences between the groups were observed 
from days 1 to 7. Different lowercase letters (a-b) within one time point represent significant 
differences (p < 0.05) between the treatment groups. Different uppercase letters (A-D) represent 
significant changes between days for each treatment group
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 The T cell+ CD8- response factors were significantly affected by day and treatment 
type in Study 1, whereas a significant effect of the interaction between time of collection and 
treatment was observed for those cells in Study 2. In Study 1, a significant increase in T cell+ 
CD8- estimates was observed on day 2 compared to baseline (see Table 40). However, the 
estimates returned to values similar to those observed at baseline by day 3 and remained 
consistent until day 7. The strongest response was observed in the IO-mIgG group, and it was 
significantly higher compared to the IOEF group, but not compared to the IO group. 
 
Table 40.  T cell+ CD8- estimates by day and treatment group, Study 1 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
T cell+ CD8- Days   
 0 0.20 ± 0.07 acd 
 0.25 0.34 ± 0.04 a 
 1 0.46 ± 0.09 ab 
 2 0.52 ± 0.05 b 
 3 0.33 ± 0.05 a 
 4 0.39 ± 0.05 ab 
 5 0.22 ± 0.04 c 
 7 0.14 ± 0.02 d 
 Treatment   
 IO 0.36 ± 0.05 ab 
 IOEF 0.21 ± 0.05 a 
 IO-mIgG 0.41 ± 0.05 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 
 In Study 2, T cell+ CD8- estimates did not change significantly by day in the IO-mIgG 
group, but they did change significantly in other groups (see Table 41). The differences between 
groups were observed from day 0.25 until day 2. Estimates in the Alum-mIgG group were 
significantly higher compared to other groups during that period, but the estimates in the Alum 
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group were also significantly higher on day 2 compared to the IO and IO-mIgG groups (see 
Figure 14). 
 The treatment main effect for T cell+ CD8- in Study 3 was significant only for the 
Alum-mIgG group, and differences between groups were observed on days 0.25, 1, and 3 (see 
Table 42). The highest response was observed in the Alum-mIgG group, and it was significantly 
higher compared to the IO-mIgG and mIgG groups (see Figure 15). After day 3, the response in 
the Alum-mIgG group decreased and no further differences between the groups were observed. 
 The analysis ofT cell+ estimates in Study 3 found that the main effect of treatment 
was significant only for the Alum-mIgG group, and the differences between the groups were 
observed on days 0.25, 1, and 3 (see Table 43). The Alum-mIgG showed a significantly higher 
response compared to other groups, but no significant differences were observed between the IO-
mIgG and mIgG groups (see Figure 16). 
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Table 41. Treatment and day interaction effect estimates and main effects p-values of  T cell+ 
CD8-, Study 2 
 Treatment  
Day Alum (࢞ഥ	േ ࡿࡱ, n = 4) 
Alum-mIgG 
(࢞ഥ	േ ࡿࡱ, n = 4) 
IO 
(࢞ഥ േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ	േ
ࡿࡱ, n = 4) 
Day main 
effect P-value 
0 1.11 ± 0.42 0.52 ± 0.42 0.62 ± 0.42 1.32 ± 0.42 0.5005 
0.25 4.78 ± 1.59 13.47 ± 1.59 1.69 ± 1.59 2.05 ± 1.59 0.0007 
1 5.35 ± 1.51 15.48 ± 1.51 2.89 ± 1.51 2.71 ± 1.51 0.0002 
2 7.96 ± 2.47 14.69 ± 2.47 1.85 ± 2.47 2.07 ± 2.47 0.0095 
5 6.37 ± 1.91 4.59 ± 1.91 3.20 ± 1.91 2.74 ± 1.91 0.5525 
7 2.73 ± 0.91 3.40 ± 0.91 1.52 ± 0.91 2.27 ± 0.91 0.5418 
Treatment 
main effect 
P-value 
0.0170 < 0.0001 0.0126 0.0583 
 
 
 
 
 
Figure 14.  T cell+ CD8- estimates by day and treatment group, Study 2. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The 
highest response was observed in the Alum-mIgG group, followed by the Alum group. 
Different lowercase letters (a-c) within one time point represent significant differences (p < 
0.05) between the treatment groups. Different uppercase letters (A-C) represent significant 
changes between days for each treatment group. 
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Table 42. Treatment and day interaction effect estimates and main effects p-values of  T cell+ 
CD8-, Study 3 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.94 ± 0.41 1.73 ± 0.41 0.93 ± 0.41 0.3271 
0.25 8.03 ± 0.92 1.98 ± 0.92 2.81 ± 0.92 0.0024 
1 15.89 ± 3.22 2.99 ± 3.22 3.23 ± 3.22 0.0309 
2 8.18 ± 2.20 5.27 ± 2.20 3.42 ± 2.20 0.3490 
3 8.64 ± 0.93 4.67 ± 0.93 3.44 ± 0.93 0.0081 
4 3.78 ± 0.99 4.01 ± 0.99 3.16 ± 0.99 0.8254 
5 3.67 ± 0.55 2.83 ± 0.55 3.09 ± 0.55 0.5625 
7 2.32 ± 0.91 4.12 ± 1.05 1.77 ± 0.91 0.2766 
Treatment main 
effect P-value < 0.0001 0.1044 0.1004 
 
 
 
 
Figure 15.  T cell+ CD8- estimates by day and treatment group, Study 3. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The 
response in the Alum-mIgG group was significantly higher compared to the other groups on 
days 0.25 and 1. Different lowercase letters (a-b) within one time point represent significant 
differences (p < 0.05) between the treatment groups. Different uppercase letters (A-D) 
represent significant changes between days for each treatment group. 
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Table 43. Treatment and day interaction effect estimates and main effects p-values of  T cell+, 
Study 3 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 1.96 ± 0.53 2.77 ± 0.53 1.82 ± 0.53 0.4315 
0.25 10.08 ± 1.00 3.05 ± 1.00 3.93 ± 1.00 0.0015 
1 19.10 ± 3.34 4.87 ± 3.34 4.74 ± 3.34 0.0211 
2 9.87 ± 2.41 6.83 ± 2.41 5.03 ± 2.41 0.3955 
3 10.52 ± 0.92 6.00 ± 0.92 4.65 ± 0.92 0.0036 
4 4.71 ± 1.27 5.38 ± 1.27 4.48 ± 1.27 0.8747 
5 4.75 ± 0.55 4.30 ± 0.55 4.52 ± 0.55 0.8476 
7 3.47 ± 1.09 6.16 ± 1.25 2.93 ± 1.09 0.1858 
Treatment main 
effect P-value < 0.0001 0.0839 0.0887 
 
 
 
 
Figure 16.  T cell+ estimates by day and treatment group, Study 3. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The response 
in the Alum-mIgG group was significantly higher compared to other groups on days 0.25 and 1. 
Different lowercase letters (a-b) within one time point represent significant differences (p < 0.05) 
between the treatment groups. Different uppercase letters (A-D) represent significant changes 
between days for each treatment group. 
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 The 1 T cell+ estimates increased significantly by day 0.25 in Study 1, and they 
continued to increase by day 5 (see Table 44). On day 7, the estimates were still elevated 
compared to baseline estimates, but the difference was not statistically significant. The response 
in the IOEF group was significantly lower compared to the IO and the IO-mIgG groups. 
 
Table 44.  T cell+ estimates by day and treatment group, Study 1 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
T cell+ Days   
 0 0.33 ± 0.06 a 
 0.25 0.89 ± 0.11 b 
 1 1.33 ± 0.35 c 
 2 2.25 ± 0.48 cd 
 3 2.54 ± 0.56 cd 
 4 2.64 ± 0.37 d 
 5 3.08 ± 0.76 cd 
 7 0.76 ± 0.22 ab 
 Treatment   
 IO 2.44 ± 0.34 a 
 IOEF 0.54 ± 0.38 b 
 IO-mIgG 2.21 ± 0.34 a 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 
 The 1 T cell+ estimates in Study 2 increased significantly by day 0.25 and continued 
increasing until day 5 (see Table 45). By day 7, the estimates decreased significantly compared 
to day 5, but they were still significantly elevated compared to baseline estimates. The highest 
response was observed in the IO group, but the response was not significantly higher compared 
to the IO-mIgG and Alum-mIgG groups. The lowest response was observed in the Alum group, 
and it was significantly lower compared to the other three groups. 
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Table 45.  T cell+ estimates by day and treatment group, Study 2 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
T cell+ Days   
 0 1.32 ± 0.34 a 
 0.25 2.87 ± 0.39 b 
 1 4.75 ± 0.71 c 
 2 4.89 ± 0.70 c 
 5 10.37 ± 0.79 d 
 7 5.83 ± 0.45 c 
 Treatment   
 Alum 3.01 ± 0.50 a 
 Alum-mIgG 5.60 ± 0.50 b 
 IO 6.35 ± 0.50 b 
 IO-mIgG 5.06 ± 0.50 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 The T cell+ CD4+ CD8+ estimates in Study 3 increased significantly by day 0.25 
from baseline and continued increasing until day 3 (see Table 46). The estimates reduced on days 
4, 5, and 7 compared to day 3, but the decrease was not statistically significant, so they remained 
elevated compared to estimates observed at baseline. The T cell+ CD4- CD8- response 
factor decreased significantly by day 0.25 and returned to baseline on day 1 (see Table 42). 
However, the estimates reduced significantly again on day 2 and remained significantly lower 
compared to baseline until day 5. On day 7, the estimates were still lower compared to baseline, 
but the difference was not statistically significant. 
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Table 46.  T cell+ CD4+ CD8+ and  T cell+ CD4- CD8- estimates by day, Study 3 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
1 T cell+ Days   
CD4+ CD8+ 0 0.10 ± 0.03 a 
 0.25 0.20 ± 0.03 b 
 1 0.26 ± 0.12 ab 
 2 0.39 ± 0.11 bd 
 3 1.10 ± 0.30 c 
 4 0.84 ± 0.27 cd 
 5 0.96 ± 0.20 c 
 7 0.99 ± 0.20 c 
1 T cell+ Days   
CD4- CD8- 0 2.19 ± 0.20 a 
 0.25 0.84 ± 0.12 b 
 1 2.46 ± 0.30 a 
 2 0.93 ± 0.09 b 
 3 0.90 ± 0.14 b 
 4 0.48 ± 0.08 c 
 5 0.83 ± 0.12 bc 
 7 1.46 ± 0.41 ab 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days. 
 
 The effects of collection time and type of treatment, but not their interaction, were 
significant only for the T cell+ CD4+ CD8- response factor in Study 3 (see Table 47). The 
estimates increased significantly by day 0.25 and continued increasing until day 3. The estimates 
remained consistent between days 3 and 5, after which they reduced significantly on day 7. 
However, they were still significantly higher compared to baseline estimates. The highest 
response was observed in the Alum-mIgG group, which was significantly higher compared to the 
mIgG group, but not compared to the IO-mIgG group. 
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Table 47.  T cell+ CD4+ CD8- estimates by day and treatment group, Study 3 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
1 T cell+ Days   
CD4+ CD8- 0 1.22 ± 0.27 a 
 0.25 3.17 ± 0.36 b 
 1 4.92 ± 0.88 b 
 2 7.47 ± 0.74 c 
 3 11.15 ± 1.04 d 
 4 8.35 ± 1.75 cde 
 5 9.21 ± 1.32 cd 
 7 4.52 ± 0.82 be 
 Treatment   
 Alum-mIgG 7.86 ± 0.62 a 
 IO-mIgG 6.14 ± 0.62 ab 
 mIgG 4.74 ± 0.62 b 
Note: Different letters (a-e) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 For the T cell+ response factor in Study 3, the treatment main effect was significant 
for all groups, whereas the day main effect was significant on days 0.25, 1, and 3 (see Table 48). 
The highest response was observed in the Alum-mIgG group, and it was significantly higher 
compared to the other groups on day 0.25. On day 1, the response in the Alum-mIgG group was 
higher compared to the IO-mIgG group only. On days 2 and 3, the response in the Alum-mIgG 
group was higher compared to the mIgG group only. The response in IO-mIgG group was the 
highest compared to other groups on day seven, but it was significantly higher only compared to 
the mIgG group, not the Alum-mIgG group (see Figure 17). 
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Table 48. Treatment and day interaction effect estimates and main effects p-values of  T 
cell+, Study 3 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 3.37 ± 0.59 4.21 ± 0.59 2.86 ± 0.59 0.3031 
0.25 7.64 ± 0.72 3.72 ± 0.72 3.87 ± 0.72 0.0061 
1 11.54 ± 1.47 5.25 ± 1.47 9.09 ± 1.47 0.0405 
2 14.11 ± 1.59 10.79 ± 1.59 8.25 ± 1.59 0.0788 
3 23.62 ± 2.74 16.64 ± 2.74 11.11 ± 2.74 0.0310 
4 16.27 ± 4.27 11.38 ± 4.27 10.55 ± 4.27 0.6098 
5 15.85 ± 2.96 15.33 ± 2.96 9.45 ± 2.96 0.2868 
7 8.39 ± 1.67 11.06 ± 1.93 5.06 ± 1.67 0.1174 
Treatment main 
effect P-value < 0.0001 < 0.0001 0.0032 
 
 
 
 
Figure 17.  T cell+ estimates by day and treatment group, Study 3. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The 
highest response was observed in the Alum-mIgG group, which was significantly different 
compared to one or both groups until day 3. On day 7, the response was significantly higher 
in the IO-mIgG group than in the mIgG group. Different lowercase letters (a-b) within one 
time point represent significant differences (p < 0.05) between the treatment groups. 
Different uppercase letters (A-D) represent significant changes between days for each 
treatment group. 
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 For the T cell+ CD4- CD8+ response factor in Study 3, the treatment main effect 
was significant for all groups, whereas the day main effect was significant on days 0.25, 2, 3, and 
7 (see Table 49). The response in the Alum-mIgG group was significantly higher compared to 
the IO-mIgG group on days 0.25 and 1. On days 2, 3, and 7, the response in the Alum-mIgG 
group was significantly higher compared to the mIgG group, but not compared to the IO-mIgG 
group (see Figure 18). 
 
Table 49. Treatment and day interaction effect estimates and main effects p-values of  T 
cell+ CD4- CD8+, Study 3 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.44 ± 0.09 0.47 ± 0.09 0.29 ± 0.09 0.3905 
0.25 1.53 ± 0.19 0.57 ± 0.19 1.24 ± 0.19 0.0171 
1 2.05 ± 0.32 0.82 ± 0.32 1.35 ± 0.32 0.0620 
2 3.60 ± 0.41 2.61 ± 0.41 1.43 ± 0.41 0.0141 
3 7.39 ± 0.81 3.75 ± 0.81 2.56 ± 0.81 0.0058 
4 5.24 ± 1.02 3.23 ± 1.02 2.40 ± 1.02 0.1843 
5 3.96 ± 0.67 2.94 ± 0.67 2.10 ± 0.67 0.2000 
7 2.99 ± 0.43 1.59 ± 0.49 1.24 ± 0.43 0.0454 
Treatment main 
effect P-value < 0.0001 0.0001 0.0009 
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 The  T cell+ response factor in Study 1 increased significantly by day 0.25 and 
continued to increase by until day 5 (see Table 50). On day 7, the estimates significantly 
decreased compared to the previous day and were similar to those observed at baseline. The 
response was significantly higher in the IO and IO-mIgG groups compared to the IOEF group. 
 The  T cell+ response factor in Study 2 increased significantly by day 0.25 and the 
highest estimates were observed on day 5 (see Table 51). The estimates reduced significantly 
from day 5 to day 7, but they were still significantly higher on day 7 compared to baseline. The 
Figure 18.  T cell+ CD4- CD8+ estimates by day and treatment group, Study 3. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The 
highest response was observed in the Alum-mIgG group, which was significantly different 
compared to one or both groups until day 3. On day 7, the response was significantly higher in 
the Alum-mIgG group than in the mIgG group. Different lowercase letters (a-b) within one 
time point represent significant differences (p < 0.05) between the treatment groups. Different 
uppercase letters (A-E) represent significant changes between days for each treatment group. 
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highest response was observed in the Alum-mIgG group, and it was significantly higher 
compared to the IO-mIgG group and the Alum group. The response in the IO-mIgG group was 
higher compared to the Alum group and lower compared to the IO group, but the differences 
were not statistically significant. 
 
Table 50.  T cell+ response by day and treatment group, Study 1 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
  Tcell+ Days   
 0 0.15 ± 0.03 a 
 0.25 0.40 ± 0.04 b 
 1 0.49 ± 0.13 bc 
 2 0.83 ± 0.15 cd 
 3 0.76 ± 0.15 cd 
 4 0.88 ± 0.13 d 
 5 1.02 ± 0.26 cd 
 7 0.21 ± 0.07 a 
 Treatment   
 IO 0.80 ± 0.13 a 
 IOEF 0.25 ± 0.14 b 
 IO-mIgG 0.73 ± 0.12 a 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
Table 51.  T cell+ response by day and treatment group, Study 2 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ Days   
 0 0.40 ± 0.10 a 
 0.25 0.94 ± 0.17 b 
 1 1.65 ± 0.26 c 
 2 1.64 ± 0.21 c 
 5 3.14 ± 0.21 d 
 7 1.75 ± 0.14 c 
 Treatment   
 Alum 0.95 ± 0.19 a 
 Alum-mIgG 2.08 ± 0.19 b 
 IO 1.85 ± 0.19 bc 
 IO-mIgG 1.45 ± 0.19 ac 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
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 In Study 3, theT cell+ CD4- CD8- response factor remained consistent with baseline 
values until day 1 (see Table 52). On day 2, a significant decrease was observed compared to 
baseline. The decrease continued until day 4, after which the estimates started increasing, but 
they were still significantly lower on day 7 compared to baseline. The T cell+ CD4+ CD8- 
response factor estimates increased significantly by day 0.25 and continued increasing until they 
peaked day 3 (see Table 52). Although the estimates decreased by day 7, they were still 
significantly higher compared to the estimates observed at baseline. 
 
Table 52.  T cell+ CD4- CD8- and  T cell+ CD4+ CD8- estimates by day, Study 3 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
2 T cell+ Days   
CD4- CD8- 0 1.05 ± 0.12 a 
 0.25 1.29 ± 0.32 a 
 1 0.93 ± 0.12 a 
 2 0.53 ± 0.06 bd 
 3 0.15 ± 0.02 c 
 4 0.12 ± 0.02 c 
 5 0.39 ± 0.04 b 
 7 0.59 ± 0.06 d 
2 T cell+ Days   
CD4+ CD8- 0 0.26 ± 0.07 a 
 0.25 0.87 ± 0.16 b 
 1 1.37 ± 0.24 bd 
 2 3.03 ± 0.57 c 
 3 3.61 ± 0.42 c 
 4 2.58 ± 0.59 cd 
 5 2.90 ± 0.43 c 
 7 1.36 ± 0.28 bd 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
 
 
 
 
108 
 
 
 
 The effect of treatment was the only significant effect for T cell+ CD4- CD8+ in 
Study 3. The strongest response was observed in the Alum-mIgG group, followed by the IO-
mIgG group. The weakest response was observed in the mIgG group, and it was significantly 
lower compared to the response observed in the Alum-mIgG group, but not compared to the 
response observed in the IO-mIgG group (see Table 53). 
 
Table 53.  T cell+ CD4- CD8+ estimates by treatment, Study 3 
Response Factor Treatment Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
2 T cell+ Alum-mIgG 1.10 ± 0.12  a 
CD4- CD8+ IO-mIgG 0.77 ± 0.12 ab 
 mIgG 0.58 ± 0.12 b 
Note: Different letters (a-b) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 
 B cells. The B cell response in Study 1 changed significantly by time of collection and 
treatment (see Table 54). A significant response compared to baseline was observed on day 0.25, 
and the estimates peaked on day 4. On day 7, B cell estimates were no longer significantly higher 
compared to baseline estimates. A significantly higher response was observed in the IO group 
compared to the IOEF group and in the IO-mIgG group compared to the IOEF group. 
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Table 54. B cell estimates by day and treatment, Study 1 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
B cells Days   
 0 0.12 ± 0.02 a 
 0.25 0.28 ± 0.05 b 
 1 0.90 ± 0.25 c 
 2 1.74 ± 0.37 cd 
 3 1.59 ± 0.42 cd 
 4 1.85 ± 0.34 d 
 5 1.61 ± 0.31 cd 
 7 0.50 ± 0.18 ab 
 Treatment   
 IO 1.42 ± 0.21 a 
 IO-mIgG 1.49 ± 0.21 a 
 IOEF 0.31 ± 0.24 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 
 The effect of the interaction between days and treatment on B cells was significant in 
Study 2. There were no significant changes by day in the Alum treatment group, but estimates 
changed significantly by day in the IO group, IO-mIgG group, and the Alum-mIgG group (see 
Table 55). Significant differences between the groups by day were observed only after day 2, 
when the response in the Alum-mIgG group significantly increased compared to other groups 
(see Figure 19). On day 5, the B cell estimates in the Alum-mIgG group were still significantly 
higher compared to other groups, but the IO-mIgG and IO groups also demonstrated a 
significantly higher response compared to the Alum group. Because the mIgG group did not 
show a significant response, the B cell estimates in that group were significantly lower compared 
to other groups on day 7.  
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Table 55. Treatment and day interaction effect estimates and main effects p-values of B cells, 
Study 2 
 Treatment  
Day Alum (࢞ഥ	േ ࡿࡱ, n = 4) 
Alum-mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) 
IO 
(࢞ഥ േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ	േ
ࡿࡱ, n = 4) 
Day main 
effect P-
value 
0 0.25 ± 0.22 0.11 ± 0.22 0.21 ± 0.22 0.51 ± 0.22 0.6288 
0.25 0.53 ± 0.19 0.90 ± 0.19 0.62 ± 0.19 0.37 ± 0.19 0.2897 
1 2.06 ± 1.22 5.72 ± 1.22 2.47 ± 1.22 2.69 ± 1.22 0.1850 
2 1.82 ± 1.89 11.44 ± 1.89 2.88 ± 1.89 3.81 ± 1.89 0.0144 
5 1.27 ± 1.34 13.31 ± 1.34 5.47 ± 1.34 6.49 ± 1.34 0.0003 
7 0.63 ± 0.99 4.30 ± 0.99 4.32 ± 0.99 5.89 ± 0.99 0.0168 
Treatment 
main effect 
P-value 
0.6105 0.0010 0.0398 0.0025 
 
 
 
 
 
Figure 19. B cell estimates by day and treatment group, Study 2. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. 
The highest response was observed in the Alum-mIgG group, and differences 
between the groups were observed from day 1 until day 7. Different lowercase letters 
(a-c) within one time point represent significant differences (p < 0.05) between the 
treatment groups. Different uppercase letters (A-C) represent significant changes 
between days for each treatment group. 
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 B cell receptors. The effect of collection time was significant for all B cell receptors in 
Study 3 (i.e., IgM+, IgM-, IgG+, and IgG-), whereas the type of treatment had a significant effect 
on IgM+ and IgG-. The interaction between time of collection and type of treatment was 
significant only for IgM-. 
 IgG+ increased significantly on day 2 compared to baseline and continued to increase 
until day 7 (see Table 56). However, because of the large standard errors on some days, the 
differences compared to baseline were not always significant. For example, the response was 
higher on day 4 compared to previous days, but it was not significantly higher compared to 
baseline estimates because of the large standard error. 
 
Table 56. B cell+ IgG+ estimates by day and treatment, Study 3 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
B cell+ IgG+ 0 0.02 ± 0.01 a 
 0.25 0.10 ± 0.07 abc 
 1 0.06 ± 0.02 ab 
 2 0.09 ± 0.02 b 
 3 0.26 ± 0.07 c 
 4 0.32 ± 0.18 abc 
 5 0.67 ± 0.21 cd 
 7 1.14 ± 0.33 e 
Note: Different letters (a-e) represent significant differences (p < 0.05) between days. 
 
 IgG- increased significantly by day 1 and continued to increase until their estimates 
peaked on day 5. A decrease was observed on day 7 compared to the previous sample collection 
time, but the estimates were still significantly higher compared to baseline. Alum-mIgG elicited 
the highest response, which was significantly higher compared to mIgG alone, but not 
significantly higher compared to IO-mIgG (see Table 57). 
 IgM+ changed significantly by day and significant differences were observed between 
treatment groups (see Table 58). A significant response was observed on day 1. The response 
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peaked on day 5 and remained significantly elevated until day 7. Alum-mIgG elicited the highest 
response, which was significantly higher compared to mIgG, but not significantly higher 
compared to IO-mIgG. The response in the IO-mIgG group was also higher compared to the 
mIgG group. 
 
Table 57. B cell+ IgG- estimates by day and treatment, Study 3 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
B cell+ IgG- Days   
 0 0.38 ± 0.10 a 
 0.25 1.14 ± 0.43 a 
 1 3.12 ± 0.75 b 
 2 8.46 ± 1.43 c 
 3 8.11 ± 1.83 c 
 4 7.43 ± 1.97 bc 
 5 14.56 ± 3.28 c 
 7 7.30 ± 2.30 bc 
 Treatment   
 Alum-mIgG 8.97 ± 1.07 a 
 IO-mIgG 5.93 ± 1.11 ab 
 mIgG 4.04 ± 1.14 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
treatment groups. 
 
Table 58. B cell+ IgM+ estimates by day and treatment, Study 3 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
B cell+ IgM+ Days   
 0 0.37 ± 0.09 a 
 0.25 0.99 ± 0.40 a 
 1 2.63 ± 0.65 b 
 2 6.67 ± 1.34 c 
 3 8.52 ± 1.86 cd 
 4 8.95 ± 2.10 cd 
 5 13.61 ± 2.55 d 
 7 6.66 ± 1.91 bc 
 Treatment   
 Alum-mIgG 8.07 ± 0.97 a 
 IO-mIgG 6.63 ± 0.99 a 
 mIgG 3.45 ± 0.97 b 
Note: Different letters (a-d) represent significant differences (p < 0.05) between days and 
treatment groups. 
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 IgM- showed a significant effect of the interaction between type of treatment and time of 
collection. The treatment main effect was significant only for the Alum-mIgG group, and 
significant changes between the groups were observed on days 0.25 and 2 (see Table 59). IgM- 
in the IO-mIgG group initially declined, and a significant response was observed only on day 3 
compared to baseline estimates. Alum-mIgG elicited a significant IgM- response by day 0.25, 
and IgM- estimates remained elevated compared to baseline on day 7. One significant difference 
between the groups was observed on day 0.25 because Alum-mIgG elicited a significantly higher 
response compared to IO-mIgG and mIgG treatments. The other significant difference between 
groups was observed on day 2 as both Alum and Alum-mIgG groups had significantly higher 
IgM- cell estimates compared to the IO-mIgG group (see Figure 20). 
 
 
Table 59. Treatment and day interaction effect estimates and main effects p-values of IgM-, 
Study 3 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.05 ± 0.04 0.11 ± 0.04 0.07 ± 0.04 0.6269 
0.25 0.43 ± 0.06 0.03 ± 0.06 0.15 ± 0.06 0.0034 
1 1.04 ± 0.33 0.36 ± 0.33 0.76 ± 0.33 0.3805 
2 3.33 ± 0.62 1.30 ± 0.62 1.55 ± 0.62 0.0836 
3 2.66 ± 0.58 1.38 ± 0.58 1.47 ± 0.58 0.2669 
4 1.12 ± 0.57 0.94 ± 0.57 1.72 ± 0.57 0.6150 
5 2.79 ± 0.69 1.18 ± 0.69 1.46 ± 0.69 0.2631 
7 1.75 ± 0.70 1.36 ± 0.80 0.77 ± 0.70 0.6313 
Treatment main 
effect P-value <.0001 0.2436 0.1111 
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 Summary. A total of 11 pulp cell responses in Study 1 changed significantly by day, 
whereas the differences between groups were observed in the following nine response factors: 
lymphocytes, CD45+, CD4- CD8+, CD4+ CD8+, CD4+ CD8-,  T cell+ CD8-, 2 T cell+, 
1 T cell+, and MHCII+ B cell+ response factors. IO-mIgG elicited a significantly higher 
response compared to IOEF for all response factors, whereas IO elicited a significantly higher 
response compared to IOEF for most response factors, with the exception of CD4+ CD8+ and  
Figure 20. B cell+ IgM- estimates by day and treatment group, Study 3. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The 
highest response was observed in the Alum-mIgG group, and it was significantly higher 
than both groups on day 0.25 and significantly higher than IO-mIgG on day 2. Different 
lowercase letters (a-c) within one time point represent significant differences (p < 0.05) 
between the treatment groups. Different uppercase letters (A-C) represent significant 
changes between days for each treatment group. 
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T cell+ CD8- responses. However, no significant differences were observed in the responses 
observed in the IO-mIgG and IO groups.  
 The interaction between time of collection and treatment in Study 1 was significant for 
live cells and  T cell+ CD8+ factors. However, the only significant difference in live cells 
between the groups was observed before the injections as the IO group had a significantly higher 
live cell count compared to the other groups. The initial response of the  T cell+ CD8+ factor 
was significant by day 0.25 and similar in all groups, but the response in the IO and IO-mIgG 
groups was significantly higher on day 4 compared to the IOEF group. The response remained 
elevated longest in the IO group, which had significantly higher live cell estimates compared to 
the other two groups on day 5.  
 In Study 2, a total of 11 response factors changed significantly by day, whereas the effect 
of treatment type was significant for the following three response factors: CD4+ CD8-, 2 T 
cell+, and 1 T cell+ response factors. Alum-mIgG and IO elicited significantly higher 
responses of all factors compared to the Alum treatment. IO-mIgG elicited a significantly higher 
response compared to Alum only for CD4+ CD8- and 1 T cell+ response factors.  
 The interaction between time of collection and treatment in Study 2 was significant for 
the following three response factors: CD45+,  T cell+ CD8-, and B cell response factors. A 
significantly higher response of all three factors was observed in the Alum-mIgG group 
compared to other groups. No significant differences were observed between the IO and IO-
mIgG groups for those factors. 
 In Study 3, a total of seven response factors changed significantly only by day. The fixed 
effect of treatment was significant for the following six response factors: CD4- CD8+, MHCII+ 
macrophages, 1 T cell+ CD4+ CD8-, 2 T cell+ CD4- CD8+, B cell+ IgG-, and B cell+ 
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IgM+ factors. Alum-mIgG and IO-mIgG elicited a significantly higher response of MHCII+ 
macrophages and B cell+ IgM+ factors compared to mIgG. Alum-mIgG elicited a significantly 
higher response of 1 T cell+ CD4+ CD8-, 2 T cell+ CD4- CD8+, and B cell+ IgG- factors 
compared to mIgG, but not compared to IO-mIgG. The CD4+ CD8- response was significantly 
higher in the Alum-mIgG group compared to other groups. 
 The interaction between time of collection and treatment in the 2014 studies was 
observed for the following ten response factors: CD45+, heterophils,  T cell+,  T cell+ CD4- 
CD8+,  T cell+ CD4- CD8-,  T cell+,  T cell+ CD4- CD8+, CD3+, CD4/CD8 ratio, 
and B cell+ IgM- factors. The highest response for all immune cells was observed in the Alum-
mIgG group, with the exception of heterophils as their estimates were significantly higher in the 
IO-mIgG group compared to the other groups. 
 The difference of least squares means and the simple effect comparisons results for pulp 
cell responses observed in all three feather injection studies are included in Appendix F. 
Discussion 
 The purpose of the feather injection studies was to monitor and assess local leukocytes 
infiltration into the pulp upon the administration of antigen-conjugated IONPs and IONPs using 
growing feather as a test site. It was hypothesized that the nature and extent of the leukocyte 
infiltration would depend on the treatment used. A total of 69 response factors in all three studies 
varied significantly by day only. However, the fixed effect of treatment was significant for a total 
of 24 response factors, whereas the interaction between treatment and type of collection was a 
significant fixed effect for a total of 23 response factors in all three studies. Therefore, a total of 
24 response factors were dependant on the type of treatment used. 
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 In Study 1, it was hypothesized that the immune reaction in the IOEF group would be 
significantly lower compared to the IO and IO-mIgG groups. Differences between treatment 
groups were observed for nine response factors in Study 1, and a significantly higher immune 
reaction was observed in the IO-mIgG group compared to the IOEF group. The immune reaction 
in the IO group was significantly higher compared to the IOEF group for seven response factors 
and similar to the IOEF group for CD4+ CD8+ and  T cell+ CD8- responses. The interaction 
between treatment and time of collection was significant for live cells and  T cell+ CD8+. The 
differences between groups for live cells were observed only prior to the injections on day 0, but 
the  T cell+ CD8+ factor was significantly lower in the IOEF group on day 4 compared to the 
other groups. Therefore, the hypothesis was confirmed as the IOEF group had significantly lower 
responses compared to other groups, so it was not included as one of the treatments in the 2013 
IO vs. Alum and 2014 studies. 
 In Study 2, it was hypothesized that the leukocyte infiltration would be significantly 
lower in the IO group compared to the other groups. Although the Alum-mIgG elicited 
significantly higher responses of for CD45+,  T cell+ CD8-, and B cell factors compared to the 
IO group, no significant differences were observed between the IO and IO-mIgG treatment 
groups for those response factors. The Alum treatment elicited a significantly weaker CD45+ and 
B cell response compared to IO and IO-mIgG , but the  T cell+ CD8- response to Alum was 
significantly higher compared to the IO and IO-mIgG treatments. The CD4+ CD8-, 2 T cell+, 
and 1 T cell+ response factors showed a significant fixed effect of treatment, but no 
significant differences were observed between the IO and Alum-mIgG or between IO and IO-
mIgG. These findings suggest that the immune responses were affected by the IONPs, not by the 
conjugated antigen. 
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 The complete blood cell count test found that lymphocyte concentration in Study 2 was 
significantly lower in the IO and IO-mIgG groups compared to the Alum Alum-mIgG group. 
However, only the Alum-mIgG group elicited a stronger T cell and B cell responses compared to 
the IO and IO-mIgG groups, whereas Alum elicited a weaker adaptive immunity response. 
Therefore, it is possible the high lymphocyte concentration in the blood is not a good predictor of 
adaptive immune cell activity at the injection site. 
 In Study 3, the mIgG concentrations were matched to observe how the immune responses 
would behave when both Alum and IONP treatments have the same antigen concentration. 
Consistent with the findings from Study 2, the Alum-mIgG group in Study 3 elicited 
significantly higher responses compared to the other groups, whereas no significant differences 
were observed between IO and IO-mIgG groups. Although the mIgG concentrations were 
matched in Study 3, whereas the IO-mIgG groups in the 2013 studies had more than 20-fold 
lower mIgG concentration compared to the other groups, matching the concentrations did not 
appear to change the response patterns. For example, the IO-mIgG group’s CD45+ response in 
Study 2 achieved a maximum mean value of 44.93 ± 5.15% pulp cells. In Study 3, the maximum 
mean value of the CD45+ response in the IO-mIgG was 43.15 ± 7.24% pulp cells. 
 The differences between the treatment groups were consistent in all studies. For most 
response factors that showed a significant fixed effect of treatment or interaction between 
treatment and sample collection time, Alum-mIgG elicited a stronger response compared to IO-
mIgG and other groups. The exception was heterophils as their concentration increased 
significantly more in the IO-mIgG group compared to the Alum-mIgG group in the complete 
blood cell count of Study 2. In Study 3, the percentage of heterophils in all live pulp cells in the 
IO-mIgG group was also significantly higher compared to the Alum-mIgG and Alum groups. 
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These results suggest that matching the mIgG concentration in all treatment groups did not 
contribute to differences in immune responses between groups. However, it is possible that 
increasing the IO concentration from 0.2 mg/ml in the 2013 study to 1 mg/ml in Study 3 
enhanced innate response to IONPs because heterophil infiltration into the growing feather pulp 
occurred only in Study 3. 
 The role of heterophils is to eliminate foreign substances by phagocytosis, so the IO-
mIgG treatment did elicit a high innate immune response. However, it appears that the 
heterophils eliminated the IONPs from the pulp as their estimates peaked on days 0.25 and 1, 
after which they significantly reduced by day 2 and were similar to the estimates observed at 
baseline. Although IO-mIgG did show a significant increase of  and  T cells in the pulp 
24-48 hours after the injection, the response was significantly higher in the Alum-mIgG group. 
The high estimates of heterophils observed in the IO-mIgG group could mean that the IONPs are 
taken up by the heterophils before they could elicit a strong adaptive immune response. 
 Based on the complete blood cell count, thrombocyte concentration in Study 3 was 
significantly higher in the Alum-mIgG group compared to the IO-mIgG group, but not compared 
to the mIgG group. Thrombocytes in chickens perform the same functions as platelets in 
mammals. The role of platelets in early innate responses has been well-established, but they also 
establish communication between innate and adaptive immunity through CD154 expression to 
signal early alterations to B cells and through inducing dendritic cell (DC) maturation to activate 
naïve T cells (Elzey et al., 2003). The role of thrombocytes in facilitating the adaptive immune 
response could explain why Alum-mIgG elicited stronger responses of T cells and B cells 
compared to the IO-mIgG and mIgG groups.  
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 The IONPs demonstrated the ability to elicit an innate immune response, but failed to 
elicit a strong adaptive response. The conjugation of mIgG was important only for Alum because 
the Alum-mIgG treatment was always associated with higher immune responses compared to 
Alum and mIgG alone. According to Walls (1977), the injection of Alum without specific 
antigenic stimulation attracts eosinophils to the injection site, which leads to the depletion of T 
cells because they are not needed when antigen recognition is not required. Although eosinophils 
in the growing feather pulp were not measured in these studies, the T cells in the Alum group in 
Study 2 reduced after day 1, whereas they continued increasing in other groups until day 5. 
These findings are consistent with the idea that Alum alone depletes T cells from the injection 
site. 
 The lack of Alum also explains why mIgG alone did not elicit strong immune cell 
responses. Without an adjuvant, the antigen is simply taken up by lymph node DCs, so the 
antigen does not remain long enough in the system to elicit an adaptive immune response. It was 
previously thought that aluminum-based adjuvants deposited at the injection site and slowly 
released the antigens, so the prolonged exposure to the antigen was considered to activate 
antigen-specific lymphocytes (Coffman et al., 2010; McKee, Munks, & Marrack, 2007). 
However, it was found that aluminum-based adjuvants produce immunopotentiation even when 
the antigen is rapidly released (Iyer, HogenEsch, & Hem, 2003). It is currently thought that the 
injection of an aluminum-containing adjuvant and antigen causes the inflammatory monocytes to 
take up the antigen instead of the lymph node DCs (Kool et al., 2008). The monocytes then 
become inflammatory DCs and induce a Th2 response. 
 At the moment there is no definite mechanism that would explain why antigen 
conjugation does not improve the immunopotentiation activities of IONPs as it does for Alum. 
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One possible explanation is that IONPs are usually taken up quickly by macrophages and 
eliminated via the reticuloendothelial system, regardless of the antigen conjugation (Chao et al., 
2012). In order to replicate the mechanism of Alum-mIgG uptake by immune cells and perhaps 
achieve a similar or higher response, surface modifications might be required to target 
monocytes so that they can take up the NPs and induce a Th2 response (Lartigue et al, 2012). 
Pre-treatment of IONPs with Intralipid proved to decrease initial uptake of particles by the 
reticuloendothelial system and increase blood monocyte labeling in rats (Liu et al., 2013).  
 The current results suggest that the leukocyte infiltration in the pulp of the growing 
feathers in LBL chickens is significantly higher in the Alum-mIgG group compared to other 
treatments used in these experiments. However, the properties of NPs also have to be considered 
to determine why the responses elicited by IONPs were lower compared to Alum-mIgG. 
Previous studies found that size and coating are some of the factors that determine how NPs 
behave in vivo. This study used 10 nm particles, which is consistent with previous findings that 
reported reduced clearance of NPs via the reticuloendothelial system for particles between 10 
and 100 nm (Longmire et al., 2008). However, IONPs with different coating should be further 
investigated to determine which coatings can prevent phagocytosis elicit an adaptive immune 
response. 
 Although further research will be required to develop IONPs capable of eliciting immune 
responses comparable to aluminum-based adjuvants, the findings of these studies have two 
important implications. The first implication stems from the fact that IONPs proved to elicit a 
significantly higher heterophil response compared to other treatments. Because the heterophils in 
avian species are similar to neutrophils in humans, it is possible to expect that IONPs can 
increase neutrophil count in deficient. The lack of neutrophils is a condition referred to as 
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neutropenia. It is a common side-effect of medication, usually chemotherapy, and reduced 
neutrophil concentration can lead to severe risks of infections (Sullivan & Moreno, 2015). If 
IONPs can elicit neutrophil responses to protect patients with high infection risks, they will have 
important implications in clinical practice. Therefore, the potential of IONPs in practice as 
protective agents for neutropenia patients should be further investigated. 
 The second implication is that these studies establish the chicken model as a minimally 
invasive alternative to existing models, as well as a reliable model that allows periodic 
monitoring of responses to substances injected in growing feathers. The pattern of immune 
responses observed in the LBL chickens’ growing feather pulp is consistent with the activation 
of different immune cells observed in previous studies. Chen, Cihak, Lösch, and Cooper (1988) 
reported that  T cells are activated first, whereas the  T cells increase after the frequency of 
 T cells diminishes. In Study 3, the T cells peaked on day 1 in the Alum-mIgG group, after 
which they continued declining, whereas the  T cells peaked on day 3.  
 The TCR3 subpopulation in avian species was distinguished from TCR2 based on 
differences in peptide chains of their heterodimers (Chen et al., 1989). However, Lahti et al. 
(1991) found that both TCR2 and TCR3 are subsets of  cells and that theirchains are 
encoded by the same diversity, joining, and constant gene region segments in the TCR locus. In 
Study 3, the 2 T cell+ CD4- CD8- response decreased significantly on day 1 compared to 
baseline, whereas the 2 T cell+ CD4+ CD8- response peaked on day 3 as the  T cells 
started decreasing after day 1. These changes by day are consistent with the fact that TCR1 cells 
are generated first, whereas the TCR2 and TCR3 cells are generated once the frequency of TCR1 
cells starts decreasing (Chen et al., 1988). 
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 In Study 3, the CD4/CD8 ratio did not change significantly by day in the mIgG group, 
but it did decrease significantly in the IO-mIgG and Alum-mIgG groups. In humans, a low 
CD4/CD8 ratio indicates ongoing immune activation, so it is usually observed in HIV patients 
because of the permanently low CD4 count and permanently high CD8 count (Serrano-Villar et 
al., 2013). A low CD4/CD8 ratio in patients after resuscitation was also established as a poor 
prognostic factor (Syrjälä, Surcel, & Ilonen, 1991). In chickens, a 1:1 CD4/CD8 ratio was 
observed at the onset of Smyth line vitiligo, but the progression of the disorder was associated 
with an increase in CD8+ cells and the reduction of the ratio to 0.3 (Erf et al., 1995). However, 
the range of the CD4/CD8 ratio in Study 3 was between 1.91 ± 0.33 and 3.39 ± 0.54 in the 
Alum-mIgG group and between 1.94 ± 0.33 and 4.49 ± 0.54 in the IO-mIgG group. The 
minimum ratio was observed on day 4 in both groups, after which it started increasing. The 
observed decrease was consistent with the fact that immune activation is characterized by a low 
CD4/CD8 ratio, but the decrease was not permanent. 
 The first mature naïve B cells express IgM in response to an infection, whereas the IgG 
antibody is produced only after the B cells receive information about the antigen through 
interaction with T cells (Racine et al., 2011). The B cell receptor responses observed in Study 3 
are consistent with this mechanism as the increase of IgM+ and IgM- cells was observed by day 
0.25. In contrast, IgG+ and IgG- cells started increasing significantly after days 2 and 1, 
respectively. 
 The immune cell infiltration in the pulp of the growing feathers observed in these studies 
suggests that the interactions between injected substances and the immune system can be 
observed in vivo over time in one subject using the chicken model. The results are considered 
reliable as the patterns of responses are consistent with the sequences of immune cell activation 
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observed in previous studies. No other current animal model can offer a non-invasive method to 
achieve the same objective. 
 It is important to note that these experiments did not use a control group with PBS. This 
is not considered a limitation because previous studies showed that PBS has no significant 
effects on immune cell activities in chickens (Bowen, Erf, Chapman, & Wideman, 2007; 
Vandaveer, Erf, & Durdik, 2001). The staining results from the pilot study conducted prior to 
these experiments are shown in Figure 21, and they also support that PBS does not elicit immune 
responses. 
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Figure 21. PBS vs. IO-mIgG immune cell induction 6 hours after feather pulp injections. 
 
Top: No immune cell induction was observed in the PBS group 6 hours after the injection 
into the feather pulp. 
 
Bottom: The IO-mIgG treatment was associated with an infiltration of immune cells into the 
pulp 6 hours after the injections. 
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 Even though tissue, organs, and plasma were collected during the experiments, the 
analysis of location trafficking and immune cell alterations is still an ongoing study. Prussian 
blue staining revealed that IONPs are present in the feather pulp (see Figure 22). This explains 
the innate immune response activities, but it is not possible to determine which cells took up the 
IONPs at the moment. Based on findings of previous studies, it is expected that macrophages 
took up the IONPs because they can easily take them up if polymer coatings are not used 
(Orlando et al., 2015). However, the high heterophil response observed in IO treatment groups 
also suggests that heterophils could have taken up IO. The ongoing study of cytokine gene 
expression based on the plasma samples will determine whether the cytokine expression was 
altered. 
 
Figure 22. Prussian blue staining of IONPs 6 hours after feather pulp injections. 
 
The blue stains show the position of IONPs in the feather pulp 6 hours after the 
injections. It is expected that innate immune cells took up the IONPs because the 
treatments did not enhance the adaptive immunity response, but ongoing studies 
will determine which innate immune cells took up the IONPs. 
127 
 
 
 
 The findings of this study show that IONPs can be used to elicit immune responses, but 
further research is required to develop particle pre-treatment strategies for targeting monocytes 
and reducing the risk of clearance by macrophages. Using that approach should replicate the 
mechanism of immune responses aluminum-based adjuvants, thus improving the strength and 
longevity of the immune response. The LBL chickens used in the experiments support the 
effectiveness of the chicken model for observing the in vivo interactions between administered 
substances and physiological processes. The model has the advantage of allowing for minimally 
invasive measuring of physiological changes over time in one subject, which makes it unique 
compared to other contemporary animal models. 
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CHAPTER 4—THE EFFECTS OF INTRAMUSCULAR IONP-mIgG INJECTIONS ON 
PRIMARY AND SECONDARY IMMUNE RESPONSES 
Abstract 
The ability of nanoparticles to stimulate both humoral and cell-mediated immune responses 
makes them a promising vaccine adjuvant. However, current animal models are highly invasive 
and do not allow researchers to monitor trends in immune responses over time in one subject. 
The purpose of these studies is to test the utility of iron oxide nanoparticles (IONPs) as vaccine 
adjuvants by monitoring the primary and memory immune responses to intramuscular injections. 
In the primary and memory response investigations of Study A, a sample of 18 and 20 chickens 
was used, respectively. In the Study A primary response, the chickens were divided into three 
groups, and the following treatments were administered: Alum-mIgG (15%-5 mg/ml), IO-mIgG 
(1 mg/ml-0.26 mg/ml), and mIgG (5 mg/ml). In the Study A memory response, the chickens 
were divided into three treatment groups and a control group, and the following treatments were 
administered: Alum-mIgG (15%-5 mg/ml), IO-mIgG (1 mg/ml-0.26 mg/ml), mIgG (5 mg/ml), 
and PBS (1X). In the primary and memory response investigations of Study B, samples of 12 and 
16 chickens were used, respectively. In the Study B primary response, the chickens were divided 
into three groups, and the following treatments were administered: Alum-mIgG (15%-0.26 
mg/ml), IO-mIgG (1 mg/ml-0.26 mg/ml), and mIgG (0.26 mg/ml). In the Study B memory 
response study, the chickens were divided into three treatment groups and one control group, and 
the following treatments were administered: Alum-mIgG (15%-0.26 mg/ml), IO-mIgG (1 
mg/ml-0.26 mg/ml), mIgG (0.26 mg/ml), and PBS (1X). The treatment preparations were 
injected in the breast muscle in the amount of 0.1 ml/chicken. In Study A, the mIgG 
concentration in the IONP group was 20-fold lower compared to the other groups, but IO-mIgG 
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elicited significantly higher responses compared to the other groups. IONPs elicited significantly 
higher MHCII+ B cell+,  T cell+ CD8+, and  T cell+ CD8- responses compared to the other 
groups. However, when the mIgG concentration for all treatment groups was matched in Study 
B, the IO-mIgG group elicited similar or significantly lower responses compared to the other 
groups. These findings suggest that growing feathers in chickens can be used to monitor immune 
responses to treatments periodically in one subject, even when the agents are not administered 
directly into the feather pulp. The clinical utility of IONPs as vaccine adjuvants is promising 
considering these findings, but further research is necessary to improve the knowledge of IONP 
biointeractions, toxicity levels, and the optimal concentration of conjugated antigen in the 
preparation. 
 Keywords: aluminum, IONP, memory response, vaccine adjuvant, primary response 
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Introduction 
 Most adjuvants improve vaccine efficiency and provide protection from pathogens by 
enhancing the humoral immune response (Plotkin, 2010). The humoral response involves B 
cells, which are responsible for producing memory cells that provide the body with future 
immunity against specific antigens. The antibody responses are usually sufficient to develop 
long-term immunity to most antigens and require no additional boosting (Amanna, Carlson, & 
Slifka, 2007). However, a major challenge for most adjuvants is eliciting a cell-mediated 
response that results in building effective and long-term T cell immunity (Coffman, Sher, & 
Seder, 2010). The ability to elicit protective T cell responses is critical for the development of 
vaccines for disease that could be prevented or regulated by T cells. 
 NPs are promising adjuvants, but their ability to stimulate both humoral and cell-
mediated immune responses must be investigated using suitable in vivo test systems. The mouse 
model is not considered suitable for investigating immune responses because they usually have 
low transferability due to various differences compared to human immunity, such as differences 
in cellular expressions of pattern recognition receptors (Campbell et al., 2009) The use of non-
human primates for researching adjuvants is recommended because they are more similar to 
humans compared to rats (Coffman et al., 2010). However, animal availability and high 
maintenance costs are often significant barriers to conducting studies using non-human primates. 
 The purpose of the intramuscular injection studies was to demonstrate the feasibility of 
the chicken model as an in vivo test system for monitoring humoral and cell-mediated immune 
responses. Compared to the mouse model, the chicken model is less invasive and offers better 
transferability of results due to the similarities between avian and mammalian immune systems. 
Compared to the non-human primate model, the chicken model is cost-effective and less 
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invasive. The chicken model is also the only model that allows for periodical monitoring of 
adaptive immune responses to injections when GF is used as a test site. These studies will also 
monitor differences in humoral and cell-mediated responses to different treatment preparations to 
determine whether NPs could address the identified limitations of conventional adjuvants. It is 
hypothesized that the antigen-conjugated NPs will stimulate a higher primary and memory 
response compared to antigen and antigen-conjugated Alum treatments. 
Study A: In Vivo Monitoring of Primary and Memory Immune Responses to 
Intramuscular Injections of IONPs in Chickens, 2013 
 In the primary response study, time of collection was defined as a class of eight levels 
with the following values: 0, 0.25, 1, 2, 3, 4, 5, and 7 days. In the memory response study, time 
of collection was defined as a class of seven levels with the following values: 0, 0.25, 1, 2, 3, 4, 
and 5 days. Type of treatment was a class with three levels in both primary and memory studies, 
and it contained the following values: Alum-mIgG, IO-mIgG, and mIgG.  
 The PBS control group was used in the memory study. The observations in that group 
were analyzed using time of collection as the only fixed effect. Time of collection was defined as 
a class of eight levels with the following values: 0, 0.25, 1, 2, 3, 4, 5, and 7 days. The fixed effect 
of collection time was not significant for any of the response factors monitored, so the results for 
this group are not reported. 
 The concentration of mIgG in Study A was 20-fold lower in the IO-mIgG group 
compared to the other groups in which mIgG was used, whereas Study B matched mIgG 
concentrations in all treatment groups. The results of the type III test of fixed effects for the 
Study A primary response are shown in Appendix G. The results of the type III test of fixed 
effects for the Study A memory response are shown in Appendix I. 
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Leukocytes 
 For CD45+ cells in the primary response study, the changes in estimates were affected by 
time of collection only (see Table 60). The estimates increased significantly by day 0.25 and 
peaked on day 1, after which they continued declining. On day 7, the CD45+ estimates were 
lower compared to the baseline estimates, but the difference was not statistically significant. 
 In the memory response study, significant changes in CD45+ estimates were observed by 
day and treatment group, but not by their interaction (see Table 61). The CD45+ estimates 
increased significantly by day 0.25 and remained consistent until day 3, when they reduced 
significantly. However, the CD45+ estimates observed between days 3 and 5 were still 
significantly higher compared to baseline estimates. A significantly higher response was 
observed in the IO-mIgG group compared to the Alum-mIgG and mIgG groups. 
 
 
Table 60. All leukocytes by day, Study A primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD45+ 0 10.31 ± 0.85 a 
 0.25 25.79 ± 1.36 b 
 1 27.02 ± 1.26 b 
 2 25.00 ± 1.50 b 
 3 18.78 ± 1.04 c 
 4 16.70 ± 1.17 c 
 5 13.74 ± 0.85 d 
 7 7.58 ± 0.81 a 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
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Table 61. All leukocytes by day and treatment group, Study A memory response 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD45+ Days   
 0 12.05 ± 0.88 a 
 0.25 33.84 ± 2.57 b 
 1 30.99 ± 2.87 b 
 2 33.38 ± 2.73 b 
 3 22.76 ± 2.52 c 
 4 21.26 ± 2.48 c 
 5 17.86 ± 1.05 c 
 Treatment   
 Alum-mIgG 22.46 ± 1.45 a 
 IO-mIgG 29.46 ± 1.45 b 
 mIgG 21.85 ± 1.59 a 
Note: different letters (a-c) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 
Major Histocompatibility Complex 
 MHCII+ macrophages were significantly affected by time of collection in the primary 
response study (see Table 62). Estimates increased significantly by day 0.25, after which they 
continued decreasing, but remained significantly elevated compared to baseline until day 5. On 
day 7, their estimates were significantly lower compared to baseline.  
 In the memory response study, the response for MHCII+ macrophages was significant on 
day 0.25, after which the estimates were significantly lower than the estimates observed at 
baseline on days 1, 2, and 5 and similar to estimates observed at baseline on days 3 and 4 (see 
Table 63). 
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Table 62. MHCII+ macrophage estimates by day, Study A primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
MHCII+ 0 0.93 ± 0.08 a 
Macrophages+ 0.25 5.38 ± 0.52 b 
 1 2.14 ± 0.16 cd 
 2 2.48 ± 0.14 c 
 3 1.78 ± 0.12 d 
 4 1.86 ± 0.20 d 
 5 1.45 ± 0.12 e 
 7 0.46 ± 0.12 f 
Note: different letters (a-f) represent significant differences (p < 0.05) between days for each 
response factor. 
 
Table 63. MHCII+ macrophage estimates by day, Study A memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
MHCII+  0 0.51 ± 0.06 a 
Macrophages+ 0.25 1.66 ± 0.40 b 
 1 0.38 ± 0.04 c 
 2 0.19 ± 0.02 d 
 3 0.38 ± 0.09 acd 
 4 0.58 ± 0.07 a 
 5 0.34 ± 0.04 c 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
 
 In the primary response study, MHCII+ B cells+ were significantly affected only by time 
of collection (see Table 64). The estimates increased significantly on day 0.25 and peaked on day 
2. The estimates decreased significantly on day 3 compared to day 2, but they were still 
significantly higher on day 7 compared to baseline estimates. No significant fixed effects were 
observed for MHCII+ B cells+ in the memory response study. 
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Table 64. MHCII+ B cell+ estimates by day, Study A primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
MHCII+ B cell+ 0 0.07 ± 0.02 a 
 0.25 0.20 ± 0.03 b 
 1 0.63 ± 0.05 c 
 2 0.89 ± 0.12 c 
 3 0.34 ± 0.04 d 
 4 0.44 ± 0.08 d 
 5 0.38 ± 0.08 d 
 7 0.29 ± 0.06 bd 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
 
 
T Cells 
 The CD4- CD8+ estimates increased significantly by day in both primary and memory 
studies. In the primary response study, the estimates increased significantly by day 0.25 and 
peaked on day 1 (see Table 65). The estimates continued reducing and returned to values similar 
to those observed at baseline on day 5. In the memory response study, the CD4- CD8+ estimates 
increased significantly by day 0.25 and peaked on day 3 (see Table 66). Despite the significant 
decrease after day 3, the estimates remained significantly higher on day 5 compared to baseline. 
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Table 65. CD4- CD8+ estimates by day, Study A primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4- CD8+  0 0.34 ± 0.04 a 
 0.25 2.59 ± 0.45 b 
 1 3.25 ± 0.89 b 
 2 2.43 ± 0.32 b 
 3 1.02 ± 0.17 c 
 4 0.71 ± 0.09 c 
 5 0.36 ± 0.10 a 
 7 0.31 ± 0.03 a 
Note: different letters (a-c) represent significant differences (p < 0.05) between days. 
 
Table 66. CD4- CD8+ estimates by day, Study A memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4- CD8+ 0 0.75 ± 0.07 a 
 0.25 2.71 ± 0.39 bc 
 1 3.28 ± 0.47 b 
 2 3.15 ± 0.30 b 
 3 3.50 ± 0.52 b 
 4 1.94 ± 0.24 cd 
 5 1.89 ± 0.18 d 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
 
 
 CD4+ CD8+ cells were significantly affected by the time of collection in the primary and 
memory response studies. In the primary response study, the estimates increased significantly by 
day 1 and peaked on day 2, after which they started declining. The CD4+ CD8+ estimates were 
no longer significantly higher compared to baseline on day 5 (see Table 67). In the memory 
response study, CD4+ CD8+ cells increased significantly on day 3 compared to baseline and 
remained significantly elevated on day 5 (see Table 68). 
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Table 67. CD4+ CD8+ estimates by day, Study A primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4+ CD8+ 0 0.09 ± 0.02 a 
 0.25 0.23 ± 0.15 ab 
 1 0.33 ± 0.03 b 
 2 0.67 ± 0.17 c 
 3 0.28 ± 0.08 bd 
 4 0.23 ± 0.05 bd 
 5 0.14 ± 0.03 ad 
 7 0.09 ± 0.01 a 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
 
Table 68. CD4+ CD8+ estimates by day, Study A memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4+ CD8+ 0 0.17 ± 0.02 a 
 0.25 0.22 ± 0.02 a 
 1 0.24 ± 0.03 a 
 2 0.19 ± 0.02 a 
 3 0.65 ± 0.09 b 
 4 0.44 ± 0.08 c 
 5 0.50 ± 0.06 bc 
Note: different letters (a-c) represent significant differences (p < 0.05) between days. 
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Table 69. Treatment and day interaction effect estimates and main effects p-values of CD4+ 
CD8-, Study A primary response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 6) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 6) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 6) Day main effect P-value 
0 0.40 ± 0.13 0.55 ± 0.13 0.84 ± 0.13 0.0777 
0.25 0.72 ± 0.27 1.16 ± 0.27 0.49 ± 0.27 0.2403 
1 5.52 ± 0.67 6.99 ± 0.67 6.29 ± 0.67 0.3223 
2 4.78 ± 0.82 6.65 ± 0.82 5.63 ± 0.82 0.3002 
3 2.98 ± 0.61 3.69 ± 0.61 2.74 ± 0.61 0.5315 
4 2.81 ± 0.69 3.22 ± 0.69 2.47 ± 0.69 0.7466 
5 1.12 ± 0.32 1.60 ± 0.32 1.41 ± 0.32 0.5710 
7 0.67 ± 0.16 0.56 ± 0.16 0.66 ± 0.16 0.8494 
Treatment main 
effect P-value 0.0009 0.0004 < 0.0001 
 
 
 
 In the primary response study, the treatment main effect was significant for CD4+ CD8- 
in all treatment groups (see Table 69). However, the day main effect was not significant for any 
time of collection because the only significant difference between the groups was observed on 
day 0 (see Figure 23). The CD4+ CD8- estimates in the Alum-mIgG group before the injections 
were significantly lower compared to the mIgG group. A significant response was observed in all 
groups by day 1, and the CD4+ CD8- estimates returned to baseline values in all groups on day 
7. 
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 In the memory response study, both time of collection and treatment, but not their 
interaction, were a significant fixed effect for CD4+ CD8- estimates (see Table 70). The 
estimates increased significantly by day 0.25 and peaked on day 1, after which they continued 
reducing. However, the estimates were still significantly higher on day 5 compared to baseline. 
The strongest response was observed in the IO-mIgG group, and it was significantly higher 
compared to the response observed in the Alum-mIgG and mIgG groups. 
 
Figure 23. CD4+ CD8- estimates by day and treatment group, Study A primary response. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The 
only significant difference between the groups was observed at baseline because the mIgG 
group had higher estimates compared to the Alum-mIgG group. Different lowercase letters 
(a-b) within one time point represent significant differences (p < 0.05) between the 
treatment groups. Different uppercase letters (A-E) represent significant changes between 
days for each treatment group. 
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Table 70. CD4+ CD8- estimates by day and treatment group, Study A memory response 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4+ CD8- Days   
 0 2.92 ± 0.26 a 
 0.25 6.00 ± 0.75 bd 
 1 8.74 ± 1.10 bc 
 2 8.33 ± 0.78 c 
 3 5.79 ± 0.79 d 
 4 4.47 ± 0.59 de 
 5 3.98 ± 0.35 e 
 Treatment   
 Alum-mIgG 5.17 ± 0.47 a 
 IO-mIgG 6.97 ± 0.47 b 
 mIgG 5.09 ± 0.52 a 
Note: different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 
 For the CD25+ CD4+ and CD25+ CD4- response factors, the only the significant fixed 
effect was collection time in the primary response study (see Table 71). The CD25+ CD4+ 
estimates increased significantly by day 1, decreased significantly on day 2, and increased 
significantly again on day 4. No significant changes were observed after day 4, and the estimates 
remained significantly higher compared to baseline on day 7. The CD25+ CD4- estimates 
increased significantly by day 0.25 and increased until day 1, after which they started decreasing. 
The minimum value was observed on day 3, and it was significantly lower compared to baseline. 
However, the estimates started increasing again on day 4 and achieved the maximum value 
during the observation on day 7, which was significantly higher compared to all other collection 
times. 
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Table 71. CD25+ CD4+ and CD25+ CD4- estimates by day, Study A primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD25+ CD4+ 0 0.04 ± 0.01 ab 
 0.25 0.04 ± 0.01 b 
 1 0.08 ± 0.01 c 
 2 0.01 ± 0.01 a 
 3 0.02 ± 0.01 ab 
 4 0.09 ± 0.02 c 
 5 0.08 ± 0.01 c 
 7 0.08 ± 0.01 c 
CD25+ CD4- 0 0.05 ± 0.01 a 
 0.25 0.09 ± 0.02 b 
 1 0.11 ± 0.02 b 
 2 0.07 ± 0.02 ab 
 3 0.02 ± 0.01 c 
 4 0.04 ± 0.01 a 
 5 0.05 ± 0.01 a 
 7 0.23 ± 0.03 d 
Note: different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
 
Table 72. CD25+ CD4+ and CD25+ CD4- estimates by day, Study A memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD25+ CD4+ 0 0.15 ± 0.02 ab 
 0.25 0.09 ± 0.02 b 
 1 0.42 ± 0.08 c 
 2 0.21 ± 0.03 ad 
 3 0.29 ± 0.04 cd 
 4 0.23 ± 0.04 cd 
 5 0.24 ± 0.03 cd 
CD25+ CD4- 0 0.58 ± 0.06 ab 
 0.25 0.66 ± 0.07 b 
 1 1.01 ± 0.09 c 
 2 0.49 ± 0.05 abd 
 3 0.40 ± 0.04 ad 
 4 0.48 ± 0.03 ad 
 5 0.44 ± 0.04 d 
Note: different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
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 The CD25+ CD4+ and CD25+ CD4- response factors were affected by collection time in 
the memory response study as well (see Table 72). The CD25+ CD4+ estimates decreased 
significantly by day 0.25 compared to baseline, but they increased on day 1 and were 
significantly higher compared to baseline. On day 2, the CD25+ CD4+ estimates were similar to 
those observed at baseline and significantly higher compared to baseline on subsequent 
collection times. The CD25+ CD4- estimates increased significantly by day 1, after which they 
reduced significantly and were no longer significantly higher compared to baseline. 
 T cell receptors. Significant fixed effects of day and treatment, but not their interaction 
were observed for the  T cell+ CD8+ response in the primary response study (see Table 73). 
The increase was significant on day 1 compared to baseline. After day 1, the response started 
decreasing and the estimates were no longer significantly different from those observed at 
baseline after day 3. The estimates in the Alum-mIgG group were significantly higher compared 
to the IO-mIgG group, but not compared to the mIgG group. 
 The  T cell+ CD8+ estimates in the memory response study increased significantly by 
day 0.25 (see Table 74). The highest estimates were observed on days 0.25, 3, and 5. Between 
those collection times, the  T cell+ CD8+ estimates would decrease significantly only to 
increase again. 
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Table 73.  T cell+ CD8+ estimates by day and treatment group, Study A primary response 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) 
Difference of Least Squares 
Means 
 T cell+ CD8+ Days   
 0 0.12 ± 0.02 ad 
 0.25 0.15 ± 0.02 ad 
 1 0.48 ± 0.04 b 
 2 0.39 ± 0.04 c 
 3 0.17 ± 0.02 a 
 4 0.16 ± 0.02 ad 
 5 0.10 ± 0.02 d 
 7 0.13 ± 0.02 ad 
 Treatment   
 Alum-mIgG 0.17 ± 0.02 a 
 IO-mIgG 0.26 ± 0.02 b 
 mIgG 0.20 ± 0.02 ab 
Note: different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
Table 74.  T cell+ CD8+ estimates by day, Study A memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ CD8+ 0 0.12 ± 0.02 a 
 0.25 0.59 ± 0.06 b 
 1 0.51 ± 0.07 bc 
 2 0.41 ± 0.03 c 
 3 0.72 ± 0.06 b 
 4 0.32 ± 0.04 d 
 5 0.49 ± 0.03 bc 
Note: different letters (a-c) represent significant differences (p < 0.05) between days. 
 
 In the primary response study, the interaction between treatment and time of collection 
was a significant fixed effect for the  T cell+ CD8- response (see Table 75). The treatment 
main effect was significant for all groups, whereas the day main effect was significant only on 
day 2 because the response in the IO-mIgG group remained elevated longer compared to the 
Alum-mIgG and mIgG groups (see Figure 24).  
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Table 75. Treatment and day interaction effect estimates and main effects p-values of  T cell+ 
CD8-, Study A primary response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 6) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 6) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 6) Day main effect P-value 
0 0.58 ± 0.18 0.33 ± 0.18 0.42 ± 0.18 0.6110 
0.25 3.20 ± 0.61 2.21 ± 0.61 1.93 ± 0.61 0.3224 
1 2.66 ± 0.55 3.35 ± 0.55 2.58 ± 0.55 0.5609 
2 0.99 ± 0.20 2.27 ± 0.20 1.15 ± 0.20 0.0006 
3 0.55 ± 0.12 0.76 ± 0.12 0.40 ± 0.12 0.1182 
4 0.27 ± 0.08 0.48 ± 0.08 0.30 ± 0.08 0.1811 
5 0.18 ± 0.07 0.31 ± 0.07 0.25 ± 0.07 0.4137 
7 0.30 ± 0.04 0.24 ± 0.04 0.21 ± 0.04 0.3870 
Treatment main 
effect P-value 0.0060 0.0003 0.0455 
 
 
 
 
 
Figure 24.  T cell+ CD8- estimates by day and treatment group, Study A primary response. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. Significant 
differences between the groups were observed on days 2 and 3 because the IO-mIgG group 
elicited a longer response compared to the mIgG group and the Alum-mIgG group. Different 
lowercase letters (a-b) within one time point represent significant differences (p < 0.05) 
between the treatment groups. Different uppercase letters (A-D) represent significant changes 
between days for each treatment group. 
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 In the memory response study, time of collection was the only significant fixed effect for 
 T cell+ CD8- estimates (see Table 76). The estimates increased significantly by day 0.25, 
after which they continued to reduce. However, the decreases observed after day 3 were not 
significant, so the response remained significantly higher compared to baseline. 
 
Table 76.  T cell+ CD8- estimates by day, Study A memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ CD8- 0 0.46 ± 0.13 a 
 0.25 5.13 ± 0.94 b 
 1 3.53 ± 0.39 b 
 2 1.58 ± 0.15 c 
 3 1.27 ± 0.16 d 
 4 0.88 ± 0.13 d 
 5 0.95 ± 0.11 d 
Note: different letters (a-c) represent significant differences (p < 0.05) between days. 
 
 The 1 T cell+ response factor estimates changed significantly by day only in the 
primary response study (see Table 77). The estimates increased significantly by day 0.25 and 
achieved the highest values on days 1 and 2, after which they continued decreasing. On day 7, 
the estimates were no longer significantly higher compared to baseline. 
 In the memory response study, the fixed effects of collection time and treatment, but not 
their interaction, were significant for the 1 T cell+ response factor (see Table 78). The 
estimates increased significantly by day 0.25, and the highest estimate was observed on day 1. 
The estimates started decreasing after day 1, but they were still significantly higher compared to 
baseline on day 5. The highest response was observed in the IO-mIgG group, and it was 
significantly higher compared to the other groups. 
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Table 77.  T cell+ estimates by day, Study A primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 0.40 ± 0.06 a 
 0.25 1.24 ± 0.16 b 
 1 4.97 ± 0.33 c 
 2 4.84 ± 0.38 c 
 3 2.54 ± 0.31 d 
 4 2.25 ± 0.33 d 
 5 1.34 ± 0.34 b 
 7 0.28 ± 0.04 a 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
 
Table 78.  T cell+ estimates by day and treatment group, Study A memory response 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) 
Difference of Least Squares 
Means 
1 T cell+ Days   
 0 0.57 ± 0.11 a 
 0.25 3.97 ± 0.61 b 
 1 6.32 ± 0.95 bc 
 2 5.93 ± 0.62 c 
 3 4.53 ± 0.70 bc 
 4 2.26 ± 0.33 d 
 5 2.45 ± 0.32 d 
 Treatment   
 Alum-mIgG 3.23 ± 0.38 b 
 IO-mIgG 4.78 ± 0.38 a 
 mIgG 3.14 ± 0.42 b 
Note: different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 
 The  T cell+ response factor estimates changed significantly only by day in the 
primary response study (see Table 79). The estimates increased significantly by day 0.25 and 
achieved the highest values on days 1 and 2. The estimates decreased significantly by day 3 and 
continued decreasing. On day 7, they were no longer significantly higher compared to baseline. 
 The  T cell+ response factor estimates also changed significantly only by day in the 
memory response study (see Table 80). The estimates increased significantly on day 0.25 and 
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remained elevated until day 3, after which they decreased significantly. However, the estimates 
on days 4 and 5 were still significantly higher compared to baseline. 
 
Table 79.  T cell+ estimates by day, Study A primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 0.15 ± 0.02 a 
 0.25 0.39 ± 0.05 b 
 1 1.57 ± 0.10 c 
 2 1.47 ± 0.11 c 
 3 0.75 ± 0.09 d 
 4 0.59 ± 0.08 bd 
 5 0.37 ± 0.05 b 
 7 0.11 ± 0.02 a 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
 
Table 80.  T cell+ estimates by day, Study A memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 0.39 ± 0.06 a 
 0.25 2.11 ± 0.36 b 
 1 2.49 ± 0.33 b 
 2 2.17 ± 0.24 b 
 3 1.81 ± 0.24 b 
 4 0.98 ± 0.12 c 
 5 1.01 ± 0.12 c 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
 
B Cells 
 B cells were significantly affected by the interaction between time of collection and 
treatment type in the primary response study (see Table 81). The main effect of treatment was 
significant for all treatment groups, whereas the day main effect was significant only for day 2. 
The only significant difference between the groups was observed on day 2 because the IO-mIgG 
treatment elicited a significantly stronger response compared to the Alum-mIgG and mIgG 
treatments (see Figure 25). 
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Table 81. Treatment and day interaction effect estimates and main effects p-values of B cells, 
Study A primary response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 6) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 6) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 6) Day main effect P-value 
0 0.08 ± 0.04 0.12 ± 0.04 0.17 ± 0.04 0.3940 
0.25 0.34 ± 0.10 0.40 ± 0.10 0.16 ± 0.10 0.2539 
1 2.65 ± 0.45 3.30 ± 0.45 2.27 ± 0.45 0.2954 
2 2.26 ± 0.91 7.50 ± 0.91 2.99 ± 0.91 0.0020 
3 1.70 ± 0.80 3.79 ± 0.80 1.53 ± 0.80 0.1147 
4 1.01 ± 0.58 2.58 ± 0.58 1.32 ± 0.58 0.1625 
5 0.57 ± 0.22 0.89 ± 0.22 0.81 ± 0.22 0.5553 
7 0.17 ± 0.25 0.48 ± 0.25 0.16 ± 0.25 0.6066 
Treatment main 
effect P-value 0.0026 < 0.0001 0.0006 
 
 
 
 
 
Figure 25. B cell estimates by day and treatment group, Study A primary response. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The IO-
mIgG treatment elicited a significantly higher response on day 2 compared to the other 
treatments. Different lowercase letters (a-b) within one time point represent significant 
differences (p < 0.05) between the treatment groups. Different uppercase letters (A-D) 
represent significant changes between days for each treatment group. 
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 In the memory response study, the fixed effects of collection time and treatment, but not 
their interaction, were significant for the B cell response (see Table 82). A significant increase 
was observed on day 0.25, and the estimates continued increasing until they peaked on day 2. On 
day 5, the estimates were still significantly higher compared to baseline. The highest response 
was observed in the IO-mIgG group, and it was significantly higher compared to the Alum-mIgG 
group, but not compared to the mIgG group. 
 
Table 82. B cell estimates by day and treatment group, Study A memory response 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) 
Difference of Least Squares 
Means 
B cells Days   
 0 0.23 ± 0.04 a 
 0.25 1.11 ± 0.14 b 
 1 4.56 ± 0.66 ce 
 2 10.23 ± 1.29 d 
 3 7.84 ± 1.36 de 
 4 5.26 ± 0.94 c 
 5 3.38 ± 0.37 c 
 Treatment   
 Alum-mIgG 3.47 ± 0.65 b 
 IO-mIgG 6.06 ± 0.65 a 
 mIgG 4.44 ± 0.71 ab 
Note: different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
Summary 
 In the primary response study, significant changes by day only were observed for 11 
response factors. The fixed effect of treatment was significant only for the  T cell+ CD8+ 
response factor. The  T cell+ CD8+ estimates in the IO-mIgG group were significantly higher 
compared to the Alum-mIgG group, but not compared to the mIgG group. 
 The fixed effect of interaction between treatment and collection time was significant for 
the following three response factors: CD4+ CD8-,  T cell+ CD8-, and B cell response factors. 
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The response in the IO-mIgG group was significantly higher for  T cell+ CD8- and B cell 
response factors. The only difference between the groups for the CD4+ CD8- was observed prior 
to the injections because the Alum-mIgG group had lower baseline estimates compared to the 
mIgG group. 
 In the memory response study, significant changes by day only were observed for ten 
response factors. The fixed effect of treatment was significant for the following four response 
factors: CD45+, CD4+ CD8-,  T cell+, and B cell response factors. The highest responses of 
those four factors were observed in the IO-mIgG group, and they were significantly higher 
compared to the Alum-mIgG and mIgG groups. The significant effect of collection time and 
treatment type was not observed for any of the response factors measured in the 2013 memory 
response study. 
 The difference of least squares means and the simple effect comparisons results for the 
primary responses observed in Study A are included in Appendix H. The difference of least 
squares means and the simple effect comparisons results for the memory responses observed in 
Study A are included in Appendix J. 
Study B: In Vivo Monitoring of Primary and Memory Immune Responses to 
Intramuscular Injections of IONPs in Chickens, 2014 
 In the primary response study, time of collection was defined as a class of eight levels 
with the following values: 0, 0.25, 1, 2, 3, 4, 5, and 7 days. In the memory response study, time 
of collection was defined as a class of seven levels with the following values: 0, 0.25, 1, 2, 3, 4, 
and 5 days. Type of treatment was a class with three levels in both primary and memory studies, 
and it contained the following values: Alum-mIgG, IO-mIgG, and mIgG.  In the memory study, 
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a PBS control group was used. Time of collection was the only fixed effect in the analysis, and it 
was defined as a class of seven levels with the following values: 0, 0.25, 1, 2, 3, 4, and 5 days. 
 The concentration of mIgG in Study A was 20-fold lower in the IO-mIgG group 
compared to the other groups in which mIgG was used, whereas Study B matched mIgG 
concentrations in all treatment groups. The results of the type III test of fixed effects for the 
Study B primary response are shown in Appendix G. The results of the type III test of fixed 
effects for the Study B memory response are shown in Appendix I. 
Live Cells 
 No significant fixed effects were observed for live cells in the primary response study. In 
the memory response study, time of collection was the only significant fixed effect for live cells 
(see Table 83). Their estimates increased significantly by day 0.25 and remained elevated until 
day 4, when they returned to values similar to those observed at baseline. In the PBS group, 
significant changes in live cell estimates by day were also observed, but only because the values 
increased significantly on days 2 and 4 compared to baseline (see Table 83). 
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Table 83. Live cell estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
Live cells 0 53.54 ± 0.82 a 
 0.25 63.20 ± 1.90 b 
 1 67.08 ± 1.78 b 
 2 65.73 ± 1.51 b 
 3 65.14 ± 0.91 b 
 4 53.73 ± 1.21 a 
 5 56.49 ± 1.37 a 
Live cells (PBS) 0 53.25 ± 0.93 a 
 0.25 51.78 ± 1.37 a 
 1 57.71 ± 3.18 ab 
 2 61.07 ± 1.35 b 
 3 58.55 ± 3.11 ab 
 4 62.37 ± 1.20 b 
 5 59.17 ± 5.99 ab 
Note: different letters (a-b) represent significant differences (p < 0.05) between days. 
 
Major Histocompatibility Complex 
 In the primary response study, the interaction between time of collection and treatment 
type had a significant effect on MHCII+ macrophages (see Table 84). The main effect of 
treatment was significant only for the Alum-mIgG study. The day main effect was not significant 
(p < 0.05) for any time of sample collection. Only one difference between the groups was 
observed on day 0.25 when MHCII+ macrophages significantly increased in the Alum-mIgG 
group and were significantly higher compared to the estimates observed in the IO-mIgG group 
(see Figure 26, top). However, a significant decrease occurred by day 1 and no further 
differences between the groups were observed. 
 In the memory response study, the control group showed no significant changes in 
MHCII+ macrophage estimates, but a significant fixed effect of the interaction between 
collection time and treatment was observed in the treatment groups (see Table 85). The treatment 
main effect was significant only in the Alum-mIgG group, and the day main effect was 
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significant only on day 2 because the response in the Alum-mIgG group lasted longer compared 
to the other groups (see Figure 26, bottom).  
 
Table 84. Treatment and day interaction effect estimates and main effects p-values of MHCII+ 
Macrophages, Study B primary response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 2.58 ± 0.41 2.48 ± 0.41 2.23 ± 0.41 0.8244 
0.25 8.83 ± 1.83 2.38 ± 1.83 4.64 ± 1.83 0.0892 
1 3.06 ± 0.52 2.39 ± 0.52 2.65 ± 0.52 0.6696 
2 2.99 ± 0.50 2.20 ± 0.50 2.49 ± 0.50 0.5477 
3 3.77 ± 0.89 1.64 ± 0.89 1.72 ± 0.89 0.2137 
4 1.84 ± 0.35 1.16 ± 0.35 1.28 ± 0.35 0.3845 
5 1.76 ± 0.22 1.26 ± 0.22 1.67 ± 0.22 0.2993 
7 2.02 ± 0.37 2.04 ± 0.37 1.75 ± 0.37 0.8278 
Treatment main 
effect P-value 0.0033 0.6701 0.0641 
 
 
Table 85. Treatment and day interaction effect estimates and main effects p-values of MHCII+ 
Macrophages+, Study B memory response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.88 ± 0.14 1.33 ± 0.14 1.26 ± 0.14 0.1020 
0.25 6.79 ± 2.03 5.46 ± 2.03 3.23 ± 2.03 0.4845 
1 4.57 ± 0.85 2.37 ± 0.85 1.95 ± 0.85 0.1168 
2 2.10 ± 0.26 0.92 ± 0.26 1.17 ± 0.26 0.0239 
3 2.41 ± 0.36 1.96 ± 0.36 1.71 ± 0.36 0.4225 
4 2.02 ± 0.74 2.91 ± 0.74 1.77 ± 0.74 0.5441 
5 2.91 ± 0.68 2.33 ± 0.68 2.39 ± 0.68 0.8040 
Treatment main 
effect P-value 0.0118 0.0875 0.5624 
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Figure 26. MHCII+ Macrophage+ estimates by day and treatment group, Study B. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. Different 
lowercase letters (a-b) within one time point represent significant differences (p < 0.05) between the 
treatment groups. Different uppercase letters (A-C) represent significant changes between days for 
each treatment group. 
 
Top: The primary response in the Alum-mIgG group was significantly higher compared to the IO-
mIgG group, but not compared to the mIgG group on day 0.25. 
 
Bottom: The memory response in the Alum-mIgG group was significantly higher compared to the 
other groups on day 2. 
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 In the primary response study, MHCII+ B cell+ estimates were significantly affected only 
by time of collection (see Table 86). The estimates increased significantly by day 1 and 
continued increasing until day 3, when the highest estimate of MHCII+ B cells+ was observed. 
Although the estimates started decreasing after day 3, MHCII+ B cells+ estimates were still 
significantly higher on day 7 compared to baseline. 
 In the memory response study, MHCII+ B cell+ estimates changed significantly only by 
day (see Table 87). The increase was significant by day 0.25, but the estimates continued 
increasing until day 3, when they peaked. On days 4 and 5, the estimates reduced significantly 
compared to day 3, but they remained significantly higher compared to baseline estimates. The 
PBS control group in the memory response study also showed significant changes by day (see 
Table 87), but a significant response was observed on day 1 and the estimates remained 
consistent until day 3. Further non-significant increases compared to days 1-3 were observed on 
days 4 and 5, when the estimates of MHCII+ B cells+ in the treatment groups were already 
declining toward baseline values. 
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Table 86. MHCII+ B cell+ estimates by day, Study B primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) 
Difference of Least Squares 
Means 
MHCII+ B cell+ 0 0.39 ± 0.11 a 
 0.25 0.68 ± 0.16 a 
 1 4.87 ± 0.57 b 
 2 6.18 ± 1.63 bd 
 3 11.86 ± 1.93 c 
 4 9.53 ± 1.89 cd 
 5 5.37 ± 0.59 b 
 7 2.42 ± 0.35 e 
Note: different letters (a-e) represent significant differences (p < 0.05) between days. 
 
Table 87. MHCII+ B cell+ estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
MHCII+ B cell+ 0 0.51 ± 0.20 a 
 0.25 1.77 ± 0.19 b 
 1 12.69 ± 2.95 c 
 2 12.55 ± 1.71 c 
 3 13.18 ± 1.55 c 
 4 3.05 ± 0.67 b 
 5 2.27 ± 0.49 b 
MHCII+ B cell+ 0 0.42 ± 0.14 a 
(PBS) 0.25 0.38 ± 0.11 a 
 1 5.07 ± 0.51 b 
 2 4.19 ± 1.02 b 
 3 5.58 ± 1.97 ab 
 4 7.95 ± 1.07 b 
 5 10.24 ± 3.67 ab 
Note: different letters (a-c) represent significant differences (p < 0.05) between days. 
 
T Cells 
 In the primary response study, the CD4- CD8+ estimates increased significantly by day 
0.25 (see Table 88). The estimates peaked on day 2 and remained significantly higher compared 
to baseline on day 7. The CD4- CD8+ estimates changed significantly only by day in the 
memory response study treatment groups and the control group (see Table 89). In the treatment 
groups, a significant response was observed by day 0.25, and the estimates peaked on day 1. A 
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significant decrease was observed from day 1 to day 2, and the estimates continued decreasing 
until day 5, but they were still significantly higher compared to baseline estimates. In the 
memory response PBS control group, a similar response trend was observed, but a significant 
increase compared to baseline was observed on day 1, and the estimates on day 5 were no longer 
significantly higher compared to baseline (see Table 89). 
 
Table 88. CD4- CD8+ estimates by day, Study B primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4- CD8+  0 0.29 ± 0.04 a 
 0.25 0.96 ± 0.17 b 
 1 3.23 ± 0.57 c 
 2 3.44 ± 0.52 c 
 3 3.25 ± 0.81 c 
 4 1.65 ± 0.27 cb 
 5 1.16 ± 0.14 b 
 7 1.33 ± 0.25 b 
Note: different letters (a-c) represent significant differences (p < 0.05) between days. 
 
Table 89. CD4- CD8+ estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4- CD8+ 0 0.54 ± 0.08 a 
 0.25 2.44 ± 0.37 b 
 1 4.19 ± 0.47 c 
 2 3.03 ± 0.42 b 
 3 2.63 ± 0.32 b 
 4 1.09 ± 0.13 d 
 5 0.95 ± 0.13 d 
CD4- CD8+ (PBS) 0 0.43 ± 0.07 a 
 0.25 0.70 ± 0.15 a 
 1 3.61 ± 0.82 b 
 2 2.19 ± 0.42 b 
 3 2.76 ± 0.88 ab 
 4 2.55 ± 0.35 b 
 5 1.71 ± 0.52 ab 
Note: different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
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Table 90. Treatment and day interaction effect estimates and main effects p-values of CD4+ 
CD8+, Study B memory response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.04 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.6898 
0.25 0.39 ± 0.16 0.18 ± 0.16 0.47 ± 0.16 0.4678 
1 0.84 ± 0.33 0.63 ± 0.33 0.66 ± 0.33 0.8906 
2 1.34 ± 0.36 0.46 ± 0.36 0.63 ± 0.36 0.2314 
3 0.64 ± 0.26 0.55 ± 0.26 0.57 ± 0.26 0.9672 
4 0.42 ± 0.11 0.22 ± 0.11 0.09 ± 0.11 0.1492 
5 0.29 ± 0.10 0.13 ± 0.10 0.08 ± 0.10 0.3480 
Treatment main 
effect P-value 0.0029 0.6578 0.4893 
 
 
 
 No significant changes in CD4+ CD8+ estimates were observed in the primary response 
study. However, in the memory response study, a significant fixed effect of the interaction 
between treatment and collection time was observed for CD4+ CD8+ estimates (see Table 90). 
The treatment main effect was significant only for Alum-mIgG, which elicited the highest 
response. However, the day main effect was not significant for any of the collection times as 
CD4+ CD8+ the estimates in the Alum-mIgG group were not significantly higher compared to 
the estimates in the other groups (see Figure 27). 
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 In the PBS control group of the memory response study, a significant fixed effect of 
collection time was observed for CD4+ CD8+ estimates (see Table 91). The response was 
significant on days 1, 2, and 4 compared to baseline. However, no significant differences were 
observed between the collection times after day 1. 
 
 
 
Figure 27. CD4+ CD8+ estimates by day and treatment group, Study B memory response. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The Alum-
mIgG treatment elicited the highest response on day 2 compared to the other treatments, but 
the difference between the groups was not statistically significant. Different lowercase letters 
(a-b) within one time point represent significant differences (p < 0.05) between the treatment 
groups. Different uppercase letters (A-C) represent significant changes between days for each 
treatment group. 
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Table 91. CD4+ CD8+ estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4+ CD8+ (PBS) 0 0.06 ± 0.02 a 
 0.25 0.07 ± 0.02 a 
 1 0.85 ± 0.09 b 
 2 0.63 ± 0.16 b 
 3 1.08 ± 0.47 ab 
 4 0.89 ± 0.15 b 
 5 0.73 ± 0.39 ab 
Note: different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
 
 
 CD4+ CD8- cells were significantly affected by the time of collection in the primary 
response study. The CD4+ CD8- estimates in the primary response study increased significantly 
by day 0.25 and continued increasing until day 2 (see Table 92). Although they decreased 
significantly by day 7 compared to maximum observed values, the estimates were still 
significantly higher on day 7 compared to baseline. 
 The CD4+ CD8- estimates changed significantly by day in the memory response study as 
well (see Table 93). In the treatment groups, the response was significant by day 0.25 and the 
highest estimates were observed on day 1. The estimates started reducing significantly after day 
1, but they were still higher compared to baseline on day 5. In the PBS control group, the 
response was significant on days 1, 2, and 4 compared to baseline. However, no significant 
differences were observed between the collection times after day 1. 
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Table 92. CD4+ CD8- estimates by day, Study B primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4+ CD8- 0 1.06 ± 0.22 a 
 0.25 2.85 ± 0.57 b 
 1 8.60 ± 0.68 c 
 2 8.73 ± 0.73 c 
 3 7.40 ± 0.82 cd 
 4 5.73 ± 0.75 d 
 5 3.85 ± 0.62 b 
 7 3.49 ± 0.61 b 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
 
Table 93. CD4+ CD8- estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
CD4+ CD8- 0 1.07 ± 0.26 a 
 0.25 4.54 ± 0.48 b 
 1 9.39 ± 1.04 c 
 2 7.09 ± 0.84 d 
 3 6.46 ± 0.56 d 
 4 2.47 ± 0.36 e 
 5 2.47 ± 0.48 e 
CD4+ CD8- (PBS) 0 0.95 ± 0.17 a 
 0.25 0.77 ± 0.16 a 
 1 5.74 ± 0.61 b 
 2 4.67 ± 0.73 b 
 3 5.25 ± 2.06 ab 
 4 4.62 ± 0.38 b 
 5 3.89 ± 1.27 ab 
Note: different letters (a-c) represent significant differences (p < 0.05) between days for each 
response factor. 
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 T cell receptors. No significant fixed effects were observed for  T cell+ CD8+ in the 
primary response study, but a significant interaction of collection time and treatment was 
observed in the memory response study. The treatment main effect was significant for all 
treatment groups, but the day main effect was not significant for any of the collection times (see 
Table 94). The highest response was observed in the Alum-mIgG group, but the only difference 
between the groups was observed on day 0 because the  T cell+ CD8+ estimates were higher in 
the IO-mIgG group compared to the mIgG group (see Figure 28). 
 
Table 94. Treatment and day interaction effect estimates and main effects p-values of  T cell+ 
CD8+, Study B memory response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.17 ± 0.06 0.33 ± 0.06 0.08 ± 0.06 0.0563 
0.25 0.68 ± 0.14 0.50 ± 0.14 0.84 ± 0.14 0.2712 
1 1.11 ± 0.27 1.89 ± 0.27 1.18 ± 0.27 0.1354 
2 0.97 ± 0.15 1.06 ± 0.15 0.69 ± 0.15 0.2490 
3 0.94 ± 0.22 1.38 ± 0.22 1.03 ± 0.22 0.3593 
4 0.49 ± 0.13 0.55 ± 0.13 0.40 ± 0.13 0.7302 
5 0.36 ± 0.08 0.51 ± 0.08 0.31 ± 0.08 0.2638 
Treatment main 
effect P-value 0.0002 0.0012 0.0001 
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 For the  T cell+ CD8- response factor, a significant fixed effect of collection time was 
observed in the primary response study (see Table 95). The estimates increased significantly by 
day 0.25 and peaked on day 1, but they decreased significantly already on day 2. However, the 
estimates were still significantly higher on day 7 compared to baseline. 
 In the memory response study, a significant effect of both collection time and treatment, 
but not their interaction, was observed of the  T cell+ CD8- response factor (see Table 96). The 
highest response was observed on day 0.25, and it started decreasing significantly after day 1. On 
day 5, the response was no longer significantly higher compared to baseline.  
Figure 28.  T cell+ CD8+ estimates by day and treatment group, Study B memory response. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The IO-
mIgG treatment elicited the highest response, but the only significant difference between the 
groups was observed at baseline because the IO-mIgG group had significantly higher estimates 
compared to the mIgG group. Different lowercase letters (a-b) within one time point represent 
significant differences (p < 0.05) between the treatment groups. Different uppercase letters (A-
C) represent significant changes between days for each treatment group. 
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Table 95.  T cell+ CD8- estimates by day, Study B primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ CD8- 0 0.69 ± 0.14 a 
 0.25 4.63 ± 1.47 b 
 1 5.87 ± 0.90 c 
 2 2.08 ± 0.23 b 
 3 2.20 ± 0.46 bd 
 4 1.66 ± 0.20 b 
 5 1.32 ± 0.17 d 
 7 1.31 ± 0.28 d 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
 
Table 96.  T cell+ CD8- estimates by day and treatment group, Study B memory response 
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ CD8- Days   
 0 0.70 ± 0.18 a 
 0.25 7.88 ± 1.48 b 
 1 5.99 ± 0.65 b 
 2 2.55 ± 0.25 c 
 3 2.38 ± 0.26 c 
 4 1.13 ± 0.15 d 
 5 1.17 ± 0.25 ad 
 Treatment   
 Alum-mIgG 3.88 ± 0.29 a 
 IO-mIgG 2.78 ± 0.29 b 
 mIgG 2.69 ± 0.29 b 
Note: different letters (a-d) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
 In the memory response study, significant changes by day for both  T cell+ CD8+ and 
 T cell+ CD8- estimates were observed in the PBS control group (see Table 97). The T 
cell+ CD8+ were significantly higher compared to baseline on days 1, 2, and 4. The  T cell+ 
CD8- estimates were significantly higher compared to baseline on days 1 and 2. 
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Table 97.  T cell+ CD8+ and CD8- estimates by day, Study B memory response (PBS) 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ CD8+ 0 0.15 ± 0.03 a 
 0.25 0.27 ± 0.06 a 
 1 1.01 ± 0.18 b 
 2 0.62 ± 0.09 b 
 3 0.77 ± 0.23 ab 
 4 0.62 ± 0.08 b 
 5 0.48 ± 0.15 ab 
 T cell+ CD8- 0 0.65 ± 0.13 a 
 0.25 1.96 ± 0.63 ab 
 1 2.84 ± 0.28 b 
 2 1.84 ± 0.35 b 
 3 1.55 ± 0.52 ab 
 4 1.29 ± 0.26 a 
 5 1.54 ± 0.54 ab 
Note: different letters (a-e) represent significant differences (p < 0.05) between days for each 
response factor. 
 
 
 The 1 T cell+ response factor estimates changed significantly only by day in the 
primary response study (see Table 98). The estimates increased significantly by day 0.25 and 
achieved the highest values on days 1 and 2, after which they continued decreasing. The 
estimates were still significantly higher on day 7 compared to baseline estimates. 
 In the memory response study treatment groups and the PBS control group, the 1 T 
cell+ response factor also changed significantly by day only (see Table 99). In the treatment 
groups, the response was significant by day 0.25 and peaked on day 1. The estimates continued 
declining, but they were still significantly higher compared to baseline estimates. In the control 
group, the estimates increased by day 1, and they remained similar until day 5, when they were 
still significantly higher compared to baseline values. 
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Table 98.  T cell+ estimates by day, Study B primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 2.20 ± 0.19 a 
 0.25 3.95 ± 0.58 b 
 1 10.63 ± 1.06 c 
 2 10.18 ± 0.72 c 
 3 7.33 ± 0.81 d 
 4 6.61 ± 0.87 d 
 5 5.17 ± 0.84 b 
 7 4.60 ± 0.72 b 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
 
Table 99.  T cell+ estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 1.89 ± 0.21 a 
 0.25 5.74 ± 0.51 b 
 1 11.29 ± 0.85 c 
 2 9.43 ± 0.81 cd 
 3 8.09 ± 0.79 df 
 4 4.22 ± 0.52 e 
 5 6.19 ± 0.46 bf 
 T cell+ (PBS) 0 1.99 ± 0.29 a 
 0.25 2.04 ± 0.17 a 
 1 8.76 ± 1.20 b 
 2 6.99 ± 1.06 b 
 3 8.07 ± 2.94 ab 
 4 6.49 ± 0.74 b 
 5 7.04 ± 1.05 b 
Note: different letters (a-f) represent significant differences (p < 0.05) between days for each 
response factor. 
 
 In the primary response study, no significant fixed effects were observed for 1 T cell+ 
CD4+ CD8+, whereas the 1 T cell+ CD4- CD8+, 1 T cell+ CD4- CD8-, and 1 T cell+ 
CD4+ CD8- response factors all changed significantly only by day (see Table 100). The 1 T 
cell+ CD4- CD8+ estimates increased significantly by day 0.25 and achieved the highest values 
on days 1 and 2. By day 3, the estimates decreased significantly compared to day 2, but they 
were still significantly higher compared to baseline on day 7. The 1 T cell+ CD4- CD8- 
estimates also increased significantly by day 0.25, but they achieved their highest values on day 
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3. Although their estimates decreased significantly after day 3, the estimates were still 
significantly higher on day 7 compared to baseline. The 1 T cell+ CD4+ CD8- estimates 
increased significantly by day 0.25 and continued to increase until they peaked on days 1 and 2. 
Although they started decreasing significantly after day 2, their estimates were significantly 
higher on day 7 compared to baseline. 
 
Table 100.  T cell+ CD4- CD8+, CD4- CD8-, and CD4+ CD8- estimates by day, Study B 
primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+  0 0.34 ± 0.09 a 
CD4- CD8+ 0.25 1.04 ± 0.09 b 
 1 2.45 ± 0.35 c 
 2 2.52 ± 0.31 cd 
 3 1.64 ± 0.20 d 
 4 1.08 ± 0.17 b 
 5 1.25 ± 0.16 bd 
 7 1.31 ± 0.19 bd 
 T cell+ 0 0.03 ± 0.01 a 
CD4- CD8- 0.25 0.23 ± 0.05 b 
 1 0.26 ± 0.03 b 
 2 0.22 ± 0.03 b 
 3 0.80 ± 0.11 c 
 4 0.24 ± 0.04 b 
 5 0.27 ± 0.03 b 
 7 0.29 ± 0.04 b 
 T cell+ 0 0.97 ± 0.19 a 
CD4+ CD8- 0.25 2.44 ± 0.44 b 
 1 7.15 ± 0.60 c 
 2 7.03 ± 0.50 c 
 3 4.59 ± 0.56 de 
 4 4.93 ± 0.66 e 
 5 3.32 ± 0.58 bd 
 7 2.74 ± 0.46 b 
Note: different letters (a-e) represent significant differences (p < 0.05) between days for each 
response factor. 
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 In the memory response study,  T cell+ CD4- CD8+,  T cell+ CD4+ CD8+, and 
 T cell+ CD4+ CD8- estimates changed significantly by day in the treatment groups (see 
Table 101). The  T cell+ CD4- CD8+ estimates increased significantly by day 0.25 and 
returned to values similar to those observed at baseline on day 4, but they increased significantly 
again on day 5. The  T cell+ CD4+ CD8+ estimates increased significantly by day 1. The 
estimates were no longer significantly higher compared to baseline on day 4, but they increased 
significantly again on day 5. The  T cell+ CD4+ CD8- estimates increased significantly by 
day 0.25 and peaked on day 1, after which they started decreasing. However, they were still 
significantly higher on day 5 compared to baseline estimates. Although a high T cell+ 
response was observed in the PBS control group, only the  T cell+ CD4+ CD8- changed 
significantly by day (see Table 101). A significant increase compared to baseline occurred on 
day 1, and no significant changes were observed after day 1. The response was significantly 
higher compared to baseline only on days 1, 2, and 4. 
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Table 101.  T cell+ CD4- CD8+, CD4+ CD8+, and CD4+ CD8- estimates by day, Study B 
memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+  0 0.82 ± 0.16 a 
CD4- CD8+ 0.25 1.64 ± 0.23 b 
 1 2.91 ± 0.29 c 
 2 2.39 ± 0.19 cd 
 3 1.88 ± 0.18 bd 
 4 1.05 ± 0.15 a 
 5 2.75 ± 0.26 c 
 T cell+ 0 0.28 ± 0.03 a 
CD4+ CD8+ 0.25 0.30 ± 0.05 a 
 1 0.82 ± 0.17 bc 
 2 0.83 ± 0.13 bc 
 3 0.75 ± 0.17 bc 
 4 0.59 ± 0.15 ac 
 5 1.15 ± 0.13 b 
 T cell+ 0 0.72 ± 0.17 a 
CD4+ CD8- 0.25 3.76 ± 0.36 b 
 1 7.46 ± 0.79 c 
 2 6.25 ± 0.71 ce 
 3 5.02 ± 0.52 be 
 4 2.08 ± 0.29 d 
 5 2.31 ± 0.47 d 
 T cell+ 0 0.73 ± 0.13 a 
CD4+ CD8- (PBS) 0.25 0.79 ± 0.16 a 
 1 4.95 ± 0.57 b 
 2 4.17 ± 0.64 b 
 3 4.22 ± 1.80 ab 
 4 4.07 ± 0.42 b 
 5 3.47 ± 1.14 ab 
Note: different letters (a-e) represent significant differences (p < 0.05) between days for each 
response factor. 
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 For the  T cell+ CD4- CD8- response in the memory response study, a significant 
interaction between treatment and time of collection was observed (see Table 102). The 
treatment main effect was significant for the Alum-mIgG and the IO-mIgG group, but not for the 
mIgG group. The day main effect was not significant for any collection time, and the only 
difference observed between the groups was at baseline because the IO-mIgG group had 
significantly higher  T cell+ CD4- CD8- estimates compared to the Alum-mIgG group (see 
Figure 29). 
 
Table 102. Treatment and day interaction effect estimates and main effects p-values of  T 
cell+ CD4- CD8-, Study B memory response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.24 ± 0.05 0.42 ± 0.05 0.30 ± 0.05 0.0590 
0.25 0.25 ± 0.05 0.14 ± 0.05 0.28 ± 0.05 0.1268 
1 0.53 ± 0.15 0.37 ± 0.15 0.36 ± 0.15 0.6931 
2 0.53 ± 0.11 0.35 ± 0.11 0.36 ± 0.11 0.4917 
3 0.92 ± 0.13 0.59 ± 0.13 0.53 ± 0.13 0.1321 
4 0.64 ± 0.23 0.86 ± 0.23 0.59 ± 0.23 0.6874 
5 0.91 ± 0.18 0.74 ± 0.18 0.68 ± 0.18 0.6413 
Treatment main 
effect P-value 0.0076 0.0195 0.2109 
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 In the primary response study, the  T cell+ response factor estimates changed 
significantly by day only (see Table 103). In Study 3, the  T cell+ estimates increased 
significantly by day 0.25 and peaked on day 1. The estimates started decreasing significantly 
after day 2, but they were still significantly higher on day 7 compared to baseline. 
 In the memory response study, the  T cell+ response factor estimates also changed 
significantly only by day in the treatment groups and the PBS control group (see Table 104). In 
Figure 29.  T cell+ CD4- CD8- estimates by day and treatment group, Study B memory 
response. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The Alum-
mIgG treatment elicited the highest response, but the only significant difference between the 
groups was observed at baseline because the IO-mIgG group had significantly higher estimates 
compared to the Alum-mIgG group. Different lowercase letters (a-b) within one time point 
represent significant differences (p < 0.05) between the treatment groups. Different uppercase 
letters (A-C) represent significant changes between days for each treatment group. 
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the treatment groups, the response was significant by day 0.25 and the estimates peaked on day 
1. The decrease after day 1 continued until day 4, and the estimates increased significantly again 
on day 5. In the PBS control group, the estimates increased significantly by day 0.25, and no 
significant differences between collection times were observed after day 1. 
 
Table 103.  T cell+ estimates by day, Study B primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 0.98 ± 0.06 a 
 0.25 2.07 ± 0.27 b 
 1 4.61 ± 0.46 c 
 2 3.67 ± 0.32 cd 
 3 2.93 ± 0.33 e 
 4 3.31 ± 0.52 de 
 5 1.71 ± 0.28 b 
 7 1.81 ± 0.30 b 
Note: different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
 
Table 104.  T cell+ estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 0.75 ± 0.11 a 
 0.25 2.87 ± 0.28 b 
 1 4.63 ± 0.53 c 
 2 3.81 ± 0.21 c 
 3 3.63 ± 0.31 bc 
 4 1.96 ± 0.22 d 
 5 4.28 ± 0.21 c 
 T cell+ (PBS) 0 0.69 ± 0.10 a 
 0.25 1.39 ± 0.14 b 
 1 2.94 ± 0.73 abc 
 2 2.72 ± 0.56 bc 
 3 2.57 ± 0.67 bc 
 4 2.10 ± 0.10 c 
 5 3.40 ± 0.18 c 
Note: different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
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 In the primary response study, no significant changes were observed in  T cell+ CD4- 
CD8- estimates, but a significant fixed effect of collection time was observed in the memory 
response study treatment groups (see Table 105). The increase was significant by day 0.25, after 
which the estimates decreased significantly on day 2. However, further significant increases were 
observed after day 2 and the  T cell+ CD4- CD8- estimates on day 5 were significantly 
higher compared to the previous days. 
 
Table 105.  T cell+ CD4- CD8- estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 0.10 ± 0.01 a 
CD4- CD8- 0.25 0.49 ± 0.08 b 
 1 0.32 ± 0.10 bc 
 2 0.22 ± 0.03 c 
 3 0.31 ± 0.03 b 
 4 0.36 ± 0.05 b 
 5 0.79 ± 0.11 d 
Note: different letters (a-d) represent significant differences (p < 0.05) between days. 
 
 
 The  T cell+ CD4- CD8+ estimates changed significantly only by day in the primary 
response study (see Table 106) and in the memory response study treatment groups (see Table 
107). In the primary response study,  T cell+ CD4- CD8+ estimates increased significantly 
by day 0.25 and peaked on day 1, after which they started decreasing significantly. However, the 
estimates on day 7 were still significantly higher compared to baseline. In the memory response 
study, a significant increase in  T cell+ CD4- CD8+ estimates was observed by day 0.25, and 
the response remained significantly higher compared to baseline on day 5. 
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Table 106.  T cell+ CD4- CD8+ estimates by day, Study B primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 0.22 ± 0.04 a 
CD4- CD8+ 0.25 0.78 ± 0.08 b 
 1 1.49 ± 0.21 c 
 2 1.02 ± 0.14 b 
 3 0.68 ± 0.10 d 
 4 1.03 ± 0.15 bd 
 5 0.42 ± 0.07 e 
 7 0.48 ± 0.09 e 
Note: different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
 
Table 107.  T cell+ CD4- CD8+ estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 0.18 ± 0.02 a 
CD4- CD8+ 0.25 0.99 ± 0.12 bc 
 1 1.33 ± 0.14 ce 
 2 1.17 ± 0.11 bc 
 3 0.91 ± 0.09 b 
 4 0.59 ± 0.08 d 
 5 1.84 ± 0.24 e 
Note: different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
 
 The  T cell+ CD4+ CD8- estimates in the primary response study showed a 
significant fixed effect of the interaction between treatment and time of collection. The treatment 
main effect was significant for all treatment groups, and the day main effect was significant only 
on day 1 (see Table 108). The only significant difference between the groups was observed on 
day 1 as the mIgG group elicited a significantly higher response compared to the other groups 
(see Figure 30). 
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Table 108. Treatment and day interaction effect estimates and main effects p-values of  T 
cell+ CD4+ CD8-, Study B primary response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.26 ± 0.10 0.24 ± 0.10 0.33 ± 0.10 0.8288 
0.25 1.05 ± 0.26 1.06 ± 0.26 0.45 ± 0.26 0.2326 
1 2.25 ± 0.35 1.70 ± 0.35 3.55 ± 0.35 0.0121 
2 2.30 ± 0.39 2.03 ± 0.39 2.49 ± 0.39 0.7114 
3 2.12 ± 0.38 1.29 ± 0.38 2.18 ± 0.38 0.2291 
4 2.25 ± 0.65 2.20 ± 0.65 1.23 ± 0.65 0.4817 
5 1.03 ± 0.27 0.88 ± 0.27 0.89 ± 0.27 0.9038 
7 0.94 ± 0.31 1.19 ± 0.31 0.63 ± 0.31 0.4731 
Treatment main 
effect P-value 0.0002 0.0003 0.0001 
 
 
 
 
 
Figure 30.  T cell+ CD4+ CD8- estimates by day and treatment group, Study B primary 
response. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The mIgG 
treatment elicited the highest response, and it was significantly higher compared to the other 
groups on day 1. Different lowercase letters (a-b) within one time point represent significant 
differences (p < 0.05) between the treatment groups. Different uppercase letters (A-C) represent 
significant changes between days for each treatment group. 
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 The  T cell+ CD4+ CD8- estimates in the treatment and control groups of the 
memory response study changed significantly only by day (see Table 109). In the treatment 
groups, the response increased significantly by day 0.25 and peaked on day 1, after which it 
started decreasing. The estimates on day 5 were still significantly higher compared to baseline. In 
the control group, the estimates increased significantly compared to baseline on day 1. No 
significant changes in estimates were observed after day 1, and they were no longer significantly 
higher compared to baseline on day 5. 
 
Table 109.  T cell+ CD4+ CD8- estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 0.33 ± 0.09 a 
CD4+ CD8- 0.25 1.37 ± 0.19 b 
 1 2.68 ± 0.43 c 
 2 2.22 ± 0.26 c 
 3 1.85 ± 0.19 b 
 4 0.68 ± 0.12 d 
 5 0.84 ± 0.15 d 
 T cell+ 0 0.20 ± 0.03 a 
CD4+ CD8- (PBS) 0.25 0.18 ± 0.04 a 
 1 1.47 ± 0.29 b 
 2 1.21 ± 0.24 b 
 3 1.11 ± 0.50 ab 
 4 1.15 ± 0.09 b 
 5 1.13 ± 0.38 ab 
Note: different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
 
 A significant fixed effect of the interaction between treatment and collection time was 
observed for the  T cell+ CD4+ CD8+ response in the primary response study (see Table 
110). The main effect of treatment was significant in the Alum-mIgG and IO-mIgG groups, but 
not in the mIgG group. The day main effect was not significant for any time of sample collection 
as no significant differences between the groups were observed by day (see Figure 31). 
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Table 110. Treatment and day interaction effect estimates and main effects p-values of  T 
cell+ CD4+ CD8+, Study B primary response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.88 ± 0.15 0.84 ± 0.15 0.71 ± 0.15 0.7376 
0.25 0.24 ± 0.15 0.35 ± 0.15 0.56 ± 0.15 0.3362 
1 0.68 ± 0.25 0.72 ± 0.25 0.58 ± 0.25 0.9183 
2 0.55 ± 0.13 0.41 ± 0.13 0.31 ± 0.13 0.4754 
3 0.43 ± 0.13 0.39 ± 0.13 0.29 ± 0.13 0.7355 
4 0.49 ± 0.11 0.36 ± 0.11 0.30 ± 0.11 0.5144 
5 0.44 ± 0.12 0.26 ± 0.12 0.40 ± 0.12 0.5699 
7 0.42 ± 0.14 0.47 ± 0.14 0.35 ± 0.14 0.8231 
Treatment main 
effect P-value 0.0045 0.0198 0.7336 
 
 
 
 
Figure 31.  T cell+ CD4+ CD8+ estimates by day and treatment group, Study B primary 
response. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. No significant 
differences were observed between the groups. Different lowercase letters (a-b) within one time 
point represent significant differences (p < 0.05) between the treatment groups. Different 
uppercase letters (A-C) represent significant changes between days for each treatment group. 
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 In the memory response study, the  T cell+ CD4+ CD8+ response changed 
significantly by day, but only in the treatment groups (see Table 111). The estimates increased 
significantly by day 1 and remained consistent until day 4. On day 5, another significant increase 
compared to previous days was observed. 
 
Table 111.  T cell+ CD4+ CD8+ estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
 T cell+ 0 0.21 ± 0.03 a 
CD4+ CD8+ 0.25 0.18 ± 0.01 a 
 1 0.37 ± 0.07 b 
 2 0.42 ± 0.06 b 
 3 0.45 ± 0.09 b 
 4 0.42 ± 0.13 ab 
 5 1.21 ± 0.18 c 
Note: different letters (a-d) represent significant differences (p < 0.05) between days for each 
response factor. 
 
 
B Cell Receptors 
 In the primary response study, the effect of collection time was significant for B cell+ 
IgM+, which increased significantly by day 1 and continued to increase until their estimates 
peaked on day 3 (see Table 112). Although the estimates started decreasing significantly after 
day 3, the estimates on day 7 were still significantly higher compared to the estimates at baseline. 
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Table 112. B cell+ IgM+ estimates by day, Study B primary response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) 
Difference of Least Squares 
Means 
B cell+ IgM+ 0 0.26 ± 0.10 a 
 0.25 0.52 ± 0.13 a 
 1 3.67 ± 0.44 b 
 2 8.16 ± 1.28 c 
 3 11.14 ± 1.70 d 
 4 9.47 ± 1.54 cd 
 5 4.75 ± 0.63 b 
 7 1.66 ± 0.28 e 
Note: different letters (a-e) represent significant differences (p < 0.05) between days. 
 
 
 In the memory response study, a significant effect of the interaction between collection 
time and treatment was observed for the B cell+ IgM+ response factor. The treatment main effect 
was significant in IO-mIgG and mIgG groups, and the collection time main effect was significant 
only on day 3 (see Table 113). The only significant difference between the groups was observed 
on day 3 as the response was significantly higher in the IO-mIgG group compared to the Alum-
mIgG group, but not compared to the mIgG group (see Figure 32). 
 
Table 113. Treatment and day interaction effect estimates and main effects p-values of B cell+ 
IgM+ cells, Study B memory response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.16 ± 0.10 0.34 ± 0.10 0.06 ± 0.10 0.1897 
0.25 0.93 ± 0.25 1.17 ± 0.25 1.30 ± 0.25 0.5915 
1 11.99 ± 4.96 13.11 ± 4.96 8.15 ± 4.96 0.7656 
2 9.73 ± 2.52 13.18 ± 2.52 10.21 ± 2.52 0.5962 
3 6.52 ± 2.02 15.79 ± 2.02 11.05 ± 2.02 0.0307 
4 2.80 ± 0.99 3.30 ± 0.99 0.98 ± 0.99 0.2663 
5 1.41 ± 0.81 3.35 ± 0.81 1.88 ± 0.81 0.2642 
Treatment main 
effect P-value 0.0904 0.0084 0.0020 
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 The B cell+ IgM+ estimates also changed significantly by day in the PBS group (see 
Table 114). Significant differences compared to baseline were observed on days 1, 2, and 4. 
Unlike the response in the treatment groups, which showed decreases in IgM+ estimates after 
day 1 or 3, the response in the control group increased progressively until day 5. 
 
 
 
Figure 32. B cell+ IgM+ estimates by day and treatment group, Study B memory response. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. IO-mIgG 
elicited the strongest response, and it was significantly higher compared to the Alum-mIgG 
group on day 3, but not compared to the mIgG group. Different lowercase letters (a-b) within 
one time point represent significant differences (p < 0.05) between the treatment groups. 
Different uppercase letters (A-D) represent significant changes between days for each treatment 
group. 
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Table 114. B cell+ IgM+ estimates by day, Study B memory response (PBS) 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) 
Difference of Least Squares 
Means 
B cell+ IgM+ 0 0.16 ± 0.05 a 
 0.25 0.18 ± 0.06 a 
 1 3.85 ± 0.36 b 
 2 3.69 ± 0.91 b 
 3 4.37 ± 1.58 ab 
 4 7.05 ± 1.05 b 
 5 9.47 ± 3.43 ab 
Note: different letters (a-e) represent significant differences (p < 0.05) between days. 
 
 B cell+ IgM- cells were significantly affected by both collection time and treatment type 
in the primary response study, but not by their interaction (see Table 115). Their estimates 
increased significantly by day 0.25, and continued increasing until they peaked on day 2. The B 
cell+ IgM- estimates remained consistent until day 7, when they reduced significantly compared 
to day 5, but they were still significantly higher compared to baseline estimates. The strongest 
response was observed in the mIgG group, and it was significantly higher compared to response 
observed in the Alum-mIgG group, but not compared to the IO-mIgG group. 
 In the memory response study, B cell+ IgM- estimates changed significantly by day in 
the treatment groups and the control group (see Table 116). In the treatment groups, the response 
increased significantly by day 1 and remained elevated until day 4, when a significant decrease 
was observed. The estimates were no longer significantly higher on day 5 compared to baseline 
estimates. In the control group, significantly higher estimates compared to baseline were 
observed on days 1, 2, and 4. Unlike the response observed in the treatment groups, the response 
in the control group progressively increased from baseline until day 5. 
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Table 115. B cell+ IgM- estimates by day and treatment group, Study B primary response  
Response Factor Fixed Effect Estimate (࢞ഥ േ ࡿࡱ) Difference of Least Squares Means 
B cell+ IgM- Days   
 0 0.05 ± 0.01 a 
 0.25 0.16 ± 0.04 b 
 1 0.95 ± 0.12 c 
 2 1.96 ± 0.40 d 
 3 1.58 ± 0.26 cd 
 4 1.66 ± 0.26 d 
 5 1.29 ± 0.17 cd 
 7 0.52 ± 0.10 e 
 Treatment   
 Alum-mIgG 0.69 ± 0.18 a 
 IO-mIgG 0.95 ± 0.18 ab 
 mIgG 1.43 ± 0.18 b 
Note: different letters (a-e) represent significant differences (p < 0.05) between days and 
between treatment groups. 
 
Table 116. B cell+ IgM- estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) 
Difference of Least Squares 
Means 
B cell+ IgM- 0 0.28 ± 0.06 ac 
 0.25 0.23 ± 0.04 a 
 1 2.57 ± 0.59 b 
 2 1.79 ± 0.43 b 
 3 2.21 ± 0.41 b 
 4 0.61 ± 0.14 c 
 5 0.42 ± 0.13 ac 
B cell+ IgM-  0 0.10 ± 0.04 a 
(PBS) 0.25 0.03 ± 0.01 a 
 1 0.72 ± 0.13 b 
 2 0.68 ± 0.12 b 
 3 0.89 ± 0.36 ab 
 4 1.01 ± 0.18 b 
 5 1.27 ± 0.48 ab 
Note: different letters (a-e) represent significant differences (p < 0.05) between days. 
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 In the primary response study, no significant changes were observed in B cell+ IgG+ 
estimates, but a significant fixed effect of collection time was observed in the treatment groups 
of the memory response study (see Table 117). The response was significant by day 0.25, and the 
estimates remained significantly higher compared to baseline estimates on subsequent sample 
collection times.  
 
Table 117. B cell+ IgG+ estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) 
Difference of Least Squares 
Means 
B cell+ IgG+ 0 0.01 ± 0.002 a 
 0.25 0.11 ± 0.04 b 
 1 0.40 ± 0.12 bcd 
 2 0.22 ± 0.03 c 
 3 0.47 ± 0.08 d 
 4 0.22 ± 0.05 c 
 5 0.15 ± 0.04 bc 
Note: different letters (a-e) represent significant differences (p < 0.05) between days. 
 
 The interaction between time of collection and treatment type was significant for B cell+ 
IgG- cells in the primary response study (see Table 118). The main effect of treatment was 
significant for all treatment groups, whereas the main effect of collection time was significant 
only on day 5. However, significant differences between the groups were observed between days 
3 and 5. On day 3, the estimates were significantly higher in the mIgG group compared to the 
Alum-mIgG group, but not compared to the IO-mIgG group. On day 4, the estimates were 
significantly higher on day 4 in the IO-mIgG group compared to the Alum-mIgG group, but not 
compared to the mIgG group. On day 5, both IO-mIgG and mIgG groups had significantly 
higher IgG- estimates compared to the Alum-mIgG group (see Figure 33). 
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Table 118. Treatment and day interaction effect estimates and main effects p-values of B cell+ 
IgG- cells, Study B primary response 
 Treatment  
Day Alum-mIgG (࢞ഥ	േ ࡿࡱ, n = 4) 
IO-mIgG (࢞ഥ േ
ࡿࡱ, n = 4) 
mIgG 
(࢞ഥ േ ࡿࡱ, n = 4) Day main effect P-value 
0 0.30 ± 0.18 0.31 ± 0.18 0.37 ± 0.18 0.9595 
0.25 0.59 ± 0.28 0.86 ± 0.28 0.33 ± 0.28 0.4245 
1 4.52 ± 0.99 3.52 ± 0.99 6.19 ± 0.99 0.2091 
2 8.12 ± 2.75 9.29 ± 2.75 12.76 ± 2.75 0.4922 
3 10.05 ± 3.63 10.75 ± 3.63 21.94 ± 3.63 0.0809 
4 6.40 ± 2.95 16.59 ± 2.95 8.47 ± 2.95 0.0824 
5 2.00 ± 1.12 8.01 ± 1.12 5.59 ± 1.12 0.0129 
7 2.21 ± 0.53 2.86 ± 0.53 1.44 ± 0.53 0.2199 
Treatment main 
effect P-value 0.0394 0.0137 0.0012 
 
 
 
 
 
Figure 33. B cell+ IgG- estimates by day and treatment group, Study B primary response. 
 
The graph shows mean differences of the treatment*day effect, not the main effect. The 
mIgG treatment elicited a stronger response on day 3 compared to the Alum-mIgG 
treatment, and the IO-mIgG treatment elicited a stronger response on day 4 compared to the 
Alum-mIgG treatment. Different lowercase letters (a-b) within one time point represent 
significant differences (p < 0.05) between the treatment groups. Different uppercase letters 
(A-D) represent significant changes between days for each treatment group. 
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 In the memory response study treatment groups and the control group, significant 
changes by day were observed in the B cell+ IgG- estimates by day (see Table 119). In the 
treatment group, a significant response was observed by day 0.25, and the highest values were 
observed on days 1-3. A significant decrease was observed on days 4 and 5, but the estimates 
were still significantly higher on those days compared to baseline estimates. In the control group, 
significantly higher estimates compared to baseline were observed on days 1, 2, and 4. Unlike 
the response observed in the treatment groups, the response in the control group progressively 
increased from baseline until day 5. 
 
Table 119. B cell+ IgG- estimates by day, Study B memory response 
Response Factor Days Estimate (࢞ഥ േ ࡿࡱ) 
Difference of Least Squares 
Means 
B cell+ IgG- 0 0.41 ± 0.16 a 
 0.25 1.42 ± 0.19 b 
 1 12.12 ± 2.84 c 
 2 12.88 ± 1.69 c 
 3 12.19 ± 1.46 c 
 4 2.83 ± 0.61 b 
 5 2.24 ± 0.49 b 
B cell+ IgG-  0 0.38 ± 0.12 a 
(PBS) 0.25 0.16 ± 0.07 a 
 1 4.70 ± 0.67 b 
 2 4.26 ± 1.14 b 
 3 5.12 ± 1.89 ab 
 4 8.03 ± 0.98 b 
 5 8.07 ± 2.82 ab 
Note: different letters (a-e) represent significant differences (p < 0.05) between days. 
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Summary 
 In the primary response study, significant changes by day only were observed for 13 
response factors. The fixed effect of treatment was significant only for the IgM- response factor 
because the estimates were significantly higher in the mIgG group compared to the Alum-mIgG 
group, but not compared to the IO-mIgG group. 
 The fixed effect of interaction between treatment and collection time was significant for 
the following three response factors: MHCII+ macrophages, 2 T cells+ CD4+ CD8+, and 
IgG-. However, no significant differences between the groups were observed for the 2 T 
cells+ CD4+ CD8+ response factor. The MHCII+ macrophage response was significantly higher 
in the Alum-mIgG group compared to the IO-mIgG group, but not compared to the mIgG group. 
The IgG- response was significantly higher in the IO-mIgG and mIgG groups compared to the 
Alum-mIgG group. 
 In the memory response study, time of collection was the only significant fixed effect for 
a total of 16 response factors. The fixed effect of treatment was significant only for the  T cell+ 
CD8- response factor. The highest estimates were observed in the Alum-mIgG group, and they 
were significantly higher compared to the other groups. 
 The interaction between treatment and time of collection in the memory response study 
was a significant fixed effect for the following 5 factors: MHCII+ macrophages, CD4+ 
CD8+,T cell+ CD8+,  T cell+ CD4- CD8-, and B cell+ IgM+ response factors. However, 
no differences were observed in CD4+ CD8+ estimates between the groups, and the only 
differences observed forT cell+ CD4- CD8+ and  T cell+ CD4- CD8- estimates were at 
baseline, not after the injections. Alum-mIgG elicited a significantly higher MHCII+ 
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macrophage response compared to the other groups, but IO-mIgG and mIgG elicited a 
significantly higher IgM+ response compared to Alum-mIgG. 
 In the PBS control group of the memory response study, a total of 15 response factors 
changed significantly by day. The PBS group was not statistically differnet compared to the 
treatment groups, but the estimates observed indicate that the response in the control group was 
weaker, slower, and shorter in duration compared to the treatment groups. For most factors, 
significant changes compared to baseline were observed only on days 1, 2, and 4, whereas the 
treatment groups would typically elicit a strong response by day 0.25. 
 The difference of least squares means and the simple effect comparisons results are 
included in Appendix H for the primary response studies and Appendix J for the memory 
response studies.  
Discussion 
 The purpose of the intramuscular injection studies was to demonstrate the feasibility of 
the chicken model as an in vivo test system for monitoring humoral and cell-mediated immune 
responses. The treatment preparations were injected into the chicken breast muscles, followed by 
feather injections of the recall Ag at the height of the primary immune response 10 days post-
primary intramuscular immunization and at the heights of the secondary immune response 5 days 
post-secondary intramuscular immunization. The recall antigen injections recruited the immune 
cells to the growing feather pulp, so it was possible to monitor the immune responses 
periodically in each subject without using invasive methods to obtain samples for the analysis. 
Therefore, the growing feather in chickens is a suitable in vivo test site for observing the 
interactions between NPs and the immune system. 
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 The second purpose of these studies was to compare the strength and duration of immune 
responses among Alum-mIgG, IO-mIgG, and mIgG treatment preparations. In Study A, the 
concentration of mIgG in the IONP group was 0.26 mg/ml, whereas a concentration of 5 mg/ml 
was used in the mIgG and Alum-mIgG groups. The treatment concentrations for all groups were 
matched in Study B by reducing the mIgG and Alum-mIgG treatment concentrations to 0. 26 
mg/ml. It was hypothesized that IONPs would elicit a significantly higher immune response 
compared to the other groups.  
 In the Study A primary response, significant changes by day only were observed for 11 
response factors, and the fixed effect of treatment was significant only for the  T cell+ CD8+ 
response factor. The  T cell+ CD8+ estimates in the IO-mIgG group were significantly higher 
compared to the Alum-mIgG group, but not compared to the mIgG group. The CD4+ CD8-,  T 
cell+ CD8-, and MHCII+ B cell+ response factors showed a significant fixed effect of the 
interaction. For the CD4+ CD8- estimates, the only significant difference was observed at 
baseline between the groups, but IO-mIgG elicited a significantly higher response for  T cell+ 
CD8- and MHCII+ B cell+ factors compared to other treatment preparations. 
 In the Study A memory response, significant changes by day only were observed for ten 
response factors. The fixed effect of treatment was significant for CD45+, CD4+ CD8-,  T 
cell+, and MHCII+ B cell+ response factors. The highest responses were observed in the IO-
mIgG group, and they were significantly higher compared to the Alum-mIgG and mIgG groups. 
 These results indicate that IONPs are more efficient adjuvants compared to an aluminum-
based adjuvant and antigen preparations alone for eliciting both primary and memory immune 
responses. However, the results of Study B were not consistent with the results observed in 
Study A. In the Study B primary response, significant changes by day only were observed for 13 
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response factors. The fixed effect of treatment was significant only for the IgM- response factor 
because the estimates were significantly higher in the mIgG group compared to the Alum-mIgG 
group, but not compared to the IO-mIgG group. 
 The fixed effect of interaction between treatment and collection time in the Study B 
primary response was significant for MHCII+ macrophages, 2 T cells+ CD4+ CD8+, and 
IgG- response factors. However, no significant differences between the groups were observed for 
the 2 T cells+ CD4+ CD8+ response factor. The MHCII+ macrophage response was 
significantly higher in the Alum-mIgG group compared to the IO-mIgG group, but not compared 
to the mIgG group. The B cell+ IgG- response was significantly higher in the IO-mIgG and 
mIgG groups compared to the Alum-mIgG group. 
 In the Study B memory response, time of collection was the only significant fixed effect 
for a total of 16 response factors. The fixed effect of treatment was significant only for the  T 
cell+ CD8- response factor. The highest estimates were observed in the Alum-mIgG group, and 
they were significantly higher compared to the other groups. The interaction between treatment 
and time of collection in the 2014 memory response study was a significant fixed effect for 
MHCII+ macrophages, CD4+ CD8+,T cell+ CD8+,  T cell+ CD4- CD8-, and B cell+ 
IgM+ response factors. No differences were observed in CD4+ CD8+ estimates between the 
groups, and the only differences observed forT cell+ CD8+ and  T cell+ CD4- CD8- 
estimates were at baseline, not after the injections. Alum-mIgG elicited a significantly higher 
MHCII+ macrophage response compared to the other groups, but IO-mIgG and mIgG elicited a 
significantly higher IgM+ response compared to Alum-mIgG. 
 The PBS memory response control group in Study A did not display significant changes 
by day in the observed response factors. However, the fixed effect of day was statistically 
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significant for 15 response factors in the PBS memory response control group. The PBS group 
was not statistically different compared to the treatment groups, but the estimates observed 
indicate that the response in the control group was not associated with the treatment preparation. 
For most factors, significant changes compared to baseline were observed only on days 1, 2, and 
4, whereas the treatment groups would typically elicit a strong response by day 0.25. Strong 
responses in the PBS group usually occurred in a progressive trend, whereas the response would 
usually decrease after days 0.25 or 1 in the treatment groups. 
 The differences between Study A and Study B were not statistically analyzed, so it is not 
possible to determine whether the changes in mIgG concentration increased the responses in the 
mIgG and Alum-mIgG groups significantly. However, the reduction of mIgG concentration in 
the mIgG and Alum-mIgG groups from 5 mg/ml to 0.26 mg/ml could explain the differences 
between the two studies. It is possible that the high mIgG concentration in Study A resulted in 
low avidity because of the excess antigen, so it was easy for the antigen to dissociate from the 
antibodies and fail to elicit a significant immune response. Therefore, antigen excess in the 
Alum-mIgG and mIgG groups of Study A could explain why IO-mIgG elicitied significantly 
higher responses compared to the other groups. Once the mIgG concentrations were matched in 
Study B, it is possible that the immune responses for Alum-mIgG and mIgG treatments increased 
because antigen excess was no longer an issue. 
 Antigen disassociation is also possible in NPs, but conjugation was used in both studies 
to achieve a strong interaction between IONPs and mIgG. Conjugation is a surface modification 
achieved when an antigen is chemically cross-linked to the NPs. These types of links result in a 
strong interaction between the antigen and NPs, and they are less likely to disassociate in vivo 
compared to other NP modification methods, such as adsorption (Zhao et al., 2014). Once an 
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immune cell takes up an NP with a conjugated antigen, the NP dissolves and releases the antigen, 
which the innate immune cells can then present to the adaptive immune cells. 
 If the differences in elicited responses between Study A and Study B Alum-mIgG and 
mIgG groups are not statistically significant, it is possible that the different adaptive immune 
system activation pathways of IONPs could account for the differences observed between the 
studies. The IO-mIgG treatment in the feather injection studies demonstrated a high innate 
response, but failed to elicit a high adaptive response. In Study A, IO-mIgG elicited did not elicit 
higher innate responses compared to the other groups, and Study B demonstrated that no 
significant changes were observed in MHCII+ macrophage+ estimates in the primary response to 
IO-mIgG. The IO-mIgG treatment elicited significantly higher T cell responses compared to the 
other groups in Study A, but not in Study B. 
 Although IO-mIgG did not elicit significantly higher innate and T cell responses 
compared to the other groups in Study B, it elicited significantly higher B cell, B cell+ IgM+, 
and B cell+ IgG- responses compared to the other treatments. In the primary response of Study 
A, the B cell response was significantly higher on day 2 in the IO-mIgG groups compared to the 
other groups. In the primary response of Study B, the B cell+ IgG- response increased 
significantly in all groups. However, the response in the IO-mIgG group was still increasing and 
significantly higher compared to the Alum-mIgG group on day 4, when the response in the other 
groups was already decreasing. In the memory response of Study B, the B cell+ IgM+ response 
was significantly higher on day 4 compared to the Alum-mIgG group, but not compared to the 
mIgG group. 
 The membrane bound IgM and IgG antibodies were not analyzed in the sample used in 
Study A, but their plasma concentration was measured and analyzed by Wilson (2014). After the 
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primary immunization, IgG and IgM levels in the plasma increased in the mIgG and Alum-mIgG 
groups between days 7-10, and they were significantly higher compared to antibody levels of the 
IO-mIgG group. However, increased plasma levels of antibodies in the IO-mIgG group were 
observed after day 10, and they were significantly higher compared to the concentrations of other 
groups, which started declining after day 7 or 10. After the secondary immunizations, the plasma 
levels of IgG and IgM increased in all groups, but the increase was significantly higher in the IO-
mIgG group compared to the other groups as the concentrations consistently increased until day 
10. 
 The possibility of direct humoral immunity stimulation is expected of small nanoparticles 
(< 30 nm) because their small size enhances tissue penetration and allows them to reach the 
mural lymph nodes without the assistance of dendritic cells (Smith, Simon, & Baker Jr, 2013). 
Perhaps the 10 nm IONPs used in these studies were trapped in the feather pulp tissue when 
injected into the feathers, so they had to be cleared by macrophages or heterophils. However, the 
IONPs injected into the breast muscles were probably able to penetrate tissues because of their 
small size and reach the mural lymph nodes even without the interference of dendritic cells. This 
could explain why IONPs could activate B cells and B cell receptors more efficiently than the 
other treatments without causing significant increases of innate immune cells. 
 Another possible explanation of these findings is the spatial organization of antigen on 
the surface of IONPs. When spherical NPs are used, the conjugation of antigen to their surface 
results in a repetitive antigen display (Smith et al., 2013). This could elicit a high B cell receptor 
response because polyvalent antigens increase the avidity of interaction between antibody and 
antigen, allowing them to form large immune complexes and initiate inflammatory reactions. 
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 These findings suggest that IO-mIgG can elicit an efficient and direct humoral immune 
response, but further research is necessary to optimize IONP-antigen treatment preparations for 
better results. The size of the IONPs used in this study (10 nm) is consistent with previous 
findings that suggest smaller particles allow the dendritic cells to take them up and present the 
antigen to the T and B cells in the mural lymph nodes (Xiang et al., 2006). Even if the dendritic 
cells fail to take up the small IONPs, the small size of the particles allows them to penetrate 
tissue membranes and reach the mural lymph nodes alone (Smith et al., 2013). However, drug 
delivery studies using IONPs demonstrated that the majority of the payload is released 
immediately upon in vivo injections (Mahmoudi, Sant, Wang, Laurent, & Sen, 2011). Perhaps 
the conjugated antigen can also be released if the concentration is too high relative to the size of 
the IONPs used or incompatible with the surface materials. 
 In the memory response of Study A, the PBS did not affect any of the monitored response 
factors, but a total of 15 significant responses were observed in the PBS group in the memory 
response of Study B. This difference between the two studies could be attributed to a 
confounding variable. Blalock (2005) demonstrated that the PBS injection alone is a stressor that 
can trigger the immune system, but injecting negligible amounts of corticotropin-releasing 
hormone after the injections amplified the immune responses significantly. The immune cells in 
the PBS control group in Study B did not behave like immune cells in the treatment groups, so it 
is possible that significant increases in immune cell estimates could be attributed to differences 
between the samples used in Study A and Study B PBS control groups rather than the injections. 
Specifically, elevated levels of stress response neurotransmitters in the Study A control could 
have affected the results. Future studies need to consider that immune responses to PBS are not 
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necessarily a placebo effect, and biological stress response factors should be considered as a 
possible confounding factor when interpreting findings. 
 An important limitation of these studies is that the doses were not calibrated for 
individual subjects. As demonstrated by Teeguarden et al. (2014), the toxicity levels of IONPs 
depend on the volume of the targeted organs. For the use of IONPs as adjuvants, it will be 
important to investigate various factors before clinical implementations are researched in 
humans, such as subject bodyweight and age. 
 These studies have important implications for future research and for guiding the 
development of clinical guidelines regarding the use of IONPs as vaccine adjuvants. The 
findings of these studies suggest that IONPs are promising adjuvants because they elicited a 
significantly higher humoral immune response compared to the other treatments. The majority of 
studies focused on determining how shape, size, surface modifications, and charge affect 
immune responses to IONPs (Gregory, Titball, & Williamson, 2013). However, none of the 
studies considered antigen concentration as a factor that determines the efficiency of IONPs as 
adjuvants. Before clinical applications and guidelines for the use of IONPs as adjuvants are 
developed, future studies need to determine how the size of the NPs determine optimal antigen 
concentrations so that the antigen can reach the mural lymph nodes and trigger an adaptive 
immune response. Other methods of achieving interactions between NPs and antigen should also 
be explored in future studies because it is possible that encapsulation could prove to be a more 
effective antigen delivery method compared to conjugation. 
 The tissue targeting ability of NPs also needs to be investigated in future studies. At the 
moment, the attempts to elicit an immune response using IONPs usually rely on uptake by 
macrophages or dendritic cells, which should then present the conjugated antigen in the mural 
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lymph nodes. However, the ability to target specific tissues and evade the innate immune cells 
would enable IONPs to reach the mural lymph nodes and present the antigen to T and B cells 
without the involvement of the innate response cells. Conventional adjuvants cannot use those 
methods to achieve the same objective, so the main advantage of IONPs is to trigger a faster 
adaptive response by directly presenting the antigen to the immune cells in the mural lymph 
nodes. 
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CONCLUSION 
 The feather injection studies demonstrated the advantages of the chicken model for 
studying IONP bioactivities in vivo. Injections of treatment preparations into the growing feather 
pulp resulted in an infiltration of leukocytes that was then monitored periodically for each 
individual subject. The model was minimally invasive as the samples for analyses can be 
obtained by plucking the growing feathers. The intramuscular injection studies also demonstrated 
that direct administrations of treatment preparations into the feather pulp are not required to 
monitor the responses using the growing feather pulp as tissue samples. 
 In the feather injection studies, IO-mIgG did not elicit a strong adaptive immune 
response, but heterophil blood concentration and MHCII+ macrophage pulp infiltration was 
significantly higher in the IO-mIgG group compared to the other groups. It is expected that those 
innate cells took up and cleared the IONPs without presenting the antigen to T or B cells. The 
CD4/CD8 ratio remained within normal ranges and returned to baseline values on day 4 in the 
IO-mIgG group of Study 3. Therefore, the application of IONPs could be considered safe, but 
more research will be required to better understand IONP clearance, degradation, and long-term 
toxicity in vivo. 
 In the intramuscular injection studies, the IO-mIgG treatment elicited a stronger immune 
response compared to the other treatment groups in Study A. However, the results of Study B 
were not consistent with the results observed in Study A. It is possible that the concentration of 
antigen in the Alum-mIgG and the mIgG groups was too high in Study A and could have 
resulted in antigen excess and low immune responses. Another possibility is that IO-mIgG was 
able to elicit a significant humoral immune response directly because the repetitive spatial 
organization of antigens on their surface increased the avidity of antibody and antigen 
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interactions. This could explain how IO-mIgG elicited a significantly higher IgG- and IgM+ 
responses in Study B compared to the Alum-mIgG group without eliciting significantly higher 
responses of other factors measured. The 10 nm IONPs used in these studies could also penetrate 
tissue because of their small size and reach the mural lymph nodes directly to deliver the antigen 
to antigen presenting cells. These results suggest that IONPs have the ability to elicit an adaptive 
response, but their efficacy can depend on various factors, including surface modifications, size, 
and antigen concentration. 
 The clinical utility of IONPs as vaccine adjuvants is promising, but needs to be further 
investigated. Future studies need to explore how antigen concentration relative to the size of the 
IONPs determines the efficacy of immune response elicitation so that the zone of equivalence 
can be reached in vivo. Surface modifications to prevent immediate releases of the conjugated 
antigen and other methods for establishing interactions between the IONPs and antigen should 
also be investigated to evaluate their efficacy. Although IONPs are already considered safe, 
longitudinal research will be necessary to monitor the long-term effects of IONP administration 
on individual subjects, as well as their effects on genetic traits of future generations. 
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APPENDIX B 
Response Factors by Study 
 
Table B1. Response factors by study 
Response Factor Feather Injection Studies Intramuscular Injection Studies 
1 2 3 Primary (A) 
Memory 
(A) 
Primary 
(B) 
Memory 
(B) 
Blood cells     
WBCs (K/ul) + + + - - - - 
Heterophils (K/ul) + + + - - - - 
Heterophils (%) + + + - - - - 
Lymphocyte (K/ul) + + + - - - - 
Lymphocyte (%) + + + - - - - 
Monocytes (K/ul) + + + - - - - 
Monocytes (%) + + + - - - - 
Eosinophils (K/ul) + + + - - - - 
Eosinophils (%) + + + - - - - 
Basophils (K/ul) + + + - - - - 
Basophil (%) + + + - - - - 
RBCs (K/ul) + + + - - - - 
Thrombocytes 
(K/ul) + + + - - - - 
Cell types     
Live cells + - + - - + + 
CD45+ + + + + + - - 
Macrophages + + - - - - - 
Heterophils - + + - - - - 
Lymphocytes + - - - - - - 
MHCII+     
Macrophages+ + + + + + + + 
B cell+ + + + + + + + 
T cells     
CD3+ - - + - + + + 
CD4- CD8+ + + + + + + + 
CD4+ CD8+ + + + + + + + 
CD4+ CD8- + + + + + + + 
CD25+ CD4+ - - - + + - - 
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Table B1. Response factors by study (Cont.) 
Response Factor Feather Injection Studies Intramuscular Injection Studies 
 2013 
IO 
2013  
IO vs. Alum
2014 Primary 
2013 
Memory 
2013 
Primary 
2014 
Memory 
2014 
T cell+ - - + - - + + 
T cell+ CD8+ + + + + + + + 
T cell+ CD8- + + + + + + + 
1 Tcell+ - - + - - + + 
2 Tcell+ + + - + + - - 
1 Tcell+ + + - + + - - 
1 T cell+ 
CD4-CD8+  - - + - - + + 
1 T cell+ 
CD4+CD8+  - - + - - + + 
1 T cell+ 
CD4-CD8-  - - + - - + + 
1 T cell+ 
CD4+CD8-  - - + - - + + 
2 T cell+ - - + - - + + 
2 T cell+ 
CD4-CD8+  - - + - - + + 
2 T cell+ 
CD4+CD8+  - - + - - + + 
2 T cell+ 
CD4-CD8-  - - + - - + + 
2 T cell+ 
CD4+CD8-  - - + - - + + 
CD4/CD8 ratio + + + - - - - 
B cells     
B cell + + - + + - - 
B cell+ IgM+ - - + - - + + 
B cell+ IgM- - - + - - + + 
B cell+ IgG+ - - + - - + + 
B cell+ IgG- - - + - - + + 
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APPENDIX C 
Type III Test of Fixed Effects Results for Blood Cell Responses 
 
  Study 1 Study 2 Study 3 
Response Factor Fixed Effect F  p F  p  F  p 
WBCs (K/uL) Day 3.37 NS 6.42 0.0142 3.79 NS 
 Treatment 0.37 NS 1.94 NS 2.06 NS 
 Treatment*Day 0.51 NS 1.53 NS 0.42 NS 
Heterophils (K/uL) Day 42.08 < 0.0001 208.21 < 0.0001 9.61 0.0075 
 Treatment 0.08 NS 0.54 NS 0.44 NS 
 Treatment*Day 2.02 NS 4.93 0.0078 0.65 NS 
Heterophils (%) Day 67.05 < 0.0001 18.02 0.0003 29.34 0.0002 
 Treatment 0.70 NS 1.60 NS 0.96 NS 
 Treatment*Day 1.52 NS 0.79 NS 2.56 NS 
Lymphocytes (K/uL) Day 25.78 0.0001 1.03 NS 28.97 0.0002 
 Treatment 0.21 NS 3.52 0.0488 2.29 NS 
 Treatment*Day 0.39 NS 1.36 NS 3.21 NS 
Lymphocytes (%) Day 21.37 0.0002 72.87 < 0.0001 20.76 0.0007 
 Treatment 0.23 NS 3.06 NS 0.93 NS 
 Treatment*Day 0.60 NS 1.63 NS 1.66 NS 
Monocytes (K/uL) Day 1.69 NS 5.36 0.0237 15.64 0.0017 
 Treatment 0.91 NS 1.44 NS 0.71 NS 
 Treatment*Day 0.62 NS 0.64 NS 0.67 NS 
Monocytes (%) Day 5.93 0.02 5.20 0.0258 5.90 0.0267 
 Treatment 0.25 NS 1.82 NS 0.02 NS 
 Treatment*Day 0.46 NS 0.24 NS 0.47 NS 
Eosinophils (K/uL) Day 0.79 NS 2.99 NS 1.40 NS 
 Treatment 0.88 NS 0.82 NS 2.16 NS 
 Treatment*Day 0.53 NS 1.14 NS 0.11 NS 
Eosinophils (%) Day 1.06 NS 2.93 NS 4.75 0.0438 
 Treatment 0.25 NS 0.91 NS 0.44 NS 
 Treatment*Day 0.48 NS 1.06 NS 0.60 NS 
Basophils (K/uL) Day 1.35 NS 12.57 0.0014 5.21 0.0356 
 Treatment 3.62 NS 1.41 NS 1.83 NS 
 Treatment*Day 1.90 NS 1.82 NS 0.24 NS 
Basophils (%) Day 0.34 NS 17.92 0.0003 0.74 NS 
 Treatment 3.75 NS 1.81 NS 0.72 NS 
 Treatment*Day 1.03 NS 1.65 NS 0.18 NS 
RBCs (K/uL) Day 0.34 NS 8.95 0.0049 2.52 NS 
 Treatment 0.54 NS 0.68 NS 0.93 NS 
 Treatment*Day 0.51 NS 1.03 NS 0.07 NS 
Thrombocytes (K/uL) Day 15.75 0.0008 1.91 NS 4.60 0.0469 
 Treatment 2.80 NS 3.06 NS 4.44 0.0455 
 Treatment*Day 1.01 NS 2.03 NS 0.52 NS 
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APPENDIX D 
Difference of Least Squares Means Results for Blood Cell Responses 
 
Table D1. Difference of least squares means for blood cell responses by day 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
Study 1        
Heterophil (K/uL) 0 0.25 -3.6740 0.4023 11 -9.13 <.0001 
 0 7 -1.2360 0.3327 11 -3.72 0.0034 
 0.25 7 2.4380 0.3110 11 7.84 <.0001 
Heterophil (%) 0 0.25 -17.2593 1.4849 11 -11.62 <.0001 
 0 7 -10.8093 4.0198 11 -2.69 0.0211 
 0.25 7 6.4500 3.5297 11 1.83 0.0949 
Lymphocyte (K/uL) 0 0.25 8.1347 1.0876 11 7.48 <.0001 
 0 7 4.7645 1.6416 11 2.90 0.0144 
 0.25 7 -3.3702 1.4579 11 -2.31 0.0412 
Lymphocyte (%) 0 0.25 24.4017 3.5894 11 6.80 <.0001 
 0 7 11.0933 4.3271 11 2.56 0.0263 
 0.25 7 -13.3083 4.8842 11 -2.72 0.0198 
Monocyte (%) 0 0.25 -3.8332 1.0905 11 -3.52 0.0048 
 0 7 0.03917 0.6331 11 0.06 0.9518 
 0.25 7 3.8723 1.1381 11 3.40 0.0059 
Thrombocyte (K/uL) 0 0.25 -7.9300 1.3850 11 -5.73 0.0001 
 0 7 -2.4600 0.9623 11 -2.56 0.0267 
 0.25 7 5.4700 1.5083 11 3.63 0.0040 
Study 2        
WBC (K/uL) 0 0.25 -4.4188 1.2304 12 -3.59 0.0037 
 0 7 -0.5937 2.4175 12 -0.25 0.8101 
 0.25 7 3.8250 2.9408 12 1.30 0.2178 
Heterophil (%) 0 0.25 -11.6062 1.8923 12 -6.13 <.0001 
 0 7 1.1900 1.4368 12 0.83 0.4237 
 0.25 7 12.7963 2.2863 12 5.60 0.0001 
Lymphocyte (%) 0 0.25 13.2312 1.6245 12 8.14 <.0001 
 0 7 5.2250 3.9693 12 1.32 0.2126 
 0.25 7 -8.0062 5.2264 12 -1.53 0.1515 
Monocyte (K/uL) 0 0.25 -1.2388 0.3707 12 -3.34 0.0059 
 0 7 -0.8013 0.4708 12 -1.70 0.1145 
 0.25 7 0.4375 0.5032 12 0.87 0.4017 
Monocyte (%) 0 0.25 -2.9069 0.9049 12 -3.21 0.0075 
 0 7 -2.4206 2.2450 12 -1.08 0.3021 
 0.25 7 0.4863 2.4020 12 0.20 0.8430 
Basophil (K/uL) 0 0.25 0.2031 0.1452 12 1.40 0.1873 
 0 7 -1.2112 0.3197 12 -3.79 0.0026 
 0.25 7 -1.4144 0.2819 12 -5.02 0.0003 
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Table D1. Difference of least squares means for blood cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
Basophil (%) 0 0.25 1.3031 0.4250 12 3.07 0.0098 
 0 7 -3.8531 1.3517 12 -2.85 0.0146 
 0.25 7 -5.1562 1.1720 12 -4.40 0.0009 
RBC (K/uL) 0 0.25 0.09000 0.02271 12 3.96 0.0019 
 0 7 0.01937 0.03162 12 0.61 0.5514 
 0.25 7 -0.07063 0.02660 12 -2.66 0.0210 
Study 3        
Heterophil (K/uL) 0 0.25 -4.6167 1.1709 9 -3.94 0.0034 
 0 7 1.3642 0.7121 9 1.92 0.0877 
 0.25 7 5.9808 1.2868 9 4.65 0.0012 
Heterophil (%) 0 0.25 -21.0083 2.7745 9 -7.57 <.0001 
 0 7 0.2583 1.4962 9 0.17 0.8667 
 0.25 7 21.2667 2.6626 9 7.99 <.0001 
Lymphocyte (K/uL) 0 0.25 8.9658 1.1304 9 7.93 <.0001 
 0 7 1.2208 1.7853 9 0.68 0.5113 
 0.25 7 -7.7450 1.8378 9 -4.21 0.0023 
Lymphocyte (%) 0 0.25 24.3017 3.7266 9 6.52 0.0001 
 0 7 -2.8083 1.8419 9 -1.52 0.1617 
 0.25 7 -27.1100 4.0247 9 -6.74 <.0001 
Monocyte (K/uL) 0 0.25 -0.5817 0.4410 9 -1.32 0.2198 
 0 7 0.9332 0.1604 9 5.82 0.0003 
 0.25 7 1.5148 0.4735 9 3.20 0.0108 
Monocyte (%) 0 0.25 -3.7408 1.6604 9 -2.25 0.0508 
 0 7 2.1950 0.6583 9 3.33 0.0087 
 0.25 7 5.9358 1.9331 9 3.07 0.0133 
Eosinophil (%) 0 0.25 -0.08917 0.03684 9 -2.42 0.0386 
 0 7 -0.09467 0.03739 9 -2.53 0.0321 
 0.25 7 -0.00550 0.04842 9 -0.11 0.9121 
Basophil (K/uL) 0 0.25 0.4102 0.2564 9 1.60 0.1440 
 0 7 0.3754 0.1167 9 3.22 0.0105 
 0.25 7 -0.03483 0.2666 9 -0.13 0.8989 
Thrombocyte (K/uL) 0 0.25 4.3583 1.4054 9 3.10 0.0127 
 0 7 3.3750 1.6863 9 2.00 0.0764 
 0.25 7 -0.9833 1.7193 9 -0.57 0.5814 
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Table D2. Difference of least squares means for blood cell responses by Treatment 
Study/Factor Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
Study 2        
Lymphocyte (K/ul) Alum Alum-mIgG 1.3000 2.6443 12 0.49 0.6318 
 Alum IO 7.6400 2.6443 12 2.89 0.0136 
 Alum IO-mIgG 5.1458 2.6443 12 1.95 0.0754 
 Alum-mIgG IO 6.3400 2.6443 12 2.40 0.0337 
 Alum-mIgG IO-mIgG 3.8458 2.6443 12 1.45 0.1715 
 IO IO-mIgG -2.4942 2.6443 12 -0.94 0.3642 
Study 3        
Thrombocyte (K/uL) Alum-mIgG IO-mIgG 4.2417 1.4997 9 2.83 0.0198 
 Alum-mIgG mIgG 3.3417 1.4997 9 2.23 0.0529 
 IO-mIgG mIgG -0.9000 1.4997 9 -0.60 0.5632 
 
Table D3. Simple effect comparisons of treatment*day least squares means by treatment for 
heterophil concentration, Study 2 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum 0 0.25 -4.3125 0.7650 12 -5.64 0.0001
Alum 0 7 0.09500 0.7489 12 0.13 0.9012
Alum 0.25 7 4.4075 0.4638 12 9.50 <.0001
Alum-mIgG 0 0.25 -3.2825 0.7650 12 -4.29 0.0010
Alum-mIgG 0 7 -0.1125 0.7489 12 -0.15 0.8831
Alum-mIgG 0.25 7 3.1700 0.4638 12 6.84 <.0001
IO 0 0.25 -4.0775 0.7650 12 -5.33 0.0002
IO 0 7 0.7925 0.7489 12 1.06 0.3108
IO 0.25 7 4.8700 0.4638 12 10.50 <.0001
IO-mIgG 0 0.25 -7.0625 0.7650 12 -9.23 <.0001
IO-mIgG 0 7 -0.4450 0.7489 12 -0.59 0.5634
IO-mIgG 0.25 7 6.6175 0.4638 12 14.27 <.0001
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Table D4. Simple effect comparisons of treatment*day least squares means by say for heterophil 
concentration, Study 2 
Simple Effect Level Treatment Treatment Estimate
Std. 
Error DF t Value Pr > |t|
0 Alum Alum-mIgG -0.05500 0.7436 12 -0.07 0.9423 
0 Alum IO -0.6050 0.7436 12 -0.81 0.4317 
0 Alum IO-mIgG 0.2225 0.7436 12 0.30 0.7699 
0 Alum-mIgG IO -0.5500 0.7436 12 -0.74 0.4737 
0 Alum-mIgG IO-mIgG 0.2775 0.7436 12 0.37 0.7155 
0 IO IO-mIgG 0.8275 0.7436 12 1.11 0.2876 
0.25 Alum Alum-mIgG 0.9750 1.2906 12 0.76 0.4646 
0.25 Alum IO -0.3700 1.2906 12 -0.29 0.7792 
0.25 Alum IO-mIgG -2.5275 1.2906 12 -1.96 0.0738 
0.25 Alum-mIgG IO -1.3450 1.2906 12 -1.04 0.3179 
0.25 Alum-mIgG IO-mIgG -3.5025 1.2906 12 -2.71 0.0188 
0.25 IO IO-mIgG -2.1575 1.2906 12 -1.67 0.1204 
7 Alum Alum-mIgG -0.2625 1.0794 12 -0.24 0.8120 
7 Alum IO 0.09250 1.0794 12 0.09 0.9331 
7 Alum IO-mIgG -0.3175 1.0794 12 -0.29 0.7737 
7 Alum-mIgG IO 0.3550 1.0794 12 0.33 0.7479 
7 Alum-mIgG IO-mIgG -0.05500 1.0794 12 -0.05 0.9602 
7 IO IO-mIgG -0.4100 1.0794 12 -0.38 0.7107 
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APPENDIX E 
Type III Test of Fixed Effects Results for 
Pulp Cell Response in Feather Injection Studies 
 
Table E1. Type III test of fixed effects results for pulp cell response in feather injection studies 
  Study 1 Study 2 Study 3 
Response Factor Fixed Effect F Value P Value F Value P Value F Value P Value 
Live cells Day  6.95 0.0243 - - 3.66 NS 
 Treatment 2.34 NS - - 2.45 NS 
 Treatment*Day 11.29 0.0040 - - 0.45 NS 
CD45+ Day  2.20 NS 73.12 <0.0001 31.09 <0.0001 
 Treatment 5.90 0.0182 10.96 0.0009 15.52 <0.0001 
 Treatment*Day 0.67 NS 2.78 0.0482 2.77 0.0102 
Macrophages Day  5.50 0.0394 12.77 0.0012 - - 
 Treatment 0.21 NS 1.47 NS - - 
 Treatment*Day 1.49 NS 0.75 NS - - 
Heterophils Day  - - 9.72 0.0030 15.56 <0.0001 
 Treatment - - 0.91 NS 22.64 <0.0001 
 Treatment*Day - - 0.82 NS 4.16 0.0006 
Lymphocytes Day  10.56 0.0098 - - - - 
 Treatment 8.26 0.0065 - - - - 
 Treatment*Day 2.68 NS - - - - 
MHCII+  Day  14.54 0.0047 5.05 0.0219 31.47 0.0084 
Macrophages+ Treatment 0.09 NS 3.44 NS 15.59 0.0011 
 Treatment*Day 0.79 NS 1.24 NS 4.50 NS 
MHCII+  Day  13.83 0.0053 20.13 0.0002 83.44 NS 
B cells+ Treatment 3.41 NS 0.23 NS 3.30 NS 
 Treatment*Day 1.31 NS 0.89 NS 15.29 NS 
CD3+ Day  - - - - 23.96 <0.0001 
 Treatment - - - - 13.73 <0.0001 
 Treatment*Day - - - - 4.01 0.0008 
CD4- CD8+ Day  12.53 0.0067 22.96 <0.0001 51.70 0.0040 
 Treatment 6.26 0.0153 0.27 NS 5.05 0.0330 
 Treatment*Day 1.80 NS 0.91 NS 6.06 NS 
CD4+ CD8+ Day  10.07 0.0109 5.68 0.0107 2.00 NS 
 Treatment 4.81 0.0316 3.15 NS 1.06 NS 
 Treatment*Day 1.15 NS 1.34 NS 1.22 NS 
CD4+ CD8- Day  15.03 0.0044 9.68 0.0017 15.86 0.0107 
 Treatment 6.88 0.0115 4.51 0.0307 3.94 NS 
 Treatment*Day 2.12 NS 0.98 NS 0.74 NS 
T cell+ Day  - - - - 11.52 <0.0001 
 Treatment - - - - 12.97 0.0001 
 Treatment*Day - - - - 3.60 0.0016 
 
218 
 
 
 
Table E1. Type III test of fixed effects results for pulp cell response in feather injection studies 
(Cont.) 
  Study 1 Study 2 Study 3 
Response Factor Fixed Effect F Value P Value F Value P Value F Value P Value 
T cell+ CD8+ Day  4.60 NS 25.70 <0.0001 9.24 <0.0001 
 Treatment 2.36 NS 0.87 NS 0.28 NS 
 Treatment*Day 5.28 0.0273 2.07 NS 2.47 0.0207 
        
T cell+ CD8- Day  9.34 0.0128 36.61 <0.0001 11.79 <0.0001 
 Treatment 4.11 0.0464 16.96 0.0001 12.79 0.0002 
 Treatment*Day 0.81 NS 5.70 0.0033 3.15 0.0042 
1 Tcell+ Day  - - - - 22.09 <0.0001 
 Treatment - - - - 9.62 0.0005 
 Treatment*Day - - - - 2.27 0.0300 
 Tcell+ Day  4.94 0.0488 31.03 <0.0001 - - 
 Treatment 4.85 0.0309 6.88 0.0060 - - 
 Treatment*Day 1.82 NS 2.74 NS - - 
1 Tcell+ Day  5.48 0.0396 23.26 0.0001 - - 
 Treatment 7.89 0.0075 8.15 0.0032 - - 
 Treatment*Day 2.23 NS 2.52 NS - - 
1 T cell+ Day  - - - - 29.91 <0.0001 
CD4-CD8+ Treatment - - - - 18.20 0.0002 
 Treatment*Day - - - - 3.27 0.0042 
1 T cell+ Day  - - - - 4.94 0.0019 
CD4+CD8+ Treatment - - - - 2.40 NS 
 Treatment*Day - - - - 1.02 NS 
1 T cell+ Day  - - - - 413.04 0.0025 
CD4-CD8- Treatment - - - - 0.29 NS 
 Treatment*Day - - - - 0.92 NS 
1 T cell+ Day  - - - - 11.39 0.0411 
CD4+CD8- Treatment - - - - 6.30 0.0204 
 Treatment*Day - - - - 2.07 NS 
2 T cell+ Day  - - - - 4.99 NS 
 Treatment - - - - 2.22 NS 
 Treatment*Day - - - - 0.62 NS 
2 T cell+ Day  - - - - 8.76 NS 
CD4-CD8+ Treatment - - - - 4.82 0.0377 
 Treatment*Day - - - - 0.49 NS 
2 T cell+ Day  - - - - 2.14 NS 
CD4+CD8+ Treatment - - - - 2.90 NS 
 Treatment*Day - - - - 0.47 NS 
2 T cell+ Day  - - - - 26.25 <0.0001 
CD4-CD8- Treatment - - - - 0.91 NS 
 Treatment*Day - - - - 1.67 NS 
2 T cell+ Day  - - - - 14.42 <0.0001 
CD4+CD8- Treatment - - - - 1.75 NS 
 Treatment*Day - - - - 1.69 NS 
CD4/CD8 ratio Day  5.40 0.0409 11.70 0.0016 18.53 0.0069 
 Treatment 0.29 NS 0.01 NS 3.26 NS 
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Table E1. Type III test of fixed effects results for pulp cell response in feather injection studies 
(Cont.) 
  Study 1 Study 2 Study 3 
Response Factor Fixed Effect F Value P Value F Value P Value F Value P Value 
 Treatment*Day 2.67 NS 1.58 NS 7.48 0.0253 
B cells Day  8.61 0.0153 15.23 0.0063 - - 
 Treatment 8.34 0.0062 6.78 0.0007 - - 
 Treatment*Day 2.25 NS 4.12 0.0121 - - 
B cell+ IgM+ Day  - - - - 13.12 <0.0001 
 Treatment - - - - 5.95 0.0054 
 Treatment*Day - - - - 1.35 NS 
B cell+ IgM- Day  - - - - 7.49 0.0001 
 Treatment - - - - 2.43 NS 
 Treatment*Day - - - - 2.13 0.0473 
B cell+ IgG+ Day  - - - - 3.86 0.0073 
 Treatment - - - - 2.69 NS 
 Treatment*Day - - - - 1.16 NS 
B cell+ IgG- Day  - - - - 12.60 <0.0001 
 Treatment - - - - 5.09 0.0121 
 Treatment*Day - - - - 1.25 NS 
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APPENDIX F 
Difference of Least Squares Means Results for Pulp Cell Responses  
in Feather Injection Studies 
 
Table F1. Difference of least squares means for pulp cell responses by day 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
Study 1        
Macrophages 0 0.25 0.02433 0.2704 11 0.09 0.9299
 0 1 0.3032 0.1854 11 1.64 0.1302
 0 2 0.8433 0.2578 11 3.27 0.0074
 0 3 0.5138 0.1914 11 2.68 0.0212
 0 4 0.2427 0.4489 11 0.54 0.5996
 0 5 0.8063 0.2375 11 3.40 0.0060
 0 7 0.6568 0.1773 11 3.70 0.0035
 0.25 1 0.2788 0.1931 11 1.44 0.1765
 0.25 2 0.8190 0.3097 11 2.64 0.0228
 0.25 3 0.4895 0.2578 11 1.90 0.0842
 0.25 4 0.2183 0.4807 11 0.45 0.6585
 0.25 5 0.7820 0.2623 11 2.98 0.0125
 0.25 7 0.6325 0.2364 11 2.68 0.0216
 1 2 0.5402 0.2965 11 1.82 0.0958
 1 3 0.2107 0.2126 11 0.99 0.3431
 1 4 -0.06050 0.4790 11 -0.13 0.9018
 1 5 0.5032 0.2502 11 2.01 0.0695
 1 7 0.3537 0.2137 11 1.66 0.1261
 2 3 -0.3295 0.2033 11 -1.62 0.1333
 2 4 -0.6007 0.5189 11 -1.16 0.2716
 2 5 -0.03700 0.2913 11 -0.13 0.9012
 2 7 -0.1865 0.2838 11 -0.66 0.5246
 3 4 -0.2712 0.4939 11 -0.55 0.5940
 3 5 0.2925 0.2238 11 1.31 0.2180
 3 7 0.1430 0.1829 11 0.78 0.4508
 4 5 0.5637 0.2886 11 1.95 0.0767
 4 7 0.4142 0.4692 11 0.88 0.3962
 5 7 -0.1495 0.2387 11 -0.63 0.5439
Lymphocytes 0 0.25 -2.1047 0.7578 11 -2.78 0.0180
 0 1 -4.1497 0.8561 11 -4.85 0.0005
 0 2 -6.8680 1.1955 11 -5.74 0.0001
 0 3 -6.2333 1.3201 11 -4.72 0.0006
 0 4 -6.0937 0.8910 11 -6.84 <.0001
 0 5 -5.3493 1.4201 11 -3.77 0.0031
 0 7 -0.3483 0.8249 11 -0.42 0.6810
 0.25 1 -2.0450 0.9838 11 -2.08 0.0618
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0.25 2 -4.7633 1.3090 11 -3.64 0.0039
 0.25 3 -4.1287 1.3266 11 -3.11 0.0099
 0.25 4 -3.9890 1.1634 11 -3.43 0.0056
 0.25 5 -3.2447 1.4316 11 -2.27 0.0446
 0.25 7 1.7563 1.0417 11 1.69 0.1199
 1 2 -2.7183 1.3847 11 -1.96 0.0754
 1 3 -2.0837 1.6161 11 -1.29 0.2237
 1 4 -1.9440 0.8671 11 -2.24 0.0465
 1 5 -1.1997 1.6850 11 -0.71 0.4913
 1 7 3.8013 0.9425 11 4.03 0.0020
 2 3 0.6347 1.4879 11 0.43 0.6779
 2 4 0.7743 1.0034 11 0.77 0.4565
 2 5 1.5187 1.1883 11 1.28 0.2276
 2 7 6.5197 1.2599 11 5.17 0.0003
 3 4 0.1397 1.8495 11 0.08 0.9412
 3 5 0.8840 1.4406 11 0.61 0.5519
 3 7 5.8850 1.3267 11 4.44 0.0010
 4 5 0.7443 1.7069 11 0.44 0.6712
 4 7 5.7453 1.2600 11 4.56 0.0008
 5 7 5.0010 1.1474 11 4.36 0.0011
CD4- CD8+ 0 0.25 -0.4038 0.07093 11 -5.69 0.0001
 0 1 -0.5285 0.09797 11 -5.39 0.0002
 0 2 -0.8775 0.1567 11 -5.60 0.0002
 0 3 -0.6535 0.1237 11 -5.28 0.0003
 0 4 -0.8855 0.1097 11 -8.07 <.0001
 0 5 -0.8162 0.1895 11 -4.31 0.0012
 0 7 -0.1628 0.08139 11 -2.00 0.0707
 0.25 1 -0.1247 0.1144 11 -1.09 0.2989
 0.25 2 -0.4737 0.1777 11 -2.67 0.0220
 0.25 3 -0.2497 0.1360 11 -1.84 0.0936
 0.25 4 -0.4817 0.1336 11 -3.61 0.0041
 0.25 5 -0.4123 0.2046 11 -2.01 0.0690
 0.25 7 0.2410 0.1162 11 2.07 0.0624
 1 2 -0.3490 0.2063 11 -1.69 0.1188
 1 3 -0.1250 0.1856 11 -0.67 0.5146
 1 4 -0.3570 0.1063 11 -3.36 0.0064
 1 5 -0.2877 0.2106 11 -1.37 0.1992
 1 7 0.3657 0.1211 11 3.02 0.0117
 2 3 0.2240 0.1800 11 1.24 0.2392
 2 4 -0.00800 0.1659 11 -0.05 0.9624
 2 5 0.06133 0.1661 11 0.37 0.7190
 2 7 0.7147 0.1615 11 4.42 0.0010
 3 4 -0.2320 0.1910 11 -1.21 0.2498
 3 5 -0.1627 0.1755 11 -0.93 0.3739
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 3 7 0.4907 0.1186 11 4.14 0.0016
 4 5 0.06933 0.2255 11 0.31 0.7642
 4 7 0.7227 0.1472 11 4.91 0.0005
 5 7 0.6533 0.1357 11 4.81 0.0005
CD4+ CD8+ 0 0.25 -0.1912 0.1002 11 -1.91 0.0830
 0 1 -0.1082 0.03454 11 -3.13 0.0096
 0 2 -0.2722 0.05121 11 -5.31 0.0002
 0 3 -0.1992 0.04076 11 -4.89 0.0005
 0 4 -0.1252 0.04424 11 -2.83 0.0164
 0 5 -0.02417 0.05052 11 -0.48 0.6418
 0 7 0.02017 0.02907 11 0.69 0.5022
 0.25 1 0.08300 0.1052 11 0.79 0.4467
 0.25 2 -0.08100 0.1184 11 -0.68 0.5079
 0.25 3 -0.00800 0.1063 11 -0.08 0.9413
 0.25 4 0.06600 0.1117 11 0.59 0.5665
 0.25 5 0.1670 0.1076 11 1.55 0.1489
 0.25 7 0.2113 0.09805 11 2.16 0.0541
 1 2 -0.1640 0.05839 11 -2.81 0.0170
 1 3 -0.09100 0.04883 11 -1.86 0.0893
 1 4 -0.01700 0.03810 11 -0.45 0.6641
 1 5 0.08400 0.06244 11 1.35 0.2056
 1 7 0.1283 0.03072 11 4.18 0.0015
 2 3 0.07300 0.04686 11 1.56 0.1476
 2 4 0.1470 0.04501 11 3.27 0.0075
 2 5 0.2480 0.04294 11 5.78 0.0001
 2 7 0.2923 0.05156 11 5.67 0.0001
 3 4 0.07400 0.05229 11 1.42 0.1847
 3 5 0.1750 0.04236 11 4.13 0.0017
 3 7 0.2193 0.02796 11 7.85 <.0001
 4 5 0.1010 0.05276 11 1.91 0.0819
 4 7 0.1453 0.04204 11 3.46 0.0054
 5 7 0.04433 0.04330 11 1.02 0.3279
CD4+ CD8- 0 0.25 -0.7853 0.1777 11 -4.42 0.0010
 0 1 -1.4153 0.3964 11 -3.57 0.0044
 0 2 -2.7940 0.5237 11 -5.33 0.0002
 0 3 -3.0877 0.5935 11 -5.20 0.0003
 0 4 -3.0917 0.4254 11 -7.27 <.0001
 0 5 -3.0313 0.8556 11 -3.54 0.0046
 0 7 -0.5870 0.4620 11 -1.27 0.2301
 0.25 1 -0.6300 0.4049 11 -1.56 0.1481
 0.25 2 -2.0087 0.4899 11 -4.10 0.0018
 0.25 3 -2.3023 0.5680 11 -4.05 0.0019
 0.25 4 -2.3063 0.4368 11 -5.28 0.0003
 0.25 5 -2.2460 0.8112 11 -2.77 0.0183
 0.25 7 0.1983 0.4349 11 0.46 0.6573
 1 2 -1.3787 0.6468 11 -2.13 0.0564
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 1 3 -1.6723 0.7391 11 -2.26 0.0449
 1 4 -1.6763 0.5152 11 -3.25 0.0077
 1 5 -1.6160 0.9801 11 -1.65 0.1274
 1 7 0.8283 0.4649 11 1.78 0.1024
 2 3 -0.2937 0.6247 11 -0.47 0.6475
 2 4 -0.2977 0.4686 11 -0.64 0.5383
 2 5 -0.2373 0.5325 11 -0.45 0.6645
 2 7 2.2070 0.4708 11 4.69 0.0007
 3 4 -0.00400 0.8589 11 -0.00 0.9964
 3 5 0.05633 0.8373 11 0.07 0.9476
 3 7 2.5007 0.6280 11 3.98 0.0022
 4 5 0.06033 0.8041 11 0.08 0.9415
 4 7 2.5047 0.5262 11 4.76 0.0006
 5 7 2.4443 0.6992 11 3.50 0.0050
 T cell+ CD8- 0 0.25 -0.1453 0.08891 11 -1.63 0.1304
 0 1 -0.2657 0.1232 11 -2.16 0.0541
 0 2 -0.3270 0.09458 11 -3.46 0.0054
 0 3 -0.1333 0.08913 11 -1.50 0.1628
 0 4 -0.1903 0.09137 11 -2.08 0.0614
 0 5 -0.02500 0.08972 11 -0.28 0.7857
 0 7 0.05800 0.07772 11 0.75 0.4711
 0.25 1 -0.1203 0.09191 11 -1.31 0.2172
 0.25 2 -0.1817 0.06577 11 -2.76 0.0185
 0.25 3 0.01200 0.05722 11 0.21 0.8377
 0.25 4 -0.04500 0.05741 11 -0.78 0.4497
 0.25 5 0.1203 0.05931 11 2.03 0.0674
 0.25 7 0.2033 0.04404 11 4.62 0.0007
 1 2 -0.06133 0.1074 11 -0.57 0.5793
 1 3 0.1323 0.1053 11 1.26 0.2348
 1 4 0.07533 0.07998 11 0.94 0.3665
 1 5 0.2407 0.09509 11 2.53 0.0279
 1 7 0.3237 0.08626 11 3.75 0.0032
 2 3 0.1937 0.04000 11 4.84 0.0005
 2 4 0.1367 0.07132 11 1.92 0.0817
 2 5 0.3020 0.04292 11 7.04 <.0001
 2 7 0.3850 0.04908 11 7.84 <.0001
 3 4 -0.05700 0.06497 11 -0.88 0.3990
 3 5 0.1083 0.03410 11 3.18 0.0088
 3 7 0.1913 0.04131 11 4.63 0.0007
 4 5 0.1653 0.05817 11 2.84 0.0160
 4 7 0.2483 0.04267 11 5.82 0.0001
 5 7 0.08300 0.03199 11 2.59 0.0249
2 T cell+ 0 0.25 -0.2460 0.05456 11 -4.51 0.0009
 0 1 -0.3390 0.1408 11 -2.41 0.0347
 0 2 -0.6753 0.1630 11 -4.14 0.0016
 0 3 -0.6097 0.1649 11 -3.70 0.0035
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 4 -0.7330 0.1319 11 -5.56 0.0002
 0 5 -0.8683 0.2735 11 -3.17 0.0088
 0 7 -0.06000 0.08047 11 -0.75 0.4715
 0.25 1 -0.09300 0.1327 11 -0.70 0.4978
 0.25 2 -0.4293 0.1596 11 -2.69 0.0210
 0.25 3 -0.3637 0.1520 11 -2.39 0.0357
 0.25 4 -0.4870 0.1357 11 -3.59 0.0043
 0.25 5 -0.6223 0.2628 11 -2.37 0.0373
 0.25 7 0.1860 0.08319 11 2.24 0.0470
 1 2 -0.3363 0.1877 11 -1.79 0.1007
 1 3 -0.2707 0.1866 11 -1.45 0.1749
 1 4 -0.3940 0.1438 11 -2.74 0.0192
 1 5 -0.5293 0.2838 11 -1.87 0.0890
 1 7 0.2790 0.1320 11 2.11 0.0582
 2 3 0.06567 0.1827 11 0.36 0.7261
 2 4 -0.05767 0.1163 11 -0.50 0.6298
 2 5 -0.1930 0.1927 11 -1.00 0.3380
 2 7 0.6153 0.1209 11 5.09 0.0004
 3 4 -0.1233 0.2166 11 -0.57 0.5805
 3 5 -0.2587 0.2265 11 -1.14 0.2776
 3 7 0.5497 0.1379 11 3.99 0.0021
 4 5 -0.1353 0.2529 11 -0.54 0.6033
 4 7 0.6730 0.1310 11 5.14 0.0003
 5 7 0.8083 0.2095 11 3.86 0.0027
1 T cell+ 0 0.25 -0.5560 0.1301 11 -4.27 0.0013
 0 1 -0.9967 0.3764 11 -2.65 0.0227
 0 2 -1.9190 0.5203 11 -3.69 0.0036
 0 3 -2.2140 0.5878 11 -3.77 0.0031
 0 4 -2.3107 0.4057 11 -5.69 0.0001
 0 5 -2.7563 0.7875 11 -3.50 0.0050
 0 7 -0.4330 0.2448 11 -1.77 0.1046
 0.25 1 -0.4407 0.3560 11 -1.24 0.2416
 0.25 2 -1.3630 0.4939 11 -2.76 0.0186
 0.25 3 -1.6580 0.5398 11 -3.07 0.0106
 0.25 4 -1.7547 0.3902 11 -4.50 0.0009
 0.25 5 -2.2003 0.7619 11 -2.89 0.0148
 0.25 7 0.1230 0.2520 11 0.49 0.6350
 1 2 -0.9223 0.6492 11 -1.42 0.1831
 1 3 -1.2173 0.6844 11 -1.78 0.1029
 1 4 -1.3140 0.4239 11 -3.10 0.0101
 1 5 -1.7597 0.8459 11 -2.08 0.0617
 1 7 0.5637 0.3582 11 1.57 0.1439
 2 3 -0.2950 0.6884 11 -0.43 0.6765
 2 4 -0.3917 0.4369 11 -0.90 0.3892
 2 5 -0.8373 0.4906 11 -1.71 0.1159
 2 7 1.4860 0.4634 11 3.21 0.0084
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 3 4 -0.09667 0.8026 11 -0.12 0.9063
 3 5 -0.5423 0.7858 11 -0.69 0.5044
 3 7 1.7810 0.5434 11 3.28 0.0074
 4 5 -0.4457 0.7712 11 -0.58 0.5750
 4 7 1.8777 0.4418 11 4.25 0.0014
 5 7 2.3233 0.6373 11 3.65 0.0038
CD4/CD8 ratio 0 0.25 3.2477 1.2033 11 2.70 0.0207
 0 1 3.0793 1.3409 11 2.30 0.0423
 0 2 2.6628 1.2342 11 2.16 0.0539
 0 3 1.4751 1.3225 11 1.12 0.2885
 0 4 2.0945 1.3660 11 1.53 0.1534
 0 5 2.6561 1.1187 11 2.37 0.0369
 0 7 1.9216 1.4294 11 1.34 0.2059
 0.25 1 -0.1683 0.3325 11 -0.51 0.6226
 0.25 2 -0.5848 0.4506 11 -1.30 0.2209
 0.25 3 -1.7726 0.4579 11 -3.87 0.0026
 0.25 4 -1.1532 0.3952 11 -2.92 0.0140
 0.25 5 -0.5916 0.4073 11 -1.45 0.1743
 0.25 7 -1.3260 0.4841 11 -2.74 0.0193
 1 2 -0.4165 0.3276 11 -1.27 0.2298
 1 3 -1.6042 0.3479 11 -4.61 0.0008
 1 4 -0.9848 0.4660 11 -2.11 0.0582
 1 5 -0.4233 0.4347 11 -0.97 0.3512
 1 7 -1.1577 0.3781 11 -3.06 0.0108
 2 3 -1.1877 0.3587 11 -3.31 0.0069
 2 4 -0.5684 0.5491 11 -1.04 0.3229
 2 5 -0.00678 0.4525 11 -0.01 0.9883
 2 7 -0.7412 0.5991 11 -1.24 0.2418
 3 4 0.6194 0.5594 11 1.11 0.2918
 3 5 1.1809 0.4351 11 2.71 0.0201
 3 7 0.4465 0.4095 11 1.09 0.2988
 4 5 0.5616 0.5361 11 1.05 0.3173
 4 7 -0.1729 0.6383 11 -0.27 0.7915
 5 7 -0.7344 0.4670 11 -1.57 0.1441
MHCII+ B cell+ 0 0.25 -0.2627 0.07720 11 -3.40 0.0059
 0 1 -0.5190 0.08780 11 -5.91 0.0001
 0 2 -0.9333 0.1192 11 -7.83 <.0001
 0 3 -0.5817 0.06813 11 -8.54 <.0001
 0 4 -0.6207 0.06594 11 -9.41 <.0001
 0 5 -0.2887 0.1776 11 -1.63 0.1324
 0 7 -0.2943 0.1196 11 -2.46 0.0316
 0.25 1 -0.2563 0.1057 11 -2.43 0.0336
 0.25 2 -0.6707 0.1322 11 -5.07 0.0004
 0.25 3 -0.3190 0.08462 11 -3.77 0.0031
 0.25 4 -0.3580 0.07066 11 -5.07 0.0004
 0.25 5 -0.02600 0.1898 11 -0.14 0.8935
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0.25 7 -0.03167 0.1316 11 -0.24 0.8142
 1 2 -0.4143 0.1116 11 -3.71 0.0034
 1 3 -0.06267 0.09649 11 -0.65 0.5294
 1 4 -0.1017 0.08940 11 -1.14 0.2796
 1 5 0.2303 0.1573 11 1.46 0.1710
 1 7 0.2247 0.1153 11 1.95 0.0773
 2 3 0.3517 0.09834 11 3.58 0.0043
 2 4 0.3127 0.1346 11 2.32 0.0403
 2 5 0.6447 0.1640 11 3.93 0.0023
 2 7 0.6390 0.1111 11 5.75 0.0001
 3 4 -0.03900 0.09519 11 -0.41 0.6899
 3 5 0.2930 0.1896 11 1.55 0.1506
 3 7 0.2873 0.1122 11 2.56 0.0264
 4 5 0.3320 0.1946 11 1.71 0.1161
 4 7 0.3263 0.1451 11 2.25 0.0459
 5 7 -0.00567 0.1256 11 -0.05 0.9648
B cells 0 0.25 -0.1620 0.04327 11 -3.74 0.0032
 0 1 -0.7797 0.2455 11 -3.18 0.0088
 0 2 -1.6153 0.3548 11 -4.55 0.0008
 0 3 -1.4667 0.4158 11 -3.53 0.0047
 0 4 -1.7297 0.3325 11 -5.20 0.0003
 0 5 -1.4910 0.3018 11 -4.94 0.0004
 0 7 -0.3753 0.1793 11 -2.09 0.0602
 0.25 1 -0.6177 0.2385 11 -2.59 0.0252
 0.25 2 -1.4533 0.3627 11 -4.01 0.0021
 0.25 3 -1.3047 0.3938 11 -3.31 0.0069
 0.25 4 -1.5677 0.3375 11 -4.64 0.0007
 0.25 5 -1.3290 0.3030 11 -4.39 0.0011
 0.25 7 -0.2133 0.1851 11 -1.15 0.2735
 1 2 -0.8357 0.4026 11 -2.08 0.0622
 1 3 -0.6870 0.4720 11 -1.46 0.1735
 1 4 -0.9500 0.2466 11 -3.85 0.0027
 1 5 -0.7113 0.4313 11 -1.65 0.1273
 1 7 0.4043 0.2511 11 1.61 0.1357
 2 3 0.1487 0.5472 11 0.27 0.7909
 2 4 -0.1143 0.3231 11 -0.35 0.7301
 2 5 0.1243 0.4589 11 0.27 0.7914
 2 7 1.2400 0.4128 11 3.00 0.0120
 3 4 -0.2630 0.6106 11 -0.43 0.6750
 3 5 -0.02433 0.4090 11 -0.06 0.9536
 3 7 1.0913 0.3811 11 2.86 0.0154
 4 5 0.2387 0.5316 11 0.45 0.6622
 4 7 1.3543 0.4074 11 3.32 0.0068
 5 7 1.1157 0.2862 11 3.90 0.0025
Study 2        
Heterophils 0 0.25 -15.1825 1.9600 12 -7.75 <.0001
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 1 -7.2706 1.3297 12 -5.47 0.0001
 0 2 -1.4650 0.4219 12 -3.47 0.0046
 0 5 -0.2950 0.1563 12 -1.89 0.0835
 0 7 -0.1069 0.1259 12.01 -0.85 0.4125
 0.25 1 7.9119 1.9163 12 4.13 0.0014
 0.25 2 13.7175 1.9663 12 6.98 <.0001
 0.25 5 14.8875 1.9251 12 7.73 <.0001
 0.25 7 15.0756 1.9305 12 7.81 <.0001
 1 2 5.8056 1.0947 12 5.30 0.0002
 1 5 6.9756 1.2364 12 5.64 0.0001
 1 7 7.1637 1.3604 12 5.27 0.0002
 2 5 1.1700 0.4265 12 2.74 0.0178
 2 7 1.3581 0.4645 12 2.92 0.0127
 5 7 0.1881 0.2017 12 0.93 0.3693
Macrophages 0 0.25 -2.4781 0.4285 12 -5.78 <.0001
 0 1 -1.6975 0.3259 12 -5.21 0.0002
 0 2 -0.6231 0.2665 12 -2.34 0.0375
 0 5 -1.2394 0.1965 12 -6.31 <.0001
 0 7 -0.7100 0.1596 12 -4.45 0.0008
 0.25 1 0.7806 0.5541 12 1.41 0.1843
 0.25 2 1.8550 0.4788 12 3.87 0.0022
 0.25 5 1.2387 0.3518 12 3.52 0.0042
 0.25 7 1.7681 0.3825 12 4.62 0.0006
 1 2 1.0744 0.3590 12 2.99 0.0112
 1 5 0.4581 0.4119 12 1.11 0.2878
 1 7 0.9875 0.3901 12 2.53 0.0264
 2 5 -0.6163 0.2626 12 -2.35 0.0369
 2 7 -0.08688 0.2720 12 -0.32 0.7549
 5 7 0.5294 0.1597 12 3.32 0.0062
CD4- CD8+ 0 0.25 -0.5606 0.1348 12 -4.16 0.0013
 0 1 -1.4844 0.3498 12 -4.24 0.0011
 0 2 -1.0687 0.2125 12 -5.03 0.0003
 0 5 -1.8631 0.1871 12 -9.96 <.0001
 0 7 -0.9963 0.1684 12 -5.91 <.0001
 0.25 1 -0.9237 0.3758 12 -2.46 0.0302
 0.25 2 -0.5081 0.2315 12 -2.20 0.0485
 0.25 5 -1.3025 0.2413 12 -5.40 0.0002
 0.25 7 -0.4356 0.2003 12 -2.18 0.0503
 1 2 0.4156 0.3282 12 1.27 0.2293
 1 5 -0.3788 0.3972 12 -0.95 0.3591
 1 7 0.4881 0.3810 12 1.28 0.2244
 2 5 -0.7944 0.2377 12 -3.34 0.0059
 2 7 0.07250 0.2415 12 0.30 0.7692
 5 7 0.8669 0.1603 12 5.41 0.0002
CD4+ CD8+ 0 0.25 -0.07875 0.03430 12 -2.30 0.0405
 0 1 -0.2519 0.1003 12 -2.51 0.0273
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 2 -0.4981 0.1454 12 -3.43 0.0050
 0 5 -0.8681 0.1549 12 -5.61 0.0001
 0 7 -0.3219 0.05490 12 -5.86 <.0001
 0.25 1 -0.1731 0.08953 12 -1.93 0.0771
 0.25 2 -0.4194 0.1508 12 -2.78 0.0166
 0.25 5 -0.7894 0.1621 12 -4.87 0.0004
 0.25 7 -0.2431 0.05051 12 -4.81 0.0004
 1 2 -0.2462 0.1031 12 -2.39 0.0342
 1 5 -0.6162 0.1370 12 -4.50 0.0007
 1 7 -0.07000 0.08662 12 -0.81 0.4348
 2 5 -0.3700 0.1157 12 -3.20 0.0076
 2 7 0.1763 0.1297 12 1.36 0.1991
 5 7 0.5463 0.1262 12 4.33 0.0010
CD4+ CD8- 0 0.25 -1.5612 0.4783 12 -3.26 0.0068
 0 1 -3.3306 0.7174 12 -4.64 0.0006
 0 2 -3.7250 0.8360 12 -4.46 0.0008
 0 5 -10.2862 1.0583 12 -9.72 <.0001
 0 7 -5.2675 0.5991 12 -8.79 <.0001
 0.25 1 -1.7694 0.7261 12 -2.44 0.0313
 0.25 2 -2.1637 0.7140 12 -3.03 0.0105
 0.25 5 -8.7250 1.1575 12 -7.54 <.0001
 0.25 7 -3.7063 0.6261 12 -5.92 <.0001
 1 2 -0.3944 0.7878 12 -0.50 0.6257
 1 5 -6.9556 1.2488 12 -5.57 0.0001
 1 7 -1.9369 0.8771 12 -2.21 0.0474
 2 5 -6.5613 1.0519 12 -6.24 <.0001
 2 7 -1.5425 0.9954 12 -1.55 0.1472
 5 7 5.0187 1.0882 12 4.61 0.0006
 T cell+ CD8+ 0 0.25 -0.1994 0.04450 12 -4.48 0.0008
 0 1 -0.3894 0.08341 12 -4.67 0.0005
 0 2 -0.4088 0.1652 12 -2.48 0.0292
 0 5 -0.4869 0.04295 12 -11.34 <.0001
 0 7 -0.2331 0.04223 12 -5.52 0.0001
 0.25 1 -0.1900 0.09573 12 -1.98 0.0705
 0.25 2 -0.2094 0.1899 12 -1.10 0.2918
 0.25 5 -0.2875 0.06164 12 -4.66 0.0005
 0.25 7 -0.03375 0.05528 12 -0.61 0.5529
 1 2 -0.01937 0.1752 12 -0.11 0.9138
 1 5 -0.09750 0.06250 12 -1.56 0.1447
 1 7 0.1562 0.06788 12 2.30 0.0401
 2 5 -0.07813 0.1688 12 -0.46 0.6518
 2 7 0.1756 0.1718 12 1.02 0.3267
 5 7 0.2537 0.03757 12 6.75 <.0001
2 T cell+ 0 0.25 -0.5431 0.1335 12 -4.07 0.0016
 0 1 -1.2550 0.2580 12 -4.86 0.0004
 0 2 -1.2400 0.2372 12 -5.23 0.0002
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 5 -2.7450 0.2341 12 -11.73 <.0001
 0 7 -1.3569 0.1592 12 -8.52 <.0001
 0.25 1 -0.7119 0.2767 12 -2.57 0.0244
 0.25 2 -0.6969 0.2218 12 -3.14 0.0085
 0.25 5 -2.2019 0.2893 12 -7.61 <.0001
 0.25 7 -0.8138 0.1957 12 -4.16 0.0013
 1 2 0.01500 0.3014 12 0.05 0.9611
 1 5 -1.4900 0.3812 12 -3.91 0.0021
 1 7 -0.1019 0.2640 12 -0.39 0.7064
 2 5 -1.5050 0.2941 12 -5.12 0.0003
 2 7 -0.1169 0.2668 12 -0.44 0.6691
 5 7 1.3881 0.2092 12 6.64 <.0001
1 T cell+ 0 0.25 -1.5481 0.3841 12 -4.03 0.0017
 0 1 -3.4250 0.7235 12 -4.73 0.0005
 0 2 -3.5700 0.7827 12 -4.56 0.0007
 0 5 -9.0469 0.8950 12 -10.11 <.0001
 0 7 -4.5044 0.5083 12 -8.86 <.0001
 0.25 1 -1.8769 0.7252 12 -2.59 0.0237
 0.25 2 -2.0219 0.7557 12 -2.68 0.0202
 0.25 5 -7.4988 1.0223 12 -7.33 <.0001
 0.25 7 -2.9563 0.5304 12 -5.57 0.0001
 1 2 -0.1450 0.8384 12 -0.17 0.8656
 1 5 -5.6219 1.1827 12 -4.75 0.0005
 1 7 -1.0794 0.8176 12 -1.32 0.2114
 2 5 -5.4769 0.9748 12 -5.62 0.0001
 2 7 -0.9344 0.9489 12 -0.98 0.3442
 5 7 4.5425 0.9339 12 4.86 0.0004
CD4/CD8 ratio 0 0.25 -0.3601 0.3380 12 -1.07 0.3077
 0 1 -0.2501 0.3130 12 -0.80 0.4399
 0 2 -1.0330 0.4122 12 -2.51 0.0276
 0 5 -2.6131 0.4913 12 -5.32 0.0002
 0 7 -2.0471 0.5568 12 -3.68 0.0032
 0.25 1 0.1101 0.3529 12 0.31 0.7605
 0.25 2 -0.6729 0.2220 12 -3.03 0.0104
 0.25 5 -2.2530 0.3754 12 -6.00 <.0001
 0.25 7 -1.6870 0.3827 12 -4.41 0.0009
 1 2 -0.7830 0.4114 12 -1.90 0.0813
 1 5 -2.3630 0.3817 12 -6.19 <.0001
 1 7 -1.7971 0.5065 12 -3.55 0.0040
 2 5 -1.5801 0.4702 12 -3.36 0.0057
 2 7 -1.0141 0.2854 12 -3.55 0.0040
 5 7 0.5659 0.5632 12 1.00 0.3348
B cells 0 0.25 0.04500 0.02942 12 1.53 0.1520
 0 1 -0.1281 0.07539 12 -1.70 0.1150
 0 2 -0.2469 0.05280 12 -4.68 0.0005
 0 5 -0.6681 0.1508 12 -4.43 0.0008
230 
 
 
 
Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 7 -0.4662 0.07020 12 -6.64 <.0001
 0.25 1 -0.1731 0.06693 12 -2.59 0.0238
 0.25 2 -0.2919 0.04712 12 -6.19 <.0001
 0.25 5 -0.7131 0.1362 12 -5.23 0.0002
 0.25 7 -0.5112 0.06959 12 -7.35 <.0001
 1 2 -0.1188 0.09245 12 -1.28 0.2232
 1 5 -0.5400 0.1205 12 -4.48 0.0008
 1 7 -0.3381 0.08821 12 -3.83 0.0024
 2 5 -0.4212 0.1522 12 -2.77 0.0170
 2 7 -0.2194 0.09171 12 -2.39 0.0340
 5 7 0.2019 0.1440 12 1.40 0.1864
MHCII+  0 0.25 -0.04125 0.04590 12 -0.90 0.3865
Macrophages+ 0 1 -0.8131 0.1788 12 -4.55 0.0007
 0 2 -0.3213 0.1219 12 -2.64 0.0218
 0 5 -0.2844 0.1249 12 -2.28 0.0419
 0 7 0.02125 0.1144 12 0.19 0.8558
 0.25 1 -0.7719 0.1851 12 -4.17 0.0013
 0.25 2 -0.2800 0.1257 12 -2.23 0.0458
 0.25 5 -0.2431 0.1208 12 -2.01 0.0672
 0.25 7 0.06250 0.1080 12 0.58 0.5736
 1 2 0.4919 0.1811 12 2.72 0.0188
 1 5 0.5288 0.1070 12 4.94 0.0003
 1 7 0.8344 0.2507 12 3.33 0.0060
 2 5 0.03687 0.1604 12 0.23 0.8221
 2 7 0.3425 0.1698 12 2.02 0.0666
 5 7 0.3056 0.1835 12 1.67 0.1216
Study 3        
MHCII+  0 0.25 -2.6608 0.4894 8.945 -5.44 0.0004
Macrophages+ 0 1 -2.4108 0.4057 9.076 -5.94 0.0002
 0 2 0.7417 0.3968 9.016 1.87 0.0944
 0 3 0.5708 0.4165 8.978 1.37 0.2038
 0 4 0.9117 0.3140 9.039 2.90 0.0174
 0 5 0.5408 0.3668 9.069 1.47 0.1742
 0 7 -0.08077 0.3708 9.14 -0.22 0.8324
 0.25 1 0.2500 0.4277 9.004 0.58 0.5733
 0.25 2 3.4025 0.2760 8.937 12.33 <.0001
 0.25 3 3.2317 0.3533 8.929 9.15 <.0001
 0.25 4 3.5725 0.3726 8.937 9.59 <.0001
 0.25 5 3.2017 0.3815 8.859 8.39 <.0001
 0.25 7 2.5801 0.3850 8.939 6.70 <.0001
 1 2 3.1525 0.3013 9.108 10.46 <.0001
 1 3 2.9817 0.2475 8.993 12.05 <.0001
 1 4 3.3225 0.3440 9.1 9.66 <.0001
 1 5 2.9517 0.3272 9.228 9.02 <.0001
 1 7 2.3301 0.4261 9.178 5.47 0.0004
 2 3 -0.1708 0.2914 8.975 -0.59 0.5722
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 2 4 0.1700 0.2177 8.982 0.78 0.4550
 2 5 -0.2008 0.2430 8.955 -0.83 0.4300
 2 7 -0.8224 0.3068 9.039 -2.68 0.0251
 3 4 0.3408 0.3325 8.965 1.02 0.3323
 3 5 -0.03000 0.2321 9.129 -0.13 0.9000
 3 7 -0.6516 0.3280 9.147 -1.99 0.0777
 4 5 -0.3708 0.2687 8.975 -1.38 0.2009
 4 7 -0.9924 0.2364 9.123 -4.20 0.0022
 5 7 -0.6216 0.1768 8.807 -3.52 0.0068
CD4- CD8+ 0 0.25 -0.5925 0.1782 9.234 -3.32 0.0086
 0 1 -2.0492 0.4079 9.052 -5.02 0.0007
 0 2 -2.8083 0.5620 9.382 -5.00 0.0007
 0 3 -5.6525 0.8421 9.191 -6.71 <.0001
 0 4 -4.2633 1.2086 8.946 -3.53 0.0065
 0 5 -3.6483 0.6389 8.92 -5.71 0.0003
 0 7 -0.7350 0.5765 8.691 -1.27 0.2354
 0.25 1 -1.4567 0.4587 9.279 -3.18 0.0108
 0.25 2 -2.2158 0.7182 9.374 -3.09 0.0124
 0.25 3 -5.0600 0.8333 9.239 -6.07 0.0002
 0.25 4 -3.6708 1.2271 9.018 -2.99 0.0151
 0.25 5 -3.0558 0.5898 8.916 -5.18 0.0006
 0.25 7 -0.1425 0.6355 8.872 -0.22 0.8276
 1 2 -0.7592 0.5681 8.957 -1.34 0.2144
 1 3 -3.6033 0.7409 9.172 -4.86 0.0008
 1 4 -2.2142 0.9913 8.984 -2.23 0.0524
 1 5 -1.5992 0.8157 8.971 -1.96 0.0817
 1 7 1.3142 0.6355 8.641 2.07 0.0699
 2 3 -2.8442 0.9541 9.202 -2.98 0.0151
 2 4 -1.4550 1.1977 8.863 -1.21 0.2558
 2 5 -0.8400 0.9843 9.108 -0.85 0.4153
 2 7 2.0733 0.5333 8.918 3.89 0.0038
 3 4 1.3892 0.9183 9.229 1.51 0.1638
 3 5 2.0042 1.0655 9.095 1.88 0.0923
 3 7 4.9175 0.8835 9.026 5.57 0.0003
 4 5 0.6150 1.5060 8.936 0.41 0.6926
 4 7 3.5283 1.3984 8.938 2.52 0.0328
 5 7 2.9133 0.8366 8.922 3.48 0.0070
CD4+ CD8- 0.25 1 -1.8475 1.2304 8.984 -1.50 0.1675
 0.25 2 -4.7867 1.3817 8.907 -3.46 0.0072
 0.25 3 -11.8367 2.4415 8.989 -4.85 0.0009
 0.25 4 -6.9533 2.5689 8.98 -2.71 0.0242
 0.25 5 -7.6925 1.4422 9.028 -5.33 0.0005
 0.25 7 -1.6815 1.2868 9.153 -1.31 0.2232
 1 2 -2.9392 1.0116 9.042 -2.91 0.0174
 1 3 -9.9892 2.0590 9 -4.85 0.0009
 1 4 -5.1058 2.0447 8.999 -2.50 0.0340
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 1 5 -5.8450 2.4106 9.013 -2.42 0.0383
 1 7 0.1660 1.3937 9.222 0.12 0.9077
 2 3 -7.0500 2.2396 9.042 -3.15 0.0117
 2 4 -2.1667 2.3235 9.059 -0.93 0.3753
 2 5 -2.9058 2.3247 8.948 -1.25 0.2430
 2 7 3.1052 0.9497 8.168 3.27 0.0110
 3 4 4.8833 2.3506 9.008 2.08 0.0675
 3 5 4.1442 3.4117 9.02 1.21 0.2553
 3 7 10.1552 2.4099 9.096 4.21 0.0022
 4 5 -0.7392 3.3181 9.022 -0.22 0.8287
 4 7 5.2719 2.4882 9.014 2.12 0.0631
 5 7 6.0110 1.8400 9.051 3.27 0.0097
1 T cell+  0 0.25 -0.09833 0.02915 19.36 -3.37 0.0031
CD4+ CD8+ 0 1 -0.1533 0.1085 6.68 -1.41 0.2023
 0 2 -0.2908 0.1008 10.8 -2.89 0.0151
 0 3 -0.9992 0.2917 10.83 -3.42 0.0058
 0 4 -0.7333 0.2634 10.43 -2.78 0.0186
 0 5 -0.8592 0.1944 10.47 -4.42 0.0012
 0 7 -0.8869 0.1968 9.242 -4.51 0.0014
 0.25 1 -0.05500 0.1079 6.731 -0.51 0.6266
 0.25 2 -0.1925 0.1003 10.95 -1.92 0.0815
 0.25 3 -0.9008 0.2909 10.84 -3.10 0.0103
 0.25 4 -0.6350 0.2626 10.43 -2.42 0.0352
 0.25 5 -0.7608 0.1937 10.48 -3.93 0.0026
 0.25 7 -0.7886 0.1961 9.278 -4.02 0.0028
 1 2 -0.1375 0.1236 18.56 -1.11 0.2801
 1 3 -0.8458 0.2768 12.19 -3.06 0.0098
 1 4 -0.5800 0.2508 12.32 -2.31 0.0388
 1 5 -0.7058 0.1903 14.85 -3.71 0.0021
 1 7 -0.7336 0.1937 13 -3.79 0.0023
 2 3 -0.7083 0.2767 11.96 -2.56 0.0251
 2 4 -0.4425 0.2503 11.96 -1.77 0.1026
 2 5 -0.5683 0.1887 13.85 -3.01 0.0094
 2 7 -0.5961 0.1920 12.14 -3.10 0.0090
 3 4 0.2658 0.3166 19.92 0.84 0.4111
 3 5 0.1400 0.2892 16.7 0.48 0.6346
 3 7 0.1123 0.2928 16.93 0.38 0.7062
 4 5 -0.1258 0.2682 17.74 -0.47 0.6446
 4 7 -0.1536 0.2718 17.79 -0.57 0.5791
 5 7 -0.02774 0.2273 19.18 -0.12 0.9041
1 T cell+  0 0.25 1.3458 0.2163 9.179 6.22 0.0001
CD4- CD8- 0 1 -0.2667 0.4443 9.33 -0.60 0.5627
 0 2 1.2617 0.1727 9.29 7.31 <.0001
 0 3 1.2883 0.2876 9.334 4.48 0.0014
 0 4 1.7058 0.1946 9.281 8.76 <.0001
 0 5 1.3600 0.1951 9.264 6.97 <.0001
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 7 0.7328 0.3916 7.473 1.87 0.1008
 0.25 1 -1.6125 0.3491 9.158 -4.62 0.0012
 0.25 2 -0.08417 0.1258 8.963 -0.67 0.5202
 0.25 3 -0.05750 0.1886 9.105 -0.30 0.7673
 0.25 4 0.3600 0.1282 8.982 2.81 0.0205
 0.25 5 0.01417 0.1912 8.905 0.07 0.9426
 0.25 7 -0.6131 0.4219 7.709 -1.45 0.1856
 1 2 1.5283 0.3061 9.268 4.99 0.0007
 1 3 1.5550 0.2437 9.105 6.38 0.0001
 1 4 1.9725 0.3196 9.192 6.17 0.0002
 1 5 1.6267 0.2865 9.289 5.68 0.0003
 1 7 0.9994 0.5542 8.768 1.80 0.1057
 2 3 0.02667 0.1439 9.249 0.19 0.8570
 2 4 0.4442 0.1032 9.022 4.30 0.0020
 2 5 0.09833 0.1282 8.954 0.77 0.4628
 2 7 -0.5289 0.3525 7.187 -1.50 0.1761
 3 4 0.4175 0.1441 9.178 2.90 0.0173
 3 5 0.07167 0.1530 9.138 0.47 0.6504
 3 7 -0.5556 0.4461 7.928 -1.25 0.2485
 4 5 -0.3458 0.1575 8.923 -2.20 0.0560
 4 7 -0.9731 0.4180 7.665 -2.33 0.0497
 5 7 -0.6272 0.4482 7.624 -1.40 0.2010
1 T cell+  0 0.25 -1.9442 0.4520 8.261 -4.30 0.0024
CD4+ CD8- 0 1 -3.6917 0.8116 8.983 -4.55 0.0014
 0 2 -6.2458 0.6893 8.779 -9.06 <.0001
 0 3 -9.9267 1.1128 8.991 -8.92 <.0001
 0 4 -7.1233 1.8998 8.99 -3.75 0.0046
 0 5 -7.9817 1.4053 8.995 -5.68 0.0003
 0 7 -3.2920 0.8616 7.759 -3.82 0.0054
 0.25 1 -1.7475 1.0581 8.865 -1.65 0.1335
 0.25 2 -4.3017 0.9212 8.123 -4.67 0.0015
 0.25 3 -7.9825 1.1210 8.709 -7.12 <.0001
 0.25 4 -5.1792 1.9607 8.992 -2.64 0.0269
 0.25 5 -6.0375 1.1737 8.729 -5.14 0.0007
 0.25 7 -1.3479 1.0917 7.535 -1.23 0.2541
 1 2 -2.5542 1.0302 8.831 -2.48 0.0355
 1 3 -6.2350 1.1032 8.989 -5.65 0.0003
 1 4 -3.4317 1.5226 8.986 -2.25 0.0507
 1 5 -4.2900 1.9387 8.99 -2.21 0.0542
 1 7 0.3996 1.2530 8.327 0.32 0.7576
 2 3 -3.6808 1.0646 8.916 -3.46 0.0073
 2 4 -0.8775 1.9258 8.945 -0.46 0.6595
 2 5 -1.7358 1.4578 8.999 -1.19 0.2642
 2 7 2.9538 0.7946 8.918 3.72 0.0049
 3 4 2.8033 1.7744 8.977 1.58 0.1487
 3 5 1.9450 1.7415 9.003 1.12 0.2930
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 3 7 6.6346 1.3061 8.643 5.08 0.0008
 4 5 -0.8583 2.5978 8.983 -0.33 0.7487
 4 7 3.8313 1.8839 8.501 2.03 0.0743
 5 7 4.6896 1.4262 8.879 3.29 0.0096
2 T cell+  0 0.25 -0.2367 0.3410 11.32 -0.69 0.5016
CD4- CD8- 0 1 0.1150 0.1628 17.94 0.71 0.4890
 0 2 0.5175 0.1334 13.97 3.88 0.0017
 0 3 0.8958 0.1185 9.495 7.56 <.0001
 0 4 0.9308 0.1183 9.467 7.87 <.0001
 0 5 0.6617 0.1230 10.95 5.38 0.0002
 0 7 0.4605 0.1340 13.95 3.44 0.0040
 0.25 1 0.3517 0.3398 11.18 1.04 0.3225
 0.25 2 0.7542 0.3266 9.722 2.31 0.0443
 0.25 3 1.1325 0.3208 9.064 3.53 0.0063
 0.25 4 1.1675 0.3207 9.06 3.64 0.0053
 0.25 5 0.8983 0.3225 9.26 2.79 0.0207
 0.25 7 0.6971 0.3268 9.747 2.13 0.0594
 1 2 0.4025 0.1302 14.22 3.09 0.0079
 1 3 0.7808 0.1150 9.532 6.79 <.0001
 1 4 0.8158 0.1148 9.503 7.11 <.0001
 1 5 0.5467 0.1196 11.08 4.57 0.0008
 1 7 0.3455 0.1309 14.19 2.64 0.0193
 2 3 0.3783 0.06754 10.57 5.60 0.0002
 2 4 0.4133 0.06730 10.43 6.14 <.0001
 2 5 0.1442 0.07518 14.17 1.92 0.0755
 2 7 -0.05703 0.09208 15.72 -0.62 0.5446
 3 4 0.03500 0.02806 16.5 1.25 0.2297
 3 5 -0.2342 0.04370 13.27 -5.36 0.0001
 3 7 -0.4354 0.06891 9.276 -6.32 0.0001
 4 5 -0.2692 0.04336 12.85 -6.21 <.0001
 4 7 -0.4704 0.06867 9.148 -6.85 <.0001
 5 7 -0.2012 0.07640 12.5 -2.63 0.0212
2 T cell+  0 0.25 -0.6167 0.1603 11.06 -3.85 0.0027
CD4+ CD8- 0 1 -1.1100 0.2384 9.989 -4.66 0.0009
 0 2 -2.7750 0.5591 9.8 -4.96 0.0006
 0 3 -3.3533 0.4151 10.03 -8.08 <.0001
 0 4 -2.3217 0.5831 9.236 -3.98 0.0030
 0 5 -2.6450 0.4284 8.659 -6.17 0.0002
 0 7 -1.1034 0.2742 8.766 -4.02 0.0032
 0.25 1 -0.4933 0.2656 15.18 -1.86 0.0828
 0.25 2 -2.1583 0.5634 10.52 -3.83 0.0030
 0.25 3 -2.7367 0.4255 11.49 -6.43 <.0001
 0.25 4 -1.7050 0.5869 9.982 -2.91 0.0157
 0.25 5 -2.0283 0.4386 10.23 -4.63 0.0009
 0.25 7 -0.4868 0.2970 12.53 -1.64 0.1261
 1 2 -1.6650 0.5794 11.98 -2.87 0.0140
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 1 3 -2.2433 0.4506 14.01 -4.98 0.0002
 1 4 -1.2117 0.6019 11.34 -2.01 0.0685
 1 5 -1.5350 0.4629 13.12 -3.32 0.0055
 1 7 0.006552 0.3382 16.24 0.02 0.9848
 2 3 -0.5783 0.6502 15.86 -0.89 0.3870
 2 4 0.4533 0.7522 17.43 0.60 0.5545
 2 5 0.1300 0.6587 16.75 0.20 0.8459
 2 7 1.6716 0.5919 12.79 2.82 0.0146
 3 4 1.0317 0.6695 15.6 1.54 0.1434
 3 5 0.7083 0.5562 17.88 1.27 0.2192
 3 7 2.2499 0.4677 15.08 4.81 0.0002
 4 5 -0.3233 0.6779 16.49 -0.48 0.6397
 4 7 1.2182 0.6139 12.2 1.98 0.0702
 5 7 1.5416 0.4796 14.14 3.21 0.0062
B cell+ IgM+ 0 0.25 -0.6300 0.4144 9.876 -1.52 0.1598
 0 1 -2.2617 0.6533 9.343 -3.46 0.0067
 0 2 -6.2983 1.3446 9.08 -4.68 0.0011
 0 3 -8.1500 1.8621 9.042 -4.38 0.0018
 0 4 -8.5842 2.0969 9.033 -4.09 0.0027
 0 5 -13.2467 2.5518 9.022 -5.19 0.0006
 0 7 -6.2942 1.9084 8.035 -3.30 0.0108
 0.25 1 -1.6317 0.7632 15.1 -2.14 0.0493
 0.25 2 -5.6683 1.4014 10.62 -4.04 0.0021
 0.25 3 -7.5200 1.9035 9.85 -3.95 0.0028
 0.25 4 -7.9542 2.1338 9.67 -3.73 0.0042
 0.25 5 -12.6167 2.5822 9.453 -4.89 0.0007
 0.25 7 -5.6642 1.9488 8.721 -2.91 0.0180
 1 2 -4.0367 1.4896 12.97 -2.71 0.0179
 1 3 -5.8883 1.9693 11.15 -2.99 0.0121
 1 4 -6.3225 2.1927 10.7 -2.88 0.0153
 1 5 -10.9850 2.6311 10.15 -4.18 0.0018
 1 7 -4.0325 2.0132 9.834 -2.00 0.0735
 2 3 -1.8517 2.2934 16.37 -0.81 0.4310
 2 4 -2.2858 2.4878 15.32 -0.92 0.3724
 2 5 -6.9483 2.8817 13.63 -2.41 0.0306
 2 7 0.004167 2.3311 14.69 0.00 0.9986
 3 4 -0.4342 2.8015 17.75 -0.15 0.8786
 3 5 -5.0967 3.1565 16.46 -1.61 0.1254
 3 7 1.8558 2.6634 16.88 0.70 0.4954
 4 5 -4.6625 3.3005 17.35 -1.41 0.1754
 4 7 2.2900 2.8326 16.98 0.81 0.4300
 5 7 6.9525 3.1840 16.18 2.18 0.0441
B cell+ IgG+ 0 0.25 -0.07583 0.06696 8.102 -1.13 0.2898
 0 1 -0.03333 0.01597 13.54 -2.09 0.0563
 0 2 -0.06500 0.01799 13.18 -3.61 0.0031
 0 3 -0.2375 0.07256 10.14 -3.27 0.0082
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 4 -0.2933 0.1775 10.17 -1.65 0.1289
 0 5 -0.6432 0.2061 9.288 -3.12 0.0118
 0 7 -1.1126 0.3330 7.921 -3.34 0.0104
 0.25 1 0.04250 0.06678 8.506 0.64 0.5413
 0.25 2 0.01083 0.06681 8.742 0.16 0.8749
 0.25 3 -0.1617 0.08962 18.42 -1.80 0.0876
 0.25 4 -0.2175 0.1780 11.72 -1.22 0.2459
 0.25 5 -0.5674 0.2054 10.15 -2.76 0.0198
 0.25 7 -1.0368 0.3284 8.232 -3.16 0.0130
 1 2 -0.03167 0.02070 18.06 -1.53 0.1434
 1 3 -0.2042 0.07226 10.36 -2.83 0.0174
 1 4 -0.2600 0.1766 10.15 -1.47 0.1712
 1 5 -0.6099 0.2051 9.251 -2.97 0.0152
 1 7 -1.0793 0.3320 7.913 -3.25 0.0119
 2 3 -0.1725 0.07224 10.51 -2.39 0.0370
 2 4 -0.2283 0.1762 10.16 -1.30 0.2238
 2 5 -0.5782 0.2048 9.246 -2.82 0.0194
 2 7 -1.0476 0.3316 7.91 -3.16 0.0136
 3 4 -0.05583 0.1788 11.93 -0.31 0.7602
 3 5 -0.4057 0.2058 10.3 -1.97 0.0762
 3 7 -0.8751 0.3281 8.312 -2.67 0.0275
 4 5 -0.3499 0.2453 16 -1.43 0.1730
 4 7 -0.8193 0.3468 11.51 -2.36 0.0367
 5 7 -0.4694 0.3587 12.76 -1.31 0.2138
B cell+ IgG- 0 0.25 -0.7575 0.4441 9.868 -1.71 0.1193
 0 1 -2.7400 0.7608 9.287 -3.60 0.0054
 0 2 -8.0858 1.4296 9.08 -5.66 0.0003
 0 3 -7.7333 1.8370 9.049 -4.21 0.0022
 0 4 -7.0542 1.9738 9.042 -3.57 0.0059
 0 5 -14.1856 3.2850 8.013 -4.32 0.0025
 0 7 -6.9181 2.3010 8.028 -3.01 0.0168
 0.25 1 -1.9825 0.8706 14.36 -2.28 0.0386
 0.25 2 -7.3283 1.4909 10.65 -4.92 0.0005
 0.25 3 -6.9758 1.8851 10 -3.70 0.0041
 0.25 4 -6.2967 2.0186 9.869 -3.12 0.0111
 0.25 5 -13.4281 3.3121 8.279 -4.05 0.0034
 0.25 7 -6.1606 2.3396 8.57 -2.63 0.0283
 1 2 -5.3458 1.6138 13.67 -3.31 0.0053
 1 3 -4.9933 1.9838 11.96 -2.52 0.0271
 1 4 -4.3142 2.1110 11.58 -2.04 0.0644
 1 5 -11.4456 3.3692 8.846 -3.40 0.0081
 1 7 -4.1781 2.4197 9.717 -1.73 0.1158
 2 3 0.3525 2.3238 16.97 0.15 0.8812
 2 4 1.0317 2.4334 16.4 0.42 0.6771
 2 5 -6.0997 3.5800 10.96 -1.70 0.1166
 2 7 1.1678 2.7056 13.56 0.43 0.6728
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Table F1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 3 4 0.6792 2.6930 17.91 0.25 0.8038
 3 5 -6.4522 3.7613 12.68 -1.72 0.1106
 3 7 0.8153 2.9413 15.75 0.28 0.7852
 4 5 -7.1314 3.8300 13.27 -1.86 0.0849
 4 7 0.1361 3.0285 16.27 0.04 0.9647
 5 7 7.2675 4.0084 14.32 1.81 0.0908
 
 
 
Table F2. Difference of least squares means for pulp cell responses by treatment 
Study/Factor Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
Study 1 
 
       
Lymphocytes IO IOEF 4.3924 1.1438 11 3.84 0.0027
 IO IOmIgG 0.6855 1.0784 11 0.64 0.5380
 IOEF IOmIgG -3.7069 1.1438 11 -3.24 0.0079
CD45+ IO IOEF 5.1513 1.5922 11 3.24 0.0079
 IO IOmIgG 0.7647 1.5011 11 0.51 0.6205
 IOEF IOmIgG -4.3865 1.5922 11 -2.75 0.0187
CD4- CD8+ IO IOEF 0.5871 0.1705 11 3.44 0.0055
 IO IOmIgG 0.1440 0.1608 11 0.90 0.3897
 IOEF IOmIgG -0.4431 0.1705 11 -2.60 0.0248
CD4+ CD8+ IO IOEF 0.06256 0.03695 11 1.69 0.1185
 IO IOmIgG -0.05200 0.03484 11 -1.49 0.1636
 IOEF IOmIgG -0.1146 0.03695 11 -3.10 0.0101
CD4+ CD8- IO IOEF 2.1476 0.6070 11 3.54 0.0046
 IO IOmIgG 0.3913 0.5723 11 0.68 0.5083
 IOEF IOmIgG -1.7564 0.6070 11 -2.89 0.0146
 T cell+ CD8- IO IOEF 0.1433 0.06846 11 2.09 0.0604
 IO IOmIgG -0.04800 0.06454 11 -0.74 0.4727
 IOEF IOmIgG -0.1913 0.06846 11 -2.79 0.0175
2 T cell+ IO IOEF 0.5582 0.1911 11 2.92 0.0139
 IO IOmIgG 0.07600 0.1802 11 0.42 0.6813
 IOEF IOmIgG -0.4823 0.1911 11 -2.52 0.0283
1 T cell+ IO IOEF 1.8976 0.5125 11 3.70 0.0035
 IO IOmIgG 0.2300 0.4834 11 0.48 0.6435
 IOEF IOmIgG -1.6676 0.5126 11 -3.25 0.0077
B cells IO IOEF 1.1184 0.3198 11 3.50 0.0050
 IO IOmIgG -0.06375 0.3014 11 -0.21 0.8364
 IOEF IOmIgG -1.1821 0.3197 11 -3.70 0.0035
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Table F2. Difference of least squares means for pulp cell responses by treatment (Cont.) 
Study/Factor Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
Study 2 
 
       
CD4+ CD8- Alu AlumIgG -2.8712 0.6657 12 -4.31 0.0010
 Alu IO -3.3167 0.6657 12 -4.98 0.0003
 Alu IOmIgG -1.8825 0.6657 12 -2.83 0.0152
 AlumIgG IO -0.4454 0.6657 12 -0.67 0.5161
 AlumIgG IOmIgG 0.9887 0.6657 12 1.49 0.1632
 IO IOmIgG 1.4342 0.6657 12 2.15 0.0522
2 T cell+ Alu AlumIgG -1.1321 0.2672 12 -4.24 0.0012
 Alu IO -0.8963 0.2672 12 -3.35 0.0057
 Alu IOmIgG -0.5017 0.2672 12 -1.88 0.0849
 AlumIgG IO 0.2358 0.2672 12 0.88 0.3947
 AlumIgG IOmIgG 0.6304 0.2672 12 2.36 0.0361
 IO IOmIgG 0.3946 0.2672 12 1.48 0.1654
1 T cell+ Alu AlumIgG -2.5963 0.7097 12 -3.66 0.0033
 Alu IO -3.3429 0.7097 12 -4.71 0.0005
 Alu IOmIgG -2.0554 0.7097 12 -2.90 0.0134
 AlumIgG IO -0.7467 0.7097 12 -1.05 0.3135
 AlumIgG IOmIgG 0.5408 0.7097 12 0.76 0.4608
 IO IOmIgG 1.2875 0.7097 12 1.81 0.0947
Study 3 
 
       
MHCII+ Macrophages AlumIgG IOmIgG -0.2456 0.1925 9.208 -1.28 0.2333
 AlumIgG mIgG 0.7834 0.1924 9.202 4.07 0.0027
 IOmIgG mIgG 1.0290 0.1925 9.208 5.35 0.0004
CD4- CD8+ AlumIgG IOmIgG 2.0691 0.8063 9.213 2.57 0.0298
 AlumIgG mIgG 2.3219 0.8169 9.211 2.84 0.0189
 IOmIgG mIgG 0.2528 0.8449 9.213 0.30 0.7714
1 T cell+  AlumIgG IOmIgG 1.7167 0.8814 8.686 1.95 0.0844
CD4+ CD8- AlumIgG mIgG 3.1162 0.8795 8.659 3.54 0.0067
 IOmIgG mIgG 1.3995 0.8814 8.686 1.59 0.1480
2 T cell+  AlumIgG IOmIgG 0.3374 0.1718 9.049 1.96 0.0810
CD4- CD8+ AlumIgG mIgG 0.5256 0.1716 9.036 3.06 0.0135
 IOmIgG mIgG 0.1883 0.1718 9.049 1.10 0.3016
B cell+ IgM+ AlumIgG IOmIgG 1.4409 1.3883 40.75 1.04 0.3054
 AlumIgG mIgG 4.6216 1.3698 40.5 3.37 0.0016
 IOmIgG mIgG 3.1806 1.3883 40.75 2.29 0.0272
B cell+ IgG- AlumIgG IOmIgG 3.0376 1.5403 33.61 1.97 0.0569
 AlumIgG mIgG 4.9223 1.5652 30.64 3.14 0.0037
 IOmIgG mIgG 1.8847 1.5888 31.1 1.19 0.2445
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Table F3. Simple effect comparisons of treatment*day least squares means by treatment for live 
cells, Study 1 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
IO 0 0.25 1.5700 3.3976 11 0.46 0.6530
IO 0 1 -7.4260 2.9533 11 -2.51 0.0288
IO 0 2 -1.4700 3.6770 11 -0.40 0.6970
IO 0 3 1.7360 3.5521 11 0.49 0.6346
IO 0 4 4.5640 3.7216 11 1.23 0.2457
IO 0 5 4.8140 2.5530 11 1.89 0.0860
IO 0 7 4.6420 2.0164 11 2.30 0.0419
IO 0.25 1 -8.9960 3.4578 11 -2.60 0.0246
IO 0.25 2 -3.0400 4.3254 11 -0.70 0.4968
IO 0.25 3 0.1660 3.5301 11 0.05 0.9633
IO 0.25 4 2.9940 3.7872 11 0.79 0.4459
IO 0.25 5 3.2440 2.1090 11 1.54 0.1523
IO 0.25 7 3.0720 3.0351 11 1.01 0.3332
IO 1 2 5.9560 2.9456 11 2.02 0.0682
IO 1 3 9.1620 2.6092 11 3.51 0.0049
IO 1 4 11.9900 3.2606 11 3.68 0.0036
IO 1 5 12.2400 2.3706 11 5.16 0.0003
IO 1 7 12.0680 2.8051 11 4.30 0.0013
IO 2 3 3.2060 2.3325 11 1.37 0.1966
IO 2 4 6.0340 3.3450 11 1.80 0.0987
IO 2 5 6.2840 3.4997 11 1.80 0.1001
IO 2 7 6.1120 2.9518 11 2.07 0.0627
IO 3 4 2.8280 3.0870 11 0.92 0.3793
IO 3 5 3.0780 2.4661 11 1.25 0.2379
IO 3 7 2.9060 3.4177 11 0.85 0.4133
IO 4 5 0.2500 2.3033 11 0.11 0.9155
IO 4 7 0.07800 3.9250 11 0.02 0.9845
IO 5 7 -0.1720 3.0093 11 -0.06 0.9554
IOEF 0 0.25 2.1325 3.7986 11 0.56 0.5858
IOEF 0 1 -15.2625 3.3019 11 -4.62 0.0007
IOEF 0 2 -8.1675 4.1111 11 -1.99 0.0724
IOEF 0 3 -5.2250 3.9714 11 -1.32 0.2150
IOEF 0 4 1.0625 4.1609 11 0.26 0.8032
IOEF 0 5 -2.3725 2.8544 11 -0.83 0.4235
IOEF 0 7 1.7275 2.2545 11 0.77 0.4596
IOEF 0.25 1 -17.3950 3.8659 11 -4.50 0.0009
IOEF 0.25 2 -10.3000 4.8360 11 -2.13 0.0566
IOEF 0.25 3 -7.3575 3.9467 11 -1.86 0.0892
IOEF 0.25 4 -1.0700 4.2343 11 -0.25 0.8052
IOEF 0.25 5 -4.5050 2.3579 11 -1.91 0.0825
IOEF 0.25 7 -0.4050 3.3933 11 -0.12 0.9071
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Table F3. Simple effect comparisons of treatment*day least squares means by treatment 
for live cells, Study 1 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
IOEF 1 2 7.0950 3.2933 11 2.15 0.0542
IOEF 1 3 10.0375 2.9171 11 3.44 0.0055
IOEF 1 4 16.3250 3.6454 11 4.48 0.0009
IOEF 1 5 12.8900 2.6504 11 4.86 0.0005
IOEF 1 7 16.9900 3.1362 11 5.42 0.0002
IOEF 2 3 2.9425 2.6078 11 1.13 0.2832
IOEF 2 4 9.2300 3.7399 11 2.47 0.0312
IOEF 2 5 5.7950 3.9128 11 1.48 0.1667
IOEF 2 7 9.8950 3.3002 11 3.00 0.0121
IOEF 3 4 6.2875 3.4514 11 1.82 0.0958
IOEF 3 5 2.8525 2.7572 11 1.03 0.3231
IOEF 3 7 6.9525 3.8211 11 1.82 0.0961
IOEF 4 5 -3.4350 2.5752 11 -1.33 0.2092
IOEF 4 7 0.6650 4.3883 11 0.15 0.8823
IOEF 5 7 4.1000 3.3645 11 1.22 0.2485
IOmIgG 0 0.25 0.9220 3.3976 11 0.27 0.7911
IOmIgG 0 1 -12.1980 2.9533 11 -4.13 0.0017
IOmIgG 0 2 -4.4780 3.6770 11 -1.22 0.2488
IOmIgG 0 3 -7.3000 3.5521 11 -2.06 0.0644
IOmIgG 0 4 -5.8280 3.7216 11 -1.57 0.1456
IOmIgG 0 5 -6.9020 2.5530 11 -2.70 0.0205
IOmIgG 0 7 -3.1380 2.0164 11 -1.56 0.1479
IOmIgG 0.25 1 -13.1200 3.4578 11 -3.79 0.0030
IOmIgG 0.25 2 -5.4000 4.3254 11 -1.25 0.2378
IOmIgG 0.25 3 -8.2220 3.5301 11 -2.33 0.0399
IOmIgG 0.25 4 -6.7500 3.7872 11 -1.78 0.1023
IOmIgG 0.25 5 -7.8240 2.1090 11 -3.71 0.0034
IOmIgG 0.25 7 -4.0600 3.0351 11 -1.34 0.2080
IOmIgG 1 2 7.7200 2.9456 11 2.62 0.0238
IOmIgG 1 3 4.8980 2.6092 11 1.88 0.0872
IOmIgG 1 4 6.3700 3.2606 11 1.95 0.0766
IOmIgG 1 5 5.2960 2.3706 11 2.23 0.0472
IOmIgG 1 7 9.0600 2.8051 11 3.23 0.0080
IOmIgG 2 3 -2.8220 2.3325 11 -1.21 0.2517
IOmIgG 2 4 -1.3500 3.3450 11 -0.40 0.6943
IOmIgG 2 5 -2.4240 3.4997 11 -0.69 0.5029
IOmIgG 2 7 1.3400 2.9518 11 0.45 0.6587
IOmIgG 3 4 1.4720 3.0870 11 0.48 0.6428
IOmIgG 3 5 0.3980 2.4661 11 0.16 0.8747
IOmIgG 3 7 4.1620 3.4177 11 1.22 0.2488
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Table F3. Simple effect comparisons of treatment*day least squares means by treatment 
for live cells, Study 1 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
IOmIgG 4 5 -1.0740 2.3033 11 -0.47 0.6501
IOmIgG 4 7 2.6900 3.9250 11 0.69 0.5073
IOmIgG 5 7 3.7640 3.0093 11 1.25 0.2370
 
 
Table F4. Simple effect comparisons of treatment*day least squares means by day for live cells, 
Study 1 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 IO IOEF 7.1235 2.6895 11 2.65 0.0226
day 0 IO IOmIgG 8.8360 2.5357 11 3.48 0.0051
day 0 IOEF IOmIgG 1.7125 2.6895 11 0.64 0.5373
day 0.25 IO IOEF 7.6860 3.8270 11 2.01 0.0698
day 0.25 IO IOmIgG 8.1880 3.6081 11 2.27 0.0444
day 0.25 IOEF IOmIgG 0.5020 3.8270 11 0.13 0.8980
day 1 IO IOEF -0.7130 3.3221 11 -0.21 0.8340
day 1 IO IOmIgG 4.0640 3.1321 11 1.30 0.2210
day 1 IOEF IOmIgG 4.7770 3.3221 11 1.44 0.1783
day 2 IO IOEF 0.4260 4.4206 11 0.10 0.9250
day 2 IO IOmIgG 5.8280 4.1678 11 1.40 0.1896
day 2 IOEF IOmIgG 5.4020 4.4206 11 1.22 0.2472
day 3 IO IOEF 0.1625 3.4697 11 0.05 0.9635
day 3 IO IOmIgG -0.2000 3.2713 11 -0.06 0.9523
day 3 IOEF IOmIgG -0.3625 3.4697 11 -0.10 0.9187
day 4 IO IOEF 3.6220 4.1736 11 0.87 0.4040
day 4 IO IOmIgG -1.5560 3.9349 11 -0.40 0.7001
day 4 IOEF IOmIgG -5.1780 4.1736 11 -1.24 0.2405
day 5 IO IOEF -0.06300 2.3296 11 -0.03 0.9789
day 5 IO IOmIgG -2.8800 2.1964 11 -1.31 0.2165
day 5 IOEF IOmIgG -2.8170 2.3296 11 -1.21 0.2519
day 7 IO IOEF 4.2090 3.2763 11 1.28 0.2253
day 7 IO IOmIgG 1.0560 3.0889 11 0.34 0.7389
day 7 IOEF IOmIgG -3.1530 3.2763 11 -0.96 0.3565
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Table F5. Simple effect comparisons of treatment*day least squares means by treatment for  T 
cell+ CD8+, Study 1 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
IO 0 0.25 -1.6840 0.8049 11 -2.09 0.0604
IO 0 1 -0.9840 0.3557 11 -2.77 0.0184
IO 0 2 -1.3160 0.3629 11 -3.63 0.0040
IO 0 3 -1.2520 0.3346 11 -3.74 0.0033
IO 0 4 -0.9120 0.1942 11 -4.70 0.0007
IO 0 5 -1.2800 0.2877 11 -4.45 0.0010
IO 0 7 -0.5720 0.2191 11 -2.61 0.0242
IO 0.25 1 0.7000 0.7601 11 0.92 0.3768
IO 0.25 2 0.3680 0.7668 11 0.48 0.6407
IO 0.25 3 0.4320 0.7283 11 0.59 0.5651
IO 0.25 4 0.7720 0.7284 11 1.06 0.3119
IO 0.25 5 0.4040 0.8036 11 0.50 0.6250
IO 0.25 7 1.1120 0.8151 11 1.36 0.1997
IO 1 2 -0.3320 0.5073 11 -0.65 0.5263
IO 1 3 -0.2680 0.4895 11 -0.55 0.5950
IO 1 4 0.07200 0.3715 11 0.19 0.8499
IO 1 5 -0.2960 0.4507 11 -0.66 0.5249
IO 1 7 0.4120 0.3884 11 1.06 0.3116
IO 2 3 0.06400 0.2788 11 0.23 0.8226
IO 2 4 0.4040 0.2491 11 1.62 0.1332
IO 2 5 0.03600 0.2260 11 0.16 0.8763
IO 2 7 0.7440 0.2808 11 2.65 0.0226
IO 3 4 0.3400 0.3059 11 1.11 0.2901
IO 3 5 -0.02800 0.2533 11 -0.11 0.9140
IO 3 7 0.6800 0.2412 11 2.82 0.0167
IO 4 5 -0.3680 0.3039 11 -1.21 0.2513
IO 4 7 0.3400 0.2520 11 1.35 0.2043
IO 5 7 0.7080 0.2010 11 3.52 0.0048
IOEF 0 0.25 -1.7000 0.8999 11 -1.89 0.0855
IOEF 0 1 -0.5400 0.3977 11 -1.36 0.2018
IOEF 0 2 -0.4600 0.4057 11 -1.13 0.2810
IOEF 0 3 -0.4100 0.3741 11 -1.10 0.2965
IOEF 0 4 -0.1450 0.2172 11 -0.67 0.5181
IOEF 0 5 -0.1050 0.3217 11 -0.33 0.7502
IOEF 0 7 -0.1350 0.2449 11 -0.55 0.5926
IOEF 0.25 1 1.1600 0.8498 11 1.37 0.1995
IOEF 0.25 2 1.2400 0.8573 11 1.45 0.1760
IOEF 0.25 3 1.2900 0.8143 11 1.58 0.1414
IOEF 0.25 4 1.5550 0.8144 11 1.91 0.0826
IOEF 0.25 5 1.5950 0.8984 11 1.78 0.1035
IOEF 0.25 7 1.5650 0.9113 11 1.72 0.1139
IOEF 1 2 0.08000 0.5672 11 0.14 0.8904
IOEF 1 3 0.1300 0.5473 11 0.24 0.8166
IOEF 1 4 0.3950 0.4153 11 0.95 0.3620
IOEF 1 5 0.4350 0.5040 11 0.86 0.4065
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Table F5. Simple effect comparisons of treatment*day least squares means by treatment 
for  T cell+ CD8+, Study 1 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
IOEF 1 7 0.4050 0.4343 11 0.93 0.3711
IOEF 2 3 0.05000 0.3117 11 0.16 0.8755
IOEF 2 4 0.3150 0.2785 11 1.13 0.2822
IOEF 2 5 0.3550 0.2527 11 1.40 0.1877
IOEF 2 7 0.3250 0.3140 11 1.04 0.3228
IOEF 3 4 0.2650 0.3420 11 0.77 0.4548
IOEF 3 5 0.3050 0.2832 11 1.08 0.3046
IOEF 3 7 0.2750 0.2697 11 1.02 0.3298
IOEF 4 5 0.04000 0.3398 11 0.12 0.9084
IOEF 4 7 0.01000 0.2817 11 0.04 0.9723
IOEF 5 7 -0.03000 0.2247 11 -0.13 0.8962
IOmIgG 0 0.25 -0.9120 0.8049 11 -1.13 0.2813
IOmIgG 0 1 -1.0760 0.3557 11 -3.02 0.0116
IOmIgG 0 2 -1.4000 0.3629 11 -3.86 0.0027
IOmIgG 0 3 -0.7280 0.3346 11 -2.18 0.0523
IOmIgG 0 4 -1.0520 0.1942 11 -5.42 0.0002
IOmIgG 0 5 -0.3600 0.2877 11 -1.25 0.2368
IOmIgG 0 7 0.04400 0.2191 11 0.20 0.8445
IOmIgG 0.25 1 -0.1640 0.7601 11 -0.22 0.8331
IOmIgG 0.25 2 -0.4880 0.7668 11 -0.64 0.5375
IOmIgG 0.25 3 0.1840 0.7283 11 0.25 0.8052
IOmIgG 0.25 4 -0.1400 0.7284 11 -0.19 0.8511
IOmIgG 0.25 5 0.5520 0.8036 11 0.69 0.5063
IOmIgG 0.25 7 0.9560 0.8151 11 1.17 0.2656
IOmIgG 1 2 -0.3240 0.5073 11 -0.64 0.5361
IOmIgG 1 3 0.3480 0.4895 11 0.71 0.4919
IOmIgG 1 4 0.02400 0.3715 11 0.06 0.9496
IOmIgG 1 5 0.7160 0.4507 11 1.59 0.1405
IOmIgG 1 7 1.1200 0.3884 11 2.88 0.0149
IOmIgG 2 3 0.6720 0.2788 11 2.41 0.0346
IOmIgG 2 4 0.3480 0.2491 11 1.40 0.1900
IOmIgG 2 5 1.0400 0.2260 11 4.60 0.0008
IOmIgG 2 7 1.4440 0.2808 11 5.14 0.0003
IOmIgG 3 4 -0.3240 0.3059 11 -1.06 0.3123
IOmIgG 3 5 0.3680 0.2533 11 1.45 0.1742
IOmIgG 3 7 0.7720 0.2412 11 3.20 0.0084
IOmIgG 4 5 0.6920 0.3039 11 2.28 0.0438
IOmIgG 4 7 1.0960 0.2520 11 4.35 0.0012
IOmIgG 5 7 0.4040 0.2010 11 2.01 0.0696
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Table F6. Simple effect comparisons of treatment*day least squares means by day for  T cell+ 
CD8+, Study 1 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 IO IOEF 0.07500 0.1341 11 0.56 0.5871
day 0 IO IOmIgG -0.06000 0.1264 11 -0.47 0.6443
day 0 IOEF IOmIgG -0.1350 0.1341 11 -1.01 0.3357
day 0.25 IO IOEF 0.05900 1.1717 11 0.05 0.9607
day 0.25 IO IOmIgG 0.7120 1.1047 11 0.64 0.5324
day 0.25 IOEF IOmIgG 0.6530 1.1717 11 0.56 0.5885
day 1 IO IOEF 0.5190 0.5950 11 0.87 0.4017
day 1 IO IOmIgG -0.1520 0.5610 11 -0.27 0.7914
day 1 IOEF IOmIgG -0.6710 0.5950 11 -1.13 0.2834
day 2 IO IOEF 0.9310 0.5047 11 1.84 0.0922
day 2 IO IOmIgG -0.1440 0.4759 11 -0.30 0.7678
day 2 IOEF IOmIgG -1.0750 0.5047 11 -2.13 0.0566
day 3 IO IOEF 0.9170 0.4027 11 2.28 0.0438
day 3 IO IOmIgG 0.4640 0.3797 11 1.22 0.2472
day 3 IOEF IOmIgG -0.4530 0.4027 11 -1.12 0.2846
day 4 IO IOEF 0.8420 0.3001 11 2.81 0.0171
day 4 IO IOmIgG -0.2000 0.2830 11 -0.71 0.4944
day 4 IOEF IOmIgG -1.0420 0.3001 11 -3.47 0.0052
day 5 IO IOEF 1.2500 0.3907 11 3.20 0.0085
day 5 IO IOmIgG 0.8600 0.3683 11 2.33 0.0395
day 5 IOEF IOmIgG -0.3900 0.3907 11 -1.00 0.3396
day 7 IO IOEF 0.5120 0.2929 11 1.75 0.1083
day 7 IO IOmIgG 0.5560 0.2761 11 2.01 0.0692
day 7 IOEF IOmIgG 0.04400 0.2929 11 0.15 0.8833
 
 
Table F7. Simple effect comparisons of treatment*day least squares means by treatment for 
CD45+, Study 2 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alu 0 0.25 -30.0875 7.3676 12 -4.08 0.0015
Alu 0 1 -25.8525 5.4672 12 -4.73 0.0005
Alu 0 2 -17.8300 5.8121 12 -3.07 0.0098
Alu 0 5 -25.0625 5.7467 12 -4.36 0.0009
Alu 0 7 -9.6550 4.9311 12 -1.96 0.0739
Alu 0.25 1 4.2350 6.8437 12 0.62 0.5476
Alu 0.25 2 12.2575 8.3297 12 1.47 0.1669
Alu 0.25 5 5.0250 11.0718 12 0.45 0.6580
Alu 0.25 7 20.4325 8.1559 12 2.51 0.0276
Alu 1 2 8.0225 5.6309 12 1.42 0.1797
Alu 1 5 0.7900 8.5602 12 0.09 0.9280
Alu 1 7 16.1975 6.7747 12 2.39 0.0341
Alu 2 5 -7.2325 6.6833 12 -1.08 0.3004
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Table F7. Simple effect comparisons of treatment*day least squares means by treatment 
for CD45+, Study 2 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alu 2 7 8.1750 5.3888 12 1.52 0.1552
Alu 5 7 15.4075 6.3612 12 2.42 0.0322
AlumIgG 0 0.25 -43.4925 7.3676 12 -5.90 <.0001
AlumIgG 0 1 -53.5800 5.4672 12 -9.80 <.0001
AlumIgG 0 2 -48.4400 5.8121 12 -8.33 <.0001
AlumIgG 0 5 -57.5500 5.7467 12 -10.01 <.0001
AlumIgG 0 7 -34.4200 4.9311 12 -6.98 <.0001
AlumIgG 0.25 1 -10.0875 6.8437 12 -1.47 0.1662
AlumIgG 0.25 2 -4.9475 8.3297 12 -0.59 0.5636
AlumIgG 0.25 5 -14.0575 11.0718 12 -1.27 0.2283
AlumIgG 0.25 7 9.0725 8.1559 12 1.11 0.2878
AlumIgG 1 2 5.1400 5.6309 12 0.91 0.3793
AlumIgG 1 5 -3.9700 8.5602 12 -0.46 0.6511
AlumIgG 1 7 19.1600 6.7747 12 2.83 0.0152
AlumIgG 2 5 -9.1100 6.6833 12 -1.36 0.1979
AlumIgG 2 7 14.0200 5.3888 12 2.60 0.0232
AlumIgG 5 7 23.1300 6.3612 12 3.64 0.0034
IO 0 0.25 -22.4025 7.3676 12 -3.04 0.0103
IO 0 1 -16.6825 5.4672 12 -3.05 0.0101
IO 0 2 -8.0100 5.8121 12 -1.38 0.1933
IO 0 5 -36.7900 5.7467 12 -6.40 <.0001
IO 0 7 -25.8825 4.9311 12 -5.25 0.0002
IO 0.25 1 5.7200 6.8437 12 0.84 0.4196
IO 0.25 2 14.3925 8.3297 12 1.73 0.1096
IO 0.25 5 -14.3875 11.0718 12 -1.30 0.2182
IO 0.25 7 -3.4800 8.1559 12 -0.43 0.6772
IO 1 2 8.6725 5.6309 12 1.54 0.1495
IO 1 5 -20.1075 8.5602 12 -2.35 0.0368
IO 1 7 -9.2000 6.7747 12 -1.36 0.1995
IO 2 5 -28.7800 6.6833 12 -4.31 0.0010
IO 2 7 -17.8725 5.3888 12 -3.32 0.0061
IO 5 7 10.9075 6.3612 12 1.71 0.1121
IOmIgG 0 0.25 -30.0825 7.3676 12 -4.08 0.0015
IOmIgG 0 1 -20.4400 5.4672 12 -3.74 0.0028
IOmIgG 0 2 -14.1325 5.8121 12 -2.43 0.0316
IOmIgG 0 5 -35.4200 5.7467 12 -6.16 <.0001
IOmIgG 0 7 -23.1750 4.9311 12 -4.70 0.0005
IOmIgG 0.25 1 9.6425 6.8437 12 1.41 0.1842
IOmIgG 0.25 2 15.9500 8.3297 12 1.91 0.0797
IOmIgG 0.25 5 -5.3375 11.0718 12 -0.48 0.6384
IOmIgG 0.25 7 6.9075 8.1559 12 0.85 0.4136
IOmIgG 1 2 6.3075 5.6309 12 1.12 0.2846
IOmIgG 1 5 -14.9800 8.5602 12 -1.75 0.1056
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Table F7. Simple effect comparisons of treatment*day least squares means by treatment 
for CD45+, Study 2 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
IOmIgG 1 7 -2.7350 6.7747 12 -0.40 0.6935
IOmIgG 2 5 -21.2875 6.6833 12 -3.19 0.0078
IOmIgG 2 7 -9.0425 5.3888 12 -1.68 0.1192
IOmIgG 5 7 12.2450 6.3612 12 1.92 0.0783
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Table F8. Simple effect comparisons of treatment*day least squares means by day for CD45+, 
Study 2 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alu AlumIgG 2.5425 3.6585 12 0.69 0.5003
day 0 Alu IO 0.7850 3.6585 12 0.21 0.8337
day 0 Alu IOmIgG -0.1000 3.6585 12 -0.03 0.9786
day 0 AlumIgG IO -1.7575 3.6585 12 -0.48 0.6396
day 0 AlumIgG IOmIgG -2.6425 3.6585 12 -0.72 0.4840
day 0 IO IOmIgG -0.8850 3.6585 12 -0.24 0.8129
day 0.25 Alu AlumIgG -10.8625 10.4830 12 -1.04 0.3205
day 0.25 Alu IO 8.4700 10.4830 12 0.81 0.4348
day 0.25 Alu IOmIgG -0.09500 10.4830 12 -0.01 0.9929
day 0.25 AlumIgG IO 19.3325 10.4830 12 1.84 0.0900
day 0.25 AlumIgG IOmIgG 10.7675 10.4830 12 1.03 0.3246
day 0.25 IO IOmIgG -8.5650 10.4830 12 -0.82 0.4298
day 1 Alu AlumIgG -25.1850 8.6075 12 -2.93 0.0127
day 1 Alu IO 9.9550 8.6075 12 1.16 0.2700
day 1 Alu IOmIgG 5.3125 8.6075 12 0.62 0.5486
day 1 AlumIgG IO 35.1400 8.6075 12 4.08 0.0015
day 1 AlumIgG IOmIgG 30.4975 8.6075 12 3.54 0.0040
day 1 IO IOmIgG -4.6425 8.6075 12 -0.54 0.5995
day 2 Alu AlumIgG -28.0675 7.5646 12 -3.71 0.0030
day 2 Alu IO 10.6050 7.5646 12 1.40 0.1863
day 2 Alu IOmIgG 3.5975 7.5646 12 0.48 0.6429
day 2 AlumIgG IO 38.6725 7.5646 12 5.11 0.0003
day 2 AlumIgG IOmIgG 31.6650 7.5646 12 4.19 0.0013
day 2 IO IOmIgG -7.0075 7.5646 12 -0.93 0.3725
day 5 Alu AlumIgG -29.9450 7.2893 12 -4.11 0.0015
day 5 Alu IO -10.9425 7.2893 12 -1.50 0.1592
day 5 Alu IOmIgG -10.4575 7.2893 12 -1.43 0.1769
day 5 AlumIgG IO 19.0025 7.2893 12 2.61 0.0229
day 5 AlumIgG IOmIgG 19.4875 7.2893 12 2.67 0.0203
day 5 IO IOmIgG 0.4850 7.2893 12 0.07 0.9480
day 7 Alu AlumIgG -22.2225 5.8717 12 -3.78 0.0026
day 7 Alu IO -15.4425 5.8717 12 -2.63 0.0220
day 7 Alu IOmIgG -13.6200 5.8717 12 -2.32 0.0388
day 7 AlumIgG IO 6.7800 5.8717 12 1.15 0.2707
day 7 AlumIgG IOmIgG 8.6025 5.8717 12 1.47 0.1686
day 7 IO IOmIgG 1.8225 5.8717 12 0.31 0.7616
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Table F9. Simple effect comparisons of treatment*day least squares means by treatment for B 
cells, Study 2 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alu 0 0.25 -0.2850 0.2457 12 -1.16 0.2686
Alu 0 1 -1.8150 1.0986 12 -1.65 0.1244
Alu 0 2 -1.5750 1.8760 12 -0.84 0.4176
Alu 0 5 -1.0275 1.3653 12 -0.75 0.4662
Alu 0 7 -0.3850 1.0612 12 -0.36 0.7231
Alu 0.25 1 -1.5300 1.0807 12 -1.42 0.1823
Alu 0.25 2 -1.2900 1.7777 12 -0.73 0.4820
Alu 0.25 5 -0.7425 1.2676 12 -0.59 0.5689
Alu 0.25 7 -0.10000 0.9034 12 -0.11 0.9137
Alu 1 2 0.2400 1.3576 12 0.18 0.8626
Alu 1 5 0.7875 1.4158 12 0.56 0.5883
Alu 1 7 1.4300 1.1872 12 1.20 0.2516
Alu 2 5 0.5475 1.5652 12 0.35 0.7326
Alu 2 7 1.1900 1.4639 12 0.81 0.4321
Alu 5 7 0.6425 1.1854 12 0.54 0.5977
AlumIgG 0 0.25 -0.7950 0.2457 12 -3.24 0.0071
AlumIgG 0 1 -5.6150 1.0986 12 -5.11 0.0003
AlumIgG 0 2 -11.3300 1.8760 12 -6.04 <.0001
AlumIgG 0 5 -13.2075 1.3653 12 -9.67 <.0001
AlumIgG 0 7 -4.1900 1.0612 12 -3.95 0.0019
AlumIgG 0.25 1 -4.8200 1.0807 12 -4.46 0.0008
AlumIgG 0.25 2 -10.5350 1.7777 12 -5.93 <.0001
AlumIgG 0.25 5 -12.4125 1.2676 12 -9.79 <.0001
AlumIgG 0.25 7 -3.3950 0.9034 12 -3.76 0.0027
AlumIgG 1 2 -5.7150 1.3576 12 -4.21 0.0012
AlumIgG 1 5 -7.5925 1.4158 12 -5.36 0.0002
AlumIgG 1 7 1.4250 1.1872 12 1.20 0.2532
AlumIgG 2 5 -1.8775 1.5652 12 -1.20 0.2535
AlumIgG 2 7 7.1400 1.4639 12 4.88 0.0004
AlumIgG 5 7 9.0175 1.1854 12 7.61 <.0001
IO 0 0.25 -0.4075 0.2457 12 -1.66 0.1231
IO 0 1 -2.2550 1.0986 12 -2.05 0.0626
IO 0 2 -2.6625 1.8760 12 -1.42 0.1813
IO 0 5 -5.2600 1.3653 12 -3.85 0.0023
IO 0 7 -4.1075 1.0612 12 -3.87 0.0022
IO 0.25 1 -1.8475 1.0807 12 -1.71 0.1130
IO 0.25 2 -2.2550 1.7777 12 -1.27 0.2287
IO 0.25 5 -4.8525 1.2676 12 -3.83 0.0024
IO 0.25 7 -3.7000 0.9034 12 -4.10 0.0015
IO 1 2 -0.4075 1.3576 12 -0.30 0.7692
IO 1 5 -3.0050 1.4158 12 -2.12 0.0553
IO 1 7 -1.8525 1.1872 12 -1.56 0.1447
IO 2 5 -2.5975 1.5652 12 -1.66 0.1229
IO 2 7 -1.4450 1.4639 12 -0.99 0.3431
IO 5 7 1.1525 1.1854 12 0.97 0.3501
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Table F9. Simple effect comparisons of treatment*day least squares means by treatment 
for B cells, Study 2 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
IOmIgG 0 0.25 0.1425 0.2457 12 0.58 0.5727
IOmIgG 0 1 -2.1775 1.0986 12 -1.98 0.0708
IOmIgG 0 2 -3.3025 1.8760 12 -1.76 0.1038
IOmIgG 0 5 -5.9750 1.3653 12 -4.38 0.0009
IOmIgG 0 7 -5.3800 1.0612 12 -5.07 0.0003
IOmIgG 0.25 1 -2.3200 1.0807 12 -2.15 0.0529
IOmIgG 0.25 2 -3.4450 1.7777 12 -1.94 0.0765
IOmIgG 0.25 5 -6.1175 1.2676 12 -4.83 0.0004
IOmIgG 0.25 7 -5.5225 0.9034 12 -6.11 <.0001
IOmIgG 1 2 -1.1250 1.3576 12 -0.83 0.4235
IOmIgG 1 5 -3.7975 1.4158 12 -2.68 0.0200
IOmIgG 1 7 -3.2025 1.1872 12 -2.70 0.0194
IOmIgG 2 5 -2.6725 1.5652 12 -1.71 0.1135
IOmIgG 2 7 -2.0775 1.4639 12 -1.42 0.1813
IOmIgG 5 7 0.5950 1.1854 12 0.50 0.6248
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Table F10. Simple effect comparisons of treatment*day least squares means by day for B cells, 
Study 2 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alu AlumIgG 0.1400 0.3147 12 0.44 0.6643
day 0 Alu IO 0.03250 0.3147 12 0.10 0.9195
day 0 Alu IOmIgG -0.2650 0.3147 12 -0.84 0.4162
day 0 AlumIgG IO -0.1075 0.3147 12 -0.34 0.7386
day 0 AlumIgG IOmIgG -0.4050 0.3147 12 -1.29 0.2224
day 0 IO IOmIgG -0.2975 0.3147 12 -0.95 0.3631
day 0.25 Alu AlumIgG -0.3700 0.2663 12 -1.39 0.1900
day 0.25 Alu IO -0.09000 0.2663 12 -0.34 0.7412
day 0.25 Alu IOmIgG 0.1625 0.2663 12 0.61 0.5531
day 0.25 AlumIgG IO 0.2800 0.2663 12 1.05 0.3138
day 0.25 AlumIgG IOmIgG 0.5325 0.2663 12 2.00 0.0687
day 0.25 IO IOmIgG 0.2525 0.2663 12 0.95 0.3618
day 1 Alu AlumIgG -3.6600 1.7256 12 -2.12 0.0554
day 1 Alu IO -0.4075 1.7256 12 -0.24 0.8173
day 1 Alu IOmIgG -0.6275 1.7256 12 -0.36 0.7225
day 1 AlumIgG IO 3.2525 1.7256 12 1.88 0.0839
day 1 AlumIgG IOmIgG 3.0325 1.7256 12 1.76 0.1043
day 1 IO IOmIgG -0.2200 1.7256 12 -0.13 0.9007
day 2 Alu AlumIgG -9.6150 2.6783 12 -3.59 0.0037
day 2 Alu IO -1.0550 2.6783 12 -0.39 0.7006
day 2 Alu IOmIgG -1.9925 2.6783 12 -0.74 0.4712
day 2 AlumIgG IO 8.5600 2.6783 12 3.20 0.0077
day 2 AlumIgG IOmIgG 7.6225 2.6783 12 2.85 0.0147
day 2 IO IOmIgG -0.9375 2.6783 12 -0.35 0.7324
day 5 Alu AlumIgG -12.0400 1.8997 12 -6.34 <.0001
day 5 Alu IO -4.2000 1.8997 12 -2.21 0.0472
day 5 Alu IOmIgG -5.2125 1.8997 12 -2.74 0.0178
day 5 AlumIgG IO 7.8400 1.8997 12 4.13 0.0014
day 5 AlumIgG IOmIgG 6.8275 1.8997 12 3.59 0.0037
day 5 IO IOmIgG -1.0125 1.8997 12 -0.53 0.6038
day 7 Alu AlumIgG -3.6650 1.3986 12 -2.62 0.0224
day 7 Alu IO -3.6900 1.3986 12 -2.64 0.0216
day 7 Alu IOmIgG -5.2600 1.3986 12 -3.76 0.0027
day 7 AlumIgG IO -0.02500 1.3986 12 -0.02 0.9860
day 7 AlumIgG IOmIgG -1.5950 1.3986 12 -1.14 0.2764
day 7 IO IOmIgG -1.5700 1.3986 12 -1.12 0.2836
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Table F11. Simple effect comparisons of treatment*day least squares means by treatment for  
T cell+ CD8+, Study 2 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alu 0 0.25 -3.6675 1.5883 12 -2.31 0.0395
Alu 0 1 -4.2400 1.5915 12 -2.66 0.0206
Alu 0 2 -6.8500 2.6142 12 -2.62 0.0224
Alu 0 5 -5.2575 1.9844 12 -2.65 0.0212
Alu 0 7 -1.6125 0.9373 12 -1.72 0.1110
Alu 0.25 1 -0.5725 2.4147 12 -0.24 0.8166
Alu 0.25 2 -3.1825 3.2150 12 -0.99 0.3418
Alu 0.25 5 -1.5900 2.8479 12 -0.56 0.5869
Alu 0.25 7 2.0550 1.4513 12 1.42 0.1822
Alu 1 2 -2.6100 2.0713 12 -1.26 0.2316
Alu 1 5 -1.0175 2.6704 12 -0.38 0.7098
Alu 1 7 2.6275 1.8828 12 1.40 0.1881
Alu 2 5 1.5925 2.3712 12 0.67 0.5146
Alu 2 7 5.2375 2.2102 12 2.37 0.0354
Alu 5 7 3.6450 1.9919 12 1.83 0.0922
AlumIgG 0 0.25 -12.9425 1.5883 12 -8.15 <.0001
AlumIgG 0 1 -14.9575 1.5915 12 -9.40 <.0001
AlumIgG 0 2 -14.1700 2.6142 12 -5.42 0.0002
AlumIgG 0 5 -4.0650 1.9844 12 -2.05 0.0630
AlumIgG 0 7 -2.8775 0.9373 12 -3.07 0.0097
AlumIgG 0.25 1 -2.0150 2.4147 12 -0.83 0.4203
AlumIgG 0.25 2 -1.2275 3.2150 12 -0.38 0.7093
AlumIgG 0.25 5 8.8775 2.8479 12 3.12 0.0089
AlumIgG 0.25 7 10.0650 1.4513 12 6.94 <.0001
AlumIgG 1 2 0.7875 2.0713 12 0.38 0.7104
AlumIgG 1 5 10.8925 2.6704 12 4.08 0.0015
AlumIgG 1 7 12.0800 1.8828 12 6.42 <.0001
AlumIgG 2 5 10.1050 2.3712 12 4.26 0.0011
AlumIgG 2 7 11.2925 2.2102 12 5.11 0.0003
AlumIgG 5 7 1.1875 1.9919 12 0.60 0.5622
IO 0 0.25 -1.0725 1.5883 12 -0.68 0.5123
IO 0 1 -2.2700 1.5915 12 -1.43 0.1793
IO 0 2 -1.2350 2.6142 12 -0.47 0.6451
IO 0 5 -2.5875 1.9844 12 -1.30 0.2167
IO 0 7 -0.9000 0.9373 12 -0.96 0.3559
IO 0.25 1 -1.1975 2.4147 12 -0.50 0.6289
IO 0.25 2 -0.1625 3.2150 12 -0.05 0.9605
IO 0.25 5 -1.5150 2.8479 12 -0.53 0.6045
IO 0.25 7 0.1725 1.4513 12 0.12 0.9074
IO 1 2 1.0350 2.0713 12 0.50 0.6263
IO 1 5 -0.3175 2.6704 12 -0.12 0.9073
IO 1 7 1.3700 1.8828 12 0.73 0.4808
IO 2 5 -1.3525 2.3712 12 -0.57 0.5789
IO 2 7 0.3350 2.2102 12 0.15 0.8820
IO 5 7 1.6875 1.9919 12 0.85 0.4135
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Table F11. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+ CD8+, 2013 IO vs. Alum (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
IOmIgG 0 0.25 -0.7325 1.5883 12 -0.46 0.6529
IOmIgG 0 1 -1.3925 1.5915 12 -0.87 0.3988
IOmIgG 0 2 -0.7500 2.6142 12 -0.29 0.7791
IOmIgG 0 5 -1.4225 1.9844 12 -0.72 0.4872
IOmIgG 0 7 -0.9500 0.9373 12 -1.01 0.3308
IOmIgG 0.25 1 -0.6600 2.4147 12 -0.27 0.7892
IOmIgG 0.25 2 -0.01750 3.2150 12 -0.01 0.9957
IOmIgG 0.25 5 -0.6900 2.8479 12 -0.24 0.8127
IOmIgG 0.25 7 -0.2175 1.4513 12 -0.15 0.8834
IOmIgG 1 2 0.6425 2.0713 12 0.31 0.7617
IOmIgG 1 5 -0.03000 2.6704 12 -0.01 0.9912
IOmIgG 1 7 0.4425 1.8828 12 0.24 0.8182
IOmIgG 2 5 -0.6725 2.3712 12 -0.28 0.7815
IOmIgG 2 7 -0.2000 2.2102 12 -0.09 0.9294
IOmIgG 5 7 0.4725 1.9919 12 0.24 0.8165
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Table F12. Simple effect comparisons of treatment*day least squares means by day for  T 
cell+ CD8+, Study 2 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alu AlumIgG 0.5900 0.5963 12 0.99 0.3420
day 0 Alu IO 0.4975 0.5963 12 0.83 0.4204
day 0 Alu IOmIgG -0.2075 0.5963 12 -0.35 0.7339
day 0 AlumIgG IO -0.09250 0.5963 12 -0.16 0.8793
day 0 AlumIgG IOmIgG -0.7975 0.5963 12 -1.34 0.2059
day 0 IO IOmIgG -0.7050 0.5963 12 -1.18 0.2600
day 0.25 Alu AlumIgG -8.6850 2.2508 12 -3.86 0.0023
day 0.25 Alu IO 3.0925 2.2508 12 1.37 0.1946
day 0.25 Alu IOmIgG 2.7275 2.2508 12 1.21 0.2489
day 0.25 AlumIgG IO 11.7775 2.2508 12 5.23 0.0002
day 0.25 AlumIgG IOmIgG 11.4125 2.2508 12 5.07 0.0003
day 0.25 IO IOmIgG -0.3650 2.2508 12 -0.16 0.8739
day 1 Alu AlumIgG -10.1275 2.1379 12 -4.74 0.0005
day 1 Alu IO 2.4675 2.1379 12 1.15 0.2709
day 1 Alu IOmIgG 2.6400 2.1379 12 1.23 0.2405
day 1 AlumIgG IO 12.5950 2.1379 12 5.89 <.0001
day 1 AlumIgG IOmIgG 12.7675 2.1379 12 5.97 <.0001
day 1 IO IOmIgG 0.1725 2.1379 12 0.08 0.9370
day 2 Alu AlumIgG -6.7300 3.4891 12 -1.93 0.0777
day 2 Alu IO 6.1125 3.4891 12 1.75 0.1053
day 2 Alu IOmIgG 5.8925 3.4891 12 1.69 0.1170
day 2 AlumIgG IO 12.8425 3.4891 12 3.68 0.0031
day 2 AlumIgG IOmIgG 12.6225 3.4891 12 3.62 0.0035
day 2 IO IOmIgG -0.2200 3.4891 12 -0.06 0.9508
day 5 Alu AlumIgG 1.7825 2.6949 12 0.66 0.5208
day 5 Alu IO 3.1675 2.6949 12 1.18 0.2626
day 5 Alu IOmIgG 3.6275 2.6949 12 1.35 0.2032
day 5 AlumIgG IO 1.3850 2.6949 12 0.51 0.6166
day 5 AlumIgG IOmIgG 1.8450 2.6949 12 0.68 0.5066
day 5 IO IOmIgG 0.4600 2.6949 12 0.17 0.8673
day 7 Alu AlumIgG -0.6750 1.2912 12 -0.52 0.6106
day 7 Alu IO 1.2100 1.2912 12 0.94 0.3672
day 7 Alu IOmIgG 0.4550 1.2912 12 0.35 0.7307
day 7 AlumIgG IO 1.8850 1.2912 12 1.46 0.1700
day 7 AlumIgG IOmIgG 1.1300 1.2912 12 0.88 0.3987
day 7 IO IOmIgG -0.7550 1.2912 12 -0.58 0.5696
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Table F13. Simple effect comparisons of treatment*day least squares means by treatment for 
CD45+, Study 3 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 0 0.25 -27.2200 3.2916 15.09 -8.27 <.0001
Alum-mIGg 0 1 -42.6175 8.8510 9.726 -4.81 0.0008
Alum-mIGg 0 2 -39.7025 5.4876 11 -7.23 <.0001
Alum-mIGg 0 3 -50.2900 7.4431 10.04 -6.76 <.0001
Alum-mIGg 0 4 -29.9200 12.1563 9.378 -2.46 0.0351
Alum-mIGg 0 5 -48.3750 9.6487 9.607 -5.01 0.0006
Alum-mIGg 0 7 -21.3125 8.2382 8.751 -2.59 0.0300
Alum-mIGg 0.25 1 -15.3975 9.1156 10.84 -1.69 0.1197
Alum-mIGg 0.25 2 -12.4825 5.9049 13.79 -2.11 0.0532
Alum-mIGg 0.25 3 -23.0700 7.7559 11.62 -2.97 0.0120
Alum-mIGg 0.25 4 -2.7000 12.3503 9.967 -0.22 0.8314
Alum-mIGg 0.25 5 -21.1550 9.8920 10.55 -2.14 0.0568
Alum-mIGg 0.25 7 5.9075 8.5218 9.912 0.69 0.5041
Alum-mIGg 1 2 2.9150 10.1180 14.73 0.29 0.7773
Alum-mIGg 1 3 -7.6725 11.2987 17.44 -0.68 0.5060
Alum-mIGg 1 4 12.6975 14.8336 16.37 0.86 0.4044
Alum-mIGg 1 5 -5.7575 12.8591 17.86 -0.45 0.6597
Alum-mIGg 1 7 21.3050 11.8375 17 1.80 0.0897
Alum-mIGg 2 3 -10.5875 8.9126 16.34 -1.19 0.2518
Alum-mIGg 2 4 9.7825 13.1076 12.25 0.75 0.4696
Alum-mIGg 2 5 -8.6725 10.8227 13.96 -0.80 0.4364
Alum-mIGg 2 7 18.3900 9.5865 13.92 1.92 0.0758
Alum-mIGg 3 4 20.3700 14.0391 14.76 1.45 0.1677
Alum-mIGg 3 5 1.9150 11.9338 16.82 0.16 0.8744
Alum-mIGg 3 7 28.9775 10.8253 16.55 2.68 0.0162
Alum-mIGg 4 5 -18.4550 15.3230 17.07 -1.20 0.2449
Alum-mIGg 4 7 8.6075 14.4763 15.39 0.59 0.5608
Alum-mIGg 5 7 27.0625 12.4452 16.82 2.17 0.0442
IO-mIgG 0 0.25 -29.8275 3.2916 15.09 -9.06 <.0001
IO-mIgG 0 1 -26.0575 8.8510 9.726 -2.94 0.0151
IO-mIgG 0 2 -24.0600 5.4876 11 -4.38 0.0011
IO-mIgG 0 3 -31.7900 7.4431 10.04 -4.27 0.0016
IO-mIgG 0 4 -24.3075 12.1563 9.378 -2.00 0.0753
IO-mIgG 0 5 -28.4100 9.6487 9.607 -2.94 0.0153
IO-mIgG 0 7 -26.1342 9.4592 8.563 -2.76 0.0230
IO-mIgG 0.25 1 3.7700 9.1156 10.84 0.41 0.6872
IO-mIgG 0.25 2 5.7675 5.9049 13.79 0.98 0.3455
IO-mIgG 0.25 3 -1.9625 7.7559 11.62 -0.25 0.8047
IO-mIgG 0.25 4 5.5200 12.3503 9.967 0.45 0.6645
IO-mIgG 0.25 5 1.4175 9.8920 10.55 0.14 0.8888
IO-mIgG 0.25 7 3.6933 9.7072 9.44 0.38 0.7120
IO-mIgG 1 2 1.9975 10.1180 14.73 0.20 0.8462
IO-mIgG 1 3 -5.7325 11.2987 17.44 -0.51 0.6183
IO-mIgG 1 4 1.7500 14.8336 16.37 0.12 0.9075
IO-mIgG 1 5 -2.3525 12.8591 17.86 -0.18 0.8569
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Table F13. Simple effect comparisons of treatment*day least squares means by 
treatment for CD45+, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
IO-mIgG 1 7 -0.07667 12.7176 16.73 -0.01 0.9953
IO-mIgG 2 3 -7.7300 8.9126 16.34 -0.87 0.3983
IO-mIgG 2 4 -0.2475 13.1076 12.25 -0.02 0.9852
IO-mIgG 2 5 -4.3500 10.8227 13.96 -0.40 0.6938
IO-mIgG 2 7 -2.0742 10.6541 12.69 -0.19 0.8487
IO-mIgG 3 4 7.4825 14.0391 14.76 0.53 0.6020
IO-mIgG 3 5 3.3800 11.9338 16.82 0.28 0.7805
IO-mIgG 3 7 5.6558 11.7812 15.55 0.48 0.6379
IO-mIgG 4 5 -4.1025 15.3230 17.07 -0.27 0.7921
IO-mIgG 4 7 -1.8267 15.2043 16.39 -0.12 0.9058
IO-mIgG 5 7 2.2758 13.2850 16.98 0.17 0.8660
mIgG 0 0.25 -8.2550 3.2916 15.09 -2.51 0.0240
mIgG 0 1 -17.7050 8.8510 9.726 -2.00 0.0742
mIgG 0 2 -13.4250 5.4876 11 -2.45 0.0325
mIgG 0 3 -18.4025 7.4431 10.04 -2.47 0.0329
mIgG 0 4 -23.6325 12.1563 9.378 -1.94 0.0825
mIgG 0 5 -22.8650 9.6487 9.607 -2.37 0.0403
mIgG 0 7 -9.2100 8.2382 8.751 -1.12 0.2933
mIgG 0.25 1 -9.4500 9.1156 10.84 -1.04 0.3224
mIgG 0.25 2 -5.1700 5.9049 13.79 -0.88 0.3963
mIgG 0.25 3 -10.1475 7.7559 11.62 -1.31 0.2160
mIgG 0.25 4 -15.3775 12.3503 9.967 -1.25 0.2416
mIgG 0.25 5 -14.6100 9.8920 10.55 -1.48 0.1689
mIgG 0.25 7 -0.9550 8.5218 9.912 -0.11 0.9130
mIgG 1 2 4.2800 10.1180 14.73 0.42 0.6784
mIgG 1 3 -0.6975 11.2987 17.44 -0.06 0.9515
mIgG 1 4 -5.9275 14.8336 16.37 -0.40 0.6946
mIgG 1 5 -5.1600 12.8591 17.86 -0.40 0.6930
mIgG 1 7 8.4950 11.8375 17 0.72 0.4827
mIgG 2 3 -4.9775 8.9126 16.34 -0.56 0.5841
mIgG 2 4 -10.2075 13.1076 12.25 -0.78 0.4509
mIgG 2 5 -9.4400 10.8227 13.96 -0.87 0.3978
mIgG 2 7 4.2150 9.5865 13.92 0.44 0.6669
mIgG 3 4 -5.2300 14.0391 14.76 -0.37 0.7148
mIgG 3 5 -4.4625 11.9338 16.82 -0.37 0.7131
mIgG 3 7 9.1925 10.8253 16.55 0.85 0.4079
mIgG 4 5 0.7675 15.3230 17.07 0.05 0.9606
mIgG 4 7 14.4225 14.4763 15.39 1.00 0.3345
mIgG 5 7 13.6550 12.4452 16.82 1.10 0.2880
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Table F14. Simple effect comparisons of treatment*day least squares means by day for CD45+, 
Study 3 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alum-mIGg IO-mIgG -0.8275 2.4659 9 -0.34 0.7449
day 0 Alum-mIGg mIgG 2.7750 2.4659 9 1.13 0.2896
day 0 IO-mIgG mIgG 3.6025 2.4659 9 1.46 0.1780
day 0.25 Alum-mIGg IO-mIgG -3.4350 3.9482 9 -0.87 0.4069
day 0.25 Alum-mIGg mIgG 21.7400 3.9482 9 5.51 0.0004
day 0.25 IO-mIgG mIgG 25.1750 3.9482 9 6.38 0.0001
day 1 Alum-mIGg IO-mIgG 15.7325 12.2719 9 1.28 0.2319
day 1 Alum-mIGg mIgG 27.6875 12.2719 9 2.26 0.0505
day 1 IO-mIgG mIgG 11.9550 12.2719 9 0.97 0.3554
day 2 Alum-mIGg IO-mIgG 14.8150 7.3585 9 2.01 0.0749
day 2 Alum-mIGg mIgG 29.0525 7.3585 9 3.95 0.0034
day 2 IO-mIgG mIgG 14.2375 7.3585 9 1.93 0.0850
day 3 Alum-mIGg IO-mIgG 17.6725 10.2333 9 1.73 0.1182
day 3 Alum-mIGg mIgG 34.6625 10.2333 9 3.39 0.0080
day 3 IO-mIgG mIgG 16.9900 10.2333 9 1.66 0.1312
day 4 Alum-mIGg IO-mIgG 4.7850 17.0139 9 0.28 0.7849
day 4 Alum-mIGg mIgG 9.0625 17.0139 9 0.53 0.6072
day 4 IO-mIgG mIgG 4.2775 17.0139 9 0.25 0.8071
day 5 Alum-mIGg IO-mIgG 19.1375 13.4206 9 1.43 0.1876
day 5 Alum-mIGg mIgG 28.2850 13.4206 9 2.11 0.0643
day 5 IO-mIgG mIgG 9.1475 13.4206 9 0.68 0.5126
day 7 Alum-mIGg IO-mIgG -5.6492 12.2989 8 -0.46 0.6582
day 7 Alum-mIGg mIgG 14.8775 11.3866 8 1.31 0.2277
day 7 IO-mIgG mIgG 20.5267 12.2989 8 1.67 0.1337
 
 
Table F15. Simple effect comparisons of treatment*day least squares means by treatment for 
heterophils, Study 3 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 0 0.25 -5.4200 1.7332 11.29 -3.13 0.0094
Alum-mIGg 0 1 -1.4550 1.8898 10.67 -0.77 0.4580
Alum-mIGg 0 2 1.0800 0.6638 11.24 1.63 0.1314
Alum-mIGg 0 3 1.1100 0.7161 14.27 1.55 0.1430
Alum-mIGg 0 4 0.6975 0.7184 14.2 0.97 0.3478
Alum-mIGg 0 5 1.3625 0.6839 12.49 1.99 0.0687
Alum-mIGg 0 7 0.4250 0.8033 16.73 0.53 0.6037
Alum-mIGg 0.25 1 3.9650 2.3762 17.36 1.67 0.1131
Alum-mIGg 0.25 2 6.5000 1.6595 9.453 3.92 0.0032
Alum-mIGg 0.25 3 6.5300 1.6751 9.875 3.90 0.0030
Alum-mIGg 0.25 4 6.1175 1.6755 9.886 3.65 0.0045
Alum-mIGg 0.25 5 6.7825 1.6656 9.607 4.07 0.0024
Alum-mIGg 0.25 7 5.8450 1.7075 10.66 3.42 0.0059
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Table F15. Simple effect comparisons of treatment*day least squares means by 
treatment for heterophils, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 1 2 2.5350 1.8239 9.051 1.39 0.1978
Alum-mIGg 1 3 2.5650 1.8376 9.451 1.40 0.1947
Alum-mIGg 1 4 2.1525 1.8379 9.469 1.17 0.2701
Alum-mIGg 1 5 2.8175 1.8293 9.199 1.54 0.1572
Alum-mIGg 1 7 1.8800 1.8665 10.15 1.01 0.3372
Alum-mIGg 2 3 0.03000 0.4395 14.77 0.07 0.9465
Alum-mIGg 2 4 -0.3825 0.4440 14.48 -0.86 0.4030
Alum-mIGg 2 5 0.2825 0.3787 16.84 0.75 0.4660
Alum-mIGg 2 7 -0.6550 0.5775 10.83 -1.13 0.2812
Alum-mIGg 3 4 -0.4125 0.5231 17.04 -0.79 0.4412
Alum-mIGg 3 5 0.2525 0.4710 16.61 0.54 0.5990
Alum-mIGg 3 7 -0.6850 0.6383 14.24 -1.07 0.3011
Alum-mIGg 4 5 0.6650 0.4750 16.56 1.40 0.1800
Alum-mIGg 4 7 -0.2725 0.6410 14.41 -0.43 0.6770
Alum-mIGg 5 7 -0.9375 0.6010 12.24 -1.56 0.1443
IO-mIgG 0 0.25 -16.9125 1.7332 11.29 -9.76 <.0001
IO-mIgG 0 1 -13.0075 1.8898 10.67 -6.88 <.0001
IO-mIgG 0 2 0.4625 0.6638 11.24 0.70 0.5001
IO-mIgG 0 3 0.3525 0.7161 14.27 0.49 0.6300
IO-mIgG 0 4 0.8750 0.7184 14.2 1.22 0.2431
IO-mIgG 0 5 0.2250 0.6839 12.49 0.33 0.7476
IO-mIgG 0 7 0.1432 0.8629 16.98 0.17 0.8702
IO-mIgG 0.25 1 3.9050 2.3762 17.36 1.64 0.1183
IO-mIgG 0.25 2 17.3750 1.6595 9.453 10.47 <.0001
IO-mIgG 0.25 3 17.2650 1.6751 9.875 10.31 <.0001
IO-mIgG 0.25 4 17.7875 1.6755 9.886 10.62 <.0001
IO-mIgG 0.25 5 17.1375 1.6656 9.607 10.29 <.0001
IO-mIgG 0.25 7 17.0557 1.7363 11.27 9.82 <.0001
IO-mIgG 1 2 13.4700 1.8239 9.051 7.39 <.0001
IO-mIgG 1 3 13.3600 1.8376 9.451 7.27 <.0001
IO-mIgG 1 4 13.8825 1.8379 9.469 7.55 <.0001
IO-mIgG 1 5 13.2325 1.8293 9.199 7.23 <.0001
IO-mIgG 1 7 13.1507 1.8929 10.66 6.95 <.0001
IO-mIgG 2 3 -0.1100 0.4395 14.77 -0.25 0.8058
IO-mIgG 2 4 0.4125 0.4440 14.48 0.93 0.3680
IO-mIgG 2 5 -0.2375 0.3787 16.84 -0.63 0.5390
IO-mIgG 2 7 -0.3193 0.6579 10.14 -0.49 0.6377
IO-mIgG 3 4 0.5225 0.5231 17.04 1.00 0.3318
IO-mIgG 3 5 -0.1275 0.4710 16.61 -0.27 0.7900
IO-mIgG 3 7 -0.2093 0.7119 13.03 -0.29 0.7734
IO-mIgG 4 5 -0.6500 0.4750 16.56 -1.37 0.1895
IO-mIgG 4 7 -0.7318 0.7142 13.2 -1.02 0.3239
IO-mIgG 5 7 -0.08182 0.6786 11.27 -0.12 0.9062
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Table F15. Simple effect comparisons of treatment*day least squares means by 
treatment for heterophils, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 0.25 -2.1975 1.7332 11.29 -1.27 0.2304
mIgG 0 1 -1.9775 1.8898 10.67 -1.05 0.3185
mIgG 0 2 0.9150 0.6638 11.24 1.38 0.1949
mIgG 0 3 0.7275 0.7161 14.27 1.02 0.3266
mIgG 0 4 1.4000 0.7184 14.2 1.95 0.0714
mIgG 0 5 1.2700 0.6839 12.49 1.86 0.0870
mIgG 0 7 0.4850 0.8033 16.73 0.60 0.5541
mIgG 0.25 1 0.2200 2.3762 17.36 0.09 0.9273
mIgG 0.25 2 3.1125 1.6595 9.453 1.88 0.0919
mIgG 0.25 3 2.9250 1.6751 9.875 1.75 0.1118
mIgG 0.25 4 3.5975 1.6755 9.886 2.15 0.0577
mIgG 0.25 5 3.4675 1.6656 9.607 2.08 0.0651
mIgG 0.25 7 2.6825 1.7075 10.66 1.57 0.1454
mIgG 1 2 2.8925 1.8239 9.051 1.59 0.1470
mIgG 1 3 2.7050 1.8376 9.451 1.47 0.1735
mIgG 1 4 3.3775 1.8379 9.469 1.84 0.0976
mIgG 1 5 3.2475 1.8293 9.199 1.78 0.1089
mIgG 1 7 2.4625 1.8665 10.15 1.32 0.2161
mIgG 2 3 -0.1875 0.4395 14.77 -0.43 0.6758
mIgG 2 4 0.4850 0.4440 14.48 1.09 0.2925
mIgG 2 5 0.3550 0.3787 16.84 0.94 0.3619
mIgG 2 7 -0.4300 0.5775 10.83 -0.74 0.4724
mIgG 3 4 0.6725 0.5231 17.04 1.29 0.2158
mIgG 3 5 0.5425 0.4710 16.61 1.15 0.2657
mIgG 3 7 -0.2425 0.6383 14.24 -0.38 0.7096
mIgG 4 5 -0.1300 0.4750 16.56 -0.27 0.7877
mIgG 4 7 -0.9150 0.6410 14.41 -1.43 0.1747
mIgG 5 7 -0.7850 0.6010 12.24 -1.31 0.2155
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Table F16. Simple effect comparisons of treatment*day least squares means by day for 
heterophils, Study 3 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alum-mIGg IO-mIgG 0.2150 0.8965 8.807 0.24 0.8160
day 0 Alum-mIGg mIgG -0.05750 0.8965 8.807 -0.06 0.9503
day 0 IO-mIgG mIgG -0.2725 0.8965 8.807 -0.30 0.7682
day 0.25 Alum-mIGg IO-mIgG -11.2775 2.3470 9.262 -4.80 0.0009
day 0.25 Alum-mIGg mIgG 3.1650 2.3470 9.262 1.35 0.2095
day 0.25 IO-mIgG mIgG 14.4425 2.3470 9.262 6.15 0.0001
day 1 Alum-mIGg IO-mIgG -11.3375 2.5810 8.802 -4.39 0.0018
day 1 Alum-mIGg mIgG -0.5800 2.5810 8.802 -0.22 0.8273
day 1 IO-mIgG mIgG 10.7575 2.5810 8.802 4.17 0.0025
day 2 Alum-mIGg IO-mIgG -0.4025 0.3511 9.265 -1.15 0.2804
day 2 Alum-mIGg mIgG -0.2225 0.3511 9.265 -0.63 0.5416
day 2 IO-mIgG mIgG 0.1800 0.3511 9.265 0.51 0.6202
day 3 Alum-mIGg IO-mIgG -0.5425 0.5397 9.154 -1.01 0.3407
day 3 Alum-mIGg mIgG -0.4400 0.5397 9.154 -0.82 0.4356
day 3 IO-mIgG mIgG 0.1025 0.5397 9.154 0.19 0.8535
day 4 Alum-mIGg IO-mIgG 0.3925 0.5477 9.31 0.72 0.4912
day 4 Alum-mIGg mIgG 0.6450 0.5477 9.31 1.18 0.2682
day 4 IO-mIgG mIgG 0.2525 0.5477 9.31 0.46 0.6554
day 5 Alum-mIGg IO-mIgG -0.9225 0.4307 8.767 -2.14 0.0616
day 5 Alum-mIGg mIgG -0.1500 0.4307 8.767 -0.35 0.7359
day 5 IO-mIgG mIgG 0.7725 0.4307 8.767 1.79 0.1074
day 7 Alum-mIGg IO-mIgG -0.06682 0.8259 7.897 -0.08 0.9375
day 7 Alum-mIGg mIgG 0.002500 0.7635 7.87 0.00 0.9975
day 7 IO-mIgG mIgG 0.06932 0.8259 7.897 0.08 0.9352
 
 
Table F17. Simple effect comparisons of treatment*day least squares means by treatment for  
T cell+, Study 3 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 0 0.25 -8.1175 1.1321 13.75 -7.17 <.0001
Alum-mIGg 0 1 -17.1350 3.3816 9.459 -5.07 0.0006
Alum-mIGg 0 2 -7.9050 2.4679 9.88 -3.20 0.0096
Alum-mIGg 0 3 -8.5600 1.0627 14.45 -8.05 <.0001
Alum-mIGg 0 4 -2.7450 1.3797 12.07 -1.99 0.0698
Alum-mIGg 0 5 -2.7925 0.7673 17.98 -3.64 0.0019
Alum-mIGg 0 7 -1.5075 1.2098 11.72 -1.25 0.2371
Alum-mIGg 0.25 1 -9.0175 3.4853 10.6 -2.59 0.0259
Alum-mIGg 0.25 2 0.2125 2.6082 12 0.08 0.9364
Alum-mIGg 0.25 3 -0.4425 1.3571 17.88 -0.33 0.7482
Alum-mIGg 0.25 4 5.3725 1.6174 17.04 3.32 0.0040
Alum-mIGg 0.25 5 5.3250 1.1406 14.02 4.67 0.0004
Alum-mIGg 0.25 7 6.6100 1.4751 16.66 4.48 0.0003
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Table F17. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 1 2 9.2300 4.1178 16.37 2.24 0.0392
Alum-mIGg 1 3 8.5750 3.4634 10.36 2.48 0.0320
Alum-mIGg 1 4 14.3900 3.5735 11.56 4.03 0.0018
Alum-mIGg 1 5 14.3425 3.3845 9.49 4.24 0.0019
Alum-mIGg 1 7 15.6275 3.5114 10.87 4.45 0.0010
Alum-mIGg 2 3 -0.6550 2.5788 11.56 -0.25 0.8040
Alum-mIGg 2 4 5.1600 2.7248 13.66 1.89 0.0796
Alum-mIGg 2 5 5.1125 2.4718 9.94 2.07 0.0656
Alum-mIGg 2 7 6.3975 2.6428 12.45 2.42 0.0316
Alum-mIGg 3 4 5.8150 1.5696 16.38 3.70 0.0019
Alum-mIGg 3 5 5.7675 1.0718 14.74 5.38 <.0001
Alum-mIGg 3 7 7.0525 1.4225 16.19 4.96 0.0001
Alum-mIGg 4 5 -0.04750 1.3867 12.27 -0.03 0.9732
Alum-mIGg 4 7 1.2375 1.6727 16.84 0.74 0.4696
Alum-mIGg 5 7 1.2850 1.2178 11.95 1.06 0.3122
IO-mIgG 0 0.25 -0.2800 1.1321 13.75 -0.25 0.8083
IO-mIgG 0 1 -2.1025 3.3816 9.459 -0.62 0.5488
IO-mIgG 0 2 -4.0625 2.4679 9.88 -1.65 0.1311
IO-mIgG 0 3 -3.2325 1.0627 14.45 -3.04 0.0085
IO-mIgG 0 4 -2.6075 1.3797 12.07 -1.89 0.0830
IO-mIgG 0 5 -1.5300 0.7673 17.98 -1.99 0.0615
IO-mIgG 0 7 -3.3933 1.3625 10.84 -2.49 0.0303
IO-mIgG 0.25 1 -1.8225 3.4853 10.6 -0.52 0.6118
IO-mIgG 0.25 2 -3.7825 2.6082 12 -1.45 0.1726
IO-mIgG 0.25 3 -2.9525 1.3571 17.88 -2.18 0.0432
IO-mIgG 0.25 4 -2.3275 1.6174 17.04 -1.44 0.1683
IO-mIgG 0.25 5 -1.2500 1.1406 14.02 -1.10 0.2916
IO-mIgG 0.25 7 -3.1133 1.6027 15.74 -1.94 0.0702
IO-mIgG 1 2 -1.9600 4.1178 16.37 -0.48 0.6404
IO-mIgG 1 3 -1.1300 3.4634 10.36 -0.33 0.7507
IO-mIgG 1 4 -0.5050 3.5735 11.56 -0.14 0.8901
IO-mIgG 1 5 0.5725 3.3845 9.49 0.17 0.8692
IO-mIgG 1 7 -1.2908 3.5669 11.46 -0.36 0.7240
IO-mIgG 2 3 0.8300 2.5788 11.56 0.32 0.7533
IO-mIgG 2 4 1.4550 2.7248 13.66 0.53 0.6019
IO-mIgG 2 5 2.5325 2.4718 9.94 1.02 0.3299
IO-mIgG 2 7 0.6692 2.7162 13.43 0.25 0.8091
IO-mIgG 3 4 0.6250 1.5696 16.38 0.40 0.6956
IO-mIgG 3 5 1.7025 1.0718 14.74 1.59 0.1334
IO-mIgG 3 7 -0.1608 1.5545 15.05 -0.10 0.9190
IO-mIgG 4 5 1.0775 1.3867 12.27 0.78 0.4519
IO-mIgG 4 7 -0.7858 1.7863 16.97 -0.44 0.6655
IO-mIgG 5 7 -1.8633 1.3696 11.03 -1.36 0.2008
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Table F17. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 0.25 -2.1050 1.1321 13.75 -1.86 0.0845
mIgG 0 1 -2.9225 3.3816 9.459 -0.86 0.4088
mIgG 0 2 -3.2050 2.4679 9.88 -1.30 0.2235
mIgG 0 3 -2.8325 1.0627 14.45 -2.67 0.0181
mIgG 0 4 -2.6550 1.3797 12.07 -1.92 0.0782
mIgG 0 5 -2.7025 0.7673 17.98 -3.52 0.0024
mIgG 0 7 -1.1125 1.2098 11.72 -0.92 0.3763
mIgG 0.25 1 -0.8175 3.4853 10.6 -0.23 0.8190
mIgG 0.25 2 -1.1000 2.6082 12 -0.42 0.6807
mIgG 0.25 3 -0.7275 1.3571 17.88 -0.54 0.5985
mIgG 0.25 4 -0.5500 1.6174 17.04 -0.34 0.7380
mIgG 0.25 5 -0.5975 1.1406 14.02 -0.52 0.6086
mIgG 0.25 7 0.9925 1.4751 16.66 0.67 0.5103
mIgG 1 2 -0.2825 4.1178 16.37 -0.07 0.9461
mIgG 1 3 0.09000 3.4634 10.36 0.03 0.9798
mIgG 1 4 0.2675 3.5735 11.56 0.07 0.9416
mIgG 1 5 0.2200 3.3845 9.49 0.07 0.9495
mIgG 1 7 1.8100 3.5114 10.87 0.52 0.6165
mIgG 2 3 0.3725 2.5788 11.56 0.14 0.8876
mIgG 2 4 0.5500 2.7248 13.66 0.20 0.8430
mIgG 2 5 0.5025 2.4718 9.94 0.20 0.8430
mIgG 2 7 2.0925 2.6428 12.45 0.79 0.4433
mIgG 3 4 0.1775 1.5696 16.38 0.11 0.9113
mIgG 3 5 0.1300 1.0718 14.74 0.12 0.9051
mIgG 3 7 1.7200 1.4225 16.19 1.21 0.2440
mIgG 4 5 -0.04750 1.3867 12.27 -0.03 0.9732
mIgG 4 7 1.5425 1.6727 16.84 0.92 0.3695
mIgG 5 7 1.5900 1.2178 11.95 1.31 0.2162
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Table F18. Simple effect comparisons of treatment*day least squares means by day for  T 
cell+, Study 3 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alum-mIGg IO-mIgG -0.8100 0.7546 9 -1.07 0.3110
day 0 Alum-mIGg mIgG 0.1400 0.7546 9 0.19 0.8569
day 0 IO-mIgG mIgG 0.9500 0.7546 9 1.26 0.2397
day 0.25 Alum-mIGg IO-mIgG 7.0275 1.4120 9 4.98 0.0008
day 0.25 Alum-mIGg mIgG 6.1525 1.4120 9 4.36 0.0018
day 0.25 IO-mIgG mIgG -0.8750 1.4120 9 -0.62 0.5508
day 1 Alum-mIGg IO-mIgG 14.2225 4.7224 9 3.01 0.0147
day 1 Alum-mIGg mIgG 14.3525 4.7224 9 3.04 0.0140
day 1 IO-mIgG mIgG 0.1300 4.7224 9 0.03 0.9786
day 2 Alum-mIGg IO-mIgG 3.0325 3.4076 9 0.89 0.3967
day 2 Alum-mIGg mIgG 4.8400 3.4076 9 1.42 0.1892
day 2 IO-mIgG mIgG 1.8075 3.4076 9 0.53 0.6086
day 3 Alum-mIGg IO-mIgG 4.5175 1.2998 9 3.48 0.0070
day 3 Alum-mIGg mIgG 5.8675 1.2998 9 4.51 0.0015
day 3 IO-mIgG mIgG 1.3500 1.2998 9 1.04 0.3261
day 4 Alum-mIGg IO-mIgG -0.6725 1.7994 9 -0.37 0.7173
day 4 Alum-mIGg mIgG 0.2300 1.7994 9 0.13 0.9011
day 4 IO-mIgG mIgG 0.9025 1.7994 9 0.50 0.6280
day 5 Alum-mIGg IO-mIgG 0.4525 0.7798 9 0.58 0.5760
day 5 Alum-mIGg mIgG 0.2300 0.7798 9 0.29 0.7747
day 5 IO-mIgG mIgG -0.2225 0.7798 9 -0.29 0.7818
day 7 Alum-mIGg IO-mIgG -2.6958 1.6585 8 -1.63 0.1427
day 7 Alum-mIGg mIgG 0.5350 1.5355 8 0.35 0.7365
day 7 IO-mIgG mIgG 3.2308 1.6585 8 1.95 0.0873
 
 
Table F19. Simple effect comparisons of treatment*day least squares means by treatment for  
T cell+ CD8+, Study 3 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 0 0.25 -0.5350 0.1015 18.87 -5.27 <.0001
Alum-mIGg 0 1 -1.1500 0.2228 11.34 -5.16 0.0003
Alum-mIGg 0 2 -0.7350 0.1859 10.3 -3.95 0.0026
Alum-mIGg 0 3 -1.0500 0.1772 11.72 -5.93 <.0001
Alum-mIGg 0 4 -0.4475 0.2554 10.58 -1.75 0.1086
Alum-mIGg 0 5 -0.4800 0.1669 12.45 -2.88 0.0135
Alum-mIGg 0 7 -0.1775 0.1985 8.35 -0.89 0.3964
Alum-mIGg 0.25 1 -0.6150 0.2217 12.25 -2.77 0.0165
Alum-mIGg 0.25 2 -0.2000 0.1864 11.72 -1.07 0.3049
Alum-mIGg 0.25 3 -0.5150 0.1782 13.37 -2.89 0.0123
Alum-mIGg 0.25 4 0.08750 0.2532 11.23 0.35 0.7360
Alum-mIGg 0.25 5 0.05500 0.1686 14.37 0.33 0.7490
Alum-mIGg 0.25 7 0.3575 0.1984 9.338 1.80 0.1038
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Table F19. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+ CD8+, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 1 2 0.4150 0.2431 20.2 1.71 0.1031
Alum-mIGg 1 3 0.1000 0.2393 19.77 0.42 0.6805
Alum-mIGg 1 4 0.7025 0.2817 20.71 2.49 0.0212
Alum-mIGg 1 5 0.6700 0.2352 18.74 2.85 0.0104
Alum-mIGg 1 7 0.9725 0.2488 20.25 3.91 0.0009
Alum-mIGg 2 3 -0.3150 0.2147 20.37 -1.47 0.1576
Alum-mIGg 2 4 0.2875 0.2665 17.97 1.08 0.2950
Alum-mIGg 2 5 0.2550 0.2091 20.42 1.22 0.2365
Alum-mIGg 2 7 0.5575 0.2269 18.89 2.46 0.0239
Alum-mIGg 3 4 0.6025 0.2637 17.08 2.29 0.0354
Alum-mIGg 3 5 0.5700 0.2035 21.43 2.80 0.0106
Alum-mIGg 3 7 0.8725 0.2224 18.39 3.92 0.0010
Alum-mIGg 4 5 -0.03250 0.2605 16.29 -0.12 0.9023
Alum-mIGg 4 7 0.2700 0.2709 18.88 1.00 0.3316
Alum-mIGg 5 7 0.3025 0.2176 16.84 1.39 0.1825
IO-mIgG 0 0.25 0.06500 0.1015 18.87 0.64 0.5295
IO-mIgG 0 1 -0.3150 0.2228 11.34 -1.41 0.1844
IO-mIgG 0 2 -0.4650 0.1859 10.3 -2.50 0.0308
IO-mIgG 0 3 -0.4525 0.1772 11.72 -2.55 0.0257
IO-mIgG 0 4 -0.6025 0.2554 10.58 -2.36 0.0387
IO-mIgG 0 5 -0.4675 0.1669 12.45 -2.80 0.0155
IO-mIgG 0 7 -0.5663 0.2249 8.568 -2.52 0.0341
IO-mIgG 0.25 1 -0.3800 0.2217 12.25 -1.71 0.1116
IO-mIgG 0.25 2 -0.5300 0.1864 11.72 -2.84 0.0151
IO-mIgG 0.25 3 -0.5175 0.1782 13.37 -2.90 0.0120
IO-mIgG 0.25 4 -0.6675 0.2532 11.23 -2.64 0.0228
IO-mIgG 0.25 5 -0.5325 0.1686 14.37 -3.16 0.0068
IO-mIgG 0.25 7 -0.6313 0.2247 9.328 -2.81 0.0197
IO-mIgG 1 2 -0.1500 0.2431 20.2 -0.62 0.5441
IO-mIgG 1 3 -0.1375 0.2393 19.77 -0.57 0.5720
IO-mIgG 1 4 -0.2875 0.2817 20.71 -1.02 0.3192
IO-mIgG 1 5 -0.1525 0.2352 18.74 -0.65 0.5247
IO-mIgG 1 7 -0.2513 0.2702 20.04 -0.93 0.3635
IO-mIgG 2 3 0.01250 0.2147 20.37 0.06 0.9541
IO-mIgG 2 4 -0.1375 0.2665 17.97 -0.52 0.6122
IO-mIgG 2 5 -0.00250 0.2091 20.42 -0.01 0.9906
IO-mIgG 2 7 -0.1013 0.2503 17.57 -0.40 0.6906
IO-mIgG 3 4 -0.1500 0.2637 17.08 -0.57 0.5768
IO-mIgG 3 5 -0.01500 0.2035 21.43 -0.07 0.9419
IO-mIgG 3 7 -0.1138 0.2461 16.79 -0.46 0.6499
IO-mIgG 4 5 0.1350 0.2605 16.29 0.52 0.6113
IO-mIgG 4 7 0.03622 0.2908 20.07 0.12 0.9021
IO-mIgG 5 7 -0.09878 0.2418 15.35 -0.41 0.6886
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Table F19. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+ CD8+, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 0.25 -0.2150 0.1015 18.87 -2.12 0.0476
mIgG 0 1 -0.6950 0.2228 11.34 -3.12 0.0094
mIgG 0 2 -0.6475 0.1859 10.3 -3.48 0.0056
mIgG 0 3 -0.4750 0.1772 11.72 -2.68 0.0204
mIgG 0 4 -0.7425 0.2554 10.58 -2.91 0.0148
mIgG 0 5 -0.7550 0.1669 12.45 -4.52 0.0006
mIgG 0 7 -0.3950 0.1985 8.35 -1.99 0.0803
mIgG 0.25 1 -0.4800 0.2217 12.25 -2.17 0.0508
mIgG 0.25 2 -0.4325 0.1864 11.72 -2.32 0.0392
mIgG 0.25 3 -0.2600 0.1782 13.37 -1.46 0.1676
mIgG 0.25 4 -0.5275 0.2532 11.23 -2.08 0.0608
mIgG 0.25 5 -0.5400 0.1686 14.37 -3.20 0.0062
mIgG 0.25 7 -0.1800 0.1984 9.338 -0.91 0.3870
mIgG 1 2 0.04750 0.2431 20.2 0.20 0.8470
mIgG 1 3 0.2200 0.2393 19.77 0.92 0.3689
mIgG 1 4 -0.04750 0.2817 20.71 -0.17 0.8677
mIgG 1 5 -0.06000 0.2352 18.74 -0.26 0.8015
mIgG 1 7 0.3000 0.2488 20.25 1.21 0.2417
mIgG 2 3 0.1725 0.2147 20.37 0.80 0.4309
mIgG 2 4 -0.09500 0.2665 17.97 -0.36 0.7257
mIgG 2 5 -0.1075 0.2091 20.42 -0.51 0.6127
mIgG 2 7 0.2525 0.2269 18.89 1.11 0.2798
mIgG 3 4 -0.2675 0.2637 17.08 -1.01 0.3245
mIgG 3 5 -0.2800 0.2035 21.43 -1.38 0.1830
mIgG 3 7 0.08000 0.2224 18.39 0.36 0.7231
mIgG 4 5 -0.01250 0.2605 16.29 -0.05 0.9623
mIgG 4 7 0.3475 0.2709 18.88 1.28 0.2151
mIgG 5 7 0.3600 0.2176 16.84 1.65 0.1165
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Table F20. Simple effect comparisons of treatment*day least squares means by day for  T 
cell+ CD8+, Study 3 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alum-mIGg IO-mIgG -0.08000 0.1181 8.37 -0.68 0.5165
day 0 Alum-mIGg mIgG 0.01500 0.1181 8.37 0.13 0.9020
day 0 IO-mIgG mIgG 0.09500 0.1181 8.37 0.80 0.4435
day 0.25 Alum-mIGg IO-mIgG 0.5200 0.1472 9.542 3.53 0.0058
day 0.25 Alum-mIGg mIgG 0.3350 0.1472 9.542 2.28 0.0473
day 0.25 IO-mIgG mIgG -0.1850 0.1472 9.542 -1.26 0.2388
day 1 Alum-mIGg IO-mIgG 0.7550 0.3477 10.43 2.17 0.0540
day 1 Alum-mIGg mIgG 0.4700 0.3477 10.43 1.35 0.2051
day 1 IO-mIgG mIgG -0.2850 0.3477 10.43 -0.82 0.4308
day 2 Alum-mIGg IO-mIgG 0.1900 0.2915 8.867 0.65 0.5311
day 2 Alum-mIGg mIgG 0.1025 0.2915 8.867 0.35 0.7334
day 2 IO-mIgG mIgG -0.08750 0.2915 8.867 -0.30 0.7710
day 3 Alum-mIGg IO-mIgG 0.5175 0.2779 9.924 1.86 0.0924
day 3 Alum-mIGg mIgG 0.5900 0.2779 9.924 2.12 0.0599
day 3 IO-mIgG mIgG 0.07250 0.2779 9.924 0.26 0.7995
day 4 Alum-mIGg IO-mIgG -0.2350 0.3962 10.04 -0.59 0.5663
day 4 Alum-mIGg mIgG -0.2800 0.3962 10.04 -0.71 0.4959
day 4 IO-mIgG mIgG -0.04500 0.3962 10.04 -0.11 0.9118
day 5 Alum-mIGg IO-mIgG -0.06750 0.2618 10.24 -0.26 0.8016
day 5 Alum-mIGg mIgG -0.2600 0.2618 10.24 -0.99 0.3435
day 5 IO-mIgG mIgG -0.1925 0.2618 10.24 -0.74 0.4786
day 7 Alum-mIGg IO-mIgG -0.4688 0.3284 7.753 -1.43 0.1925
day 7 Alum-mIGg mIgG -0.2025 0.3110 7.468 -0.65 0.5345
day 7 IO-mIgG mIgG 0.2663 0.3284 7.753 0.81 0.4417
 
Table F21. Simple effect comparisons of treatment*day least squares means by treatment for  
T cell+ CD8-, Study 3 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 0 0.25 -7.0925 1.0085 12.41 -7.03 <.0001
Alum-mIGg 0 1 -14.9575 3.2499 9.289 -4.60 0.0012
Alum-mIGg 0 2 -7.2425 2.2401 9.619 -3.23 0.0094
Alum-mIGg 0 3 -7.7075 1.0114 12.39 -7.62 <.0001
Alum-mIGg 0 4 -2.8450 1.0768 11.95 -2.64 0.0216
Alum-mIGg 0 5 -2.7300 0.6827 16.67 -4.00 0.0010
Alum-mIGg 0 7 -1.3850 0.9973 11.15 -1.39 0.1920
Alum-mIGg 0.25 1 -7.8650 3.3534 10.46 -2.35 0.0399
Alum-mIGg 0.25 2 -0.1500 2.3877 12.06 -0.06 0.9509
Alum-mIGg 0.25 3 -0.6150 1.3061 18 -0.47 0.6434
Alum-mIGg 0.25 4 4.2475 1.3573 17.89 3.13 0.0058
Alum-mIGg 0.25 5 4.3625 1.0719 14.63 4.07 0.0011
Alum-mIGg 0.25 7 5.7075 1.2952 16.96 4.41 0.0004
Alum-mIGg 1 2 7.7150 3.9046 15.9 1.98 0.0658
Alum-mIGg 1 3 7.2500 3.3542 10.47 2.16 0.0548
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Table F21. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+ CD8-, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 1 4 12.1125 3.3745 10.7 3.59 0.0044
Alum-mIGg 1 5 12.2275 3.2702 9.517 3.74 0.0042
Alum-mIGg 1 7 13.5725 3.3500 10.42 4.05 0.0021
Alum-mIGg 2 3 -0.4650 2.3889 12.08 -0.19 0.8489
Alum-mIGg 2 4 4.3975 2.4173 12.53 1.82 0.0928
Alum-mIGg 2 5 4.5125 2.2693 10.11 1.99 0.0745
Alum-mIGg 2 7 5.8575 2.3829 11.94 2.46 0.0302
Alum-mIGg 3 4 4.8625 1.3595 17.9 3.58 0.0022
Alum-mIGg 3 5 4.9775 1.0746 14.6 4.63 0.0003
Alum-mIGg 3 7 6.3225 1.2974 16.97 4.87 0.0001
Alum-mIGg 4 5 0.1150 1.1364 13.97 0.10 0.9208
Alum-mIGg 4 7 1.4600 1.3490 16.98 1.08 0.2943
Alum-mIGg 5 7 1.3450 1.0613 13.28 1.27 0.2268
IO-mIgG 0 0.25 -0.2500 1.0085 12.41 -0.25 0.8083
IO-mIgG 0 1 -1.2625 3.2499 9.289 -0.39 0.7064
IO-mIgG 0 2 -3.5350 2.2401 9.619 -1.58 0.1468
IO-mIgG 0 3 -2.9400 1.0114 12.39 -2.91 0.0128
IO-mIgG 0 4 -2.2800 1.0768 11.95 -2.12 0.0559
IO-mIgG 0 5 -1.0975 0.6827 16.67 -1.61 0.1267
IO-mIgG 0 7 -2.3900 1.1271 10.4 -2.12 0.0590
IO-mIgG 0.25 1 -1.0125 3.3534 10.46 -0.30 0.7686
IO-mIgG 0.25 2 -3.2850 2.3877 12.06 -1.38 0.1939
IO-mIgG 0.25 3 -2.6900 1.3061 18 -2.06 0.0542
IO-mIgG 0.25 4 -2.0300 1.3573 17.89 -1.50 0.1522
IO-mIgG 0.25 5 -0.8475 1.0719 14.63 -0.79 0.4418
IO-mIgG 0.25 7 -2.1400 1.3976 16.41 -1.53 0.1448
IO-mIgG 1 2 -2.2725 3.9046 15.9 -0.58 0.5687
IO-mIgG 1 3 -1.6775 3.3542 10.47 -0.50 0.6273
IO-mIgG 1 4 -1.0175 3.3745 10.7 -0.30 0.7688
IO-mIgG 1 5 0.1650 3.2702 9.517 0.05 0.9608
IO-mIgG 1 7 -1.1275 3.3909 10.87 -0.33 0.7458
IO-mIgG 2 3 0.5950 2.3889 12.08 0.25 0.8075
IO-mIgG 2 4 1.2550 2.4173 12.53 0.52 0.6127
IO-mIgG 2 5 2.4375 2.2693 10.11 1.07 0.3078
IO-mIgG 2 7 1.1450 2.4401 12.81 0.47 0.6468
IO-mIgG 3 4 0.6600 1.3595 17.9 0.49 0.6332
IO-mIgG 3 5 1.8425 1.0746 14.6 1.71 0.1076
IO-mIgG 3 7 0.5500 1.3997 16.43 0.39 0.6994
IO-mIgG 4 5 1.1825 1.1364 13.97 1.04 0.3157
IO-mIgG 4 7 -0.1100 1.4476 16.79 -0.08 0.9403
IO-mIgG 5 7 -1.2925 1.1842 12.13 -1.09 0.2963
mIgG 0 0.25 -1.8800 1.0085 12.41 -1.86 0.0861
mIgG 0 1 -2.2950 3.2499 9.289 -0.71 0.4974
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Table F21. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+ CD8-, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 2 -2.4900 2.2401 9.619 -1.11 0.2933
mIgG 0 3 -2.5100 1.0114 12.39 -2.48 0.0283
mIgG 0 4 -2.2275 1.0768 11.95 -2.07 0.0609
mIgG 0 5 -2.1600 0.6827 16.67 -3.16 0.0058
mIgG 0 7 -0.8350 0.9973 11.15 -0.84 0.4200
mIgG 0.25 1 -0.4150 3.3534 10.46 -0.12 0.9039
mIgG 0.25 2 -0.6100 2.3877 12.06 -0.26 0.8027
mIgG 0.25 3 -0.6300 1.3061 18 -0.48 0.6354
mIgG 0.25 4 -0.3475 1.3573 17.89 -0.26 0.8009
mIgG 0.25 5 -0.2800 1.0719 14.63 -0.26 0.7976
mIgG 0.25 7 1.0450 1.2952 16.96 0.81 0.4309
mIgG 1 2 -0.1950 3.9046 15.9 -0.05 0.9608
mIgG 1 3 -0.2150 3.3542 10.47 -0.06 0.9501
mIgG 1 4 0.06750 3.3745 10.7 0.02 0.9844
mIgG 1 5 0.1350 3.2702 9.517 0.04 0.9679
mIgG 1 7 1.4600 3.3500 10.42 0.44 0.6719
mIgG 2 3 -0.02000 2.3889 12.08 -0.01 0.9935
mIgG 2 4 0.2625 2.4173 12.53 0.11 0.9152
mIgG 2 5 0.3300 2.2693 10.11 0.15 0.8872
mIgG 2 7 1.6550 2.3829 11.94 0.69 0.5006
mIgG 3 4 0.2825 1.3595 17.9 0.21 0.8377
mIgG 3 5 0.3500 1.0746 14.6 0.33 0.7493
mIgG 3 7 1.6750 1.2974 16.97 1.29 0.2140
mIgG 4 5 0.06750 1.1364 13.97 0.06 0.9535
mIgG 4 7 1.3925 1.3490 16.98 1.03 0.3164
mIgG 5 7 1.3250 1.0613 13.28 1.25 0.2334
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Table F22. Simple effect comparisons of treatment*day least squares means by day for  T 
cell+ CD8-, Study 3 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alum-mIGg IO-mIgG -0.7950 0.5781 9 -1.38 0.2024
day 0 Alum-mIGg mIgG 0.005000 0.5781 9 0.01 0.9933
day 0 IO-mIgG mIgG 0.8000 0.5781 9 1.38 0.1998
day 0.25 Alum-mIGg IO-mIgG 6.0475 1.3039 9 4.64 0.0012
day 0.25 Alum-mIGg mIgG 5.2175 1.3039 9 4.00 0.0031
day 0.25 IO-mIgG mIgG -0.8300 1.3039 9 -0.64 0.5403
day 1 Alum-mIGg IO-mIgG 12.9000 4.5596 9 2.83 0.0197
day 1 Alum-mIGg mIgG 12.6675 4.5596 9 2.78 0.0215
day 1 IO-mIgG mIgG -0.2325 4.5596 9 -0.05 0.9604
day 2 Alum-mIGg IO-mIgG 2.9125 3.1148 9 0.94 0.3742
day 2 Alum-mIGg mIgG 4.7575 3.1148 9 1.53 0.1610
day 2 IO-mIgG mIgG 1.8450 3.1148 9 0.59 0.5682
day 3 Alum-mIGg IO-mIgG 3.9725 1.3083 9 3.04 0.0141
day 3 Alum-mIGg mIgG 5.2025 1.3083 9 3.98 0.0032
day 3 IO-mIgG mIgG 1.2300 1.3083 9 0.94 0.3717
day 4 Alum-mIGg IO-mIgG -0.2300 1.4088 9 -0.16 0.8739
day 4 Alum-mIGg mIgG 0.6225 1.4088 9 0.44 0.6690
day 4 IO-mIgG mIgG 0.8525 1.4088 9 0.61 0.5600
day 5 Alum-mIGg IO-mIgG 0.8375 0.7733 9 1.08 0.3069
day 5 Alum-mIGg mIgG 0.5750 0.7733 9 0.74 0.4761
day 5 IO-mIgG mIgG -0.2625 0.7733 9 -0.34 0.7420
day 7 Alum-mIGg IO-mIgG -1.8000 1.3895 8 -1.30 0.2313
day 7 Alum-mIGg mIgG 0.5550 1.2864 8 0.43 0.6776
day 7 IO-mIgG mIgG 2.3550 1.3895 8 1.69 0.1286
 
Table F23. Simple effect comparisons of treatment*day least squares means by treatment for 
 T cell+, Study 3 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 0 0.25 -4.2700 0.9287 17.26 -4.60 0.0002
Alum-mIGg 0 1 -8.1675 1.5796 11.79 -5.17 0.0002
Alum-mIGg 0 2 -10.7375 1.6944 11.39 -6.34 <.0001
Alum-mIGg 0 3 -20.2475 2.7999 9.82 -7.23 <.0001
Alum-mIGg 0 4 -12.9025 4.3145 9.337 -2.99 0.0146
Alum-mIGg 0 5 -12.4750 3.0202 9.701 -4.13 0.0022
Alum-mIGg 0 7 -5.0225 1.7692 9.951 -2.84 0.0177
Alum-mIGg 0.25 1 -3.8975 1.6350 13.11 -2.38 0.0329
Alum-mIGg 0.25 2 -6.4675 1.7461 12.55 -3.70 0.0028
Alum-mIGg 0.25 3 -15.9775 2.8315 10.24 -5.64 0.0002
Alum-mIGg 0.25 4 -8.6325 4.3351 9.512 -1.99 0.0759
Alum-mIGg 0.25 5 -8.2050 3.0496 10.06 -2.69 0.0226
Alum-mIGg 0.25 7 -0.7525 1.8188 10.93 -0.41 0.6871
Alum-mIGg 1 2 -2.5700 2.1637 17.88 -1.19 0.2505
Alum-mIGg 1 3 -12.0800 3.1065 13.78 -3.89 0.0017
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Table F23. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 1 4 -4.7350 4.5194 11.09 -1.05 0.3171
Alum-mIGg 1 5 -4.3075 3.3064 13.16 -1.30 0.2150
Alum-mIGg 1 7 3.1450 2.2228 16.42 1.41 0.1758
Alum-mIGg 2 3 -9.5100 3.1664 14.45 -3.00 0.0092
Alum-mIGg 2 4 -2.1650 4.5608 11.44 -0.47 0.6439
Alum-mIGg 2 5 -1.7375 3.3628 13.79 -0.52 0.6136
Alum-mIGg 2 7 5.7150 2.3058 16.8 2.48 0.0241
Alum-mIGg 3 4 7.3450 5.0764 15.32 1.45 0.1681
Alum-mIGg 3 5 7.7725 4.0345 17.89 1.93 0.0701
Alum-mIGg 3 7 15.2250 3.2070 14.66 4.75 0.0003
Alum-mIGg 4 5 0.4275 5.2012 16.03 0.08 0.9355
Alum-mIGg 4 7 7.8800 4.5892 11.65 1.72 0.1124
Alum-mIGg 5 7 7.4525 3.4011 14.03 2.19 0.0458
IO-mIgG 0 0.25 0.4925 0.9287 17.26 0.53 0.6027
IO-mIgG 0 1 -1.0350 1.5796 11.79 -0.66 0.5249
IO-mIgG 0 2 -6.5775 1.6944 11.39 -3.88 0.0024
IO-mIgG 0 3 -12.4275 2.7999 9.82 -4.44 0.0013
IO-mIgG 0 4 -7.1725 4.3145 9.337 -1.66 0.1296
IO-mIgG 0 5 -11.1175 3.0202 9.701 -3.68 0.0045
IO-mIgG 0 7 -6.8500 2.0148 9.47 -3.40 0.0073
IO-mIgG 0.25 1 -1.5275 1.6350 13.11 -0.93 0.3671
IO-mIgG 0.25 2 -7.0700 1.7461 12.55 -4.05 0.0015
IO-mIgG 0.25 3 -12.9200 2.8315 10.24 -4.56 0.0010
IO-mIgG 0.25 4 -7.6650 4.3351 9.512 -1.77 0.1090
IO-mIgG 0.25 5 -11.6100 3.0496 10.06 -3.81 0.0034
IO-mIgG 0.25 7 -7.3425 2.0585 10.22 -3.57 0.0050
IO-mIgG 1 2 -5.5425 2.1637 17.88 -2.56 0.0197
IO-mIgG 1 3 -11.3925 3.1065 13.78 -3.67 0.0026
IO-mIgG 1 4 -6.1375 4.5194 11.09 -1.36 0.2014
IO-mIgG 1 5 -10.0825 3.3064 13.16 -3.05 0.0092
IO-mIgG 1 7 -5.8150 2.4228 15.37 -2.40 0.0295
IO-mIgG 2 3 -5.8500 3.1664 14.45 -1.85 0.0852
IO-mIgG 2 4 -0.5950 4.5608 11.44 -0.13 0.8985
IO-mIgG 2 5 -4.5400 3.3628 13.79 -1.35 0.1987
IO-mIgG 2 7 -0.2725 2.4992 16 -0.11 0.9145
IO-mIgG 3 4 5.2550 5.0764 15.32 1.04 0.3166
IO-mIgG 3 5 1.3100 4.0345 17.89 0.32 0.7492
IO-mIgG 3 7 5.5775 3.3488 15.77 1.67 0.1155
IO-mIgG 4 5 -3.9450 5.2012 16.03 -0.76 0.4592
IO-mIgG 4 7 0.3225 4.6893 12.45 0.07 0.9463
IO-mIgG 5 7 4.2675 3.5351 15.17 1.21 0.2458
mIgG 0 0.25 -1.0150 0.9287 17.26 -1.09 0.2894
mIgG 0 1 -6.2375 1.5796 11.79 -3.95 0.0020
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Table F23. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 2 -5.3925 1.6944 11.39 -3.18 0.0084
mIgG 0 3 -8.2550 2.7999 9.82 -2.95 0.0149
mIgG 0 4 -7.6975 4.3145 9.337 -1.78 0.1069
mIgG 0 5 -6.5900 3.0202 9.701 -2.18 0.0549
mIgG 0 7 -2.2050 1.7692 9.951 -1.25 0.2412
mIgG 0.25 1 -5.2225 1.6350 13.11 -3.19 0.0070
mIgG 0.25 2 -4.3775 1.7461 12.55 -2.51 0.0268
mIgG 0.25 3 -7.2400 2.8315 10.24 -2.56 0.0280
mIgG 0.25 4 -6.6825 4.3351 9.512 -1.54 0.1558
mIgG 0.25 5 -5.5750 3.0496 10.06 -1.83 0.0973
mIgG 0.25 7 -1.1900 1.8188 10.93 -0.65 0.5265
mIgG 1 2 0.8450 2.1637 17.88 0.39 0.7008
mIgG 1 3 -2.0175 3.1065 13.78 -0.65 0.5267
mIgG 1 4 -1.4600 4.5194 11.09 -0.32 0.7527
mIgG 1 5 -0.3525 3.3064 13.16 -0.11 0.9167
mIgG 1 7 4.0325 2.2228 16.42 1.81 0.0880
mIgG 2 3 -2.8625 3.1664 14.45 -0.90 0.3808
mIgG 2 4 -2.3050 4.5608 11.44 -0.51 0.6229
mIgG 2 5 -1.1975 3.3628 13.79 -0.36 0.7272
mIgG 2 7 3.1875 2.3058 16.8 1.38 0.1849
mIgG 3 4 0.5575 5.0764 15.32 0.11 0.9140
mIgG 3 5 1.6650 4.0345 17.89 0.41 0.6847
mIgG 3 7 6.0500 3.2070 14.66 1.89 0.0792
mIgG 4 5 1.1075 5.2012 16.03 0.21 0.8341
mIgG 4 7 5.4925 4.5892 11.65 1.20 0.2552
mIgG 5 7 4.3850 3.4011 14.03 1.29 0.2181
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Table F24. Simple effect comparisons of treatment*day least squares means by day for  T 
cell+, Study 3 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alum-mIGg IO-mIgG -0.8400 0.8273 9 -1.02 0.3365
day 0 Alum-mIGg mIgG 0.5150 0.8273 9 0.62 0.5491
day 0 IO-mIgG mIgG 1.3550 0.8273 9 1.64 0.1359
day 0.25 Alum-mIGg IO-mIgG 3.9225 1.0201 9 3.85 0.0039
day 0.25 Alum-mIGg mIgG 3.7700 1.0201 9 3.70 0.0050
day 0.25 IO-mIgG mIgG -0.1525 1.0201 9 -0.15 0.8845
day 1 Alum-mIGg IO-mIgG 6.2925 2.0750 9 3.03 0.0142
day 1 Alum-mIGg mIgG 2.4450 2.0750 9 1.18 0.2689
day 1 IO-mIgG mIgG -3.8475 2.0750 9 -1.85 0.0967
day 2 Alum-mIGg IO-mIgG 3.3200 2.2488 9 1.48 0.1740
day 2 Alum-mIGg mIgG 5.8600 2.2488 9 2.61 0.0285
day 2 IO-mIgG mIgG 2.5400 2.2488 9 1.13 0.2879
day 3 Alum-mIGg IO-mIgG 6.9800 3.8723 9 1.80 0.1050
day 3 Alum-mIGg mIgG 12.5075 3.8723 9 3.23 0.0103
day 3 IO-mIgG mIgG 5.5275 3.8723 9 1.43 0.1872
day 4 Alum-mIGg IO-mIgG 4.8900 6.0452 9 0.81 0.4394
day 4 Alum-mIGg mIgG 5.7200 6.0452 9 0.95 0.3688
day 4 IO-mIgG mIgG 0.8300 6.0452 9 0.14 0.8938
day 5 Alum-mIGg IO-mIgG 0.5175 4.1904 9 0.12 0.9044
day 5 Alum-mIGg mIgG 6.4000 4.1904 9 1.53 0.1610
day 5 IO-mIgG mIgG 5.8825 4.1904 9 1.40 0.1939
day 7 Alum-mIGg IO-mIgG -2.6675 2.5505 8 -1.05 0.3262
day 7 Alum-mIGg mIgG 3.3325 2.3613 8 1.41 0.1958
day 7 IO-mIgG mIgG 6.0000 2.5505 8 2.35 0.0465
 
Table F25. Simple effect comparisons of treatment*day least squares means by treatment for 
 T cell+ CD4- CD8+, Study 3 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 0 0.25 -1.0925 0.2100 12.62 -5.20 0.0002
Alum-mIGg 0 1 -1.6100 0.3258 10.33 -4.94 0.0005
Alum-mIGg 0 2 -3.1575 0.4136 9.764 -7.63 <.0001
Alum-mIGg 0 3 -6.9500 0.8147 9.236 -8.53 <.0001
Alum-mIGg 0 4 -4.7950 1.0189 9.153 -4.71 0.0011
Alum-mIGg 0 5 -3.5200 0.6724 9.098 -5.24 0.0005
Alum-mIGg 0 7 -2.5550 0.4338 8.667 -5.89 0.0003
Alum-mIGg 0.25 1 -0.5175 0.3631 14.28 -1.43 0.1755
Alum-mIGg 0.25 2 -2.0650 0.4428 12.54 -4.66 0.0005
Alum-mIGg 0.25 3 -5.8575 0.8277 9.879 -7.08 <.0001
Alum-mIGg 0.25 4 -3.7025 1.0285 9.559 -3.60 0.0052
Alum-mIGg 0.25 5 -2.4275 0.6892 10.16 -3.52 0.0054
Alum-mIGg 0.25 7 -1.4625 0.4613 10.81 -3.17 0.0091
Alum-mIGg 1 2 -1.5475 0.5044 16.31 -3.07 0.0072
Alum-mIGg 1 3 -5.3400 0.8592 11.28 -6.21 <.0001
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Table F25. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+ CD4- CD8+, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 1 4 -3.1850 1.0529 10.48 -3.02 0.0122
Alum-mIGg 1 5 -1.9100 0.7283 12.5 -2.62 0.0216
Alum-mIGg 1 7 -0.9450 0.5203 14.19 -1.82 0.0905
Alum-mIGg 2 3 -3.7925 0.8934 12.8 -4.24 0.0010
Alum-mIGg 2 4 -1.6375 1.0804 11.52 -1.52 0.1566
Alum-mIGg 2 5 -0.3625 0.7692 14.48 -0.47 0.6445
Alum-mIGg 2 7 0.6025 0.5772 16.12 1.04 0.3120
Alum-mIGg 3 4 2.1550 1.2748 16.22 1.69 0.1101
Alum-mIGg 3 5 3.4300 1.0313 17.03 3.33 0.0040
Alum-mIGg 3 7 4.3950 0.9015 12.92 4.88 0.0003
Alum-mIGg 4 5 1.2750 1.1952 15.22 1.07 0.3027
Alum-mIGg 4 7 2.2400 1.0868 11.65 2.06 0.0623
Alum-mIGg 5 7 0.9650 0.7789 14.58 1.24 0.2350
IO-mIgG 0 0.25 -0.1000 0.2100 12.62 -0.48 0.6420
IO-mIgG 0 1 -0.3500 0.3258 10.33 -1.07 0.3072
IO-mIgG 0 2 -2.1400 0.4136 9.764 -5.17 0.0004
IO-mIgG 0 3 -3.2825 0.8147 9.236 -4.03 0.0028
IO-mIgG 0 4 -2.7675 1.0189 9.153 -2.72 0.0234
IO-mIgG 0 5 -2.4775 0.6724 9.098 -3.68 0.0049
IO-mIgG 0 7 -1.1268 0.5013 8.513 -2.25 0.0528
IO-mIgG 0.25 1 -0.2500 0.3631 14.28 -0.69 0.5021
IO-mIgG 0.25 2 -2.0400 0.4428 12.54 -4.61 0.0005
IO-mIgG 0.25 3 -3.1825 0.8277 9.879 -3.85 0.0033
IO-mIgG 0.25 4 -2.6675 1.0285 9.559 -2.59 0.0277
IO-mIgG 0.25 5 -2.3775 0.6892 10.16 -3.45 0.0061
IO-mIgG 0.25 7 -1.0268 0.5253 10.15 -1.95 0.0787
IO-mIgG 1 2 -1.7900 0.5044 16.31 -3.55 0.0026
IO-mIgG 1 3 -2.9325 0.8592 11.28 -3.41 0.0056
IO-mIgG 1 4 -2.4175 1.0529 10.48 -2.30 0.0434
IO-mIgG 1 5 -2.1275 0.7283 12.5 -2.92 0.0123
IO-mIgG 1 7 -0.7768 0.5778 13.16 -1.34 0.2015
IO-mIgG 2 3 -1.1425 0.8934 12.8 -1.28 0.2237
IO-mIgG 2 4 -0.6275 1.0804 11.52 -0.58 0.5726
IO-mIgG 2 5 -0.3375 0.7692 14.48 -0.44 0.6673
IO-mIgG 2 7 1.0132 0.6295 15.46 1.61 0.1277
IO-mIgG 3 4 0.5150 1.2748 16.22 0.40 0.6915
IO-mIgG 3 5 0.8050 1.0313 17.03 0.78 0.4458
IO-mIgG 3 7 2.1557 0.9359 14.03 2.30 0.0371
IO-mIgG 4 5 0.2900 1.1952 15.22 0.24 0.8115
IO-mIgG 4 7 1.6407 1.1154 12.53 1.47 0.1660
IO-mIgG 5 7 1.3507 0.8184 15.7 1.65 0.1187
mIgG 0 0.25 -0.9500 0.2100 12.62 -4.52 0.0006
mIgG 0 1 -1.0625 0.3258 10.33 -3.26 0.0082
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Table F25. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+ CD4- CD8+, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 2 -1.1400 0.4136 9.764 -2.76 0.0207
mIgG 0 3 -2.2700 0.8147 9.236 -2.79 0.0207
mIgG 0 4 -2.1075 1.0189 9.153 -2.07 0.0680
mIgG 0 5 -1.8050 0.6724 9.098 -2.68 0.0248
mIgG 0 7 -0.9450 0.4338 8.667 -2.18 0.0584
mIgG 0.25 1 -0.1125 0.3631 14.28 -0.31 0.7611
mIgG 0.25 2 -0.1900 0.4428 12.54 -0.43 0.6751
mIgG 0.25 3 -1.3200 0.8277 9.879 -1.59 0.1422
mIgG 0.25 4 -1.1575 1.0285 9.559 -1.13 0.2879
mIgG 0.25 5 -0.8550 0.6892 10.16 -1.24 0.2427
mIgG 0.25 7 0.005000 0.4613 10.81 0.01 0.9915
mIgG 1 2 -0.07750 0.5044 16.31 -0.15 0.8798
mIgG 1 3 -1.2075 0.8592 11.28 -1.41 0.1869
mIgG 1 4 -1.0450 1.0529 10.48 -0.99 0.3433
mIgG 1 5 -0.7425 0.7283 12.5 -1.02 0.3273
mIgG 1 7 0.1175 0.5203 14.19 0.23 0.8245
mIgG 2 3 -1.1300 0.8934 12.8 -1.26 0.2285
mIgG 2 4 -0.9675 1.0804 11.52 -0.90 0.3888
mIgG 2 5 -0.6650 0.7692 14.48 -0.86 0.4014
mIgG 2 7 0.1950 0.5772 16.12 0.34 0.7399
mIgG 3 4 0.1625 1.2748 16.22 0.13 0.9001
mIgG 3 5 0.4650 1.0313 17.03 0.45 0.6578
mIgG 3 7 1.3250 0.9015 12.92 1.47 0.1656
mIgG 4 5 0.3025 1.1952 15.22 0.25 0.8036
mIgG 4 7 1.1625 1.0868 11.65 1.07 0.3064
mIgG 5 7 0.8600 0.7789 14.58 1.10 0.2874
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Table F26. Simple effect comparisons of treatment*day least squares means by day for  T 
cell+ CD4- CD8+, Study 3 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alum-mIGg IO-mIgG -0.02500 0.1308 8.849 -0.19 0.8527
day 0 Alum-mIGg mIgG 0.1500 0.1308 8.849 1.15 0.2814
day 0 IO-mIgG mIgG 0.1750 0.1308 8.849 1.34 0.2142
day 0.25 Alum-mIGg IO-mIgG 0.9675 0.2720 8.911 3.56 0.0063
day 0.25 Alum-mIGg mIgG 0.2925 0.2720 8.911 1.08 0.3105
day 0.25 IO-mIgG mIgG -0.6750 0.2720 8.911 -2.48 0.0352
day 1 Alum-mIGg IO-mIgG 1.2350 0.4476 9.137 2.76 0.0218
day 1 Alum-mIGg mIgG 0.6975 0.4476 9.137 1.56 0.1531
day 1 IO-mIgG mIgG -0.5375 0.4476 9.137 -1.20 0.2600
day 2 Alum-mIGg IO-mIgG 0.9925 0.5756 8.976 1.72 0.1188
day 2 Alum-mIGg mIgG 2.1675 0.5756 8.976 3.77 0.0045
day 2 IO-mIgG mIgG 1.1750 0.5756 8.976 2.04 0.0717
day 3 Alum-mIGg IO-mIgG 3.6425 1.1504 9.107 3.17 0.0113
day 3 Alum-mIGg mIgG 4.8300 1.1504 9.107 4.20 0.0023
day 3 IO-mIgG mIgG 1.1875 1.1504 9.107 1.03 0.3286
day 4 Alum-mIGg IO-mIgG 2.0025 1.4406 9.074 1.39 0.1977
day 4 Alum-mIGg mIgG 2.8375 1.4406 9.074 1.97 0.0801
day 4 IO-mIgG mIgG 0.8350 1.4406 9.074 0.58 0.5763
day 5 Alum-mIGg IO-mIgG 1.0175 0.9472 8.782 1.07 0.3114
day 5 Alum-mIGg mIgG 1.8650 0.9472 8.782 1.97 0.0813
day 5 IO-mIgG mIgG 0.8475 0.9472 8.782 0.89 0.3948
day 7 Alum-mIGg IO-mIgG 1.4032 0.6552 8.126 2.14 0.0641
day 7 Alum-mIGg mIgG 1.7600 0.6052 8.133 2.91 0.0193
day 7 IO-mIgG mIgG 0.3568 0.6552 8.126 0.54 0.6007
 
 
Table F27. Simple effect comparisons of treatment*day least squares means by treatment for  
cell+ IgM-, Study 3 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 0 0.25 -0.3775 0.06440 15.04 -5.86 <.0001
Alum-mIGg 0 1 -0.9900 0.3233 9.903 -3.06 0.0121
Alum-mIGg 0 2 -3.2800 0.6095 10.06 -5.38 0.0003
Alum-mIGg 0 3 -2.6050 0.5721 10.24 -4.55 0.0010
Alum-mIGg 0 4 -1.0675 0.5603 8.325 -1.91 0.0918
Alum-mIGg 0 5 -2.7425 0.6818 8.871 -4.02 0.0031
Alum-mIGg 0 7 -1.6975 0.6946 8.462 -2.44 0.0387
Alum-mIGg 0.25 1 -0.6125 0.3210 10.06 -1.91 0.0853
Alum-mIGg 0.25 2 -2.9025 0.6057 10.07 -4.79 0.0007
Alum-mIGg 0.25 3 -2.2275 0.5683 10.24 -3.92 0.0027
Alum-mIGg 0.25 4 -0.6900 0.5566 8.363 -1.24 0.2488
Alum-mIGg 0.25 5 -2.3650 0.6778 8.89 -3.49 0.0070
Alum-mIGg 0.25 7 -1.3200 0.6905 8.454 -1.91 0.0903
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Table F27. Simple effect comparisons of treatment*day least squares means by 
treatment for  cell+ IgM-, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 1 2 -2.2900 0.6230 13.76 -3.68 0.0026
Alum-mIGg 1 3 -1.6150 0.5912 14.3 -2.73 0.0160
Alum-mIGg 1 4 -0.07750 0.5822 12.99 -0.13 0.8961
Alum-mIGg 1 5 -1.7525 0.6867 11.94 -2.55 0.0254
Alum-mIGg 1 7 -0.7075 0.6976 10.94 -1.01 0.3324
Alum-mIGg 2 3 0.6750 0.7331 18.7 0.92 0.3689
Alum-mIGg 2 4 2.2125 0.7276 18.83 3.04 0.0068
Alum-mIGg 2 5 0.5375 0.8028 18.12 0.67 0.5116
Alum-mIGg 2 7 1.5825 0.8104 17.04 1.95 0.0675
Alum-mIGg 3 4 1.5375 0.7036 18.6 2.19 0.0419
Alum-mIGg 3 5 -0.1375 0.7824 17.89 -0.18 0.8625
Alum-mIGg 3 7 0.9075 0.7906 16.24 1.15 0.2677
Alum-mIGg 4 5 -1.6750 0.7777 17.93 -2.15 0.0451
Alum-mIGg 4 7 -0.6300 0.7861 16.15 -0.80 0.4345
Alum-mIGg 5 7 1.0450 0.8530 17.53 1.23 0.2367
IO-mIgG 0 0.25 0.07750 0.06440 15.04 1.20 0.2475
IO-mIgG 0 1 -0.2550 0.3233 9.903 -0.79 0.4488
IO-mIgG 0 2 -1.1975 0.6095 10.06 -1.96 0.0777
IO-mIgG 0 3 -1.2725 0.5721 10.24 -2.22 0.0497
IO-mIgG 0 4 -0.8325 0.5603 8.325 -1.49 0.1742
IO-mIgG 0 5 -1.0750 0.6818 8.871 -1.58 0.1498
IO-mIgG 0 7 -1.2509 0.7906 8.673 -1.58 0.1493
IO-mIgG 0.25 1 -0.3325 0.3210 10.06 -1.04 0.3245
IO-mIgG 0.25 2 -1.2750 0.6057 10.07 -2.11 0.0614
IO-mIgG 0.25 3 -1.3500 0.5683 10.24 -2.38 0.0384
IO-mIgG 0.25 4 -0.9100 0.5566 8.363 -1.63 0.1391
IO-mIgG 0.25 5 -1.1525 0.6778 8.89 -1.70 0.1237
IO-mIgG 0.25 7 -1.3284 0.7870 8.654 -1.69 0.1270
IO-mIgG 1 2 -0.9425 0.6230 13.76 -1.51 0.1530
IO-mIgG 1 3 -1.0175 0.5912 14.3 -1.72 0.1068
IO-mIgG 1 4 -0.5775 0.5822 12.99 -0.99 0.3393
IO-mIgG 1 5 -0.8200 0.6867 11.94 -1.19 0.2556
IO-mIgG 1 7 -0.9959 0.7932 10.45 -1.26 0.2366
IO-mIgG 2 3 -0.07500 0.7331 18.7 -0.10 0.9196
IO-mIgG 2 4 0.3650 0.7276 18.83 0.50 0.6217
IO-mIgG 2 5 0.1225 0.8028 18.12 0.15 0.8804
IO-mIgG 2 7 -0.05342 0.8940 15.86 -0.06 0.9531
IO-mIgG 3 4 0.4400 0.7036 18.6 0.63 0.5393
IO-mIgG 3 5 0.1975 0.7824 17.89 0.25 0.8036
IO-mIgG 3 7 0.02158 0.8761 15 0.02 0.9807
IO-mIgG 4 5 -0.2425 0.7777 17.93 -0.31 0.7588
IO-mIgG 4 7 -0.4184 0.8721 14.93 -0.48 0.6383
IO-mIgG 5 7 -0.1759 0.9328 16.9 -0.19 0.8527
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Table F27. Simple effect comparisons of treatment*day least squares means by 
treatment for  cell+ IgM-, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 0.25 -0.07750 0.06440 15.04 -1.20 0.2475
mIgG 0 1 -0.6900 0.3233 9.903 -2.13 0.0589
mIgG 0 2 -1.4800 0.6095 10.06 -2.43 0.0354
mIgG 0 3 -1.4000 0.5721 10.24 -2.45 0.0339
mIgG 0 4 -1.6475 0.5603 8.325 -2.94 0.0179
mIgG 0 5 -1.3900 0.6818 8.871 -2.04 0.0724
mIgG 0 7 -0.7025 0.6946 8.462 -1.01 0.3399
mIgG 0.25 1 -0.6125 0.3210 10.06 -1.91 0.0853
mIgG 0.25 2 -1.4025 0.6057 10.07 -2.32 0.0429
mIgG 0.25 3 -1.3225 0.5683 10.24 -2.33 0.0417
mIgG 0.25 4 -1.5700 0.5566 8.363 -2.82 0.0215
mIgG 0.25 5 -1.3125 0.6778 8.89 -1.94 0.0852
mIgG 0.25 7 -0.6250 0.6905 8.454 -0.91 0.3905
mIgG 1 2 -0.7900 0.6230 13.76 -1.27 0.2258
mIgG 1 3 -0.7100 0.5912 14.3 -1.20 0.2493
mIgG 1 4 -0.9575 0.5822 12.99 -1.64 0.1240
mIgG 1 5 -0.7000 0.6867 11.94 -1.02 0.3282
mIgG 1 7 -0.01250 0.6976 10.94 -0.02 0.9860
mIgG 2 3 0.08000 0.7331 18.7 0.11 0.9143
mIgG 2 4 -0.1675 0.7276 18.83 -0.23 0.8204
mIgG 2 5 0.09000 0.8028 18.12 0.11 0.9120
mIgG 2 7 0.7775 0.8104 17.04 0.96 0.3508
mIgG 3 4 -0.2475 0.7036 18.6 -0.35 0.7290
mIgG 3 5 0.01000 0.7824 17.89 0.01 0.9899
mIgG 3 7 0.6975 0.7906 16.24 0.88 0.3905
mIgG 4 5 0.2575 0.7777 17.93 0.33 0.7444
mIgG 4 7 0.9450 0.7861 16.15 1.20 0.2467
mIgG 5 7 0.6875 0.8530 17.53 0.81 0.4310
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Table F28. Simple effect comparisons of treatment*day least squares means by day for B cell+ 
IgM-, Study 3 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alum-mIGg IO-mIgG -0.05500 0.05598 8.241 -0.98 0.3539
day 0 Alum-mIGg mIgG -0.02000 0.05598 8.241 -0.36 0.7299
day 0 IO-mIgG mIgG 0.03500 0.05598 8.241 0.63 0.5488
day 0.25 Alum-mIGg IO-mIgG 0.4000 0.08713 9.363 4.59 0.0012
day 0.25 Alum-mIGg mIgG 0.2800 0.08713 9.363 3.21 0.0101
day 0.25 IO-mIgG mIgG -0.1200 0.08713 9.363 -1.38 0.2005
day 1 Alum-mIGg IO-mIgG 0.6800 0.4680 9.963 1.45 0.1770
day 1 Alum-mIGg mIgG 0.2800 0.4680 9.963 0.60 0.5630
day 1 IO-mIgG mIgG -0.4000 0.4680 9.963 -0.85 0.4128
day 2 Alum-mIGg IO-mIgG 2.0275 0.8743 10.16 2.32 0.0425
day 2 Alum-mIGg mIgG 1.7800 0.8743 10.16 2.04 0.0687
day 2 IO-mIgG mIgG -0.2475 0.8743 10.16 -0.28 0.7828
day 3 Alum-mIGg IO-mIgG 1.2775 0.8213 10.35 1.56 0.1499
day 3 Alum-mIGg mIgG 1.1850 0.8213 10.35 1.44 0.1786
day 3 IO-mIgG mIgG -0.09250 0.8213 10.35 -0.11 0.9125
day 4 Alum-mIGg IO-mIgG 0.1800 0.8044 8.35 0.22 0.8283
day 4 Alum-mIGg mIgG -0.6000 0.8044 8.35 -0.75 0.4762
day 4 IO-mIgG mIgG -0.7800 0.8044 8.35 -0.97 0.3595
day 5 Alum-mIGg IO-mIgG 1.6125 0.9767 8.916 1.65 0.1334
day 5 Alum-mIGg mIgG 1.3325 0.9767 8.916 1.36 0.2059
day 5 IO-mIgG mIgG -0.2800 0.9767 8.916 -0.29 0.7809
day 7 Alum-mIGg IO-mIgG 0.3916 1.0641 8.673 0.37 0.7217
day 7 Alum-mIGg mIgG 0.9750 0.9949 8.538 0.98 0.3540
day 7 IO-mIgG mIgG 0.5834 1.0641 8.673 0.55 0.5973
 
 
Table F29. Simple effect comparisons of treatment*day least squares means by treatment for 
CD3+, Study 3 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 0 0.25 -13.4550 1.5051 17.76 -8.94 <.0001
Alum-mIGg 0 1 -24.4000 5.2199 9.685 -4.67 0.0010
Alum-mIGg 0 2 -28.0525 3.2938 10.81 -8.52 <.0001
Alum-mIGg 0 3 -35.0775 4.3593 9.997 -8.05 <.0001
Alum-mIGg 0 4 -19.8425 6.6738 9.413 -2.97 0.0149
Alum-mIGg 0 5 -21.6850 4.7388 8.747 -4.58 0.0014
Alum-mIGg 0 7 -5.2950 3.5584 9.37 -1.49 0.1696
Alum-mIGg 0.25 1 -10.9450 5.2451 9.865 -2.09 0.0639
Alum-mIGg 0.25 2 -14.5975 3.3336 11.27 -4.38 0.0010
Alum-mIGg 0.25 3 -21.6225 4.3895 10.26 -4.93 0.0006
Alum-mIGg 0.25 4 -6.3875 6.6936 9.522 -0.95 0.3635
Alum-mIGg 0.25 5 -8.2300 4.7666 8.943 -1.73 0.1185
Alum-mIGg 0.25 7 8.1600 3.5953 9.728 2.27 0.0473
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Table F29. Simple effect comparisons of treatment*day least squares means by 
treatment for CD3+, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 1 2 -3.6525 6.0079 14.92 -0.61 0.5524
Alum-mIGg 1 3 -10.6775 6.6520 17.4 -1.61 0.1265
Alum-mIGg 1 4 4.5575 8.3538 16.96 0.55 0.5925
Alum-mIGg 1 5 2.7150 6.9066 16.97 0.39 0.6991
Alum-mIGg 1 7 19.1050 6.1570 15.36 3.10 0.0071
Alum-mIGg 2 3 -7.0250 5.2775 16.58 -1.33 0.2012
Alum-mIGg 2 4 8.2100 7.3067 12.87 1.12 0.2817
Alum-mIGg 2 5 6.3675 5.5950 14.34 1.14 0.2737
Alum-mIGg 2 7 22.7575 4.6379 16.66 4.91 0.0001
Alum-mIGg 3 4 15.2350 7.8449 15.36 1.94 0.0707
Alum-mIGg 3 5 13.3925 6.2816 16.64 2.13 0.0482
Alum-mIGg 3 7 29.7825 5.4465 16.6 5.47 <.0001
Alum-mIGg 4 5 -1.8425 8.0619 15.75 -0.23 0.8222
Alum-mIGg 4 7 14.5475 7.4297 13.39 1.96 0.0714
Alum-mIGg 5 7 16.3900 5.7547 14.71 2.85 0.0124
IO-mIgG 0 0.25 -1.4750 1.5051 17.76 -0.98 0.3402
IO-mIgG 0 1 -3.1150 5.2199 9.685 -0.60 0.5644
IO-mIgG 0 2 -11.7075 3.2938 10.81 -3.55 0.0046
IO-mIgG 0 3 -19.1175 4.3593 9.997 -4.39 0.0014
IO-mIgG 0 4 -12.6600 6.6738 9.413 -1.90 0.0889
IO-mIgG 0 5 -10.0800 4.7388 8.747 -2.13 0.0632
IO-mIgG 0 7 -11.8400 4.0681 9.03 -2.91 0.0172
IO-mIgG 0.25 1 -1.6400 5.2451 9.865 -0.31 0.7610
IO-mIgG 0.25 2 -10.2325 3.3336 11.27 -3.07 0.0104
IO-mIgG 0.25 3 -17.6425 4.3895 10.26 -4.02 0.0023
IO-mIgG 0.25 4 -11.1850 6.6936 9.522 -1.67 0.1272
IO-mIgG 0.25 5 -8.6050 4.7666 8.943 -1.81 0.1047
IO-mIgG 0.25 7 -10.3650 4.1004 9.3 -2.53 0.0316
IO-mIgG 1 2 -8.5925 6.0079 14.92 -1.43 0.1733
IO-mIgG 1 3 -16.0025 6.6520 17.4 -2.41 0.0275
IO-mIgG 1 4 -9.5450 8.3538 16.96 -1.14 0.2691
IO-mIgG 1 5 -6.9650 6.9066 16.97 -1.01 0.3274
IO-mIgG 1 7 -8.7250 6.4649 16.36 -1.35 0.1955
IO-mIgG 2 3 -7.4100 5.2775 16.58 -1.40 0.1787
IO-mIgG 2 4 -0.9525 7.3067 12.87 -0.13 0.8983
IO-mIgG 2 5 1.6275 5.5950 14.34 0.29 0.7753
IO-mIgG 2 7 -0.1325 5.0396 15.73 -0.03 0.9794
IO-mIgG 3 4 6.4575 7.8449 15.36 0.82 0.4230
IO-mIgG 3 5 9.0375 6.2816 16.64 1.44 0.1688
IO-mIgG 3 7 7.2775 5.7924 17 1.26 0.2260
IO-mIgG 4 5 2.5800 8.0619 15.75 0.32 0.7532
IO-mIgG 4 7 0.8200 7.6869 14.5 0.11 0.9165
IO-mIgG 5 7 -1.7600 6.0831 15.6 -0.29 0.7761
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Table F29. Simple effect comparisons of treatment*day least squares means by 
treatment for CD3+, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 0.25 -2.9850 1.5051 17.76 -1.98 0.0630
mIgG 0 1 -9.8325 5.2199 9.685 -1.88 0.0899
mIgG 0 2 -9.9700 3.2938 10.81 -3.03 0.0117
mIgG 0 3 -13.1925 4.3593 9.997 -3.03 0.0128
mIgG 0 4 -12.5425 6.6738 9.413 -1.88 0.0915
mIgG 0 5 -13.2583 5.4413 8.56 -2.44 0.0389
mIgG 0 7 -4.0625 3.5584 9.37 -1.14 0.2819
mIgG 0.25 1 -6.8475 5.2451 9.865 -1.31 0.2213
mIgG 0.25 2 -6.9850 3.3336 11.27 -2.10 0.0595
mIgG 0.25 3 -10.2075 4.3895 10.26 -2.33 0.0418
mIgG 0.25 4 -9.5575 6.6936 9.522 -1.43 0.1853
mIgG 0.25 5 -10.2733 5.4655 8.708 -1.88 0.0940
mIgG 0.25 7 -1.0775 3.5953 9.728 -0.30 0.7707
mIgG 1 2 -0.1375 6.0079 14.92 -0.02 0.9820
mIgG 1 3 -3.3600 6.6520 17.4 -0.51 0.6198
mIgG 1 4 -2.7100 8.3538 16.96 -0.32 0.7496
mIgG 1 5 -3.4258 7.4063 16.82 -0.46 0.6496
mIgG 1 7 5.7700 6.1570 15.36 0.94 0.3632
mIgG 2 3 -3.2225 5.2775 16.58 -0.61 0.5497
mIgG 2 4 -2.5725 7.3067 12.87 -0.35 0.7305
mIgG 2 5 -3.2883 6.2012 13.08 -0.53 0.6048
mIgG 2 7 5.9075 4.6379 16.66 1.27 0.2202
mIgG 3 4 0.6500 7.8449 15.36 0.08 0.9350
mIgG 3 5 -0.06583 6.8272 15.71 -0.01 0.9924
mIgG 3 7 9.1300 5.4465 16.6 1.68 0.1124
mIgG 4 5 -0.7158 8.4939 16.63 -0.08 0.9338
mIgG 4 7 8.4800 7.4297 13.39 1.14 0.2737
mIgG 5 7 9.1958 6.3458 13.59 1.45 0.1700
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Table F30. Simple effect comparisons of treatment*day least squares means by day for CD3+, 
Study 3 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 Alum-mIGg IO-mIgG -2.0000 1.4146 9 -1.41 0.1911
day 0 Alum-mIGg mIgG 0.1350 1.4146 9 0.10 0.9261
day 0 IO-mIgG mIgG 2.1350 1.4146 9 1.51 0.1655
day 0.25 Alum-mIGg IO-mIgG 9.9800 1.5904 9 6.28 0.0001
day 0.25 Alum-mIGg mIgG 10.6050 1.5904 9 6.67 <.0001
day 0.25 IO-mIgG mIgG 0.6250 1.5904 9 0.39 0.7035
day 1 Alum-mIGg IO-mIgG 19.2850 7.2452 9 2.66 0.0260
day 1 Alum-mIGg mIgG 14.7025 7.2452 9 2.03 0.0730
day 1 IO-mIgG mIgG -4.5825 7.2452 9 -0.63 0.5428
day 2 Alum-mIGg IO-mIgG 14.3450 4.4381 9 3.23 0.0103
day 2 Alum-mIGg mIgG 18.2175 4.4381 9 4.10 0.0027
day 2 IO-mIgG mIgG 3.8725 4.4381 9 0.87 0.4056
day 3 Alum-mIGg IO-mIgG 13.9600 6.0005 9 2.33 0.0450
day 3 Alum-mIGg mIgG 22.0200 6.0005 9 3.67 0.0052
day 3 IO-mIgG mIgG 8.0600 6.0005 9 1.34 0.2121
day 4 Alum-mIGg IO-mIgG 5.1825 9.3316 9 0.56 0.5922
day 4 Alum-mIGg mIgG 7.4350 9.3316 9 0.80 0.4461
day 4 IO-mIgG mIgG 2.2525 9.3316 9 0.24 0.8147
day 5 Alum-mIGg IO-mIgG 9.6050 6.5506 8 1.47 0.1807
day 5 Alum-mIGg mIgG 8.5617 7.0755 8 1.21 0.2608
day 5 IO-mIgG mIgG -1.0433 7.0755 8 -0.15 0.8864
day 7 Alum-mIGg IO-mIgG -8.5450 5.2164 8 -1.64 0.1400
day 7 Alum-mIGg mIgG 1.3675 4.8294 8 0.28 0.7842
day 7 IO-mIgG mIgG 9.9125 5.2164 8 1.90 0.0939
 
 
Table F31. Simple effect comparisons of treatment*day least squares means by treatment for 
CD4/CD8 ratio, Study 3 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 0.25 1 1.3732 0.4648 9.053 2.95 0.0160
Alum-mIGg 0.25 2 0.8164 0.8385 9.121 0.97 0.3553
Alum-mIGg 0.25 3 1.0537 0.6638 9.044 1.59 0.1467
Alum-mIGg 0.25 4 1.4693 0.6991 9.091 2.10 0.0646
Alum-mIGg 0.25 5 1.3021 0.7086 9.088 1.84 0.0990
Alum-mIGg 0.25 7 1.3747 0.4179 8.932 3.29 0.0095
Alum-mIGg 1 2 -0.5568 0.7283 9.081 -0.76 0.4640
Alum-mIGg 1 3 -0.3195 0.5443 9.026 -0.59 0.5716
Alum-mIGg 1 4 0.09612 0.4468 9.067 0.22 0.8344
Alum-mIGg 1 5 -0.07115 0.5628 9.056 -0.13 0.9022
Alum-mIGg 1 7 0.001506 0.6003 8.981 0.00 0.9981
Alum-mIGg 2 3 0.2373 0.6698 9.083 0.35 0.7312
Alum-mIGg 2 4 0.6529 0.6248 9.003 1.04 0.3233
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Table F31. Simple effect comparisons of treatment*day least squares means by 
treatment for CD4/CD8 ratio, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIGg 2 5 0.4856 0.5013 9.012 0.97 0.3579
Alum-mIGg 2 7 0.5583 0.9948 9.076 0.56 0.5883
Alum-mIGg 3 4 0.4156 0.5490 9.038 0.76 0.4683
Alum-mIGg 3 5 0.2483 0.4437 9.05 0.56 0.5893
Alum-mIGg 3 7 0.3210 0.6527 8.998 0.49 0.6346
Alum-mIGg 4 5 -0.1673 0.3523 9.015 -0.47 0.6462
Alum-mIGg 4 7 -0.09462 0.6861 9.086 -0.14 0.8933
Alum-mIGg 5 7 0.07265 0.6479 9.101 0.11 0.9131
IO-mIgG 0.25 1 2.3322 0.4648 9.053 5.02 0.0007
IO-mIgG 0.25 2 1.3725 0.8384 9.121 1.64 0.1356
IO-mIgG 0.25 3 1.6422 0.6638 9.044 2.47 0.0352
IO-mIgG 0.25 4 2.5461 0.6991 9.091 3.64 0.0053
IO-mIgG 0.25 5 0.8879 0.7086 9.088 1.25 0.2415
IO-mIgG 0.25 7 0.7626 0.4200 9.001 1.82 0.1028
IO-mIgG 1 2 -0.9597 0.7283 9.081 -1.32 0.2199
IO-mIgG 1 3 -0.6900 0.5443 9.026 -1.27 0.2366
IO-mIgG 1 4 0.2139 0.4468 9.067 0.48 0.6434
IO-mIgG 1 5 -1.4443 0.5628 9.056 -2.57 0.0302
IO-mIgG 1 7 -1.5696 0.6017 9.015 -2.61 0.0283
IO-mIgG 2 3 0.2697 0.6698 9.083 0.40 0.6966
IO-mIgG 2 4 1.1736 0.6248 9.003 1.88 0.0931
IO-mIgG 2 5 -0.4846 0.5013 9.012 -0.97 0.3589
IO-mIgG 2 7 -0.6099 0.9957 9.089 -0.61 0.5552
IO-mIgG 3 4 0.9039 0.5490 9.038 1.65 0.1339
IO-mIgG 3 5 -0.7543 0.4437 9.05 -1.70 0.1232
IO-mIgG 3 7 -0.8796 0.6540 9.027 -1.34 0.2114
IO-mIgG 4 5 -1.6582 0.3523 9.015 -4.71 0.0011
IO-mIgG 4 7 -1.7835 0.6873 9.112 -2.59 0.0287
IO-mIgG 5 7 -0.1253 0.6492 9.131 -0.19 0.8511
mIgG 0.25 1 -0.1474 0.4648 9.053 -0.32 0.7584
mIgG 0.25 2 -0.7977 0.8384 9.121 -0.95 0.3659
mIgG 0.25 3 -1.1368 0.6638 9.044 -1.71 0.1208
mIgG 0.25 4 -0.8564 0.6991 9.091 -1.23 0.2513
mIgG 0.25 5 -0.6846 0.7086 9.088 -0.97 0.3590
mIgG 0.25 7 -0.2611 0.4179 8.932 -0.62 0.5477
mIgG 1 2 -0.6503 0.7282 9.081 -0.89 0.3949
mIgG 1 3 -0.9894 0.5443 9.026 -1.82 0.1024
mIgG 1 4 -0.7091 0.4468 9.067 -1.59 0.1467
mIgG 1 5 -0.5372 0.5628 9.056 -0.95 0.3646
mIgG 1 7 -0.1137 0.6003 8.981 -0.19 0.8539
mIgG 2 3 -0.3391 0.6698 9.083 -0.51 0.6248
mIgG 2 4 -0.05874 0.6248 9.003 -0.09 0.9272
mIgG 2 5 0.1131 0.5013 9.012 0.23 0.8266
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Table F31. Simple effect comparisons of treatment*day least squares means by 
treatment for CD4/CD8 ratio, Study 3 (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 2 7 0.5366 0.9948 9.076 0.54 0.6026
mIgG 3 4 0.2804 0.5490 9.038 0.51 0.6218
mIgG 3 5 0.4522 0.4437 9.05 1.02 0.3346
mIgG 3 7 0.8757 0.6527 8.998 1.34 0.2126
mIgG 4 5 0.1718 0.3523 9.015 0.49 0.6374
mIgG 4 7 0.5953 0.6861 9.086 0.87 0.4079
mIgG 5 7 0.4235 0.6479 9.101 0.65 0.5295
  
 
Table F32. Simple effect comparisons of treatment*day least squares means by day for 
CD4/CD8 ratio, Study 3 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0.25 Alum-mIGg IO-mIgG -1.1001 0.7664 9.122 -1.44 0.1846
day 0.25 Alum-mIGg mIgG 1.2784 0.7664 9.122 1.67 0.1292
day 0.25 IO-mIgG mIgG 2.3785 0.7664 9.122 3.10 0.0124
day 1 Alum-mIGg IO-mIgG -0.1411 0.6029 9.061 -0.23 0.8201
day 1 Alum-mIGg mIgG -0.2422 0.6029 9.061 -0.40 0.6972
day 1 IO-mIgG mIgG -0.1011 0.6029 9.061 -0.17 0.8706
day 2 Alum-mIGg IO-mIgG -0.5440 0.7414 9.025 -0.73 0.4817
day 2 Alum-mIGg mIgG -0.3357 0.7414 9.025 -0.45 0.6614
day 2 IO-mIgG mIgG 0.2083 0.7414 9.025 0.28 0.7851
day 3 Alum-mIGg IO-mIgG -0.5116 0.6636 9.042 -0.77 0.4604
day 3 Alum-mIGg mIgG -0.9121 0.6636 9.042 -1.37 0.2024
day 3 IO-mIgG mIgG -0.4005 0.6636 9.042 -0.60 0.5610
day 4 Alum-mIGg IO-mIgG -0.02333 0.4604 9.002 -0.05 0.9607
day 4 Alum-mIGg mIgG -1.0473 0.4604 9.002 -2.27 0.0490
day 4 IO-mIgG mIgG -1.0240 0.4604 9.002 -2.22 0.0532
day 5 Alum-mIGg IO-mIgG -1.5142 0.4136 9.013 -3.66 0.0052
day 5 Alum-mIGg mIgG -0.7083 0.4136 9.013 -1.71 0.1209
day 5 IO-mIgG mIgG 0.8060 0.4136 9.013 1.95 0.0831
day 7 Alum-mIGg IO-mIgG -1.7122 0.8448 9.111 -2.03 0.0729
day 7 Alum-mIGg mIgG -0.3574 0.8438 9.094 -0.42 0.6817
day 7 IO-mIgG mIgG 1.3548 0.8448 9.111 1.60 0.1428
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APPENDIX G 
Type III Test of Fixed Effects Results for 
Primary Response in Intramuscular Injection Studies 
 
Table G1. Type III test of fixed effects results for primary response in intramuscular injection 
studies 
  Study A Study B 
Response Factor Fixed Effect F Value P Value F Value P Value 
CD45+ Day  59.59 < 0.0001 - - 
 Treatment 0.81 NS - - 
 Treatment*Day 1.11 NS - - 
Macrophages Day  7.49 0.0037 - - 
 Treatment 2.37 NS - - 
 Treatment*Day 1.89 NS - - 
MHCII+  Day  35.30 < 0.0001 38.57 0.0062 
Macrophages+ Treatment 0.33 NS 6.23 0.0200 
 Treatment*Day 1.24 NS 10.31 0.0238 
MHCII+  Day  11.38 0.0009 23.71 0.0119 
B cells+ Treatment 0.54 NS 2.30 NS 
 Treatment*Day 0.45 NS 6.53 NS 
CD4- CD8+ Day  16.24 0.0003 9.44 0.0460 
 Treatment 1.72 NS 0.56 NS 
 Treatment*Day 1.43 NS 2.31 NS 
CD4+ CD8+ Day  8.44 0.0024 7.10 NS 
 Treatment 1.80 NS 0.60 NS 
 Treatment*Day 1.06 NS 0.19 NS 
CD4+ CD8- Day  48.05 < 0.0001 112.43 0.0013 
 Treatment 1.57 NS 0.83 NS 
 Treatment*Day 2.94 0.0365 2.48 NS 
CD25+ CD4+ Day  3.63 0.0398 - - 
 Treatment 0.29 NS - - 
 Treatment*Day 0.89 NS - - 
CD25+ CD4- Day  10.63 0.0013 - - 
 Treatment 3.52 NS - - 
 Treatment*Day 0.65 NS - - 
T cell+ CD8+ Day  14.33 0.0004 3.83 NS 
 Treatment 3.72 0.0488 1.53 NS 
 Treatment*Day 0.74 NS 1.57 NS 
T cell+ CD8- Day  15.64 0.0003 11.15 0.0366 
 Treatment 1.56 NS 0.35 NS 
 Treatment*Day 4.90 0.0050 0.73 NS 
1 Tcell+ Day  41.49 < 0.0001 149.72 0.0008 
 Treatment 2.50 NS 1.78 NS 
 Treatment*Day 1.21 NS 4.78 NS 
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Table G1. Type III test of fixed effects results for primary response in intramuscular injection 
studies (Cont.) 
  Study A Study B 
Response Factor Fixed Effect F Value P Value F Value P Value 
1 T cell+ Day  - - 20.51 0.0154 
CD4-CD8+ Treatment - - 2.48 NS 
 Treatment*Day - - 6.01 NS 
1 T cell+ Day  - - 7.85 NS 
CD4+CD8+ Treatment - - 1.24 NS 
 Treatment*Day - - 0.72 NS 
1 T cell+ Day  - - 33.57 0.0075 
CD4-CD8- Treatment - - 1.97 NS 
 Treatment*Day - - 0.79 NS 
1 T cell+ Day  - - 79.81 0.0021 
CD4+CD8- Treatment - - 1.69 NS 
 Treatment*Day - - 1.57 NS 
2 T cell+ Day  39.89 < 0.0001 24.32 0.0121 
 Treatment 2.56 NS 0.29 NS 
 Treatment*Day 1.85 NS 0.66 NS 
2 T cell+ Day  - - 24.29 0.0121 
CD4-CD8+ Treatment - - 0.39 NS 
 Treatment*Day - - 1.80 NS 
2 T cell+ Day  - - 42.76 0.0053 
CD4+CD8+ Treatment - - 0.15 NS 
 Treatment*Day - - 8.35 0.0339 
2 T cell+ Day  - - 6.46 NS 
CD4-CD8- Treatment - - 1.01 NS 
 Treatment*Day - - 0.26 NS 
2 T cell+ Day  - - 257.06 0.0458 
CD4+CD8- Treatment - - 0.04 NS 
 Treatment*Day - - 0.04 NS 
B cell Day  48.19 < 0.0001 - - 
 Treatment 16.04 0.0002 - - 
 Treatment*Day 5.02 0.0045 - - 
B cell+ IgM+ Day  - - 21.65 0.0143 
 Treatment - - 1.88 NS 
 Treatment*Day - - 6.31 NS 
B cell+ IgM- Day  - - 29.00 0.0093 
 Treatment - - 4.47 0.0449 
 Treatment*Day - - 2.96 NS 
B cell+ IgG+ Day  - - 5.87 NS 
 Treatment - - 0.86 NS 
 Treatment*Day - - 0.79 NS 
B cell+ IgG- Day  - - 106.05 0.0013 
 Treatment - - 2.57 NS 
 Treatment*Day - - 14.54 0.0132 
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APPENDIX H 
Difference of Least Squares Means Results for Primary Response 
 in Intramuscular Injection Studies 
 
Table H1. Difference of least squares means for pulp cell responses by day 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
Study A        
CD45+ 0 0.25 -15.4800 1.2634 14.99 -12.25 <.0001
 0 1 -16.7111 1.2270 15 -13.62 <.0001
 0 2 -14.6950 1.6447 14.98 -8.93 <.0001
 0 3 -8.4694 1.3065 15 -6.48 <.0001
 0 4 -6.3896 1.2527 15.08 -5.10 0.0001
 0 5 -3.4341 1.0765 12.29 -3.19 0.0076
 0 7 2.7261 1.3168 15.01 2.07 0.0561
 0.25 1 -1.2311 1.6911 14.99 -0.73 0.4778
 0.25 2 0.7850 2.2212 14.98 0.35 0.7287
 0.25 3 7.0106 1.5596 15 4.49 0.0004
 0.25 4 9.0904 1.9196 15.19 4.74 0.0003
 0.25 5 12.0459 1.8222 12.96 6.61 <.0001
 0.25 7 18.2061 1.5822 15 11.51 <.0001
 1 2 2.0161 1.7803 14.99 1.13 0.2752
 1 3 8.2417 1.5033 15 5.48 <.0001
 1 4 10.3216 1.6808 14.87 6.14 <.0001
 1 5 13.2770 1.4757 15.17 9.00 <.0001
 1 7 19.4372 1.7096 15.01 11.37 <.0001
 2 3 6.2256 1.7385 14.97 3.58 0.0027
 2 4 8.3054 2.1101 15.16 3.94 0.0013
 2 5 11.2609 1.7025 14.21 6.61 <.0001
 2 7 17.4211 1.5384 14.97 11.32 <.0001
 3 4 2.0799 1.5135 11.01 1.37 0.1967
 3 5 5.0354 1.2842 14.07 3.92 0.0015
 3 7 11.1956 1.2049 15 9.29 <.0001
 4 5 2.9555 0.8615 14.34 3.43 0.0039
 4 7 9.1157 1.4928 15.23 6.11 <.0001
 5 7 6.1602 1.2882 14.77 4.78 0.0003
Macrophages 0 0.25 -3.9006 0.5027 15 -7.76 <.0001
 0 1 0.1061 0.3279 15 0.32 0.7507
 0 2 -0.01722 0.2626 15.01 -0.07 0.9486
 0 3 0.1194 0.2949 15 0.41 0.6912
 0 4 0.2461 0.2006 15.22 1.23 0.2384
 0 5 0.07227 0.3819 14.58 0.19 0.8525
 0 7 0.8789 0.3650 15 2.41 0.0294
 0.25 1 4.0067 0.6499 15.02 6.17 <.0001
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0.25 2 3.8833 0.6121 15.01 6.34 <.0001
 0.25 3 4.0200 0.5789 15.01 6.94 <.0001
 0.25 4 4.1467 0.6107 15.04 6.79 <.0001
 0.25 5 3.9728 0.6749 15.09 5.89 <.0001
 0.25 7 4.7794 0.7133 15 6.70 <.0001
 1 2 -0.1233 0.3406 14.99 -0.36 0.7223
 1 3 0.01333 0.2231 14.99 0.06 0.9531
 1 4 0.1400 0.2485 15.16 0.56 0.5814
 1 5 -0.03384 0.3012 14.62 -0.11 0.9121
 1 7 0.7728 0.3413 14.97 2.26 0.0389
 2 3 0.1367 0.2743 15 0.50 0.6256
 2 4 0.2633 0.2510 15.19 1.05 0.3105
 2 5 0.08950 0.2992 14.86 0.30 0.7690
 2 7 0.8961 0.3647 15 2.46 0.0267
 3 4 0.1267 0.2163 14.93 0.59 0.5669
 3 5 -0.04717 0.2899 13.26 -0.16 0.8732
 3 7 0.7594 0.3125 14.97 2.43 0.0281
 4 5 -0.1738 0.2866 14.92 -0.61 0.5532
 4 7 0.6328 0.2528 15.15 2.50 0.0242
 5 7 0.8066 0.3653 15.09 2.21 0.0431
MHCII+  0 0.25 -4.4467 0.4785 15 -9.29 <.0001
Macrophages+ 0 1 -1.2117 0.1685 15 -7.19 <.0001
 0 2 -1.5467 0.1768 14.98 -8.75 <.0001
 0 3 -0.8494 0.1479 14.99 -5.74 <.0001
 0 4 -0.9311 0.2054 15.01 -4.53 0.0004
 0 5 -0.5238 0.1353 12.34 -3.87 0.0021
 0 7 0.4744 0.1621 14.98 2.93 0.0104
 0.25 1 3.2350 0.5204 15.02 6.22 <.0001
 0.25 2 2.9000 0.5682 14.98 5.10 0.0001
 0.25 3 3.5972 0.5261 15 6.84 <.0001
 0.25 4 3.5156 0.5395 15.02 6.52 <.0001
 0.25 5 3.9229 0.5307 14.96 7.39 <.0001
 0.25 7 4.9211 0.5419 14.98 9.08 <.0001
 1 2 -0.3350 0.2280 14.97 -1.47 0.1624
 1 3 0.3622 0.1723 14.98 2.10 0.0529
 1 4 0.2806 0.2182 15.01 1.29 0.2179
 1 5 0.6879 0.1981 14.24 3.47 0.0036
 1 7 1.6861 0.2326 14.98 7.25 <.0001
 2 3 0.6972 0.1662 14.99 4.19 0.0008
 2 4 0.6156 0.2787 14.99 2.21 0.0432
 2 5 1.0229 0.1816 14.2 5.63 <.0001
 2 7 2.0211 0.1529 15 13.22 <.0001
 3 4 -0.08167 0.1683 15.01 -0.49 0.6345
 3 5 0.3257 0.1557 13.96 2.09 0.0553
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 3 7 1.3239 0.1690 14.98 7.84 <.0001
 4 5 0.4073 0.1683 14.81 2.42 0.0288
 4 7 1.4056 0.2756 15 5.10 0.0001
 5 7 0.9982 0.2010 14.95 4.97 0.0002
Lymphocytes 0 0.25 -3.6533 0.5767 15.02 -6.34 <.0001
 0 1 -12.4206 1.0393 15.12 -11.95 <.0001
 0 2 -11.9700 1.0501 14.94 -11.40 <.0001
 0 3 -5.7156 0.8677 14.98 -6.59 <.0001
 0 4 -3.6022 0.7507 14.94 -4.80 0.0002
 0 5 -1.0857 0.3890 14.25 -2.79 0.0142
 0 7 -0.9456 0.2653 15.05 -3.56 0.0028
 0.25 1 -8.7672 1.0269 15.04 -8.54 <.0001
 0.25 2 -8.3167 0.9878 14.97 -8.42 <.0001
 0.25 3 -2.0622 1.0421 15.02 -1.98 0.0665
 0.25 4 0.05111 1.0701 14.92 0.05 0.9625
 0.25 5 2.5676 0.5539 15.11 4.64 0.0003
 0.25 7 2.7078 0.6050 15.01 4.48 0.0004
 1 2 0.4506 1.2964 14.93 0.35 0.7330
 1 3 6.7050 1.2206 15.01 5.49 <.0001
 1 4 8.8183 1.1067 15.06 7.97 <.0001
 1 5 11.3348 0.8942 14.86 12.68 <.0001
 1 7 11.4750 0.8861 15.12 12.95 <.0001
 2 3 6.2544 1.2204 14.94 5.12 0.0001
 2 4 8.3678 1.4941 14.88 5.60 <.0001
 2 5 10.8843 1.1253 14.59 9.67 <.0001
 2 7 11.0244 1.0402 14.93 10.60 <.0001
 3 4 2.1133 0.9958 14.86 2.12 0.0510
 3 5 4.6298 0.9345 15 4.95 0.0002
 3 7 4.7700 0.8543 14.97 5.58 <.0001
 4 5 2.5165 0.6585 15.05 3.82 0.0017
 4 7 2.6567 0.8436 14.95 3.15 0.0066
 5 7 0.1402 0.4603 14.82 0.30 0.7649
CD4+ CD8+ 0 0.25 -0.1422 0.1495 15 -0.95 0.3566
 0 1 -0.2400 0.04141 15.03 -5.80 <.0001
 0 2 -0.5789 0.1663 15.02 -3.48 0.0033
 0 3 -0.1911 0.08126 15 -2.35 0.0328
 0 4 -0.1389 0.04034 15.01 -3.44 0.0036
 0 5 -0.05325 0.02840 15.03 -1.87 0.0804
 0 7 -0.00167 0.02009 15 -0.08 0.9350
 0.25 1 -0.09778 0.1345 14.98 -0.73 0.4784
 0.25 2 -0.4367 0.1138 15.01 -3.84 0.0016
 0.25 3 -0.04889 0.08191 15 -0.60 0.5595
 0.25 4 0.003333 0.1640 15 0.02 0.9841
 0.25 5 0.08897 0.1499 14.98 0.59 0.5618
 0.25 7 0.1406 0.1398 15 1.01 0.3308
 1 2 -0.3389 0.1650 15 -2.05 0.0579
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 1 3 0.04889 0.07695 14.95 0.64 0.5348
 1 4 0.1011 0.06219 15.01 1.63 0.1248
 1 5 0.1867 0.03932 15.12 4.75 0.0003
 1 7 0.2383 0.03609 15.02 6.60 <.0001
 2 3 0.3878 0.09886 15.04 3.92 0.0014
 2 4 0.4400 0.1629 15.02 2.70 0.0164
 2 5 0.5256 0.1647 14.99 3.19 0.0061
 2 7 0.5772 0.1663 15.01 3.47 0.0034
 3 4 0.05222 0.09104 15 0.57 0.5747
 3 5 0.1379 0.08355 14.96 1.65 0.1198
 3 7 0.1894 0.07675 14.98 2.47 0.0261
 4 5 0.08564 0.04520 15.04 1.89 0.0775
 4 7 0.1372 0.05004 15 2.74 0.0151
 5 7 0.05159 0.03323 15.12 1.55 0.1412
CD4- CD8+ 0 0.25 -2.2533 0.4541 14.96 -4.96 0.0002
 0 1 -2.9100 0.8957 14.99 -3.25 0.0054
 0 2 -2.0911 0.3107 15.02 -6.73 <.0001
 0 3 -0.6772 0.1731 15.15 -3.91 0.0014
 0 4 -0.3706 0.08908 14.98 -4.16 0.0008
 0 5 -0.02488 0.1084 7.644 -0.23 0.8245
 0 7 0.02556 0.03694 14.94 0.69 0.4997
 0.25 1 -0.6567 0.9172 15.13 -0.72 0.4849
 0.25 2 0.1622 0.2975 14.61 0.55 0.5938
 0.25 3 1.5761 0.3440 14.85 4.58 0.0004
 0.25 4 1.8828 0.4974 14.95 3.79 0.0018
 0.25 5 2.2285 0.4826 14.81 4.62 0.0003
 0.25 7 2.2789 0.4381 14.96 5.20 0.0001
 1 2 0.8189 0.9478 14.84 0.86 0.4014
 1 3 2.2328 0.8845 14.92 2.52 0.0234
 1 4 2.5394 0.9153 14.99 2.77 0.0142
 1 5 2.8851 0.8826 14.89 3.27 0.0052
 1 7 2.9356 0.8820 15 3.33 0.0046
 2 3 1.4139 0.1880 14.89 7.52 <.0001
 2 4 1.7206 0.3419 15.04 5.03 0.0001
 2 5 2.0662 0.3106 14.97 6.65 <.0001
 2 7 2.1167 0.3056 14.98 6.93 <.0001
 3 4 0.3067 0.1977 15.14 1.55 0.1416
 3 5 0.6523 0.1984 14.47 3.29 0.0052
 3 7 0.7028 0.1586 15.11 4.43 0.0005
 4 5 0.3457 0.1305 12.4 2.65 0.0207
 4 7 0.3961 0.09865 14.97 4.02 0.0011
 5 7 0.05043 0.1135 7.619 0.44 0.6692
CD25+ CD4- 0 0.25 -0.04333 0.01647 15 -2.63 0.0189
 0 1 -0.06833 0.01752 14.99 -3.90 0.0014
 0 2 -0.02278 0.02027 15 -1.12 0.2789
 0 3 0.02944 0.009654 14.98 3.05 0.0081
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 4 0.006667 0.01306 14.99 0.51 0.6170
 0 5 -0.00361 0.01345 14.56 -0.27 0.7920
 0 7 -0.1878 0.02924 14.99 -6.42 <.0001
 0.25 1 -0.02500 0.01660 15 -1.51 0.1529
 0.25 2 0.02056 0.02386 15 0.86 0.4026
 0.25 3 0.07278 0.01702 15 4.28 0.0007
 0.25 4 0.05000 0.01956 15 2.56 0.0219
 0.25 5 0.03972 0.01923 13.94 2.07 0.0580
 0.25 7 -0.1444 0.03700 15 -3.90 0.0014
 1 2 0.04556 0.02405 14.99 1.89 0.0776
 1 3 0.09778 0.01705 14.99 5.73 <.0001
 1 4 0.07500 0.01443 14.99 5.20 0.0001
 1 5 0.06472 0.01978 15.2 3.27 0.0051
 1 7 -0.1194 0.03254 14.99 -3.67 0.0023
 2 3 0.05222 0.01716 15 3.04 0.0082
 2 4 0.02944 0.01965 15 1.50 0.1547
 2 5 0.01917 0.01980 14.88 0.97 0.3486
 2 7 -0.1650 0.03668 15 -4.50 0.0004
 3 4 -0.02278 0.009166 15 -2.48 0.0252
 3 5 -0.03306 0.008386 13.75 -3.94 0.0015
 3 7 -0.2172 0.02930 15 -7.41 <.0001
 4 5 -0.01028 0.01186 13.9 -0.87 0.4008
 4 7 -0.1944 0.02857 15 -6.81 <.0001
 5 7 -0.1842 0.02869 15.11 -6.42 <.0001
CD25+ CD4+ 0 0.25 -0.00111 0.01302 15 -0.09 0.9331
 0 1 -0.04444 0.01820 15.01 -2.44 0.0275
 0 2 0.02111 0.01233 15 1.71 0.1075
 0 3 0.01167 0.01246 15 0.94 0.3641
 0 4 -0.05000 0.01886 15 -2.65 0.0182
 0 5 -0.04230 0.01817 13.09 -2.33 0.0366
 0 7 -0.04667 0.01459 15 -3.20 0.0060
 0.25 1 -0.04333 0.01427 15.01 -3.04 0.0083
 0.25 2 0.02222 0.008876 14.99 2.50 0.0243
 0.25 3 0.01278 0.01005 14.99 1.27 0.2231
 0.25 4 -0.04889 0.01486 15 -3.29 0.0050
 0.25 5 -0.04119 0.01157 14.68 -3.56 0.0029
 0.25 7 -0.04556 0.01289 15.01 -3.53 0.0030
 1 2 0.06556 0.01615 15 4.06 0.0010
 1 3 0.05611 0.01703 15 3.29 0.0049
 1 4 -0.00556 0.02195 15 -0.25 0.8036
 1 5 0.002143 0.01330 15.28 0.16 0.8741
 1 7 -0.00222 0.01902 15.01 -0.12 0.9085
 2 3 -0.00944 0.006464 15 -1.46 0.1646
 2 4 -0.07111 0.01659 15 -4.29 0.0007
 2 5 -0.06341 0.01291 14.6 -4.91 0.0002
 2 7 -0.06778 0.01294 15.01 -5.24 <.0001
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 3 4 -0.06167 0.01557 14.99 -3.96 0.0013
 3 5 -0.05397 0.01281 14.4 -4.21 0.0008
 3 7 -0.05833 0.01274 15 -4.58 0.0004
 4 5 0.007698 0.01538 14.94 0.50 0.6240
 4 7 0.003333 0.01373 14.99 0.24 0.8114
 5 7 -0.00436 0.01323 13.73 -0.33 0.7465
 T cell+ CD8+ 0 0.25 -0.03000 0.01652 15 -1.82 0.0894
 0 1 -0.3611 0.04807 15 -7.51 <.0001
 0 2 -0.2644 0.04139 14.99 -6.39 <.0001
 0 3 -0.04444 0.02453 15 -1.81 0.0901
 0 4 -0.03889 0.02071 15.01 -1.88 0.0799
 0 5 0.01617 0.02236 14.9 0.72 0.4807
 0 7 -0.00389 0.02687 14.99 -0.14 0.8868
 0.25 1 -0.3311 0.05262 15 -6.29 <.0001
 0.25 2 -0.2344 0.04315 14.99 -5.43 <.0001
 0.25 3 -0.01444 0.02879 14.99 -0.50 0.6231
 0.25 4 -0.00889 0.02271 15.01 -0.39 0.7010
 0.25 5 0.04617 0.02571 14.98 1.80 0.0927
 0.25 7 0.02611 0.02989 14.99 0.87 0.3961
 1 2 0.09667 0.04329 15 2.23 0.0412
 1 3 0.3167 0.03585 15 8.83 <.0001
 1 4 0.3222 0.04826 15 6.68 <.0001
 1 5 0.3773 0.03869 14.64 9.75 <.0001
 1 7 0.3572 0.04694 15.01 7.61 <.0001
 2 3 0.2200 0.03424 15 6.42 <.0001
 2 4 0.2256 0.04295 15 5.25 <.0001
 2 5 0.2806 0.04057 14.58 6.92 <.0001
 2 7 0.2606 0.03328 15 7.83 <.0001
 3 4 0.005556 0.02668 15 0.21 0.8379
 3 5 0.06062 0.02474 13.96 2.45 0.0281
 3 7 0.04056 0.02474 15.01 1.64 0.1219
 4 5 0.05506 0.02606 15.27 2.11 0.0515
 4 7 0.03500 0.03290 15 1.06 0.3042
 5 7 -0.02006 0.02576 15.22 -0.78 0.4481
1 T cell+ 0 0.25 -0.8367 0.1532 15.01 -5.46 <.0001
 0 1 -4.5689 0.3644 15.02 -12.54 <.0001
 0 2 -4.4339 0.3673 14.99 -12.07 <.0001
 0 3 -2.1406 0.3239 15.06 -6.61 <.0001
 0 4 -1.8533 0.3201 15 -5.79 <.0001
 0 5 -0.9435 0.3376 14.9 -2.79 0.0137
 0 7 0.1183 0.07208 14.99 1.64 0.1215
 0.25 1 -3.7322 0.3499 15.03 -10.67 <.0001
 0.25 2 -3.5972 0.4076 15 -8.82 <.0001
 0.25 3 -1.3039 0.3669 15.05 -3.55 0.0029
 0.25 4 -1.0167 0.3931 14.99 -2.59 0.0207
 0.25 5 -0.1068 0.3426 14.1 -0.31 0.7597
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0.25 7 0.9550 0.1380 15.01 6.92 <.0001
 1 2 0.1350 0.4158 14.96 0.32 0.7499
 1 3 2.4283 0.3846 14.96 6.31 <.0001
 1 4 2.7156 0.4121 14.91 6.59 <.0001
 1 5 3.6254 0.4393 14.11 8.25 <.0001
 1 7 4.6872 0.3188 15.03 14.70 <.0001
 2 3 2.2933 0.3916 14.97 5.86 <.0001
 2 4 2.5806 0.4314 14.86 5.98 <.0001
 2 5 3.4904 0.4971 12.35 7.02 <.0001
 2 7 4.5522 0.3725 14.99 12.22 <.0001
 3 4 0.2872 0.3209 14.95 0.90 0.3849
 3 5 1.1971 0.3880 14.92 3.09 0.0076
 3 7 2.2589 0.3068 15.06 7.36 <.0001
 4 5 0.9098 0.3806 14.09 2.39 0.0313
 4 7 1.9717 0.3341 14.99 5.90 <.0001
 5 7 1.0618 0.3424 14.79 3.10 0.0074
2 T cell+ 0 0.25 -0.2433 0.05426 15.01 -4.48 0.0004
 0 1 -1.4228 0.1082 14.99 -13.14 <.0001
 0 2 -1.3194 0.1143 15.02 -11.54 <.0001
 0 3 -0.6083 0.09285 14.98 -6.55 <.0001
 0 4 -0.4444 0.07202 15.01 -6.17 <.0001
 0 5 -0.2215 0.05426 14.29 -4.08 0.0011
 0 7 0.03722 0.02593 15 1.44 0.1716
 0.25 1 -1.1794 0.09478 14.99 -12.44 <.0001
 0.25 2 -1.0761 0.1232 15.02 -8.73 <.0001
 0.25 3 -0.3650 0.09588 14.97 -3.81 0.0017
 0.25 4 -0.2011 0.1012 15.01 -1.99 0.0655
 0.25 5 0.02185 0.05811 14.9 0.38 0.7122
 0.25 7 0.2806 0.04392 15 6.39 <.0001
 1 2 0.1033 0.1399 15.01 0.74 0.4715
 1 3 0.8144 0.09800 15 8.31 <.0001
 1 4 0.9783 0.1399 15.01 6.99 <.0001
 1 5 1.2013 0.1161 14.77 10.35 <.0001
 1 7 1.4600 0.09836 14.99 14.84 <.0001
 2 3 0.7111 0.1322 15.01 5.38 <.0001
 2 4 0.8750 0.1343 15.01 6.52 <.0001
 2 5 1.0980 0.1301 13.56 8.44 <.0001
 2 7 1.3567 0.1139 15.02 11.92 <.0001
 3 4 0.1639 0.1056 14.99 1.55 0.1415
 3 5 0.3868 0.08625 15.13 4.49 0.0004
 3 7 0.6456 0.08056 14.97 8.01 <.0001
 4 5 0.2230 0.07949 13.71 2.81 0.0143
 4 7 0.4817 0.07988 15.01 6.03 <.0001
 5 7 0.2587 0.04575 14.64 5.66 <.0001
MHCII+ B cell+ 0 0.25 -0.1367 0.03147 14.99 -4.34 0.0006
 0 1 -0.5672 0.05878 14.99 -9.65 <.0001
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 2 -0.8300 0.1225 15.12 -6.77 <.0001
 0 3 -0.2700 0.05053 14.99 -5.34 <.0001
 0 4 -0.3767 0.08272 15.02 -4.55 0.0004
 0 5 -0.3181 0.08252 14.93 -3.85 0.0016
 0 7 -0.2283 0.05846 15 -3.91 0.0014
 0.25 1 -0.4306 0.04945 15 -8.71 <.0001
 0.25 2 -0.6933 0.1289 15.12 -5.38 <.0001
 0.25 3 -0.1333 0.04449 15 -3.00 0.0090
 0.25 4 -0.2400 0.07859 15.04 -3.05 0.0080
 0.25 5 -0.1814 0.07934 15.09 -2.29 0.0371
 0.25 7 -0.09167 0.04968 15 -1.85 0.0849
 1 2 -0.2628 0.1269 15.1 -2.07 0.0560
 1 3 0.2972 0.04608 15 6.45 <.0001
 1 4 0.1906 0.07586 15.03 2.51 0.0239
 1 5 0.2492 0.07274 15.23 3.43 0.0037
 1 7 0.3389 0.06818 15 4.97 0.0002
 2 3 0.5600 0.1304 15.11 4.29 0.0006
 2 4 0.4533 0.1089 15.06 4.16 0.0008
 2 5 0.5119 0.1234 14.63 4.15 0.0009
 2 7 0.6017 0.1423 15.11 4.23 0.0007
 3 4 -0.1067 0.07514 15.04 -1.42 0.1762
 3 5 -0.04806 0.06395 14 -0.75 0.4648
 3 7 0.04167 0.06501 15 0.64 0.5312
 4 5 0.05861 0.06956 14.7 0.84 0.4130
 4 7 0.1483 0.09311 15.04 1.59 0.1319
 5 7 0.08973 0.1111 15.12 0.81 0.4319
Study B 
 
   
MHCII+ 0 0.25 -0.2992 0.1907 9.001 -1.57 0.1512
B cells+ 0 1 -4.4825 0.5134 9 -8.73 <.0001
 0 2 -5.7983 1.6145 9 -3.59 0.0058
 0 3 -11.4775 1.9290 9 -5.95 0.0002
 0 4 -9.1417 1.9239 9 -4.75 0.0010
 0 5 -4.9858 0.6365 9 -7.83 <.0001
 0 7 -2.0308 0.2865 9 -7.09 <.0001
 0.25 1 -4.1833 0.5433 9 -7.70 <.0001
 0.25 2 -5.4992 1.4904 9 -3.69 0.0050
 0.25 3 -11.1783 1.8197 9 -6.14 0.0002
 0.25 4 -8.8425 1.8534 9 -4.77 0.0010
 0.25 5 -4.6867 0.6475 9 -7.24 <.0001
 0.25 7 -1.7317 0.3717 9 -4.66 0.0012
 1 2 -1.3158 1.3321 9 -0.99 0.3491
 1 3 -6.9950 2.0636 9 -3.39 0.0080
 1 4 -4.6592 2.0468 9 -2.28 0.0489
 1 5 -0.5033 0.9610 9 -0.52 0.6131
 1 7 2.4517 0.6297 9 3.89 0.0037
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 2 3 -5.6792 1.8986 9 -2.99 0.0152
 2 4 -3.3433 2.4562 9 -1.36 0.2066
 2 5 0.8125 1.9403 9 0.42 0.6852
 2 7 3.7675 1.6685 9 2.26 0.0503
 3 4 2.3358 2.7256 9 0.86 0.4137
 3 5 6.4917 2.1369 9 3.04 0.0141
 3 7 9.4467 1.8021 9 5.24 0.0005
 4 5 4.1558 1.5915 9 2.61 0.0282
 4 7 7.1108 1.9509 9 3.64 0.0054
 5 7 2.9550 0.6884 9 4.29 0.0020
CD4- CD8+ 0 0.25 -0.6708 0.1766 9 -3.80 0.0042
 0 1 -2.9425 0.5710 9 -5.15 0.0006
 0 2 -3.1525 0.5201 9 -6.06 0.0002
 0 3 -2.9667 0.7971 9 -3.72 0.0048
 0 4 -1.3600 0.2489 9 -5.46 0.0004
 0 5 -0.8683 0.1293 9 -6.71 <.0001
 0 7 -1.0392 0.2511 9 -4.14 0.0025
 0.25 1 -2.2717 0.5673 9 -4.00 0.0031
 0.25 2 -2.4817 0.3811 9 -6.51 0.0001
 0.25 3 -2.2958 0.7639 9 -3.01 0.0148
 0.25 4 -0.6892 0.3239 9 -2.13 0.0622
 0.25 5 -0.1975 0.1888 9 -1.05 0.3229
 0.25 7 -0.3683 0.1957 9 -1.88 0.0925
 1 2 -0.2100 0.8466 9 -0.25 0.8097
 1 3 -0.02417 0.9281 9 -0.03 0.9798
 1 4 1.5825 0.5369 9 2.95 0.0163
 1 5 2.0742 0.4898 9 4.23 0.0022
 1 7 1.9033 0.5816 9 3.27 0.0096
 2 3 0.1858 0.8324 9 0.22 0.8283
 2 4 1.7925 0.6128 9 2.93 0.0169
 2 5 2.2842 0.5396 9 4.23 0.0022
 2 7 2.1133 0.4111 9 5.14 0.0006
 3 4 1.6067 0.8221 9 1.95 0.0824
 3 5 2.0983 0.7402 9 2.84 0.0196
 3 7 1.9275 0.7207 9 2.67 0.0254
 4 5 0.4917 0.2356 9 2.09 0.0665
 4 7 0.3208 0.3168 9 1.01 0.3376
 5 7 -0.1708 0.2762 9 -0.62 0.5516
CD4+ CD8- 0 0.25 -1.7933 0.6322 9 -2.84 0.0195
 0 1 -7.5408 0.6470 9 -11.66 <.0001
 0 2 -7.6783 0.7985 9 -9.62 <.0001
 0 3 -6.3408 0.7174 9 -8.84 <.0001
 0 4 -4.6775 0.7850 9 -5.96 0.0002
 0 5 -2.7983 0.6666 9 -4.20 0.0023
 0 7 -2.4342 0.6039 9 -4.03 0.0030
 0.25 1 -5.7475 0.8723 9 -6.59 0.0001
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0.25 2 -5.8850 0.5992 9 -9.82 <.0001
 0.25 3 -4.5475 0.6260 9 -7.26 <.0001
 0.25 4 -2.8842 0.9452 9 -3.05 0.0138
 0.25 5 -1.0050 0.8681 9 -1.16 0.2768
 0.25 7 -0.6408 0.4035 9 -1.59 0.1467
 1 2 -0.1375 1.2408 9 -0.11 0.9142
 1 3 1.2000 0.9022 9 1.33 0.2162
 1 4 2.8633 1.1274 9 2.54 0.0317
 1 5 4.7425 0.7891 9 6.01 0.0002
 1 7 5.1067 0.8430 9 6.06 0.0002
 2 3 1.3375 0.9324 9 1.43 0.1852
 2 4 3.0008 0.9975 9 3.01 0.0148
 2 5 4.8800 1.0444 9 4.67 0.0012
 2 7 5.2442 0.7709 9 6.80 <.0001
 3 4 1.6633 1.0952 9 1.52 0.1631
 3 5 3.5425 0.9797 9 3.62 0.0056
 3 7 3.9067 0.5859 9 6.67 <.0001
 4 5 1.8792 0.5768 9 3.26 0.0099
 4 7 2.2433 0.8475 9 2.65 0.0266
 5 7 0.3642 0.9088 9 0.40 0.6980
 T cell+ CD8- 0 0.25 -3.9350 1.4936 9 -2.63 0.0272
 0 1 -5.1767 0.8841 9 -5.86 0.0002
 0 2 -1.3850 0.3048 9 -4.54 0.0014
 0 3 -1.5017 0.4940 9 -3.04 0.0140
 0 4 -0.9675 0.2206 9 -4.39 0.0018
 0 5 -0.6208 0.1737 9 -3.57 0.0060
 0 7 -0.6175 0.2466 9 -2.50 0.0336
 0.25 1 -1.2417 1.8891 9 -0.66 0.5275
 0.25 2 2.5500 1.4446 9 1.77 0.1113
 0.25 3 2.4333 1.3440 9 1.81 0.1037
 0.25 4 2.9675 1.3977 9 2.12 0.0627
 0.25 5 3.3142 1.3907 9 2.38 0.0410
 0.25 7 3.3175 1.4686 9 2.26 0.0503
 1 2 3.7917 1.0520 9 3.60 0.0057
 1 3 3.6750 1.2476 9 2.95 0.0163
 1 4 4.2092 0.8817 9 4.77 0.0010
 1 5 4.5558 0.8295 9 5.49 0.0004
 1 7 4.5592 0.9854 9 4.63 0.0012
 2 3 -0.1167 0.2917 9 -0.40 0.6986
 2 4 0.4175 0.2623 9 1.59 0.1459
 2 5 0.7642 0.3064 9 2.49 0.0342
 2 7 0.7675 0.3205 9 2.39 0.0402
 3 4 0.5342 0.4394 9 1.22 0.2550
 3 5 0.8808 0.4835 9 1.82 0.1018
 3 7 0.8842 0.4347 9 2.03 0.0725
 4 5 0.3467 0.1324 9 2.62 0.0279
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 4 7 0.3500 0.3045 9 1.15 0.2800
 5 7 0.003333 0.3063 9 0.01 0.9916
 T cell+ 0 0.25 -1.7450 0.6045 9 -2.89 0.0180
 0 1 -8.4300 1.1364 9 -7.42 <.0001
 0 2 -7.9742 0.7253 9 -10.99 <.0001
 0 3 -5.1258 0.7627 9 -6.72 <.0001
 0 4 -4.4108 0.9482 9 -4.65 0.0012
 0 5 -2.9692 0.9514 9 -3.12 0.0123
 0 7 -2.4008 0.7093 9 -3.38 0.0081
 0.25 1 -6.6850 1.1314 9 -5.91 0.0002
 0.25 2 -6.2292 0.5551 9 -11.22 <.0001
 0.25 3 -3.3808 0.4340 9 -7.79 <.0001
 0.25 4 -2.6658 1.0733 9 -2.48 0.0348
 0.25 5 -1.2242 0.9808 9 -1.25 0.2435
 0.25 7 -0.6558 0.5527 9 -1.19 0.2658
 1 2 0.4558 1.4897 9 0.31 0.7666
 1 3 3.3042 1.1156 9 2.96 0.0159
 1 4 4.0192 1.2477 9 3.22 0.0105
 1 5 5.4608 0.9096 9 6.00 0.0002
 1 7 6.0292 1.1808 9 5.11 0.0006
 2 3 2.8483 0.7667 9 3.72 0.0048
 2 4 3.5633 1.1779 9 3.03 0.0144
 2 5 5.0050 1.1431 9 4.38 0.0018
 2 7 5.5733 0.7542 9 7.39 <.0001
 3 4 0.7150 1.1953 9 0.60 0.5645
 3 5 2.1567 1.1242 9 1.92 0.0873
 3 7 2.7250 0.5099 9 5.34 0.0005
 4 5 1.4417 0.7233 9 1.99 0.0774
 4 7 2.0100 1.0752 9 1.87 0.0944
 5 7 0.5683 1.2203 9 0.47 0.6525
 T cell+  0 0.25 -0.7025 0.1351 9 -5.20 0.0006
CD4- CD8+ 0 1 -2.1100 0.4115 9 -5.13 0.0006
 0 2 -2.1800 0.3079 9 -7.08 <.0001
 0 3 -1.3058 0.2409 9 -5.42 0.0004
 0 4 -0.7467 0.2038 9 -3.66 0.0052
 0 5 -0.9133 0.1952 9 -4.68 0.0012
 0 7 -0.9708 0.2317 9 -4.19 0.0023
 0.25 1 -1.4075 0.3472 9 -4.05 0.0029
 0.25 2 -1.4775 0.2799 9 -5.28 0.0005
 0.25 3 -0.6033 0.1861 9 -3.24 0.0101
 0.25 4 -0.04417 0.2150 9 -0.21 0.8418
 0.25 5 -0.2108 0.1573 9 -1.34 0.2131
 0.25 7 -0.2683 0.1746 9 -1.54 0.1586
 1 2 -0.07000 0.5098 9 -0.14 0.8938
 1 3 0.8042 0.2601 9 3.09 0.0129
 1 4 1.3633 0.3122 9 4.37 0.0018
296 
 
 
 
Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 1 5 1.1967 0.2657 9 4.50 0.0015
 1 7 1.1392 0.3899 9 2.92 0.0170
 2 3 0.8742 0.3556 9 2.46 0.0363
 2 4 1.4333 0.3590 9 3.99 0.0031
 2 5 1.2667 0.3116 9 4.06 0.0028
 2 7 1.2092 0.2449 9 4.94 0.0008
 3 4 0.5592 0.1863 9 3.00 0.0149
 3 5 0.3925 0.2080 9 1.89 0.0917
 3 7 0.3350 0.2044 9 1.64 0.1356
 4 5 -0.1667 0.1938 9 -0.86 0.4121
 4 7 -0.2242 0.2534 9 -0.88 0.3994
 5 7 -0.05750 0.2679 9 -0.21 0.8348
 T cell+  0 0.25 -0.2025 0.05549 9 -3.65 0.0053
CD4- CD8- 0 1 -0.2350 0.03540 9 -6.64 <.0001
 0 2 -0.1958 0.02725 9 -7.19 <.0001
 0 3 -0.7692 0.1093 9 -7.04 <.0001
 0 4 -0.2167 0.04111 9 -5.27 0.0005
 0 5 -0.2417 0.03201 9 -7.55 <.0001
 0 7 -0.2617 0.04010 9 -6.53 0.0001
 0.25 1 -0.03250 0.05655 9 -0.57 0.5796
 0.25 2 0.006667 0.06381 9 0.10 0.9191
 0.25 3 -0.5667 0.1009 9 -5.61 0.0003
 0.25 4 -0.01417 0.06130 9 -0.23 0.8224
 0.25 5 -0.03917 0.07465 9 -0.52 0.6125
 0.25 7 -0.05917 0.05704 9 -1.04 0.3267
 1 2 0.03917 0.03194 9 1.23 0.2512
 1 3 -0.5342 0.1012 9 -5.28 0.0005
 1 4 0.01833 0.05172 9 0.35 0.7311
 1 5 -0.00667 0.04743 9 -0.14 0.8913
 1 7 -0.02667 0.05743 9 -0.46 0.6534
 2 3 -0.5733 0.1050 9 -5.46 0.0004
 2 4 -0.02083 0.04972 9 -0.42 0.6851
 2 5 -0.04583 0.04254 9 -1.08 0.3093
 2 7 -0.06583 0.03978 9 -1.66 0.1323
 3 4 0.5525 0.1296 9 4.26 0.0021
 3 5 0.5275 0.1185 9 4.45 0.0016
 3 7 0.5075 0.1195 9 4.25 0.0022
 4 5 -0.02500 0.04377 9 -0.57 0.5819
 4 7 -0.04500 0.04927 9 -0.91 0.3849
 5 7 -0.02000 0.06447 9 -0.31 0.7634
 T cell+  0 0.25 -1.4717 0.4902 9 -3.00 0.0149
CD4+ CD8- 0 1 -6.1867 0.5954 9 -10.39 <.0001
 0 2 -6.0600 0.5668 9 -10.69 <.0001
 0 3 -3.6233 0.5056 9 -7.17 <.0001
 0 4 -3.9642 0.6801 9 -5.83 0.0003
 0 5 -2.3542 0.6434 9 -3.66 0.0052
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 7 -1.7758 0.4450 9 -3.99 0.0032
 0.25 1 -4.7150 0.7969 9 -5.92 0.0002
 0.25 2 -4.5883 0.4150 9 -11.06 <.0001
 0.25 3 -2.1517 0.3514 9 -6.12 0.0002
 0.25 4 -2.4925 0.7667 9 -3.25 0.0100
 0.25 5 -0.8825 0.7196 9 -1.23 0.2512
 0.25 7 -0.3042 0.3485 9 -0.87 0.4055
 1 2 0.1267 0.9778 9 0.13 0.8998
 1 3 2.5633 0.7877 9 3.25 0.0099
 1 4 2.2225 0.9775 9 2.27 0.0491
 1 5 3.8325 0.6581 9 5.82 0.0003
 1 7 4.4108 0.7515 9 5.87 0.0002
 2 3 2.4367 0.5348 9 4.56 0.0014
 2 4 2.0958 0.8046 9 2.60 0.0285
 2 5 3.7058 0.8148 9 4.55 0.0014
 2 7 4.2842 0.5434 9 7.88 <.0001
 3 4 -0.3408 0.9042 9 -0.38 0.7150
 3 5 1.2692 0.8626 9 1.47 0.1753
 3 7 1.8475 0.3200 9 5.77 0.0003
 4 5 1.6100 0.5340 9 3.02 0.0146
 4 7 2.1883 0.7857 9 2.79 0.0212
 5 7 0.5783 0.8115 9 0.71 0.4941
 T cell+ 0 0.25 -1.0900 0.2399 9 -4.54 0.0014
 0 1 -3.6292 0.4540 9 -7.99 <.0001
 0 2 -2.6858 0.2904 9 -9.25 <.0001
 0 3 -1.9542 0.2872 9 -6.81 <.0001
 0 4 -2.3275 0.4881 9 -4.77 0.0010
 0 5 -0.7283 0.2756 9 -2.64 0.0268
 0 7 -0.8342 0.2642 9 -3.16 0.0116
 0.25 1 -2.5392 0.3695 9 -6.87 <.0001
 0.25 2 -1.5958 0.3264 9 -4.89 0.0009
 0.25 3 -0.8642 0.1935 9 -4.47 0.0016
 0.25 4 -1.2375 0.5346 9 -2.31 0.0459
 0.25 5 0.3617 0.3571 9 1.01 0.3376
 0.25 7 0.2558 0.2374 9 1.08 0.3093
 1 2 0.9433 0.5954 9 1.58 0.1476
 1 3 1.6750 0.4114 9 4.07 0.0028
 1 4 1.3017 0.6500 9 2.00 0.0763
 1 5 2.9008 0.4525 9 6.41 0.0001
 1 7 2.7950 0.4581 9 6.10 0.0002
 2 3 0.7317 0.2555 9 2.86 0.0187
 2 4 0.3583 0.5225 9 0.69 0.5101
 2 5 1.9575 0.4099 9 4.78 0.0010
 2 7 1.8517 0.3106 9 5.96 0.0002
 3 4 -0.3733 0.5875 9 -0.64 0.5409
 3 5 1.2258 0.4302 9 2.85 0.0191
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 3 7 1.1200 0.2535 9 4.42 0.0017
 4 5 1.5992 0.4240 9 3.77 0.0044
 4 7 1.4933 0.4618 9 3.23 0.0103
 5 7 -0.1058 0.4235 9 -0.25 0.8083
 T cell+ 0 0.25 -0.5583 0.09746 9 -5.73 0.0003
CD4- CD8+ 0 1 -1.2775 0.2046 9 -6.24 0.0002
 0 2 -0.8025 0.1276 9 -6.29 0.0001
 0 3 -0.4583 0.1021 9 -4.49 0.0015
 0 4 -0.8058 0.1503 9 -5.36 0.0005
 0 5 -0.2042 0.06874 9 -2.97 0.0157
 0 7 -0.2633 0.07356 9 -3.58 0.0059
 0.25 1 -0.7192 0.1637 9 -4.39 0.0017
 0.25 2 -0.2442 0.1499 9 -1.63 0.1378
 0.25 3 0.1000 0.05504 9 1.82 0.1026
 0.25 4 -0.2475 0.1753 9 -1.41 0.1916
 0.25 5 0.3542 0.1055 9 3.36 0.0084
 0.25 7 0.2950 0.09658 9 3.05 0.0137
 1 2 0.4750 0.2354 9 2.02 0.0744
 1 3 0.8192 0.1467 9 5.58 0.0003
 1 4 0.4717 0.2067 9 2.28 0.0484
 1 5 1.0733 0.1759 9 6.10 0.0002
 1 7 1.0142 0.1945 9 5.21 0.0006
 2 3 0.3442 0.1206 9 2.85 0.0190
 2 4 -0.00333 0.1966 9 -0.02 0.9868
 2 5 0.5983 0.1393 9 4.29 0.0020
 2 7 0.5392 0.1169 9 4.61 0.0013
 3 4 -0.3475 0.1823 9 -1.91 0.0890
 3 5 0.2542 0.09974 9 2.55 0.0313
 3 7 0.1950 0.09615 9 2.03 0.0731
 4 5 0.6017 0.1381 9 4.36 0.0018
 4 7 0.5425 0.1686 9 3.22 0.0105
 5 7 -0.05917 0.1203 9 -0.49 0.6347
 T cell+ 0 0.25 -0.5742 0.1686 9 -3.41 0.0078
CD4+ CD8- 0 1 -2.2208 0.1819 9 -12.21 <.0001
 0 2 -1.9942 0.2216 9 -9.00 <.0001
 0 3 -1.5850 0.1964 9 -8.07 <.0001
 0 4 -1.6117 0.3718 9 -4.34 0.0019
 0 5 -0.6550 0.1762 9 -3.72 0.0048
 0 7 -0.6442 0.1752 9 -3.68 0.0051
 0.25 1 -1.6467 0.2888 9 -5.70 0.0003
 0.25 2 -1.4200 0.1899 9 -7.48 <.0001
 0.25 3 -1.0108 0.1535 9 -6.59 0.0001
 0.25 4 -1.0375 0.3546 9 -2.93 0.0169
 0.25 5 -0.08083 0.1981 9 -0.41 0.6927
 0.25 7 -0.07000 0.1050 9 -0.67 0.5217
 1 2 0.2267 0.3697 9 0.61 0.5550
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 1 3 0.6358 0.2713 9 2.34 0.0438
 1 4 0.6092 0.4731 9 1.29 0.2300
 1 5 1.5658 0.2502 9 6.26 0.0001
 1 7 1.5767 0.2756 9 5.72 0.0003
 2 3 0.4092 0.1851 9 2.21 0.0544
 2 4 0.3825 0.3328 9 1.15 0.2801
 2 5 1.3392 0.2568 9 5.22 0.0006
 2 7 1.3500 0.2096 9 6.44 0.0001
 3 4 -0.02667 0.3986 9 -0.07 0.9481
 3 5 0.9300 0.2651 9 3.51 0.0066
 3 7 0.9408 0.1555 9 6.05 0.0002
 4 5 0.9567 0.2908 9 3.29 0.0094
 4 7 0.9675 0.3157 9 3.06 0.0135
 5 7 0.01083 0.2182 9 0.05 0.9615
B cell+ IgM+ 0 0.25 -0.2642 0.1690 9 -1.56 0.1524
 0 1 -3.4100 0.4113 9 -8.29 <.0001
 0 2 -7.9050 1.2724 9 -6.21 0.0002
 0 3 -10.8850 1.6984 9 -6.41 0.0001
 0 4 -9.2183 1.5669 9 -5.88 0.0002
 0 5 -4.4900 0.6490 9 -6.92 <.0001
 0 7 -1.4058 0.2225 9 -6.32 0.0001
 0.25 1 -3.1458 0.4436 9 -7.09 <.0001
 0.25 2 -7.6408 1.1640 9 -6.56 0.0001
 0.25 3 -10.6208 1.6066 9 -6.61 <.0001
 0.25 4 -8.9542 1.5273 9 -5.86 0.0002
 0.25 5 -4.2258 0.6674 9 -6.33 0.0001
 0.25 7 -1.1417 0.3105 9 -3.68 0.0051
 1 2 -4.4950 1.3293 9 -3.38 0.0081
 1 3 -7.4750 1.8021 9 -4.15 0.0025
 1 4 -5.8083 1.6705 9 -3.48 0.0070
 1 5 -1.0800 0.8398 9 -1.29 0.2305
 1 7 2.0042 0.4996 9 4.01 0.0031
 2 3 -2.9800 1.0670 9 -2.79 0.0210
 2 4 -1.3133 1.5889 9 -0.83 0.4298
 2 5 3.4150 1.4429 9 2.37 0.0421
 2 7 6.4992 1.2677 9 5.13 0.0006
 3 4 1.6667 2.0763 9 0.80 0.4428
 3 5 6.3950 1.9231 9 3.33 0.0089
 3 7 9.4792 1.6121 9 5.88 0.0002
 4 5 4.7283 1.1183 9 4.23 0.0022
 4 7 7.8125 1.5429 9 5.06 0.0007
 5 7 3.0842 0.6328 9 4.87 0.0009
B cell+ IgM- 0 0.25 -0.1142 0.04209 9.001 -2.71 0.0239
 0 1 -0.9008 0.1175 9 -7.67 <.0001
 0 2 -1.9092 0.3959 9 -4.82 0.0009
 0 3 -1.5283 0.2654 9 -5.76 0.0003
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Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 4 -1.6067 0.2578 9 -6.23 0.0002
 0 5 -1.2367 0.1722 9 -7.18 <.0001
 0 7 -0.4733 0.09084 9 -5.21 0.0006
 0.25 1 -0.7867 0.1246 9 -6.31 0.0001
 0.25 2 -1.7950 0.3721 9 -4.82 0.0009
 0.25 3 -1.4142 0.2340 9 -6.04 0.0002
 0.25 4 -1.4925 0.2521 9 -5.92 0.0002
 0.25 5 -1.1225 0.1843 9 -6.09 0.0002
 0.25 7 -0.3592 0.1111 9 -3.23 0.0103
 1 2 -1.0083 0.3756 9 -2.68 0.0250
 1 3 -0.6275 0.2803 9 -2.24 0.0520
 1 4 -0.7058 0.2672 9 -2.64 0.0268
 1 5 -0.3358 0.1905 9 -1.76 0.1118
 1 7 0.4275 0.1623 9 2.63 0.0272
 2 3 0.3808 0.2105 9 1.81 0.1038
 2 4 0.3025 0.2976 9 1.02 0.3359
 2 5 0.6725 0.4692 9 1.43 0.1856
 2 7 1.4358 0.4354 9 3.30 0.0093
 3 4 -0.07833 0.3080 9 -0.25 0.8049
 3 5 0.2917 0.3632 9 0.80 0.4426
 3 7 1.0550 0.2998 9 3.52 0.0065
 4 5 0.3700 0.3116 9 1.19 0.2654
 4 7 1.1333 0.2875 9 3.94 0.0034
 5 7 0.7633 0.2026 9 3.77 0.0044
CD3+ 0 0.25 -5.2133 1.6677 9 -3.13 0.0122
 0 1 -15.7692 2.0218 9 -7.80 <.0001
 0 2 -12.3567 1.2383 9 -9.98 <.0001
 0 3 -11.5425 1.4058 9 -8.21 <.0001
 0 4 -7.7417 1.2744 9 -6.07 0.0002
 0 5 -4.6483 1.1255 9 -4.13 0.0026
 0 7 -4.1300 1.0407 9 -3.97 0.0033
 0.25 1 -10.5558 2.1289 9 -4.96 0.0008
 0.25 2 -7.1433 1.9560 9 -3.65 0.0053
 0.25 3 -6.3292 1.8547 9 -3.41 0.0077
 0.25 4 -2.5283 1.6907 9 -1.50 0.1690
 0.25 5 0.5650 1.3036 9 0.43 0.6749
 0.25 7 1.0833 1.4435 9 0.75 0.4721
 1 2 3.4125 2.9749 9 1.15 0.2809
 1 3 4.2267 2.7260 9 1.55 0.1554
 1 4 8.0275 2.1216 9 3.78 0.0043
 1 5 11.1208 1.6000 9 6.95 <.0001
 1 7 11.6392 2.4501 9 4.75 0.0010
 2 3 0.8142 1.3886 9 0.59 0.5721
 2 4 4.6150 1.7868 9 2.58 0.0296
 2 5 7.7083 1.6692 9 4.62 0.0013
 2 7 8.2267 1.2047 9 6.83 <.0001
301 
 
 
 
Table H1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 3 4 3.8008 2.0504 9 1.85 0.0968
 3 5 6.8942 1.8338 9 3.76 0.0045
 3 7 7.4125 1.2176 9 6.09 0.0002
 4 5 3.0933 1.0253 9 3.02 0.0146
 4 7 3.6117 1.5700 9 2.30 0.0470
 5 7 0.5183 1.5981 9 0.32 0.7531
 
 
Table H2. Difference of least squares means for pulp cell responses by treatment 
Study/Factor Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
Study A 
 
       
 T cell+ CD8+ ALUmIgG IOmIgG -0.08752 0.03281 14.95 -2.67 0.0176
 ALUmIgG mIgG -0.02773 0.03281 14.95 -0.85 0.4113
 IOmIgG mIgG 0.05979 0.03276 14.9 1.83 0.0881
Study B 
 
       
B cell+ IgM- AlummIgG IOmIgG -0.2609 0.2518 9 -1.04 0.3271
 AlummIgG mIgG -0.7419 0.2518 9 -2.95 0.0163
 IOmIgG mIgG -0.4809 0.2518 9 -1.91 0.0885
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Table H3. Simple effect comparisons of treatment*day least squares means by treatment for B 
cells, Study A 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 0 0.25 -0.2567 0.09742 15.04 -2.63 0.0187
Alum-mIgG 0 1 -2.5717 0.4586 14.96 -5.61 <.0001
Alum-mIgG 0 2 -2.1750 0.9113 15.03 -2.39 0.0306
Alum-mIgG 0 3 -1.6200 0.8019 15 -2.02 0.0616
Alum-mIgG 0 4 -0.9267 0.5831 14.89 -1.59 0.1330
Alum-mIgG 0 5 -0.4919 0.2118 15.19 -2.32 0.0345
Alum-mIgG 0 7 -0.09000 0.2619 14.98 -0.34 0.7359
Alum-mIgG 0.25 1 -2.3150 0.3937 14.95 -5.88 <.0001
Alum-mIgG 0.25 2 -1.9183 0.8754 15.01 -2.19 0.0446
Alum-mIgG 0.25 3 -1.3633 0.8007 15.01 -1.70 0.1092
Alum-mIgG 0.25 4 -0.6700 0.6215 14.91 -1.08 0.2981
Alum-mIgG 0.25 5 -0.2352 0.1984 14.41 -1.19 0.2549
Alum-mIgG 0.25 7 0.1667 0.2758 15.01 0.60 0.5546
Alum-mIgG 1 2 0.3967 0.9900 14.9 0.40 0.6944
Alum-mIgG 1 3 0.9517 1.0122 15 0.94 0.3620
Alum-mIgG 1 4 1.6450 0.7257 14.98 2.27 0.0387
Alum-mIgG 1 5 2.0798 0.3830 15.28 5.43 <.0001
Alum-mIgG 1 7 2.4817 0.5307 14.96 4.68 0.0003
Alum-mIgG 2 3 0.5550 1.0431 15.06 0.53 0.6024
Alum-mIgG 2 4 1.2483 1.3803 14.94 0.90 0.3801
Alum-mIgG 2 5 1.6831 0.9335 15 1.80 0.0915
Alum-mIgG 2 7 2.0850 0.8393 15.1 2.48 0.0252
Alum-mIgG 3 4 0.6933 1.0183 14.96 0.68 0.5064
Alum-mIgG 3 5 1.1281 0.8774 15.07 1.29 0.2179
Alum-mIgG 3 7 1.5300 0.6869 15.01 2.23 0.0416
Alum-mIgG 4 5 0.4348 0.5297 15.12 0.82 0.4245
Alum-mIgG 4 7 0.8367 0.7249 14.89 1.15 0.2666
Alum-mIgG 5 7 0.4019 0.3780 15.35 1.06 0.3042
IO-mIgG 0 0.25 -0.2800 0.09742 15.04 -2.87 0.0116
IO-mIgG 0 1 -3.1783 0.4586 14.96 -6.93 <.0001
IO-mIgG 0 2 -7.3800 0.9113 15.03 -8.10 <.0001
IO-mIgG 0 3 -3.6748 0.8019 15 -4.58 0.0004
IO-mIgG 0 4 -2.4533 0.5831 14.89 -4.21 0.0008
IO-mIgG 0 5 -0.7700 0.2025 14.21 -3.80 0.0019
IO-mIgG 0 7 -0.3533 0.2619 14.98 -1.35 0.1974
IO-mIgG 0.25 1 -2.8983 0.3937 14.95 -7.36 <.0001
IO-mIgG 0.25 2 -7.1000 0.8754 15.01 -8.11 <.0001
IO-mIgG 0.25 3 -3.3948 0.8007 15.01 -4.24 0.0007
IO-mIgG 0.25 4 -2.1733 0.6215 14.91 -3.50 0.0033
IO-mIgG 0.25 5 -0.4900 0.1884 13.37 -2.60 0.0216
IO-mIgG 0.25 7 -0.07333 0.2758 15.01 -0.27 0.7939
IO-mIgG 1 2 -4.2017 0.9900 14.9 -4.24 0.0007
IO-mIgG 1 3 -0.4965 1.0122 15 -0.49 0.6309
IO-mIgG 1 4 0.7250 0.7257 14.98 1.00 0.3337
IO-mIgG 1 5 2.4083 0.3779 14.92 6.37 <.0001
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Table H3. Simple effect comparisons of treatment*day least squares means by 
treatment for B cells, Study A (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
IO-mIgG 1 7 2.8250 0.5307 14.96 5.32 <.0001
IO-mIgG 2 3 3.7052 1.0431 15.06 3.55 0.0029
IO-mIgG 2 4 4.9267 1.3803 14.94 3.57 0.0028
IO-mIgG 2 5 6.6100 0.9315 14.94 7.10 <.0001
IO-mIgG 2 7 7.0267 0.8393 15.1 8.37 <.0001
IO-mIgG 3 4 1.2215 1.0183 14.96 1.20 0.2490
IO-mIgG 3 5 2.9048 0.8752 15 3.32 0.0047
IO-mIgG 3 7 3.3215 0.6869 15.01 4.84 0.0002
IO-mIgG 4 5 1.6833 0.5261 14.92 3.20 0.0060
IO-mIgG 4 7 2.1000 0.7249 14.89 2.90 0.0111
IO-mIgG 5 7 0.4167 0.3729 14.97 1.12 0.2814
mIgG 0 0.25 0.006667 0.09742 15.04 0.07 0.9463
mIgG 0 1 -2.1017 0.4586 14.96 -4.58 0.0004
mIgG 0 2 -2.8317 0.9113 15.03 -3.11 0.0072
mIgG 0 3 -1.3650 0.8019 15 -1.70 0.1093
mIgG 0 4 -1.1567 0.5831 14.89 -1.98 0.0660
mIgG 0 5 -0.6433 0.2025 14.21 -3.18 0.0066
mIgG 0 7 0.005000 0.2619 14.98 0.02 0.9850
mIgG 0.25 1 -2.1083 0.3937 14.95 -5.36 <.0001
mIgG 0.25 2 -2.8383 0.8754 15.01 -3.24 0.0055
mIgG 0.25 3 -1.3717 0.8007 15.01 -1.71 0.1073
mIgG 0.25 4 -1.1633 0.6215 14.91 -1.87 0.0810
mIgG 0.25 5 -0.6500 0.1884 13.37 -3.45 0.0041
mIgG 0.25 7 -0.00167 0.2758 15.01 -0.01 0.9953
mIgG 1 2 -0.7300 0.9900 14.9 -0.74 0.4724
mIgG 1 3 0.7367 1.0122 15 0.73 0.4780
mIgG 1 4 0.9450 0.7257 14.98 1.30 0.2125
mIgG 1 5 1.4583 0.3779 14.92 3.86 0.0016
mIgG 1 7 2.1067 0.5307 14.96 3.97 0.0012
mIgG 2 3 1.4667 1.0431 15.06 1.41 0.1800
mIgG 2 4 1.6750 1.3803 14.94 1.21 0.2438
mIgG 2 5 2.1883 0.9315 14.94 2.35 0.0330
mIgG 2 7 2.8367 0.8393 15.1 3.38 0.0041
mIgG 3 4 0.2083 1.0183 14.96 0.20 0.8407
mIgG 3 5 0.7217 0.8752 15 0.82 0.4225
mIgG 3 7 1.3700 0.6869 15.01 1.99 0.0646
mIgG 4 5 0.5133 0.5261 14.92 0.98 0.3447
mIgG 4 7 1.1617 0.7249 14.89 1.60 0.1300
mIgG 5 7 0.6483 0.3729 14.97 1.74 0.1026
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Table H4. Simple effect comparisons of treatment*day least squares means by day for, B cells, 
Study A 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 ALUmIgG IOmIgG -0.04333 0.06154 15.01 -0.70 0.4921
day 0 ALUmIgG mIgG -0.08667 0.06154 15.01 -1.41 0.1794
day 0 IOmIgG mIgG -0.04333 0.06154 15.01 -0.70 0.4921
day 0.25 ALUmIgG IOmIgG -0.06667 0.1450 15.07 -0.46 0.6523
day 0.25 ALUmIgG mIgG 0.1767 0.1450 15.07 1.22 0.2419
day 0.25 IOmIgG mIgG 0.2433 0.1450 15.07 1.68 0.1140
day 1 ALUmIgG IOmIgG -0.6500 0.6419 14.97 -1.01 0.3273
day 1 ALUmIgG mIgG 0.3833 0.6419 14.97 0.60 0.5593
day 1 IOmIgG mIgG 1.0333 0.6419 14.97 1.61 0.1283
day 2 ALUmIgG IOmIgG -5.2483 1.2909 15.04 -4.07 0.0010
day 2 ALUmIgG mIgG -0.7433 1.2909 15.04 -0.58 0.5732
day 2 IOmIgG mIgG 4.5050 1.2909 15.04 3.49 0.0033
day 3 ALUmIgG IOmIgG -2.0982 1.1271 15 -1.86 0.0824
day 3 ALUmIgG mIgG 0.1683 1.1271 15 0.15 0.8833
day 3 IOmIgG mIgG 2.2665 1.1271 15 2.01 0.0627
day 4 ALUmIgG IOmIgG -1.5700 0.8185 14.89 -1.92 0.0745
day 4 ALUmIgG mIgG -0.3167 0.8185 14.89 -0.39 0.7043
day 4 IOmIgG mIgG 1.2533 0.8185 14.89 1.53 0.1467
day 5 ALUmIgG IOmIgG -0.3215 0.2999 14.91 -1.07 0.3009
day 5 ALUmIgG mIgG -0.2381 0.2999 14.91 -0.79 0.4397
day 5 IOmIgG mIgG 0.08333 0.2934 14.43 0.28 0.7805
day 7 ALUmIgG IOmIgG -0.3067 0.3531 14.97 -0.87 0.3988
day 7 ALUmIgG mIgG 0.008333 0.3531 14.97 0.02 0.9815
day 7 IOmIgG mIgG 0.3150 0.3531 14.97 0.89 0.3864
 
 
Table H5. Simple effect comparisons of treatment*day least squares means by treatment for 
CD4+ CD8-, Study A 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 0 0.25 -0.3167 0.2957 14.98 -1.07 0.3012
Alum-mIgG 0 1 -5.1200 0.7280 15.19 -7.03 <.0001
Alum-mIgG 0 2 -4.3800 0.8176 15.06 -5.36 <.0001
Alum-mIgG 0 3 -2.5767 0.6334 15 -4.07 0.0010
Alum-mIgG 0 4 -2.4083 0.6886 15.07 -3.50 0.0032
Alum-mIgG 0 5 -0.7241 0.3722 15.45 -1.95 0.0701
Alum-mIgG 0 7 -0.2700 0.2124 14.99 -1.27 0.2231
Alum-mIgG 0.25 1 -4.8033 0.6483 15.19 -7.41 <.0001
Alum-mIgG 0.25 2 -4.0633 0.7624 15.05 -5.33 <.0001
Alum-mIgG 0.25 3 -2.2600 0.5914 14.98 -3.82 0.0017
Alum-mIgG 0.25 4 -2.0917 0.8409 15.01 -2.49 0.0251
Alum-mIgG 0.25 5 -0.4074 0.4682 15.59 -0.87 0.3974
Alum-mIgG 0.25 7 0.04667 0.1984 14.91 0.24 0.8173
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Table H5. Simple effect comparisons of treatment*day least squares means by 
treatment for CD4+ CD8-, Study A (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 1 2 0.7400 0.8240 14.83 0.90 0.3835
Alum-mIgG 1 3 2.5433 0.7240 14.98 3.51 0.0031
Alum-mIgG 1 4 2.7117 0.8501 14.94 3.19 0.0061
Alum-mIgG 1 5 4.3959 0.5693 15.37 7.72 <.0001
Alum-mIgG 1 7 4.8500 0.6457 15.2 7.51 <.0001
Alum-mIgG 2 3 1.8033 0.8289 14.95 2.18 0.0460
Alum-mIgG 2 4 1.9717 0.8994 14.9 2.19 0.0447
Alum-mIgG 2 5 3.6559 0.7858 14.34 4.65 0.0004
Alum-mIgG 2 7 4.1100 0.8128 15.02 5.06 0.0001
Alum-mIgG 3 4 0.1683 0.7366 14.95 0.23 0.8223
Alum-mIgG 3 5 1.8526 0.6128 15.39 3.02 0.0084
Alum-mIgG 3 7 2.3067 0.6257 14.96 3.69 0.0022
Alum-mIgG 4 5 1.6843 0.6777 15.21 2.49 0.0250
Alum-mIgG 4 7 2.1383 0.7201 15.04 2.97 0.0095
Alum-mIgG 5 7 0.4541 0.3966 15.56 1.15 0.2695
IO-mIgG 0 0.25 -0.6100 0.2957 14.98 -2.06 0.0569
IO-mIgG 0 1 -6.4450 0.7280 15.19 -8.85 <.0001
IO-mIgG 0 2 -6.1050 0.8176 15.06 -7.47 <.0001
IO-mIgG 0 3 -3.1467 0.6334 15 -4.97 0.0002
IO-mIgG 0 4 -2.6733 0.6886 15.07 -3.88 0.0015
IO-mIgG 0 5 -1.0533 0.3546 14.42 -2.97 0.0099
IO-mIgG 0 7 -0.01000 0.2124 14.99 -0.05 0.9631
IO-mIgG 0.25 1 -5.8350 0.6483 15.19 -9.00 <.0001
IO-mIgG 0.25 2 -5.4950 0.7624 15.05 -7.21 <.0001
IO-mIgG 0.25 3 -2.5367 0.5914 14.98 -4.29 0.0006
IO-mIgG 0.25 4 -2.0633 0.8409 15.01 -2.45 0.0268
IO-mIgG 0.25 5 -0.4433 0.4543 14.84 -0.98 0.3448
IO-mIgG 0.25 7 0.6000 0.1984 14.91 3.02 0.0086
IO-mIgG 1 2 0.3400 0.8240 14.83 0.41 0.6858
IO-mIgG 1 3 3.2983 0.7240 14.98 4.56 0.0004
IO-mIgG 1 4 3.7717 0.8501 14.94 4.44 0.0005
IO-mIgG 1 5 5.3917 0.5579 14.84 9.66 <.0001
IO-mIgG 1 7 6.4350 0.6457 15.2 9.97 <.0001
IO-mIgG 2 3 2.9583 0.8289 14.95 3.57 0.0028
IO-mIgG 2 4 3.4317 0.8994 14.9 3.82 0.0017
IO-mIgG 2 5 5.0517 0.7776 14.07 6.50 <.0001
IO-mIgG 2 7 6.0950 0.8128 15.02 7.50 <.0001
IO-mIgG 3 4 0.4733 0.7366 14.95 0.64 0.5302
IO-mIgG 3 5 2.0933 0.6022 14.93 3.48 0.0034
IO-mIgG 3 7 3.1367 0.6257 14.96 5.01 0.0002
IO-mIgG 4 5 1.6200 0.6682 14.83 2.42 0.0286
IO-mIgG 4 7 2.6633 0.7201 15.04 3.70 0.0021
IO-mIgG 5 7 1.0433 0.3801 14.61 2.74 0.0153
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Table H5. Simple effect comparisons of treatment*day least squares means by 
treatment for CD4+ CD8-, Study A (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 0.25 0.3567 0.2957 14.98 1.21 0.2465
mIgG 0 1 -5.4467 0.7280 15.19 -7.48 <.0001
mIgG 0 2 -4.7867 0.8176 15.06 -5.85 <.0001
mIgG 0 3 -1.8917 0.6334 15 -2.99 0.0092
mIgG 0 4 -1.6233 0.6886 15.07 -2.36 0.0323
mIgG 0 5 -0.5633 0.3546 14.42 -1.59 0.1338
mIgG 0 7 0.1800 0.2124 14.99 0.85 0.4101
mIgG 0.25 1 -5.8033 0.6483 15.19 -8.95 <.0001
mIgG 0.25 2 -5.1433 0.7624 15.05 -6.75 <.0001
mIgG 0.25 3 -2.2483 0.5914 14.98 -3.80 0.0017
mIgG 0.25 4 -1.9800 0.8409 15.01 -2.35 0.0326
mIgG 0.25 5 -0.9200 0.4543 14.84 -2.03 0.0612
mIgG 0.25 7 -0.1767 0.1984 14.91 -0.89 0.3874
mIgG 1 2 0.6600 0.8240 14.83 0.80 0.4358
mIgG 1 3 3.5550 0.7240 14.98 4.91 0.0002
mIgG 1 4 3.8233 0.8501 14.94 4.50 0.0004
mIgG 1 5 4.8833 0.5579 14.84 8.75 <.0001
mIgG 1 7 5.6267 0.6457 15.2 8.71 <.0001
mIgG 2 3 2.8950 0.8289 14.95 3.49 0.0033
mIgG 2 4 3.1633 0.8994 14.9 3.52 0.0031
mIgG 2 5 4.2233 0.7776 14.07 5.43 <.0001
mIgG 2 7 4.9667 0.8128 15.02 6.11 <.0001
mIgG 3 4 0.2683 0.7366 14.95 0.36 0.7208
mIgG 3 5 1.3283 0.6022 14.93 2.21 0.0435
mIgG 3 7 2.0717 0.6257 14.96 3.31 0.0048
mIgG 4 5 1.0600 0.6682 14.83 1.59 0.1338
mIgG 4 7 1.8033 0.7201 15.04 2.50 0.0243
mIgG 5 7 0.7433 0.3801 14.61 1.96 0.0699
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Table H6. Simple effect comparisons of treatment*day least squares means by day for CD4+ 
CD8-, Study A 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 ALUmIgG IOmIgG -0.1467 0.1830 14.96 -0.80 0.4355
day 0 ALUmIgG mIgG -0.4433 0.1830 14.96 -2.42 0.0286
day 0 IOmIgG mIgG -0.2967 0.1830 14.96 -1.62 0.1259
day 0.25 ALUmIgG IOmIgG -0.4400 0.3841 14.95 -1.15 0.2700
day 0.25 ALUmIgG mIgG 0.2300 0.3841 14.95 0.60 0.5583
day 0.25 IOmIgG mIgG 0.6700 0.3841 14.95 1.74 0.1016
day 1 ALUmIgG IOmIgG -1.4717 0.9422 15.22 -1.56 0.1389
day 1 ALUmIgG mIgG -0.7700 0.9422 15.22 -0.82 0.4264
day 1 IOmIgG mIgG 0.7017 0.9422 15.22 0.74 0.4678
day 2 ALUmIgG IOmIgG -1.8717 1.1601 15.03 -1.61 0.1275
day 2 ALUmIgG mIgG -0.8500 1.1601 15.03 -0.73 0.4750
day 2 IOmIgG mIgG 1.0217 1.1601 15.03 0.88 0.3924
day 3 ALUmIgG IOmIgG -0.7167 0.8680 14.98 -0.83 0.4219
day 3 ALUmIgG mIgG 0.2417 0.8680 14.98 0.28 0.7845
day 3 IOmIgG mIgG 0.9583 0.8680 14.98 1.10 0.2870
day 4 ALUmIgG IOmIgG -0.4117 0.9774 15.06 -0.42 0.6796
day 4 ALUmIgG mIgG 0.3417 0.9774 15.06 0.35 0.7315
day 4 IOmIgG mIgG 0.7533 0.9774 15.06 0.77 0.4528
day 5 ALUmIgG IOmIgG -0.4759 0.4417 14.15 -1.08 0.2993
day 5 ALUmIgG mIgG -0.2826 0.4417 14.15 -0.64 0.5325
day 5 IOmIgG mIgG 0.1933 0.4270 13.54 0.45 0.6579
day 7 ALUmIgG IOmIgG 0.1133 0.2214 14.98 0.51 0.6162
day 7 ALUmIgG mIgG 0.006667 0.2214 14.98 0.03 0.9764
day 7 IOmIgG mIgG -0.1067 0.2214 14.98 -0.48 0.6370
 
 
Table H5. Simple effect comparisons of treatment*day least squares means by treatment for  T 
cell+ CD8-, Study A 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 0 0.25 -2.6250 0.6789 15 -3.87 0.0015
Alum-mIgG 0 1 -2.0817 0.6004 15 -3.47 0.0034
Alum-mIgG 0 2 -0.4200 0.2492 15.01 -1.69 0.1126
Alum-mIgG 0 3 0.02833 0.2070 14.99 0.14 0.8930
Alum-mIgG 0 4 0.3067 0.1892 14.97 1.62 0.1258
Alum-mIgG 0 5 0.3935 0.1952 15.06 2.02 0.0620
Alum-mIgG 0 7 0.2800 0.1979 15 1.41 0.1776
Alum-mIgG 0.25 1 0.5433 0.7195 14.99 0.76 0.4619
Alum-mIgG 0.25 2 2.2050 0.5520 14.99 3.99 0.0012
Alum-mIgG 0.25 3 2.6533 0.6047 15 4.39 0.0005
Alum-mIgG 0.25 4 2.9317 0.6208 15.01 4.72 0.0003
Alum-mIgG 0.25 5 3.0185 0.5767 15.02 5.23 0.0001
Alum-mIgG 0.25 7 2.9050 0.5823 15 4.99 0.0002
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Table H5. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+ CD8-, Study A (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 1 2 1.6617 0.5280 15 3.15 0.0066
Alum-mIgG 1 3 2.1100 0.5323 14.99 3.96 0.0012
Alum-mIgG 1 4 2.3883 0.5108 15 4.68 0.0003
Alum-mIgG 1 5 2.4751 0.5448 15.03 4.54 0.0004
Alum-mIgG 1 7 2.3617 0.5582 15 4.23 0.0007
Alum-mIgG 2 3 0.4483 0.1404 15.02 3.19 0.0060
Alum-mIgG 2 4 0.7267 0.2212 15.02 3.29 0.0050
Alum-mIgG 2 5 0.8135 0.1987 14.95 4.09 0.0010
Alum-mIgG 2 7 0.7000 0.1822 15.01 3.84 0.0016
Alum-mIgG 3 4 0.2783 0.1284 14.98 2.17 0.0467
Alum-mIgG 3 5 0.3651 0.1285 15.46 2.84 0.0121
Alum-mIgG 3 7 0.2517 0.1056 14.99 2.38 0.0308
Alum-mIgG 4 5 0.08681 0.09519 15.88 0.91 0.3754
Alum-mIgG 4 7 -0.02667 0.1008 15.05 -0.26 0.7950
Alum-mIgG 5 7 -0.1135 0.06078 14.78 -1.87 0.0819
IO-mIgG 0 0.25 -1.8867 0.6789 15 -2.78 0.0141
IO-mIgG 0 1 -3.0250 0.6004 15 -5.04 0.0001
IO-mIgG 0 2 -1.9383 0.2492 15.01 -7.78 <.0001
IO-mIgG 0 3 -0.4350 0.2070 14.99 -2.10 0.0529
IO-mIgG 0 4 -0.1500 0.1892 14.97 -0.79 0.4402
IO-mIgG 0 5 0.02167 0.1933 14.79 0.11 0.9123
IO-mIgG 0 7 0.08333 0.1979 15 0.42 0.6797
IO-mIgG 0.25 1 -1.1383 0.7195 14.99 -1.58 0.1345
IO-mIgG 0.25 2 -0.05167 0.5520 14.99 -0.09 0.9267
IO-mIgG 0.25 3 1.4517 0.6047 15 2.40 0.0298
IO-mIgG 0.25 4 1.7367 0.6208 15.01 2.80 0.0135
IO-mIgG 0.25 5 1.9083 0.5760 14.99 3.31 0.0047
IO-mIgG 0.25 7 1.9700 0.5823 15 3.38 0.0041
IO-mIgG 1 2 1.0867 0.5280 15 2.06 0.0574
IO-mIgG 1 3 2.5900 0.5323 14.99 4.87 0.0002
IO-mIgG 1 4 2.8750 0.5108 15 5.63 <.0001
IO-mIgG 1 5 3.0467 0.5442 14.99 5.60 <.0001
IO-mIgG 1 7 3.1083 0.5582 15 5.57 <.0001
IO-mIgG 2 3 1.5033 0.1404 15.02 10.71 <.0001
IO-mIgG 2 4 1.7883 0.2212 15.02 8.09 <.0001
IO-mIgG 2 5 1.9600 0.1969 14.69 9.95 <.0001
IO-mIgG 2 7 2.0217 0.1822 15.01 11.10 <.0001
IO-mIgG 3 4 0.2850 0.1284 14.98 2.22 0.0423
IO-mIgG 3 5 0.4567 0.1256 14.87 3.64 0.0025
IO-mIgG 3 7 0.5183 0.1056 14.99 4.91 0.0002
IO-mIgG 4 5 0.1717 0.09128 14.91 1.88 0.0797
IO-mIgG 4 7 0.2333 0.1008 15.05 2.31 0.0352
IO-mIgG 5 7 0.06167 0.05445 13.6 1.13 0.2770
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Table H5. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+ CD8-, Study A (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 0.25 -1.5033 0.6789 15 -2.21 0.0427
mIgG 0 1 -2.1550 0.6004 15 -3.59 0.0027
mIgG 0 2 -0.7250 0.2492 15.01 -2.91 0.0108
mIgG 0 3 0.02167 0.2070 14.99 0.10 0.9180
mIgG 0 4 0.1267 0.1892 14.97 0.67 0.5133
mIgG 0 5 0.1700 0.1933 14.79 0.88 0.3933
mIgG 0 7 0.2117 0.1979 15 1.07 0.3018
mIgG 0.25 1 -0.6517 0.7195 14.99 -0.91 0.3794
mIgG 0.25 2 0.7783 0.5520 14.99 1.41 0.1789
mIgG 0.25 3 1.5250 0.6047 15 2.52 0.0235
mIgG 0.25 4 1.6300 0.6208 15.01 2.63 0.0191
mIgG 0.25 5 1.6733 0.5760 14.99 2.90 0.0109
mIgG 0.25 7 1.7150 0.5823 15 2.95 0.0100
mIgG 1 2 1.4300 0.5280 15 2.71 0.0162
mIgG 1 3 2.1767 0.5323 14.99 4.09 0.0010
mIgG 1 4 2.2817 0.5108 15 4.47 0.0005
mIgG 1 5 2.3250 0.5442 14.99 4.27 0.0007
mIgG 1 7 2.3667 0.5582 15 4.24 0.0007
mIgG 2 3 0.7467 0.1404 15.02 5.32 <.0001
mIgG 2 4 0.8517 0.2212 15.02 3.85 0.0016
mIgG 2 5 0.8950 0.1969 14.69 4.55 0.0004
mIgG 2 7 0.9367 0.1822 15.01 5.14 0.0001
mIgG 3 4 0.1050 0.1284 14.98 0.82 0.4264
mIgG 3 5 0.1483 0.1256 14.87 1.18 0.2563
mIgG 3 7 0.1900 0.1056 14.99 1.80 0.0921
mIgG 4 5 0.04333 0.09128 14.91 0.47 0.6418
mIgG 4 7 0.08500 0.1008 15.05 0.84 0.4123
mIgG 5 7 0.04167 0.05445 13.6 0.77 0.4572
  
 
 
 
 
 
 
 
310 
 
 
 
Table H6. Simple effect comparisons of treatment*day least squares means by day for  T cell+ 
CD8-, Study A 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 ALUmIgG IOmIgG 0.2500 0.2499 15 1.00 0.3329
day 0 ALUmIgG mIgG 0.1533 0.2499 15 0.61 0.5486
day 0 IOmIgG mIgG -0.09667 0.2499 15 -0.39 0.7043
day 0.25 ALUmIgG IOmIgG 0.9883 0.8557 15 1.15 0.2662
day 0.25 ALUmIgG mIgG 1.2750 0.8557 15 1.49 0.1570
day 0.25 IOmIgG mIgG 0.2867 0.8557 15 0.33 0.7423
day 1 ALUmIgG IOmIgG -0.6933 0.7757 15 -0.89 0.3855
day 1 ALUmIgG mIgG 0.08000 0.7757 15 0.10 0.9192
day 1 IOmIgG mIgG 0.7733 0.7757 15 1.00 0.3346
day 2 ALUmIgG IOmIgG -1.2683 0.2765 15.01 -4.59 0.0004
day 2 ALUmIgG mIgG -0.1517 0.2765 15.01 -0.55 0.5914
day 2 IOmIgG mIgG 1.1167 0.2765 15.01 4.04 0.0011
day 3 ALUmIgG IOmIgG -0.2133 0.1628 14.97 -1.31 0.2099
day 3 ALUmIgG mIgG 0.1467 0.1628 14.97 0.90 0.3820
day 3 IOmIgG mIgG 0.3600 0.1628 14.97 2.21 0.0430
day 4 ALUmIgG IOmIgG -0.2067 0.1148 15.03 -1.80 0.0919
day 4 ALUmIgG mIgG -0.02667 0.1148 15.03 -0.23 0.8194
day 4 IOmIgG mIgG 0.1800 0.1148 15.03 1.57 0.1376
day 5 ALUmIgG IOmIgG -0.1218 0.08906 15.26 -1.37 0.1912
day 5 ALUmIgG mIgG -0.07015 0.08906 15.26 -0.79 0.4430
day 5 IOmIgG mIgG 0.05167 0.08487 14.6 0.61 0.5520
day 7 ALUmIgG IOmIgG 0.05333 0.06039 14.97 0.88 0.3911
day 7 ALUmIgG mIgG 0.08500 0.06039 14.97 1.41 0.1797
day 7 IOmIgG mIgG 0.03167 0.06039 14.97 0.52 0.6077
 
 
Table H5. Simple effect comparisons of treatment*day least squares means by treatment for 
MHCII+ Macrophages+, Study B 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 0 0.25 -6.2525 1.8208 9 -3.43 0.0075
Alum-mIgG 0 1 -0.4800 0.3573 9 -1.34 0.2120
Alum-mIgG 0 2 -0.4125 0.3801 9 -1.09 0.3060
Alum-mIgG 0 3 -1.1900 1.0421 9 -1.14 0.2829
Alum-mIgG 0 4 0.7425 0.6134 9 1.21 0.2569
Alum-mIgG 0 5 0.8225 0.4984 9 1.65 0.1333
Alum-mIgG 0 7 0.5550 0.5341 9 1.04 0.3258
Alum-mIgG 0.25 1 5.7725 1.8465 9 3.13 0.0122
Alum-mIgG 0.25 2 5.8400 1.8526 9 3.15 0.0117
Alum-mIgG 0.25 3 5.0625 2.4376 9 2.08 0.0676
Alum-mIgG 0.25 4 6.9950 1.8722 9 3.74 0.0047
Alum-mIgG 0.25 5 7.0750 1.8602 9 3.80 0.0042
Alum-mIgG 0.25 7 6.8075 2.0383 9 3.34 0.0087
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Table H5. Simple effect comparisons of treatment*day least squares means by 
treatment for MHCII+ Macrophages+, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 1 2 0.06750 0.07688 9 0.88 0.4028
Alum-mIgG 1 3 -0.7100 1.0354 9 -0.69 0.5101
Alum-mIgG 1 4 1.2225 0.6071 9 2.01 0.0749
Alum-mIgG 1 5 1.3025 0.5555 9 2.34 0.0437
Alum-mIgG 1 7 1.0350 0.5543 9 1.87 0.0947
Alum-mIgG 2 3 -0.7775 1.0382 9 -0.75 0.4730
Alum-mIgG 2 4 1.1550 0.5899 9 1.96 0.0819
Alum-mIgG 2 5 1.2350 0.5335 9 2.32 0.0459
Alum-mIgG 2 7 0.9675 0.5498 9 1.76 0.1123
Alum-mIgG 3 4 1.9325 0.6741 9 2.87 0.0186
Alum-mIgG 3 5 2.0125 0.9032 9 2.23 0.0529
Alum-mIgG 3 7 1.7450 0.5967 9 2.92 0.0169
Alum-mIgG 4 5 0.08000 0.3335 9 0.24 0.8158
Alum-mIgG 4 7 -0.1875 0.3270 9 -0.57 0.5804
Alum-mIgG 5 7 -0.2675 0.4242 9 -0.63 0.5440
IO-mIgG 0 0.25 0.1050 1.8208 9 0.06 0.9553
IO-mIgG 0 1 0.09500 0.3572 9 0.27 0.7963
IO-mIgG 0 2 0.2850 0.3801 9 0.75 0.4725
IO-mIgG 0 3 0.8450 1.0420 9 0.81 0.4383
IO-mIgG 0 4 1.3200 0.6134 9 2.15 0.0598
IO-mIgG 0 5 1.2200 0.4984 9 2.45 0.0369
IO-mIgG 0 7 0.4400 0.5341 9 0.82 0.4313
IO-mIgG 0.25 1 -0.01000 1.8465 9 -0.01 0.9958
IO-mIgG 0.25 2 0.1800 1.8526 9 0.10 0.9247
IO-mIgG 0.25 3 0.7400 2.4376 9 0.30 0.7684
IO-mIgG 0.25 4 1.2150 1.8722 9 0.65 0.5326
IO-mIgG 0.25 5 1.1150 1.8602 9 0.60 0.5637
IO-mIgG 0.25 7 0.3350 2.0383 9 0.16 0.8731
IO-mIgG 1 2 0.1900 0.07688 9 2.47 0.0355
IO-mIgG 1 3 0.7500 1.0353 9 0.72 0.4872
IO-mIgG 1 4 1.2250 0.6071 9 2.02 0.0744
IO-mIgG 1 5 1.1250 0.5555 9 2.03 0.0735
IO-mIgG 1 7 0.3450 0.5542 9 0.62 0.5491
IO-mIgG 2 3 0.5600 1.0382 9 0.54 0.6027
IO-mIgG 2 4 1.0350 0.5899 9 1.75 0.1132
IO-mIgG 2 5 0.9350 0.5335 9 1.75 0.1136
IO-mIgG 2 7 0.1550 0.5497 9 0.28 0.7844
IO-mIgG 3 4 0.4750 0.6741 9 0.70 0.4988
IO-mIgG 3 5 0.3750 0.9032 9 0.42 0.6877
IO-mIgG 3 7 -0.4050 0.5967 9 -0.68 0.5144
IO-mIgG 4 5 -0.1000 0.3335 9 -0.30 0.7711
IO-mIgG 4 7 -0.8800 0.3270 9 -2.69 0.0247
IO-mIgG 5 7 -0.7800 0.4242 9 -1.84 0.0991
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Table H5. Simple effect comparisons of treatment*day least squares means by 
treatment for MHCII+ Macrophages+, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 0.25 -2.4175 1.8208 9 -1.33 0.2170
mIgG 0 1 -0.4250 0.3573 9 -1.19 0.2646
mIgG 0 2 -0.2600 0.3801 9 -0.68 0.5111
mIgG 0 3 0.5075 1.0421 9 0.49 0.6379
mIgG 0 4 0.9425 0.6134 9 1.54 0.1588
mIgG 0 5 0.5600 0.4984 9 1.12 0.2902
mIgG 0 7 0.4725 0.5341 9 0.88 0.3993
mIgG 0.25 1 1.9925 1.8465 9 1.08 0.3086
mIgG 0.25 2 2.1575 1.8526 9 1.16 0.2741
mIgG 0.25 3 2.9250 2.4376 9 1.20 0.2608
mIgG 0.25 4 3.3600 1.8722 9 1.79 0.1063
mIgG 0.25 5 2.9775 1.8603 9 1.60 0.1439
mIgG 0.25 7 2.8900 2.0383 9 1.42 0.1899
mIgG 1 2 0.1650 0.07688 9 2.15 0.0604
mIgG 1 3 0.9325 1.0354 9 0.90 0.3912
mIgG 1 4 1.3675 0.6071 9 2.25 0.0508
mIgG 1 5 0.9850 0.5555 9 1.77 0.1099
mIgG 1 7 0.8975 0.5543 9 1.62 0.1398
mIgG 2 3 0.7675 1.0382 9 0.74 0.4786
mIgG 2 4 1.2025 0.5899 9 2.04 0.0719
mIgG 2 5 0.8200 0.5335 9 1.54 0.1586
mIgG 2 7 0.7325 0.5498 9 1.33 0.2155
mIgG 3 4 0.4350 0.6741 9 0.65 0.5348
mIgG 3 5 0.05250 0.9032 9 0.06 0.9549
mIgG 3 7 -0.03500 0.5967 9 -0.06 0.9545
mIgG 4 5 -0.3825 0.3335 9 -1.15 0.2809
mIgG 4 7 -0.4700 0.3270 9 -1.44 0.1844
mIgG 5 7 -0.08750 0.4242 9 -0.21 0.8412
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Table H6. Simple effect comparisons of treatment*day least squares means by day for MHCII+ 
Macrophages+, Study B 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 AlummIgG IOmIgG 0.09500 0.5808 9 0.16 0.8737
day 0 AlummIgG mIgG 0.3525 0.5808 9 0.61 0.5589
day 0 IOmIgG mIgG 0.2575 0.5808 9 0.44 0.6680
day 0.25 AlummIgG IOmIgG 6.4525 2.5884 9 2.49 0.0343
day 0.25 AlummIgG mIgG 4.1875 2.5884 9 1.62 0.1402
day 0.25 IOmIgG mIgG -2.2650 2.5884 9 -0.88 0.4043
day 1 AlummIgG IOmIgG 0.6700 0.7372 9 0.91 0.3871
day 1 AlummIgG mIgG 0.4075 0.7372 9 0.55 0.5939
day 1 IOmIgG mIgG -0.2625 0.7372 9 -0.36 0.7300
day 2 AlummIgG IOmIgG 0.7925 0.7069 9 1.12 0.2913
day 2 AlummIgG mIgG 0.5050 0.7069 9 0.71 0.4931
day 2 IOmIgG mIgG -0.2875 0.7069 9 -0.41 0.6937
day 3 AlummIgG IOmIgG 2.1300 1.2584 9 1.69 0.1248
day 3 AlummIgG mIgG 2.0500 1.2584 9 1.63 0.1377
day 3 IOmIgG mIgG -0.08000 1.2584 9 -0.06 0.9507
day 4 AlummIgG IOmIgG 0.6725 0.4916 9 1.37 0.2045
day 4 AlummIgG mIgG 0.5525 0.4916 9 1.12 0.2901
day 4 IOmIgG mIgG -0.1200 0.4916 9 -0.24 0.8126
day 5 AlummIgG IOmIgG 0.4925 0.3153 9 1.56 0.1527
day 5 AlummIgG mIgG 0.09000 0.3153 9 0.29 0.7818
day 5 IOmIgG mIgG -0.4025 0.3153 9 -1.28 0.2337
day 7 AlummIgG IOmIgG -0.02000 0.5215 9 -0.04 0.9702
day 7 AlummIgG mIgG 0.2700 0.5215 9 0.52 0.6171
day 7 IOmIgG mIgG 0.2900 0.5215 9 0.56 0.5917
 
Table H7. Simple effect comparisons of treatment*day least squares means by treatment for  
T cell+ CD4+ CD8+, Study B 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 0 0.25 0.6350 0.1988 9 3.19 0.0109
Alum-mIgG 0 1 0.1925 0.2816 9 0.68 0.5114
Alum-mIgG 0 2 0.3225 0.2338 9 1.38 0.2010
Alum-mIgG 0 3 0.4425 0.2107 9 2.10 0.0651
Alum-mIgG 0 4 0.3850 0.2019 9 1.91 0.0889
Alum-mIgG 0 5 0.4325 0.1972 9 2.19 0.0560
Alum-mIgG 0 7 0.4550 0.2316 9 1.96 0.0810
Alum-mIgG 0.25 1 -0.4425 0.1207 9 -3.67 0.0052
Alum-mIgG 0.25 2 -0.3125 0.1030 9 -3.03 0.0142
Alum-mIgG 0.25 3 -0.1925 0.1165 9 -1.65 0.1329
Alum-mIgG 0.25 4 -0.2500 0.1285 9 -1.95 0.0836
Alum-mIgG 0.25 5 -0.2025 0.1938 9 -1.05 0.3232
Alum-mIgG 0.25 7 -0.1800 0.1528 9 -1.18 0.2691
Alum-mIgG 1 2 0.1300 0.1647 9 0.79 0.4502
Alum-mIgG 1 3 0.2500 0.1713 9 1.46 0.1784
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Table H7. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+ CD4+ CD8+, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 1 4 0.1925 0.2042 9 0.94 0.3705
Alum-mIgG 1 5 0.2400 0.2567 9 0.93 0.3743
Alum-mIgG 1 7 0.2625 0.2213 9 1.19 0.2659
Alum-mIgG 2 3 0.1200 0.06227 9 1.93 0.0861
Alum-mIgG 2 4 0.06250 0.07389 9 0.85 0.4196
Alum-mIgG 2 5 0.1100 0.1551 9 0.71 0.4960
Alum-mIgG 2 7 0.1325 0.09269 9 1.43 0.1866
Alum-mIgG 3 4 -0.05750 0.1013 9 -0.57 0.5842
Alum-mIgG 3 5 -0.01000 0.1615 9 -0.06 0.9520
Alum-mIgG 3 7 0.01250 0.1032 9 0.12 0.9063
Alum-mIgG 4 5 0.04750 0.1150 9 0.41 0.6893
Alum-mIgG 4 7 0.07000 0.1111 9 0.63 0.5442
Alum-mIgG 5 7 0.02250 0.1850 9 0.12 0.9059
IO-mIgG 0 0.25 0.4850 0.1988 9 2.44 0.0374
IO-mIgG 0 1 0.1175 0.2816 9 0.42 0.6862
IO-mIgG 0 2 0.4250 0.2338 9 1.82 0.1024
IO-mIgG 0 3 0.4500 0.2107 9 2.14 0.0614
IO-mIgG 0 4 0.4750 0.2019 9 2.35 0.0431
IO-mIgG 0 5 0.5750 0.1972 9 2.92 0.0172
IO-mIgG 0 7 0.3700 0.2316 9 1.60 0.1446
IO-mIgG 0.25 1 -0.3675 0.1207 9 -3.04 0.0139
IO-mIgG 0.25 2 -0.06000 0.1030 9 -0.58 0.5745
IO-mIgG 0.25 3 -0.03500 0.1165 9 -0.30 0.7707
IO-mIgG 0.25 4 -0.01000 0.1285 9 -0.08 0.9397
IO-mIgG 0.25 5 0.09000 0.1938 9 0.46 0.6533
IO-mIgG 0.25 7 -0.1150 0.1528 9 -0.75 0.4710
IO-mIgG 1 2 0.3075 0.1647 9 1.87 0.0947
IO-mIgG 1 3 0.3325 0.1713 9 1.94 0.0841
IO-mIgG 1 4 0.3575 0.2042 9 1.75 0.1140
IO-mIgG 1 5 0.4575 0.2567 9 1.78 0.1084
IO-mIgG 1 7 0.2525 0.2213 9 1.14 0.2833
IO-mIgG 2 3 0.02500 0.06227 9 0.40 0.6974
IO-mIgG 2 4 0.05000 0.07389 9 0.68 0.5156
IO-mIgG 2 5 0.1500 0.1551 9 0.97 0.3586
IO-mIgG 2 7 -0.05500 0.09269 9 -0.59 0.5675
IO-mIgG 3 4 0.02500 0.1013 9 0.25 0.8106
IO-mIgG 3 5 0.1250 0.1615 9 0.77 0.4588
IO-mIgG 3 7 -0.08000 0.1032 9 -0.78 0.4581
IO-mIgG 4 5 0.1000 0.1150 9 0.87 0.4072
IO-mIgG 4 7 -0.1050 0.1111 9 -0.95 0.3692
IO-mIgG 5 7 -0.2050 0.1850 9 -1.11 0.2965
mIgG 0 0.25 0.1500 0.1988 9 0.75 0.4697
mIgG 0 1 0.1325 0.2816 9 0.47 0.6491
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Table H7. Simple effect comparisons of treatment*day least squares means by 
treatment for  T cell+ CD4+ CD8+, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 2 0.4000 0.2338 9 1.71 0.1212
mIgG 0 3 0.4250 0.2107 9 2.02 0.0745
mIgG 0 4 0.4125 0.2019 9 2.04 0.0714
mIgG 0 5 0.3175 0.1972 9 1.61 0.1419
mIgG 0 7 0.3650 0.2316 9 1.58 0.1494
mIgG 0.25 1 -0.01750 0.1207 9 -0.14 0.8879
mIgG 0.25 2 0.2500 0.1030 9 2.43 0.0381
mIgG 0.25 3 0.2750 0.1165 9 2.36 0.0426
mIgG 0.25 4 0.2625 0.1285 9 2.04 0.0714
mIgG 0.25 5 0.1675 0.1938 9 0.86 0.4098
mIgG 0.25 7 0.2150 0.1528 9 1.41 0.1931
mIgG 1 2 0.2675 0.1647 9 1.62 0.1388
mIgG 1 3 0.2925 0.1713 9 1.71 0.1218
mIgG 1 4 0.2800 0.2042 9 1.37 0.2036
mIgG 1 5 0.1850 0.2567 9 0.72 0.4895
mIgG 1 7 0.2325 0.2213 9 1.05 0.3208
mIgG 2 3 0.02500 0.06227 9 0.40 0.6974
mIgG 2 4 0.01250 0.07389 9 0.17 0.8694
mIgG 2 5 -0.08250 0.1551 9 -0.53 0.6076
mIgG 2 7 -0.03500 0.09269 9 -0.38 0.7145
mIgG 3 4 -0.01250 0.1013 9 -0.12 0.9045
mIgG 3 5 -0.1075 0.1615 9 -0.67 0.5223
mIgG 3 7 -0.06000 0.1032 9 -0.58 0.5753
mIgG 4 5 -0.09500 0.1150 9 -0.83 0.4301
mIgG 4 7 -0.04750 0.1111 9 -0.43 0.6790
mIgG 5 7 0.04750 0.1850 9 0.26 0.8031
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Table H8. Simple effect comparisons of treatment*day least squares means by day for  T 
cell+ CD4+ CD8+, Study B 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 AlummIgG IOmIgG 0.03750 0.2145 9 0.17 0.8651
day 0 AlummIgG mIgG 0.1625 0.2145 9 0.76 0.4680
day 0 IOmIgG mIgG 0.1250 0.2145 9 0.58 0.5743
day 0.25 AlummIgG IOmIgG -0.1125 0.2084 9 -0.54 0.6025
day 0.25 AlummIgG mIgG -0.3225 0.2084 9 -1.55 0.1562
day 0.25 IOmIgG mIgG -0.2100 0.2084 9 -1.01 0.3400
day 1 AlummIgG IOmIgG -0.03750 0.3494 9 -0.11 0.9169
day 1 AlummIgG mIgG 0.1025 0.3494 9 0.29 0.7759
day 1 IOmIgG mIgG 0.1400 0.3494 9 0.40 0.6980
day 2 AlummIgG IOmIgG 0.1400 0.1896 9 0.74 0.4791
day 2 AlummIgG mIgG 0.2400 0.1896 9 1.27 0.2373
day 2 IOmIgG mIgG 0.1000 0.1896 9 0.53 0.6106
day 3 AlummIgG IOmIgG 0.04500 0.1861 9 0.24 0.8144
day 3 AlummIgG mIgG 0.1450 0.1861 9 0.78 0.4560
day 3 IOmIgG mIgG 0.1000 0.1861 9 0.54 0.6041
day 4 AlummIgG IOmIgG 0.1275 0.1618 9 0.79 0.4510
day 4 AlummIgG mIgG 0.1900 0.1618 9 1.17 0.2704
day 4 IOmIgG mIgG 0.06250 0.1618 9 0.39 0.7083
day 5 AlummIgG IOmIgG 0.1800 0.1705 9 1.06 0.3185
day 5 AlummIgG mIgG 0.04750 0.1705 9 0.28 0.7868
day 5 IOmIgG mIgG -0.1325 0.1705 9 -0.78 0.4569
day 7 AlummIgG IOmIgG -0.04750 0.1916 9 -0.25 0.8098
day 7 AlummIgG mIgG 0.07250 0.1916 9 0.38 0.7139
day 7 IOmIgG mIgG 0.1200 0.1916 9 0.63 0.5467
 
Table H9. Simple effect comparisons of treatment*day least squares means by treatment for B 
cell+ IgG-, Study B 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 0 0.25 -0.2825 0.3275 9.003 -0.86 0.4108
Alum-mIgG 0 1 -4.2125 0.9337 9 -4.51 0.0015
Alum-mIgG 0 2 -7.8200 2.7561 9 -2.84 0.0195
Alum-mIgG 0 3 -9.7425 3.6333 9 -2.68 0.0251
Alum-mIgG 0 4 -6.1000 2.9839 9 -2.04 0.0713
Alum-mIgG 0 5 -1.7000 1.1836 9 -1.44 0.1847
Alum-mIgG 0 7 -1.9100 0.4480 9 -4.26 0.0021
Alum-mIgG 0.25 1 -3.9300 0.9823 9 -4.00 0.0031
Alum-mIgG 0.25 2 -7.5375 2.5035 9 -3.01 0.0147
Alum-mIgG 0.25 3 -9.4600 3.4281 9 -2.76 0.0221
Alum-mIgG 0.25 4 -5.8175 2.9216 9 -1.99 0.0776
Alum-mIgG 0.25 5 -1.4175 1.2325 9 -1.15 0.2798
Alum-mIgG 0.25 7 -1.6275 0.6182 9 -2.63 0.0272
Alum-mIgG 1 2 -3.6075 2.9867 9 -1.21 0.2579
Alum-mIgG 1 3 -5.5300 4.0177 9 -1.38 0.2020
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Table H9. Simple effect comparisons of treatment*day least squares means by 
treatment for B cell+ IgG-, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 1 4 -1.8875 3.3280 9 -0.57 0.5845
Alum-mIgG 1 5 2.5125 1.7489 9 1.44 0.1847
Alum-mIgG 1 7 2.3025 1.2163 9 1.89 0.0909
Alum-mIgG 2 3 -1.9225 2.3777 9 -0.81 0.4396
Alum-mIgG 2 4 1.7200 3.1825 9 0.54 0.6020
Alum-mIgG 2 5 6.1200 3.1412 9 1.95 0.0832
Alum-mIgG 2 7 5.9100 2.8213 9 2.09 0.0657
Alum-mIgG 3 4 3.6425 4.3859 9 0.83 0.4277
Alum-mIgG 3 5 8.0425 4.1664 9 1.93 0.0856
Alum-mIgG 3 7 7.8325 3.4995 9 2.24 0.0520
Alum-mIgG 4 5 4.4000 2.3152 9 1.90 0.0898
Alum-mIgG 4 7 4.1900 2.8997 9 1.44 0.1824
Alum-mIgG 5 7 -0.2100 1.1801 9 -0.18 0.8627
IO-mIgG 0 0.25 -0.5550 0.3275 9.003 -1.69 0.1244
IO-mIgG 0 1 -3.2125 0.9337 9 -3.44 0.0074
IO-mIgG 0 2 -8.9875 2.7561 9 -3.26 0.0098
IO-mIgG 0 3 -10.4425 3.6333 9 -2.87 0.0184
IO-mIgG 0 4 -16.2775 2.9839 9 -5.46 0.0004
IO-mIgG 0 5 -7.7000 1.1836 9 -6.51 0.0001
IO-mIgG 0 7 -2.5525 0.4480 9 -5.70 0.0003
IO-mIgG 0.25 1 -2.6575 0.9823 9 -2.71 0.0242
IO-mIgG 0.25 2 -8.4325 2.5035 9 -3.37 0.0083
IO-mIgG 0.25 3 -9.8875 3.4281 9 -2.88 0.0181
IO-mIgG 0.25 4 -15.7225 2.9216 9 -5.38 0.0004
IO-mIgG 0.25 5 -7.1450 1.2325 9 -5.80 0.0003
IO-mIgG 0.25 7 -1.9975 0.6182 9 -3.23 0.0103
IO-mIgG 1 2 -5.7750 2.9867 9 -1.93 0.0852
IO-mIgG 1 3 -7.2300 4.0177 9 -1.80 0.1055
IO-mIgG 1 4 -13.0650 3.3280 9 -3.93 0.0035
IO-mIgG 1 5 -4.4875 1.7489 9 -2.57 0.0304
IO-mIgG 1 7 0.6600 1.2163 9 0.54 0.6005
IO-mIgG 2 3 -1.4550 2.3777 9 -0.61 0.5557
IO-mIgG 2 4 -7.2900 3.1825 9 -2.29 0.0477
IO-mIgG 2 5 1.2875 3.1412 9 0.41 0.6915
IO-mIgG 2 7 6.4350 2.8213 9 2.28 0.0485
IO-mIgG 3 4 -5.8350 4.3859 9 -1.33 0.2161
IO-mIgG 3 5 2.7425 4.1664 9 0.66 0.5269
IO-mIgG 3 7 7.8900 3.4995 9 2.25 0.0506
IO-mIgG 4 5 8.5775 2.3152 9 3.70 0.0049
IO-mIgG 4 7 13.7250 2.8997 9 4.73 0.0011
IO-mIgG 5 7 5.1475 1.1801 9 4.36 0.0018
mIgG 0 0.25 0.04250 0.3275 9.003 0.13 0.8996
mIgG 0 1 -5.8275 0.9337 9 -6.24 0.0002
318 
 
 
 
Table H9. Simple effect comparisons of treatment*day least squares means by 
treatment for B cell+ IgG-, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 2 -12.3850 2.7561 9 -4.49 0.0015
mIgG 0 3 -21.5650 3.6333 9 -5.94 0.0002
mIgG 0 4 -8.1025 2.9839 9 -2.72 0.0238
mIgG 0 5 -5.2250 1.1836 9 -4.41 0.0017
mIgG 0 7 -1.0650 0.4480 9 -2.38 0.0414
mIgG 0.25 1 -5.8700 0.9823 9 -5.98 0.0002
mIgG 0.25 2 -12.4275 2.5035 9 -4.96 0.0008
mIgG 0.25 3 -21.6075 3.4281 9 -6.30 0.0001
mIgG 0.25 4 -8.1450 2.9216 9 -2.79 0.0211
mIgG 0.25 5 -5.2675 1.2325 9 -4.27 0.0021
mIgG 0.25 7 -1.1075 0.6182 9 -1.79 0.1068
mIgG 1 2 -6.5575 2.9867 9 -2.20 0.0557
mIgG 1 3 -15.7375 4.0177 9 -3.92 0.0035
mIgG 1 4 -2.2750 3.3280 9 -0.68 0.5114
mIgG 1 5 0.6025 1.7489 9 0.34 0.7384
mIgG 1 7 4.7625 1.2163 9 3.92 0.0035
mIgG 2 3 -9.1800 2.3777 9 -3.86 0.0038
mIgG 2 4 4.2825 3.1825 9 1.35 0.2113
mIgG 2 5 7.1600 3.1411 9 2.28 0.0486
mIgG 2 7 11.3200 2.8213 9 4.01 0.0031
mIgG 3 4 13.4625 4.3859 9 3.07 0.0134
mIgG 3 5 16.3400 4.1664 9 3.92 0.0035
mIgG 3 7 20.5000 3.4995 9 5.86 0.0002
mIgG 4 5 2.8775 2.3152 9 1.24 0.2453
mIgG 4 7 7.0375 2.8997 9 2.43 0.0382
mIgG 5 7 4.1600 1.1801 9 3.53 0.0065
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Table H10. Simple effect comparisons of treatment*day least squares means by day for B cell+ 
IgG-, Study B 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 AlummIgG IOmIgG -0.00500 0.2608 9 -0.02 0.9851
day 0 AlummIgG mIgG -0.06750 0.2608 9 -0.26 0.8016
day 0 IOmIgG mIgG -0.06250 0.2608 9 -0.24 0.8160
day 0.25 AlummIgG IOmIgG -0.2775 0.3895 9 -0.71 0.4942
day 0.25 AlummIgG mIgG 0.2575 0.3895 9 0.66 0.5251
day 0.25 IOmIgG mIgG 0.5350 0.3895 9 1.37 0.2028
day 1 AlummIgG IOmIgG 0.9950 1.3991 9 0.71 0.4950
day 1 AlummIgG mIgG -1.6825 1.3991 9 -1.20 0.2598
day 1 IOmIgG mIgG -2.6775 1.3991 9 -1.91 0.0879
day 2 AlummIgG IOmIgG -1.1725 3.8872 9 -0.30 0.7698
day 2 AlummIgG mIgG -4.6325 3.8872 9 -1.19 0.2638
day 2 IOmIgG mIgG -3.4600 3.8872 9 -0.89 0.3966
day 3 AlummIgG IOmIgG -0.7050 5.1406 9 -0.14 0.8939
day 3 AlummIgG mIgG -11.8900 5.1406 9 -2.31 0.0460
day 3 IOmIgG mIgG -11.1850 5.1406 9 -2.18 0.0576
day 4 AlummIgG IOmIgG -10.1825 4.1669 9 -2.44 0.0371
day 4 AlummIgG mIgG -2.0700 4.1669 9 -0.50 0.6313
day 4 IOmIgG mIgG 8.1125 4.1669 9 1.95 0.0834
day 5 AlummIgG IOmIgG -6.0050 1.5779 9 -3.81 0.0042
day 5 AlummIgG mIgG -3.5925 1.5779 9 -2.28 0.0488
day 5 IOmIgG mIgG 2.4125 1.5779 9 1.53 0.1606
day 7 AlummIgG IOmIgG -0.6475 0.7520 9 -0.86 0.4116
day 7 AlummIgG mIgG 0.7775 0.7520 9 1.03 0.3281
day 7 IOmIgG mIgG 1.4250 0.7520 9 1.90 0.0906
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APPENDIX I 
Type III Test of Fixed Effects Results for 
Memory Response in Intramuscular Injection Studies 
 
Table I1. Type III test of fixed effects results for memory response in intramuscular injection 
studies 
  Study A Study B 
Response Factor Fixed Effect F Value P Value F Value P Value 
Live cells Day  - - 63.36 0.0006 
 Treatment - - 0.22 NS 
 Treatment*Day - - 2.52 NS 
CD45+ Day  20.51 < 0.0001 - - 
 Treatment 8.19 0.0044 - - 
 Treatment*Day 2.05 NS - - 
MHCII+  Day  20.98 < 0.0001 4.70 NS 
Macrophages+ Treatment 1.05 NS 1.71 NS 
 Treatment*Day 1.53 NS 6.55 0.0326 
MHCII+  Day  2.06 NS 15.44 0.0097 
B cells+ Treatment 2.47 NS 1.49 NS 
 Treatment*Day 1.44 NS 5.13 NS 
CD3+ Day  18.55 < 0.0001 86.56 < 0.0001 
 Treatment 3.03 NS 0.20 NS 
 Treatment*Day 1.00 NS 0.92 NS 
CD4- CD8+ Day  22.45 < 0.0001 38.89 0.0017 
 Treatment 0.63 NS 0.07 NS 
 Treatment*Day 1.00 NS 2.88 NS 
CD4+ CD8+ Day  5.68 0.0107 8.93 0.0263 
 Treatment 3.15 NS 0.80 NS 
 Treatment*Day 1.34 NS 10.04 0.0140 
CD4+ CD8- Day  8.93 0.0023 11.63 0.0164 
 Treatment 4.78 0.0262 0.14 NS 
 Treatment*Day 1.03 NS 1.32 NS 
CD25+ CD4+ Day  5.97 0.0091 - - 
 Treatment 2.39 NS - - 
 Treatment*Day 0.67 NS - - 
CD25+ CD4- Day  5.81 0.0099 - - 
 Treatment 1.91 NS - - 
 Treatment*Day 0.93 NS - - 
T cell+ CD8+ Day  25.98 < 0.0001 289.44 < 0.0001 
 Treatment 0.57 NS 2.09 NS 
 Treatment*Day 2.06 NS 7.52 0.0249 
T cell+ CD8- Day  24.85 < 0.0001 23.70 0.0043 
 Treatment 2.09 NS 5.23 0.0312 
 Treatment*Day 1.01 NS 0.71 NS 
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Table I1. Type III test of fixed effects results for memory response in intramuscular 
injection studies (Cont.) 
  Study A Study B 
Response Factor Fixed Effect F Value P Value F Value P Value 
1 Tcell+ Day  21.42 < 0.0001 18.90 0.0067 
 Treatment 5.69 0.0155 1.44 NS 
 Treatment*Day 1.25 NS 4.00 NS 
1 T cell+ Day  - - 8.77 0.0272 
CD4-CD8+ Treatment - - 2.37 NS 
 Treatment*Day - - 2.33 NS 
1 T cell+ Day  - - 19.11 0.0065 
CD4+CD8+ Treatment - - 0.76 NS 
 Treatment*Day - - 2.92 NS 
1 T cell+ Day  - - 12.19 0.0150 
CD4-CD8- Treatment - - 1.35 NS 
 Treatment*Day - - 8.29 0.0206 
1 T cell+ Day  - - 18.84 0.0067 
CD4+CD8- Treatment - - 0.06 NS 
 Treatment*Day - - 2.04 NS 
2 T cell+ Day  25.58 < 0.0001 216.43 < 0.0001 
 Treatment 2.72 NS 0.09 NS 
 Treatment*Day 0.66 NS 4.51 NS 
2 T cell+ Day  - - 20.87 0.0055 
CD4-CD8+ Treatment - - 1.09 NS 
 Treatment*Day - - 3.11 NS 
2 T cell+ Day  - - 6.28 0.0484 
CD4+CD8+ Treatment - - 0.92 NS 
 Treatment*Day - - 3.14 NS 
2 T cell+ Day  - - 30.46 0.0027 
CD4-CD8- Treatment - - 0.96 NS 
 Treatment*Day - - 0.73 NS 
2 T cell+ Day  - - 7.28 0.0376 
CD4+CD8- Treatment - - 0.63 NS 
 Treatment*Day - - 1.80 NS 
B cells Day  36.38 < 0.0001 - - 
 Treatment 4.08 0.0402 - - 
 Treatment*Day 1.43 NS - - 
B cell+ IgM+ Day  - - 44.39 0.0013 
 Treatment - - 1.38 NS 
 Treatment*Day - - 5.38 0.0475 
B cell+ IgM- Day  - - 10.48 0.0198 
 Treatment - - 0.18 NS 
 Treatment*Day - - 0.68 NS 
B cell+ IgG+ Day  - - 15.45 0.0097 
 Treatment - - 1.67 NS 
 Treatment*Day - - 0.74 NS 
B cell+ IgG- Day  - - 11.25 0.0174 
 Treatment - - 1.52 NS 
 Treatment*Day - - 4.23 NS 
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APPENDIX J 
Difference of Least Squares Means Results for Memory Response 
 in Intramuscular Injection Studies 
 
Table J1. Difference of least squares means for pulp cell responses by day 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
Study A        
CD45+ 0 0.25 -21.7877 2.9063 14 -7.50 <.0001
 0 1 -18.9327 2.7888 14 -6.79 <.0001
 0 2 -21.3263 2.9461 14 -7.24 <.0001
 0 3 -10.7033 2.4912 14 -4.30 0.0007
 0 4 -9.2061 2.4231 14 -3.80 0.0020
 0 5 -5.8034 1.1620 14 -4.99 0.0002
 0.25 1 2.8550 4.3062 14 0.66 0.5181
 0.25 2 0.4613 3.4048 14 0.14 0.8942
 0.25 3 11.0843 4.4154 14 2.51 0.0250
 0.25 4 12.5816 3.6513 14 3.45 0.0039
 0.25 5 15.9842 2.8999 14 5.51 <.0001
 1 2 -2.3937 4.4810 14 -0.53 0.6016
 1 3 8.2293 3.6433 14 2.26 0.0404
 1 4 9.7266 4.1312 14 2.35 0.0337
 1 5 13.1292 2.5416 14 5.17 0.0001
 2 3 10.6230 3.1694 14 3.35 0.0047
 2 4 12.1202 3.0460 14 3.98 0.0014
 2 5 15.5229 3.1316 14 4.96 0.0002
 3 4 1.4972 2.9716 14 0.50 0.6222
 3 5 4.8999 2.5444 14 1.93 0.0747
 4 5 3.4027 3.0134 14 1.13 0.2778
MHCII+  0 0.25 -1.1486 0.3993 14 -2.88 0.0122
Macrophages+ 0 1 0.1271 0.05785 14 2.20 0.0453
 0 2 0.3261 0.06054 14 5.39 <.0001
 0 3 0.1359 0.1006 14 1.35 0.1983
 0 4 -0.06456 0.1059 14 -0.61 0.5519
 0 5 0.1692 0.06728 14 2.52 0.0247
 0.25 1 1.2757 0.4106 14 3.11 0.0077
 0.25 2 1.4747 0.3998 14 3.69 0.0024
 0.25 3 1.2844 0.4363 14 2.94 0.0107
 0.25 4 1.0840 0.4324 14 2.51 0.0251
 0.25 5 1.3178 0.4155 14 3.17 0.0068
 1 2 0.1990 0.04347 14 4.58 0.0004
 1 3 0.008778 0.08728 14 0.10 0.9213
 1 4 -0.1917 0.07846 14 -2.44 0.0284
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 1 5 0.04211 0.06045 14 0.70 0.4974
 2 3 -0.1902 0.08913 14 -2.13 0.0510
 2 4 -0.3907 0.07344 14 -5.32 0.0001
 2 5 -0.1569 0.03437 14 -4.56 0.0004
 3 4 -0.2004 0.09345 14 -2.15 0.0500
 3 5 0.03333 0.08093 14 0.41 0.6867
 4 5 0.2338 0.07807 14 2.99 0.0097
CD4+ CD8+ 0 0.25 -0.04422 0.02983 14 -1.48 0.1604
 0 1 -0.06500 0.03184 14 -2.04 0.0605
 0 2 -0.01711 0.02421 14 -0.71 0.4913
 0 3 -0.4812 0.09480 14 -5.08 0.0002
 0 4 -0.2661 0.07623 14 -3.49 0.0036
 0 5 -0.3301 0.05495 14 -6.01 <.0001
 0.25 1 -0.02078 0.03208 14 -0.65 0.5277
 0.25 2 0.02711 0.03172 14 0.85 0.4071
 0.25 3 -0.4370 0.09220 14 -4.74 0.0003
 0.25 4 -0.2219 0.08429 14 -2.63 0.0197
 0.25 5 -0.2859 0.05696 14 -5.02 0.0002
 1 2 0.04789 0.03519 14 1.36 0.1950
 1 3 -0.4162 0.09911 14 -4.20 0.0009
 1 4 -0.2011 0.09171 14 -2.19 0.0457
 1 5 -0.2651 0.06550 14 -4.05 0.0012
 2 3 -0.4641 0.09130 14 -5.08 0.0002
 2 4 -0.2490 0.06885 14 -3.62 0.0028
 2 5 -0.3130 0.06642 14 -4.71 0.0003
 3 4 0.2151 0.07543 14 2.85 0.0128
 3 5 0.1511 0.08329 14 1.81 0.0911
 4 5 -0.06400 0.08068 14 -0.79 0.4409
CD4+ CD8- 0 0.25 -3.0803 0.8306 14 -3.71 0.0023
 0 1 -5.8193 1.1818 14 -4.92 0.0002
 0 2 -5.4109 0.8328 14 -6.50 <.0001
 0 3 -2.8750 0.8153 14 -3.53 0.0034
 0 4 -1.5489 0.6026 14 -2.57 0.0222
 0 5 -1.0569 0.4365 14 -2.42 0.0296
 0.25 1 -2.7390 1.4675 14 -1.87 0.0831
 0.25 2 -2.3306 1.0702 14 -2.18 0.0470
 0.25 3 0.2053 1.2687 14 0.16 0.8737
 0.25 4 1.5314 1.0157 14 1.51 0.1539
 0.25 5 2.0234 0.7178 14 2.82 0.0137
 1 2 0.4084 1.3583 14 0.30 0.7681
 1 3 2.9443 1.2260 14 2.40 0.0308
 1 4 4.2704 1.1934 14 3.58 0.0030
 1 5 4.7624 1.0801 14 4.41 0.0006
 2 3 2.5359 1.0535 14 2.41 0.0304
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 2 4 3.8620 0.8730 14 4.42 0.0006
 2 5 4.3540 0.9605 14 4.53 0.0005
 3 4 1.3261 0.8035 14 1.65 0.1211
 3 5 1.8181 0.7257 14 2.51 0.0252
 4 5 0.4920 0.7116 14 0.69 0.5006
CD4- CD8+ 0 0.25 -1.9666 0.3817 14 -5.15 0.0001
 0 1 -2.5330 0.4617 14 -5.49 <.0001
 0 2 -2.4003 0.3122 14 -7.69 <.0001
 0 3 -2.7570 0.5166 14 -5.34 0.0001
 0 4 -1.1937 0.2322 14 -5.14 0.0001
 0 5 -1.1458 0.1741 14 -6.58 <.0001
 0.25 1 -0.5664 0.6129 14 -0.92 0.3710
 0.25 2 -0.4338 0.5093 14 -0.85 0.4087
 0.25 3 -0.7904 0.7284 14 -1.09 0.2962
 0.25 4 0.7729 0.5089 14 1.52 0.1511
 0.25 5 0.8208 0.3651 14 2.25 0.0412
 1 2 0.1327 0.5458 14 0.24 0.8115
 1 3 -0.2240 0.6944 14 -0.32 0.7518
 1 4 1.3393 0.5461 14 2.45 0.0279
 1 5 1.3872 0.4674 14 2.97 0.0102
 2 3 -0.3567 0.5937 14 -0.60 0.5576
 2 4 1.2067 0.3610 14 3.34 0.0048
 2 5 1.2546 0.3790 14 3.31 0.0052
 3 4 1.5633 0.4986 14 3.14 0.0073
 3 5 1.6112 0.4860 14 3.32 0.0051
 4 5 0.04789 0.2386 14 0.20 0.8438
CD25+ CD4+ 0 0.25 0.05956 0.03374 14 1.76 0.0994
 0 1 -0.2738 0.08314 14 -3.29 0.0053
 0 2 -0.06089 0.04237 14 -1.44 0.1726
 0 3 -0.1439 0.04340 14 -3.32 0.0051
 0 4 -0.08167 0.03631 14 -2.25 0.0411
 0 5 -0.08944 0.03684 14 -2.43 0.0293
 0.25 1 -0.3333 0.08304 14 -4.01 0.0013
 0.25 2 -0.1204 0.04138 14 -2.91 0.0114
 0.25 3 -0.2034 0.04070 14 -5.00 0.0002
 0.25 4 -0.1412 0.04184 14 -3.38 0.0045
 0.25 5 -0.1490 0.03027 14 -4.92 0.0002
 1 2 0.2129 0.07889 14 2.70 0.0173
 1 3 0.1299 0.07693 14 1.69 0.1135
 1 4 0.1921 0.09935 14 1.93 0.0736
 1 5 0.1843 0.08810 14 2.09 0.0551
 2 3 -0.08300 0.05497 14 -1.51 0.1533
 2 4 -0.02078 0.05684 14 -0.37 0.7202
 2 5 -0.02856 0.05533 14 -0.52 0.6138
 3 4 0.06222 0.04571 14 1.36 0.1950
 3 5 0.05444 0.03639 14 1.50 0.1568
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 4 5 -0.00778 0.03474 14 -0.22 0.8261
CD25+ CD4- 0 0.25 -0.07533 0.06612 14 -1.14 0.2737
 0 1 -0.4262 0.1029 14 -4.14 0.0010
 0 2 0.1004 0.08237 14 1.22 0.2428
 0 3 0.1856 0.08705 14 2.13 0.0512
 0 4 0.1129 0.06602 14 1.71 0.1093
 0 5 0.1520 0.06374 14 2.38 0.0318
 0.25 1 -0.3509 0.1085 14 -3.23 0.0060
 0.25 2 0.1758 0.09042 14 1.94 0.0723
 0.25 3 0.2609 0.08154 14 3.20 0.0064
 0.25 4 0.1882 0.06433 14 2.93 0.0111
 0.25 5 0.2273 0.08845 14 2.57 0.0222
 1 2 0.5267 0.1172 14 4.49 0.0005
 1 3 0.6118 0.1111 14 5.51 <.0001
 1 4 0.5391 0.09268 14 5.82 <.0001
 1 5 0.5782 0.1011 14 5.72 <.0001
 2 3 0.08511 0.04860 14 1.75 0.1018
 2 4 0.01244 0.05570 14 0.22 0.8264
 2 5 0.05156 0.06101 14 0.84 0.4123
 3 4 -0.07267 0.05369 14 -1.35 0.1974
 3 5 -0.03356 0.05905 14 -0.57 0.5789
 4 5 0.03911 0.05845 14 0.67 0.5143
 T cell+ CD8+ 0 0.25 -0.4692 0.05912 14 -7.94 <.0001
 0 1 -0.3897 0.07367 14 -5.29 0.0001
 0 2 -0.2857 0.03830 14 -7.46 <.0001
 0 3 -0.5936 0.06892 14 -8.61 <.0001
 0 4 -0.1984 0.04007 14 -4.95 0.0002
 0 5 -0.3780 0.03541 14 -10.67 <.0001
 0.25 1 0.07956 0.09932 14 0.80 0.4365
 0.25 2 0.1836 0.07739 14 2.37 0.0326
 0.25 3 -0.1243 0.09613 14 -1.29 0.2168
 0.25 4 0.2708 0.08100 14 3.34 0.0048
 0.25 5 0.09122 0.06092 14 1.50 0.1565
 1 2 0.1040 0.07202 14 1.44 0.1707
 1 3 -0.2039 0.1001 14 -2.04 0.0609
 1 4 0.1912 0.08406 14 2.27 0.0392
 1 5 0.01167 0.08631 14 0.14 0.8944
 2 3 -0.3079 0.06060 14 -5.08 0.0002
 2 4 0.08722 0.02364 14 3.69 0.0024
 2 5 -0.09233 0.04872 14 -1.90 0.0789
 3 4 0.3951 0.05392 14 7.33 <.0001
 3 5 0.2156 0.05949 14 3.62 0.0028
 4 5 -0.1796 0.04541 14 -3.95 0.0014
 T cell+ CD8- 0 0.25 -4.6739 0.9623 14 -4.86 0.0003
 0 1 -3.0680 0.3891 14 -7.88 <.0001
 0 2 -1.1196 0.1669 14 -6.71 <.0001
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 3 -0.8113 0.1345 14 -6.03 <.0001
 0 4 -0.4184 0.1730 14 -2.42 0.0298
 0 5 -0.4967 0.1306 14 -3.80 0.0019
 0.25 1 1.6059 1.1013 14 1.46 0.1668
 0.25 2 3.5543 0.9347 14 3.80 0.0019
 0.25 3 3.8626 0.9849 14 3.92 0.0015
 0.25 4 4.2554 0.9227 14 4.61 0.0004
 0.25 5 4.1772 0.9873 14 4.23 0.0008
 1 2 1.9484 0.4727 14 4.12 0.0010
 1 3 2.2567 0.4399 14 5.13 0.0002
 1 4 2.6496 0.4348 14 6.09 <.0001
 1 5 2.5713 0.3806 14 6.76 <.0001
 2 3 0.3082 0.1442 14 2.14 0.0507
 2 4 0.7011 0.1546 14 4.54 0.0005
 2 5 0.6229 0.1899 14 3.28 0.0055
 3 4 0.3929 0.1902 14 2.07 0.0579
 3 5 0.3147 0.1714 14 1.84 0.0877
 4 5 -0.07822 0.1742 14 -0.45 0.6603
 T cell+ 0 0.25 -3.4014 0.6301 14 -5.40 <.0001
 0 1 -5.7460 0.9658 14 -5.95 <.0001
 0 2 -5.3638 0.6428 14 -8.34 <.0001
 0 3 -3.9572 0.7030 14 -5.63 <.0001
 0 4 -1.6892 0.3405 14 -4.96 0.0002
 0 5 -1.8833 0.3233 14 -5.83 <.0001
 0.25 1 -2.3446 1.3052 14 -1.80 0.0941
 0.25 2 -1.9623 0.8816 14 -2.23 0.0430
 0.25 3 -0.5558 1.1125 14 -0.50 0.6251
 0.25 4 1.7122 0.7645 14 2.24 0.0419
 0.25 5 1.5181 0.6299 14 2.41 0.0303
 1 2 0.3822 1.2005 14 0.32 0.7549
 1 3 1.7888 1.0295 14 1.74 0.1042
 1 4 4.0568 0.9637 14 4.21 0.0009
 1 5 3.8627 0.8929 14 4.33 0.0007
 2 3 1.4066 0.8497 14 1.66 0.1201
 2 4 3.6746 0.6291 14 5.84 <.0001
 2 5 3.4804 0.7662 14 4.54 0.0005
 3 4 2.2680 0.6534 14 3.47 0.0037
 3 5 2.0739 0.6180 14 3.36 0.0047
 4 5 -0.1941 0.4673 14 -0.42 0.6842
 T cell+ 0 0.25 -1.7231 0.3737 14 -4.61 0.0004
 0 1 -2.1064 0.3528 14 -5.97 <.0001
 0 2 -1.7837 0.2511 14 -7.10 <.0001
 0 3 -1.4296 0.2532 14 -5.65 <.0001
 0 4 -0.5901 0.1236 14 -4.77 0.0003
 0 5 -0.6206 0.1504 14 -4.13 0.0010
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0.25 1 -0.3833 0.5621 14 -0.68 0.5064
 0.25 2 -0.06056 0.4472 14 -0.14 0.8942
 0.25 3 0.2936 0.5117 14 0.57 0.5753
 0.25 4 1.1330 0.4048 14 2.80 0.0142
 0.25 5 1.1026 0.3558 14 3.10 0.0079
 1 2 0.3228 0.4250 14 0.76 0.4602
 1 3 0.6769 0.4128 14 1.64 0.1234
 1 4 1.5163 0.3508 14 4.32 0.0007
 1 5 1.4859 0.3286 14 4.52 0.0005
 2 3 0.3541 0.3719 14 0.95 0.3572
 2 4 1.1936 0.2452 14 4.87 0.0002
 2 5 1.1631 0.3115 14 3.73 0.0022
 3 4 0.8394 0.2575 14 3.26 0.0057
 3 5 0.8090 0.2146 14 3.77 0.0021
 4 5 -0.03044 0.1897 14 -0.16 0.8748
CD3+ 0 0.25 -9.2509 1.6671 14 -5.55 <.0001
 0 1 -9.8456 1.6019 14 -6.15 <.0001
 0 2 -9.5484 1.2316 14 -7.75 <.0001
 0 3 -6.2850 0.9423 14 -6.67 <.0001
 0 4 -3.3744 0.7157 14 -4.71 0.0003
 0 5 -3.1467 0.5182 14 -6.07 <.0001
 0.25 1 -0.5947 2.4631 14 -0.24 0.8127
 0.25 2 -0.2976 2.0104 14 -0.15 0.8844
 0.25 3 2.9659 2.1160 14 1.40 0.1828
 0.25 4 5.8764 1.6728 14 3.51 0.0034
 0.25 5 6.1042 1.7224 14 3.54 0.0032
 1 2 0.2971 2.1401 14 0.14 0.8916
 1 3 3.5606 1.7968 14 1.98 0.0675
 1 4 6.4711 1.6966 14 3.81 0.0019
 1 5 6.6989 1.4336 14 4.67 0.0004
 2 3 3.2634 1.0813 14 3.02 0.0092
 2 4 6.1740 1.0929 14 5.65 <.0001
 2 5 6.4018 1.3715 14 4.67 0.0004
 3 4 2.9106 0.9459 14 3.08 0.0082
 3 5 3.1383 0.9675 14 3.24 0.0059
 4 5 0.2278 0.8611 14 0.26 0.7952
B cells 0 0.25 -0.8827 0.1437 14 -6.14 <.0001
 0 1 -4.3372 0.6659 14 -6.51 <.0001
 0 2 -10.0049 1.2916 14 -7.75 <.0001
 0 3 -7.6129 1.3606 14 -5.60 <.0001
 0 4 -5.0324 0.9314 14 -5.40 <.0001
 0 5 -3.1478 0.3652 14 -8.62 <.0001
 0.25 1 -3.4546 0.6999 14 -4.94 0.0002
 0.25 2 -9.1222 1.2831 14 -7.11 <.0001
 0.25 3 -6.7302 1.4131 14 -4.76 0.0003
 0.25 4 -4.1498 0.9375 14 -4.43 0.0006
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0.25 5 -2.2651 0.4484 14 -5.05 0.0002
 1 2 -5.6677 1.6244 14 -3.49 0.0036
 1 3 -3.2757 1.5804 14 -2.07 0.0571
 1 4 -0.6952 1.2346 14 -0.56 0.5823
 1 5 1.1894 0.7127 14 1.67 0.1173
 2 3 2.3920 1.5239 14 1.57 0.1388
 2 4 4.9724 1.3927 14 3.57 0.0031
 2 5 6.8571 1.3179 14 5.20 0.0001
 3 4 2.5804 1.2711 14 2.03 0.0618
 3 5 4.4651 1.2967 14 3.44 0.0040
 4 5 1.8847 1.0353 14 1.82 0.0901
Study B 
 
   
Live cells 0 0.25 -9.6550 1.7301 9 -5.58 0.0003
 0 1 -13.5367 1.6694 9 -8.11 <.0001
 0 2 -12.1867 1.7722 9 -6.88 <.0001
 0 3 -11.5925 1.2064 9 -9.61 <.0001
 0 4 -0.1900 1.2066 9 -0.16 0.8784
 0 5 -2.9425 1.4683 9 -2.00 0.0761
 0.25 1 -3.8817 3.0501 9 -1.27 0.2350
 0.25 2 -2.5317 2.9000 9 -0.87 0.4054
 0.25 3 -1.9375 2.1577 9 -0.90 0.3926
 0.25 4 9.4650 2.0933 9 4.52 0.0014
 0.25 5 6.7125 2.1182 9 3.17 0.0114
 1 2 1.3500 1.2434 9 1.09 0.3058
 1 3 1.9442 2.0167 9 0.96 0.3602
 1 4 13.3467 1.8016 9 7.41 <.0001
 1 5 10.5942 2.3511 9 4.51 0.0015
 2 3 0.5942 1.4174 9 0.42 0.6849
 2 4 11.9967 2.2002 9 5.45 0.0004
 2 5 9.2442 2.3339 9 3.96 0.0033
 3 4 11.4025 1.8690 9 6.10 0.0002
 3 5 8.6500 1.6635 9 5.20 0.0006
 4 5 -2.7525 1.2970 9 -2.12 0.0628
MHCII+ B cells+ 0 0.25 -1.2667 0.1253 9 -10.11 <.0001
 0 1 -12.1825 2.9036 9 -4.20 0.0023
 0 2 -12.0450 1.8015 9 -6.69 <.0001
 0 3 -12.6717 1.6376 9 -7.74 <.0001
 0 4 -2.5392 0.7223 9 -3.52 0.0066
 0 5 -1.7633 0.4898 9 -3.60 0.0057
 0.25 1 -10.9158 2.8871 9 -3.78 0.0043
 0.25 2 -10.7783 1.7187 9 -6.27 0.0001
 0.25 3 -11.4050 1.6067 9 -7.10 <.0001
 0.25 4 -1.2725 0.6945 9 -1.83 0.1002
 0.25 5 -0.4967 0.4827 9 -1.03 0.3303
 1 2 0.1375 2.6393 9 0.05 0.9596
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 1 3 -0.4892 2.8525 9 -0.17 0.8676
 1 4 9.6433 3.3100 9 2.91 0.0172
 1 5 10.4192 3.0033 9 3.47 0.0071
 2 3 -0.6267 1.5080 9 -0.42 0.6875
 2 4 9.5058 2.0114 9 4.73 0.0011
 2 5 10.2817 1.8816 9 5.46 0.0004
 3 4 10.1325 1.6181 9 6.26 0.0001
 3 5 10.9083 1.5070 9 7.24 <.0001
 4 5 0.7758 0.7442 9 1.04 0.3244
CD4- CD8+ 0 0.25 -1.9000 0.3498 9 -5.43 0.0004
 0 1 -3.6533 0.4453 9 -8.20 <.0001
 0 2 -2.4850 0.4484 9 -5.54 0.0004
 0 3 -2.0900 0.3416 9 -6.12 0.0002
 0 4 -0.5458 0.09998 9 -5.46 0.0004
 0 5 -0.4142 0.1609 9 -2.57 0.0300
 0.25 1 -1.7533 0.6649 9 -2.64 0.0270
 0.25 2 -0.5850 0.7063 9 -0.83 0.4290
 0.25 3 -0.1900 0.4845 9 -0.39 0.7041
 0.25 4 1.3542 0.3905 9 3.47 0.0071
 0.25 5 1.4858 0.3806 9 3.90 0.0036
 1 2 1.1683 0.4093 9 2.85 0.0190
 1 3 1.5633 0.5074 9 3.08 0.0131
 1 4 3.1075 0.4507 9 6.89 <.0001
 1 5 3.2392 0.4553 9 7.11 <.0001
 2 3 0.3950 0.3672 9 1.08 0.3100
 2 4 1.9392 0.4899 9 3.96 0.0033
 2 5 2.0708 0.4341 9 4.77 0.0010
 3 4 1.5442 0.4113 9 3.75 0.0045
 3 5 1.6758 0.3678 9 4.56 0.0014
 4 5 0.1317 0.1820 9 0.72 0.4878
CD4+ CD8- 0 0.25 -3.4767 0.4284 9 -8.12 <.0001
 0 1 -8.3225 1.0370 9 -8.03 <.0001
 0 2 -6.0192 0.9518 9 -6.32 0.0001
 0 3 -5.3975 0.7370 9 -7.32 <.0001
 0 4 -1.4058 0.4048 9 -3.47 0.0070
 0 5 -1.4033 0.4901 9 -2.86 0.0187
 0.25 1 -4.8458 1.0217 9 -4.74 0.0011
 0.25 2 -2.5425 1.1173 9 -2.28 0.0489
 0.25 3 -1.9208 0.7909 9 -2.43 0.0381
 0.25 4 2.0708 0.4359 9 4.75 0.0010
 0.25 5 2.0733 0.3150 9 6.58 0.0001
 1 2 2.3033 0.9657 9 2.39 0.0409
 1 3 2.9250 0.9820 9 2.98 0.0155
 1 4 6.9167 1.1051 9 6.26 0.0001
 1 5 6.9192 1.0525 9 6.57 0.0001
 2 3 0.6217 0.6214 9 1.00 0.3432
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 2 4 4.6133 1.0560 9 4.37 0.0018
 2 5 4.6158 1.1737 9 3.93 0.0034
 3 4 3.9917 0.7742 9 5.16 0.0006
 3 5 3.9942 0.8594 9 4.65 0.0012
 4 5 0.002500 0.4264 9 0.01 0.9954
 T cell+ CD8- 0 0.25 -7.1725 1.4801 9 -4.85 0.0009
 0 1 -5.2842 0.6724 9 -7.86 <.0001
 0 2 -1.8517 0.3129 9 -5.92 0.0002
 0 3 -1.6792 0.3783 9 -4.44 0.0016
 0 4 -0.4275 0.1672 9 -2.56 0.0309
 0 5 -0.4692 0.2361 9 -1.99 0.0782
 0.25 1 1.8883 1.8649 9 1.01 0.3377
 0.25 2 5.3208 1.5416 9 3.45 0.0073
 0.25 3 5.4933 1.7005 9 3.23 0.0103
 0.25 4 6.7450 1.4759 9 4.57 0.0013
 0.25 5 6.7033 1.4355 9 4.67 0.0012
 1 2 3.4325 0.7360 9 4.66 0.0012
 1 3 3.6050 0.5954 9 6.05 0.0002
 1 4 4.8567 0.6571 9 7.39 <.0001
 1 5 4.8150 0.7792 9 6.18 0.0002
 2 3 0.1725 0.3455 9 0.50 0.6295
 2 4 1.4242 0.2451 9 5.81 0.0003
 2 5 1.3825 0.4092 9 3.38 0.0081
 3 4 1.2517 0.3414 9 3.67 0.0052
 3 5 1.2100 0.4283 9 2.83 0.0199
 4 5 -0.04167 0.2534 9 -0.16 0.8730
 T cell+ 0 0.25 -3.8400 0.5452 9 -7.04 <.0001
 0 1 -9.3992 0.9718 9 -9.67 <.0001
 0 2 -7.5258 0.9393 9 -8.01 <.0001
 0 3 -6.1992 0.9740 9 -6.36 0.0001
 0 4 -2.3200 0.5778 9 -4.02 0.0030
 0 5 -4.2983 0.4524 9 -9.50 <.0001
 0.25 1 -5.5592 1.0418 9 -5.34 0.0005
 0.25 2 -3.6858 1.2010 9 -3.07 0.0134
 0.25 3 -2.3592 1.0929 9 -2.16 0.0592
 0.25 4 1.5200 0.4753 9 3.20 0.0109
 0.25 5 -0.4583 0.5240 9 -0.87 0.4045
 1 2 1.8733 0.8797 9 2.13 0.0621
 1 3 3.2000 0.9263 9 3.45 0.0072
 1 4 7.0792 1.1294 9 6.27 0.0001
 1 5 5.1008 1.0182 9 5.01 0.0007
 2 3 1.3267 0.7762 9 1.71 0.1216
 2 4 5.2058 1.0260 9 5.07 0.0007
 2 5 3.2275 1.1638 9 2.77 0.0216
 3 4 3.8792 1.0383 9 3.74 0.0047
 3 5 1.9008 1.0975 9 1.73 0.1173
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 4 5 -1.9783 0.7520 9 -2.63 0.0273
 T cell+  0 0.25 -0.8233 0.2108 9 -3.91 0.0036
CD4- CD8+ 0 1 -2.0908 0.3376 9 -6.19 0.0002
 0 2 -1.5767 0.2838 9 -5.55 0.0004
 0 3 -1.0575 0.2278 9 -4.64 0.0012
 0 4 -0.2258 0.1397 9 -1.62 0.1405
 0 5 -1.9275 0.2568 9 -7.51 <.0001
 0.25 1 -1.2675 0.2588 9 -4.90 0.0008
 0.25 2 -0.7533 0.2334 9 -3.23 0.0104
 0.25 3 -0.2342 0.2914 9 -0.80 0.4424
 0.25 4 0.5975 0.1347 9 4.44 0.0016
 0.25 5 -1.1042 0.3683 9 -3.00 0.0150
 1 2 0.5142 0.2672 9 1.92 0.0865
 1 3 1.0333 0.2978 9 3.47 0.0070
 1 4 1.8650 0.2573 9 7.25 <.0001
 1 5 0.1633 0.4373 9 0.37 0.7174
 2 3 0.5192 0.2768 9 1.88 0.0935
 2 4 1.3508 0.2531 9 5.34 0.0005
 2 5 -0.3508 0.3436 9 -1.02 0.3339
 3 4 0.8317 0.2113 9 3.94 0.0034
 3 5 -0.8700 0.2605 9 -3.34 0.0087
 4 5 -1.7017 0.3246 9 -5.24 0.0005
 T cell+  0 0.25 -0.02083 0.05928 9 -0.35 0.7334
CD4+ CD8+ 0 1 -0.5383 0.1729 9 -3.11 0.0124
 0 2 -0.5517 0.1371 9 -4.02 0.0030
 0 3 -0.4700 0.1700 9 -2.77 0.0219
 0 4 -0.3067 0.1524 9 -2.01 0.0751
 0 5 -0.8717 0.1110 9 -7.85 <.0001
 0.25 1 -0.5175 0.1383 9 -3.74 0.0046
 0.25 2 -0.5308 0.1145 9 -4.63 0.0012
 0.25 3 -0.4492 0.1476 9 -3.04 0.0140
 0.25 4 -0.2858 0.1319 9 -2.17 0.0583
 0.25 5 -0.8508 0.1480 9 -5.75 0.0003
 1 2 -0.01333 0.1049 9 -0.13 0.9017
 1 3 0.06833 0.08464 9 0.81 0.4403
 1 4 0.2317 0.1377 9 1.68 0.1267
 1 5 -0.3333 0.2425 9 -1.37 0.2025
 2 3 0.08167 0.09909 9 0.82 0.4311
 2 4 0.2450 0.1244 9 1.97 0.0805
 2 5 -0.3200 0.2212 9 -1.45 0.1819
 3 4 0.1633 0.1232 9 1.33 0.2176
 3 5 -0.4017 0.2561 9 -1.57 0.1512
 4 5 -0.5650 0.2234 9 -2.53 0.0323
 T cell+  0 0.25 -3.0350 0.3482 9 -8.72 <.0001
CD4+ CD8- 0 1 -6.7408 0.8250 9 -8.17 <.0001
 0 2 -5.5250 0.7908 9 -6.99 <.0001
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 3 -4.2958 0.6360 9 -6.75 <.0001
 0 4 -1.3542 0.3040 9 -4.46 0.0016
 0 5 -1.5867 0.4756 9 -3.34 0.0087
 0.25 1 -3.7058 0.8826 9 -4.20 0.0023
 0.25 2 -2.4900 0.9509 9 -2.62 0.0279
 0.25 3 -1.2608 0.6794 9 -1.86 0.0965
 0.25 4 1.6808 0.2893 9 5.81 0.0003
 0.25 5 1.4483 0.3082 9 4.70 0.0011
 1 2 1.2158 0.7350 9 1.65 0.1325
 1 3 2.4450 0.6672 9 3.66 0.0052
 1 4 5.3867 0.8853 9 6.08 0.0002
 1 5 5.1542 0.9208 9 5.60 0.0003
 2 3 1.2292 0.5617 9 2.19 0.0564
 2 4 4.1708 0.8358 9 4.99 0.0007
 2 5 3.9383 1.0413 9 3.78 0.0043
 3 4 2.9417 0.6929 9 4.25 0.0022
 3 5 2.7092 0.7812 9 3.47 0.0071
 4 5 -0.2325 0.4355 9 -0.53 0.6063
 T cell+ 0 0.25 -2.1192 0.2736 9 -7.75 <.0001
 0 1 -3.8750 0.5214 9 -7.43 <.0001
 0 2 -3.0550 0.2601 9 -11.75 <.0001
 0 3 -2.8775 0.3644 9 -7.90 <.0001
 0 4 -1.2067 0.2830 9 -4.26 0.0021
 0 5 -3.5258 0.1212 9 -29.10 <.0001
 0.25 1 -1.7558 0.4231 9 -4.15 0.0025
 0.25 2 -0.9358 0.4002 9 -2.34 0.0441
 0.25 3 -0.7583 0.4161 9 -1.82 0.1017
 0.25 4 0.9125 0.3111 9 2.93 0.0167
 0.25 5 -1.4067 0.2815 9 -5.00 0.0007
 1 2 0.8200 0.4613 9 1.78 0.1092
 1 3 0.9975 0.5060 9 1.97 0.0802
 1 4 2.6683 0.5569 9 4.79 0.0010
 1 5 0.3492 0.5450 9 0.64 0.5377
 2 3 0.1775 0.3265 9 0.54 0.5999
 2 4 1.8483 0.3187 9 5.80 0.0003
 2 5 -0.4708 0.3462 9 -1.36 0.2069
 3 4 1.6708 0.3695 9 4.52 0.0014
 3 5 -0.6483 0.4351 9 -1.49 0.1704
 4 5 -2.3192 0.3411 9 -6.80 <.0001
 T cell+ 0 0.25 -0.8108 0.1155 9 -7.02 <.0001
CD4- CD8+ 0 1 -1.1425 0.1448 9 -7.89 <.0001
 0 2 -0.9833 0.1069 9 -9.20 <.0001
 0 3 -0.7258 0.08936 9 -8.12 <.0001
 0 4 -0.4142 0.08032 9 -5.16 0.0006
 0 5 -1.6608 0.2383 9 -6.97 <.0001
 0.25 1 -0.3317 0.1478 9 -2.24 0.0515
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0.25 2 -0.1725 0.07937 9 -2.17 0.0578
 0.25 3 0.08500 0.1281 9 0.66 0.5238
 0.25 4 0.3967 0.1072 9 3.70 0.0049
 0.25 5 -0.8500 0.2802 9 -3.03 0.0142
 1 2 0.1592 0.1512 9 1.05 0.3200
 1 3 0.4167 0.1380 9 3.02 0.0145
 1 4 0.7283 0.1565 9 4.65 0.0012
 1 5 -0.5183 0.3062 9 -1.69 0.1248
 2 3 0.2575 0.1497 9 1.72 0.1194
 2 4 0.5692 0.1106 9 5.15 0.0006
 2 5 -0.6775 0.2903 9 -2.33 0.0445
 3 4 0.3117 0.09727 9 3.20 0.0108
 3 5 -0.9350 0.2228 9 -4.20 0.0023
 4 5 -1.2467 0.2511 9 -4.97 0.0008
 T cell+ 0 0.25 0.02917 0.02392 9 1.22 0.2536
CD4+ CD8+ 0 1 -0.1675 0.07394 9 -2.27 0.0497
 0 2 -0.2100 0.06299 9 -3.33 0.0087
 0 3 -0.2450 0.08964 9 -2.73 0.0231
 0 4 -0.2100 0.1416 9 -1.48 0.1721
 0 5 -1.0042 0.1653 9 -6.08 0.0002
 0.25 1 -0.1967 0.06789 9 -2.90 0.0177
 0.25 2 -0.2392 0.05787 9 -4.13 0.0025
 0.25 3 -0.2742 0.07821 9 -3.51 0.0067
 0.25 4 -0.2392 0.1285 9 -1.86 0.0956
 0.25 5 -1.0333 0.1806 9 -5.72 0.0003
 1 2 -0.04250 0.04950 9 -0.86 0.4129
 1 3 -0.07750 0.04695 9 -1.65 0.1332
 1 4 -0.04250 0.1166 9 -0.36 0.7239
 1 5 -0.8367 0.1829 9 -4.57 0.0013
 2 3 -0.03500 0.07160 9 -0.49 0.6366
 2 4 -11E-14 0.1056 9 -0.00 1.0000
 2 5 -0.7942 0.1735 9 -4.58 0.0013
 3 4 0.03500 0.1233 9 0.28 0.7830
 3 5 -0.7592 0.2117 9 -3.59 0.0059
 4 5 -0.7942 0.2366 9 -3.36 0.0084
 T cell+ 0 0.25 -0.3900 0.07349 9 -5.31 0.0005
CD4- CD8- 0 1 -0.2217 0.09384 9 -2.36 0.0424
 0 2 -0.1158 0.02535 9 -4.57 0.0013
 0 3 -0.2075 0.02453 9 -8.46 <.0001
 0 4 -0.2583 0.04538 9 -5.69 0.0003
 0 5 -0.6875 0.1077 9 -6.38 0.0001
 0.25 1 0.1683 0.1072 9 1.57 0.1507
 0.25 2 0.2742 0.07508 9 3.65 0.0053
 0.25 3 0.1825 0.07999 9 2.28 0.0484
 0.25 4 0.1317 0.08967 9 1.47 0.1761
 0.25 5 -0.2975 0.09502 9 -3.13 0.0121
334 
 
 
 
Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 1 2 0.1058 0.08347 9 1.27 0.2366
 1 3 0.01417 0.09326 9 0.15 0.8826
 1 4 -0.03667 0.09139 9 -0.40 0.6976
 1 5 -0.4658 0.09556 9 -4.87 0.0009
 2 3 -0.09167 0.02957 9 -3.10 0.0127
 2 4 -0.1425 0.04107 9 -3.47 0.0071
 2 5 -0.5717 0.1133 9 -5.04 0.0007
 3 4 -0.05083 0.05460 9 -0.93 0.3762
 3 5 -0.4800 0.1166 9 -4.12 0.0026
 4 5 -0.4292 0.1213 9 -3.54 0.0063
 T cell+ 0 0.25 -1.0417 0.1770 9 -5.88 0.0002
CD4+ CD8- 0 1 -2.3567 0.4116 9 -5.73 0.0003
 0 2 -1.8967 0.2859 9 -6.63 <.0001
 0 3 -1.5242 0.2263 9 -6.73 <.0001
 0 4 -0.3558 0.1113 9 -3.20 0.0109
 0 5 -0.5100 0.1412 9 -3.61 0.0057
 0.25 1 -1.3150 0.3301 9 -3.98 0.0032
 0.25 2 -0.8550 0.3396 9 -2.52 0.0329
 0.25 3 -0.4825 0.2239 9 -2.15 0.0596
 0.25 4 0.6858 0.1478 9 4.64 0.0012
 0.25 5 0.5317 0.1241 9 4.28 0.0020
 1 2 0.4600 0.3778 9 1.22 0.2543
 1 3 0.8325 0.3249 9 2.56 0.0306
 1 4 2.0008 0.3919 9 5.11 0.0006
 1 5 1.8467 0.3940 9 4.69 0.0011
 2 3 0.3725 0.1651 9 2.26 0.0505
 2 4 1.5408 0.3038 9 5.07 0.0007
 2 5 1.3867 0.3428 9 4.05 0.0029
 3 4 1.1683 0.2189 9 5.34 0.0005
 3 5 1.0142 0.2391 9 4.24 0.0022
 4 5 -0.1542 0.1426 9 -1.08 0.3079
B cell+ IgM- 0 0.25 0.05250 0.05795 9 0.91 0.3886
 0 1 -2.2942 0.6005 9 -3.82 0.0041
 0 2 -1.5167 0.4673 9 -3.25 0.0101
 0 3 -1.9233 0.4147 9 -4.64 0.0012
 0 4 -0.3283 0.1518 9 -2.16 0.0588
 0 5 -0.1333 0.1500 9 -0.89 0.3972
 0.25 1 -2.3467 0.5794 9 -4.05 0.0029
 0.25 2 -1.5692 0.4342 9 -3.61 0.0056
 0.25 3 -1.9758 0.4025 9 -4.91 0.0008
 0.25 4 -0.3808 0.1268 9 -3.00 0.0149
 0.25 5 -0.1858 0.1114 9 -1.67 0.1297
 1 2 0.7775 0.7217 9 1.08 0.3094
 1 3 0.3708 0.7354 9 0.50 0.6262
 1 4 1.9658 0.6293 9 3.12 0.0122
 1 5 2.1608 0.5914 9 3.65 0.0053
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 2 3 -0.4067 0.3323 9 -1.22 0.2521
 2 4 1.1883 0.3779 9 3.14 0.0118
 2 5 1.3833 0.4182 9 3.31 0.0091
 3 4 1.5950 0.3959 9 4.03 0.0030
 3 5 1.7900 0.3773 9 4.74 0.0011
 4 5 0.1950 0.1891 9 1.03 0.3293
B cell+ IgG+ 0 0.25 -0.09750 0.03542 9 -2.75 0.0224
 0 1 -0.3942 0.1246 9 -3.16 0.0115
 0 2 -0.2100 0.02716 9 -7.73 <.0001
 0 3 -0.4558 0.07417 9 -6.15 0.0002
 0 4 -0.2117 0.05054 9 -4.19 0.0023
 0 5 -0.1425 0.04342 9 -3.28 0.0095
 0.25 1 -0.2967 0.1416 9 -2.09 0.0657
 0.25 2 -0.1125 0.04265 9 -2.64 0.0270
 0.25 3 -0.3583 0.06358 9 -5.64 0.0003
 0.25 4 -0.1142 0.04829 9 -2.36 0.0423
 0.25 5 -0.04500 0.02161 9 -2.08 0.0670
 1 2 0.1842 0.1331 9 1.38 0.1999
 1 3 -0.06167 0.1337 9 -0.46 0.6557
 1 4 0.1825 0.1444 9 1.26 0.2380
 1 5 0.2517 0.1353 9 1.86 0.0958
 2 3 -0.2458 0.06002 9 -4.10 0.0027
 2 4 -0.00167 0.05164 9 -0.03 0.9750
 2 5 0.06750 0.05223 9 1.29 0.2284
 3 4 0.2442 0.08114 9 3.01 0.0147
 3 5 0.3133 0.06591 9 4.75 0.0010
 4 5 0.06917 0.05132 9 1.35 0.2107
B cell+ IgG- 0 0.25 -1.0100 0.1082 9 -9.33 <.0001
 0 1 -11.7142 2.8034 9 -4.18 0.0024
 0 2 -12.4742 1.7649 9 -7.07 <.0001
 0 3 -11.7875 1.5359 9 -7.67 <.0001
 0 4 -2.4192 0.6575 9 -3.68 0.0051
 0 5 -1.8267 0.4548 9 -4.02 0.0030
 0.25 1 -10.7042 2.7626 9 -3.87 0.0038
 0.25 2 -11.4642 1.7484 9 -6.56 0.0001
 0.25 3 -10.7775 1.5146 9 -7.12 <.0001
 0.25 4 -1.4092 0.6257 9 -2.25 0.0508
 0.25 5 -0.8167 0.4318 9 -1.89 0.0912
 1 2 -0.7600 2.3889 9 -0.32 0.7576
 1 3 -0.07333 2.7145 9 -0.03 0.9790
 1 4 9.2950 3.1601 9 2.94 0.0165
 1 5 9.8875 2.8382 9 3.48 0.0069
 2 3 0.6867 1.5557 9 0.44 0.6694
 2 4 10.0550 1.9633 9 5.12 0.0006
 2 5 10.6475 1.9010 9 5.60 0.0003
 3 4 9.3683 1.4303 9 6.55 0.0001
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 3 5 9.9608 1.4453 9 6.89 <.0001
 4 5 0.5925 0.6558 9 0.90 0.3898
Study B PBS Control 
 
   
Live cells 0 0.25 1.4725 1.6522 5.279 0.89 0.4116
 0 1 -4.4525 3.3081 3.508 -1.35 0.2587
 0 2 -7.8125 1.6390 5.313 -4.77 0.0043
 0 3 -5.2925 3.2474 3.529 -1.63 0.1879
 0 4 -9.1200 1.5164 5.642 -6.01 0.0012
 0 5 -5.9125 6.0654 3.144 -0.97 0.3986
 0.25 1 -5.9250 3.4573 4.075 -1.71 0.1604
 0.25 2 -9.2850 1.9224 5.999 -4.83 0.0029
 0.25 3 -6.7650 3.3992 4.117 -1.99 0.1154
 0.25 4 -10.5925 1.8190 5.9 -5.82 0.0012
 0.25 5 -7.3850 6.1480 3.311 -1.20 0.3085
 1 2 -3.3600 3.4510 4.052 -0.97 0.3847
 1 3 -0.8400 4.4462 5.998 -0.19 0.8564
 1 4 -4.6675 3.3945 3.839 -1.38 0.2439
 1 5 -1.4600 6.7832 4.561 -0.22 0.8389
 2 3 2.5200 3.3928 4.092 0.74 0.4980
 2 4 -1.3075 1.8070 5.917 -0.72 0.4969
 2 5 1.9000 6.1445 3.304 0.31 0.7756
 3 4 -3.8275 3.3353 3.872 -1.15 0.3171
 3 5 -0.6200 6.7538 4.508 -0.09 0.9308
 4 5 3.2075 6.1129 3.24 0.52 0.6336
MHCII+ B cells+ 0 0.25 0.04000 0.1775 5.821 0.23 0.8294
 0 1 -4.6425 0.5247 3.43 -8.85 0.0018
 0 2 -3.7675 1.0339 3.106 -3.64 0.0337
 0 3 -5.1525 1.9781 3.029 -2.60 0.0793
 0 4 -7.5275 1.0736 3.098 -7.01 0.0054
 0 5 -9.8175 3.6717 3.008 -2.67 0.0752
 0.25 1 -4.6825 0.5194 3.303 -9.02 0.0019
 0.25 2 -3.8075 1.0312 3.074 -3.69 0.0331
 0.25 3 -5.1925 1.9767 3.02 -2.63 0.0780
 0.25 4 -7.5675 1.0711 3.069 -7.07 0.0054
 0.25 5 -9.8575 3.6710 3.006 -2.69 0.0746
 1 2 0.8750 1.1433 4.384 0.77 0.4832
 1 3 -0.5100 2.0374 3.394 -0.25 0.8167
 1 4 -2.8850 1.1794 4.292 -2.45 0.0664
 1 5 -5.1750 3.7040 3.114 -1.40 0.2536
 2 3 -1.3850 2.2237 4.509 -0.62 0.5635
 2 4 -3.7600 1.4781 5.991 -2.54 0.0439
 2 5 -6.0500 3.8096 3.465 -1.59 0.1983
 3 4 -2.3750 2.2424 4.611 -1.06 0.3418
 3 5 -4.6650 4.1662 4.602 -1.12 0.3178
 4 5 -2.2900 3.8206 3.502 -0.60 0.5855
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
CD4- CD8+ 0 0.25 -0.2750 0.1599 3.5 -1.72 0.1707
 0 1 -3.1825 0.8222 2.916 -3.87 0.0321
 0 2 -1.7625 0.4279 3.009 -4.12 0.0258
 0 3 -2.3325 0.8815 3.007 -2.65 0.0771
 0 4 -2.1250 0.3613 2.804 -5.88 0.0118
 0 5 -1.2850 0.5266 3.001 -2.44 0.0925
 0.25 1 -2.9075 0.8300 3.008 -3.50 0.0392
 0.25 2 -1.4875 0.4450 3.387 -3.34 0.0370
 0.25 3 -2.0575 0.8891 3.113 -2.31 0.1005
 0.25 4 -1.8500 0.3847 3.774 -4.81 0.0099
 0.25 5 -1.0100 0.5421 3.444 -1.86 0.1473
 1 2 1.4200 0.9174 3.913 1.55 0.1981
 1 3 0.8500 1.1968 5.086 0.71 0.5088
 1 4 1.0575 0.9002 3.86 1.17 0.3075
 1 5 1.8975 0.9758 4.713 1.94 0.1129
 2 3 -0.5700 0.9727 4.035 -0.59 0.5891
 2 4 -0.3625 0.5577 5.741 -0.65 0.5408
 2 5 0.4775 0.6749 5.676 0.71 0.5072
 3 4 0.2075 0.9569 3.882 0.22 0.8392
 3 5 1.0475 1.0290 4.718 1.02 0.3580
 4 5 0.8400 0.6434 5.114 1.31 0.2473
CD4+ CD8+ 0 0.25 -0.00750 0.02874 5.61 -0.26 0.8035
 0 1 -0.7850 0.09235 2.923 -8.50 0.0038
 0 2 -0.5675 0.1622 3.279 -3.50 0.0343
 0 3 -1.0175 0.4712 3.301 -2.16 0.1114
 0 4 -0.8225 0.1459 3.182 -5.64 0.0094
 0 5 -0.6700 0.3896 2.695 -1.72 0.1942
 0.25 1 -0.7775 0.09317 3.049 -8.34 0.0034
 0.25 2 -0.5600 0.1624 3.298 -3.45 0.0354
 0.25 3 -1.0100 0.4709 3.295 -2.14 0.1132
 0.25 4 -0.8150 0.1461 3.213 -5.58 0.0095
 0.25 5 -0.6625 0.3895 2.704 -1.70 0.1974
 1 2 0.2175 0.1756 4.69 1.24 0.2739
 1 3 -0.2325 0.4683 3.36 -0.50 0.6502
 1 4 -0.03750 0.1621 4.89 -0.23 0.8264
 1 5 0.1150 0.3900 2.947 0.29 0.7877
 2 3 -0.4500 0.4734 3.67 -0.95 0.4002
 2 4 -0.2550 0.2012 5.622 -1.27 0.2550
 2 5 -0.1025 0.4006 3.55 -0.26 0.8122
 3 4 0.1950 0.4714 3.572 0.41 0.7027
 3 5 0.3475 0.5645 5.834 0.62 0.5614
 4 5 0.1525 0.3969 3.4 0.38 0.7236
CD4+ CD8- 0 0.25 0.1825 0.2279 5.538 0.80 0.4563
 0 1 -4.7875 0.6236 3.367 -7.68 0.0030
 0 2 -3.7125 0.7369 3.229 -5.04 0.0126
 0 3 -4.2925 2.0529 3.069 -2.09 0.1256
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0 4 -3.6625 0.4068 3.956 -9.00 0.0009
 0 5 -2.9425 1.2723 2.979 -2.31 0.1044
 0.25 1 -4.9700 0.6202 3.289 -8.01 0.0029
 0.25 2 -3.8950 0.7344 3.189 -5.30 0.0112
 0.25 3 -4.4750 2.0522 3.066 -2.18 0.1154
 0.25 4 -3.8450 0.4011 3.829 -9.59 0.0008
 0.25 5 -3.1250 1.2709 2.961 -2.46 0.0921
 1 2 1.0750 0.9171 5.306 1.17 0.2911
 1 3 0.4950 2.1092 3.442 0.23 0.8277
 1 4 1.1250 0.7019 4.898 1.60 0.1711
 1 5 1.8450 1.3815 4.116 1.34 0.2508
 2 3 -0.5800 2.1270 3.593 -0.27 0.8000
 2 4 0.05000 0.7997 4.225 0.06 0.9530
 2 5 0.7700 1.4211 4.55 0.54 0.6134
 3 4 0.6300 2.0713 3.178 0.30 0.7799
 3 5 1.3500 2.3519 4.833 0.57 0.5916
 4 5 0.7200 1.3097 3.369 0.55 0.6168
 T cell+ CD8+ 0 0.25 -0.1150 0.06486 4.256 -1.77 0.1466
 0 1 -0.8575 0.1816 3.027 -4.72 0.0176
 0 2 -0.4625 0.09146 3.511 -5.06 0.0101
 0 3 -0.6200 0.2307 3.054 -2.69 0.0731
 0 4 -0.4650 0.08387 3.506 -5.54 0.0076
 0 5 -0.3250 0.1545 3.219 -2.10 0.1200
 0.25 1 -0.7425 0.1858 3.261 -4.00 0.0240
 0.25 2 -0.3475 0.1014 4.317 -3.43 0.0236
 0.25 3 -0.5050 0.2341 3.299 -2.16 0.1117
 0.25 4 -0.3500 0.09563 5.372 -3.66 0.0129
 0.25 5 -0.2100 0.1602 3.742 -1.31 0.2646
 1 2 0.3950 0.1950 3.692 2.03 0.1186
 1 3 0.2375 0.2849 5.263 0.83 0.4407
 1 4 0.3925 0.1946 3.792 2.02 0.1178
 1 5 0.5325 0.2302 5.099 2.31 0.0676
 2 3 -0.1575 0.2416 3.737 -0.65 0.5524
 2 4 -0.00250 0.1153 5.872 -0.02 0.9834
 2 5 0.1375 0.1717 4.561 0.80 0.4629
 3 4 0.1550 0.2420 3.59 0.64 0.5604
 3 5 0.2950 0.2717 5.127 1.09 0.3261
 4 5 0.1400 0.1705 4.34 0.82 0.4543
 T cell+ CD8- 0 0.25 -1.3150 0.6237 2.828 -2.11 0.1311
 0 1 -2.1975 0.2877 4.199 -7.64 0.0013
 0 2 -1.1900 0.3477 3.839 -3.42 0.0285
 0 3 -0.9025 0.5096 3.367 -1.77 0.1646
 0 4 -0.6400 0.2722 4.306 -2.35 0.0738
 0 5 -0.8900 0.5322 3.031 -1.67 0.1921
 0.25 1 -0.8825 0.6437 3.634 -1.37 0.2489
 0.25 2 0.1250 0.6636 4.165 0.19 0.8594
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0.25 3 0.4125 0.7425 5.667 0.56 0.5997
 0.25 4 0.6750 0.6400 3.504 1.05 0.3588
 0.25 5 0.4250 0.7605 5.585 0.56 0.5980
 1 2 1.0075 0.4008 5.453 2.51 0.0496
 1 3 1.2950 0.5380 4.404 2.41 0.0680
 1 4 1.5575 0.3459 5.598 4.50 0.0049
 1 5 1.3075 0.5601 4.071 2.33 0.0787
 2 3 0.2875 0.5634 4.915 0.51 0.6319
 2 4 0.5500 0.3923 5.371 1.40 0.2159
 2 5 0.3000 0.5841 4.812 0.51 0.6303
 3 4 0.2625 0.5330 4.258 0.49 0.6467
 3 5 0.01250 0.6757 6.1 0.02 0.9858
 4 5 -0.2500 0.5553 3.903 -0.45 0.6764
T cell+ 0 0.25 -0.04500 0.3361 4.946 -0.13 0.8988
 0 1 -6.7625 1.2331 3.343 -5.48 0.0089
 0 2 -5.0000 1.0960 3.441 -4.56 0.0146
 0 3 -6.0750 2.9523 3.057 -2.06 0.1301
 0 4 -4.4975 0.7893 3.896 -5.70 0.0051
 0 5 -5.0475 1.0899 3.446 -4.63 0.0139
 0.25 1 -6.7175 1.2118 3.127 -5.54 0.0104
 0.25 2 -4.9550 1.0719 3.163 -4.62 0.0170
 0.25 3 -6.0300 2.9434 3.021 -2.05 0.1323
 0.25 4 -4.4525 0.7555 3.337 -5.89 0.0072
 0.25 5 -5.0025 1.0657 3.165 -4.69 0.0162
 1 2 1.7625 1.5989 5.908 1.10 0.3132
 1 3 0.6875 3.1735 3.972 0.22 0.8392
 1 4 2.2650 1.4065 4.976 1.61 0.1685
 1 5 1.7150 1.5948 5.899 1.08 0.3242
 2 3 -1.0750 3.1228 3.765 -0.34 0.7490
 2 4 0.5025 1.2880 5.35 0.39 0.7115
 2 5 -0.04750 1.4913 6 -0.03 0.9756
 3 4 1.5775 3.0288 3.374 0.52 0.6348
 3 5 1.0275 3.1207 3.756 0.33 0.7595
 4 5 -0.5500 1.2829 5.367 -0.43 0.6848
T cell+ 0 0.25 -0.05500 0.2074 5.703 -0.27 0.8002
CD4+ CD8- 0 1 -4.2150 0.5800 3.311 -7.27 0.0038
 0 2 -3.4375 0.6549 3.241 -5.25 0.0111
 0 3 -3.4875 1.8068 3.031 -1.93 0.1482
 0 4 -3.3375 0.4397 3.559 -7.59 0.0025
 0 5 -2.7375 1.1453 3.077 -2.39 0.0946
 0.25 1 -4.1600 0.5884 3.492 -7.07 0.0035
 0.25 2 -3.3825 0.6624 3.383 -5.11 0.0108
 0.25 3 -3.4325 1.8095 3.049 -1.90 0.1526
 0.25 4 -3.2825 0.4507 3.878 -7.28 0.0021
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 0.25 5 -2.6825 1.1496 3.122 -2.33 0.0984
 1 2 0.7775 0.8557 5.906 0.91 0.3991
 1 3 0.7275 1.8888 3.585 0.39 0.7219
 1 4 0.8775 0.7046 5.54 1.25 0.2631
 1 5 1.4775 1.2708 4.396 1.16 0.3042
 2 3 -0.05000 1.9132 3.75 -0.03 0.9805
 2 4 0.1000 0.7675 5.172 0.13 0.9013
 2 5 0.7000 1.3067 4.735 0.54 0.6164
 3 4 0.1500 1.8506 3.325 0.08 0.9400
 3 5 0.7500 2.1314 5.064 0.35 0.7391
 4 5 0.6000 1.2132 3.804 0.49 0.6481
T cell+ 0 0.25 -0.7000 0.1322 5.888 -5.29 0.0020
 0 1 -2.2475 0.6957 2.24 -3.23 0.0722
 0 2 -2.0250 0.5253 2.943 -3.86 0.0319
 0 3 -1.8775 0.6322 3.438 -2.97 0.0498
 0 4 -1.4050 0.1073 6.972 -13.10 <.0001
 0 5 -2.7050 0.1641 4.619 -16.48 <.0001
 0.25 1 -1.5475 0.6840 2.271 -2.26 0.1368
 0.25 2 -1.3250 0.5156 3.03 -2.57 0.0817
 0.25 3 -1.1775 0.6209 3.483 -1.90 0.1413
 0.25 4 -0.7050 0.1335 6.101 -5.28 0.0018
 0.25 5 -2.0050 0.1744 6.18 -11.50 <.0001
 1 2 0.2225 0.7088 4.911 0.31 0.7665
 1 3 0.3700 0.7493 6.393 0.49 0.6380
 1 4 0.8425 0.6952 2.255 1.21 0.3372
 1 5 -0.4575 0.6747 2.319 -0.68 0.5591
 2 3 0.1475 0.6616 6.733 0.22 0.8302
 2 4 0.6200 0.5244 2.951 1.18 0.3235
 2 5 -0.6800 0.5095 3.171 -1.33 0.2697
 3 4 0.4725 0.6310 3.433 0.75 0.5020
 3 5 -0.8275 0.6126 3.565 -1.35 0.2561
 4 5 -1.3000 0.1645 4.785 -7.90 0.0006
T cell+ 0 0.25 0.02250 0.04452 5.102 0.51 0.6343
CD4+ CD8- 0 1 -1.2700 0.2887 3.124 -4.40 0.0200
 0 2 -1.0100 0.2374 3.551 -4.25 0.0169
 0 3 -0.9125 0.4971 2.44 -1.84 0.1845
 0 4 -0.9450 0.08677 3.794 -10.89 0.0005
 0 5 -0.9325 0.3692 2.97 -2.53 0.0866
 0.25 1 -1.2925 0.2851 3.157 -4.53 0.0180
 0.25 2 -1.0325 0.2342 3.585 -4.41 0.0148
 0.25 3 -0.9350 0.4926 2.439 -1.90 0.1747
 0.25 4 -0.9675 0.08791 4.414 -11.01 0.0002
 0.25 5 -0.9550 0.3651 2.983 -2.62 0.0798
 1 2 0.2600 0.3205 5.862 0.81 0.4489
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 1 3 0.3575 0.5044 4.035 0.71 0.5173
 1 4 0.3250 0.2813 3.398 1.16 0.3226
 1 5 0.3375 0.4028 5.562 0.84 0.4366
 2 3 0.09750 0.4908 3.425 0.20 0.8538
 2 4 0.06500 0.2325 3.961 0.28 0.7938
 2 5 0.07750 0.3811 4.833 0.20 0.8471
 3 4 -0.03250 0.4848 2.51 -0.07 0.9515
 3 5 -0.02000 0.5341 5.249 -0.04 0.9715
 4 5 0.01250 0.3590 3.113 0.03 0.9743
B cell+ IgM+ 0 0.25 -0.02250 0.08215 5.854 -0.27 0.7936
 0 1 -3.6900 0.3604 3.134 -10.24 0.0016
 0 2 -3.5375 0.9120 3.021 -3.88 0.0300
 0 3 -4.2175 1.5801 3.007 -2.67 0.0756
 0 4 -6.8950 1.0553 3.015 -6.53 0.0072
 0 5 -9.3175 3.4314 3.001 -2.72 0.0728
 0.25 1 -3.6675 0.3619 3.184 -10.13 0.0016
 0.25 2 -3.5150 0.9126 3.028 -3.85 0.0304
 0.25 3 -4.1950 1.5804 3.009 -2.65 0.0765
 0.25 4 -6.8725 1.0558 3.021 -6.51 0.0072
 0.25 5 -9.2950 3.4315 3.002 -2.71 0.0732
 1 2 0.1525 0.9778 3.898 0.16 0.8838
 1 3 -0.5275 1.6189 3.305 -0.33 0.7641
 1 4 -3.2050 1.1126 3.677 -2.88 0.0497
 1 5 -5.6275 3.4494 3.065 -1.63 0.1994
 2 3 -0.6800 1.8228 4.796 -0.37 0.7250
 2 4 -3.3575 1.3927 5.876 -2.41 0.0534
 2 5 -5.7800 3.5497 3.42 -1.63 0.1907
 3 4 -2.6775 1.8986 5.23 -1.41 0.2151
 3 5 -5.1000 3.7770 4.217 -1.35 0.2449
 4 5 -2.4225 3.5892 3.561 -0.67 0.5410
B cell+ IgM- 0 0.25 0.07250 0.04151 3.567 1.75 0.1643
 0 1 -0.6200 0.1393 3.525 -4.45 0.0149
 0 2 -0.5775 0.1296 3.614 -4.46 0.0141
 0 3 -0.7950 0.3575 3.075 -2.22 0.1105
 0 4 -0.9050 0.1891 3.276 -4.79 0.0141
 0 5 -1.1650 0.4797 3.041 -2.43 0.0923
 0.25 1 -0.6925 0.1341 3.05 -5.17 0.0135
 0.25 2 -0.6500 0.1240 3.059 -5.24 0.0129
 0.25 3 -0.8675 0.3555 3.007 -2.44 0.0923
 0.25 4 -0.9775 0.1853 3.026 -5.28 0.0130
 0.25 5 -1.2375 0.4782 3.004 -2.59 0.0811
 1 2 0.04250 0.1818 5.963 0.23 0.8229
 1 3 -0.1750 0.3795 3.831 -0.46 0.6697
 1 4 -0.2850 0.2280 5.46 -1.25 0.2623
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Table J1. Difference of least squares means for pulp cell responses by day (Cont.) 
Study/Factor Day Day Estimate Std. Error DF t Value Pr > |t| 
 1 5 -0.5450 0.4964 3.465 -1.10 0.3426
 2 3 -0.2175 0.3761 3.713 -0.58 0.5963
 2 4 -0.3275 0.2222 5.23 -1.47 0.1981
 2 5 -0.5875 0.4937 3.398 -1.19 0.3105
 3 4 -0.1100 0.4005 4.514 -0.27 0.7957
 3 5 -0.3700 0.5956 5.539 -0.62 0.5591
 4 5 -0.2600 0.5126 3.877 -0.51 0.6395
B cell+ IgG- 0 0.25 0.2175 0.1395 4.635 1.56 0.1842
 0 1 -4.3225 0.6853 3.198 -6.31 0.0066
 0 2 -3.8825 1.1470 3.069 -3.38 0.0415
 0 3 -4.7425 1.9007 3.025 -2.50 0.0874
 0 4 -7.6550 0.9856 3.094 -7.77 0.0040
 0 5 -7.6925 2.8197 3.011 -2.73 0.0718
 0.25 1 -4.5400 0.6775 3.059 -6.70 0.0064
 0.25 2 -4.1000 1.1424 3.021 -3.59 0.0366
 0.25 3 -4.9600 1.8979 3.007 -2.61 0.0792
 0.25 4 -7.8725 0.9802 3.028 -8.03 0.0039
 0.25 5 -7.9100 2.8178 3.003 -2.81 0.0674
 1 2 0.4400 1.3248 4.869 0.33 0.7536
 1 3 -0.4200 2.0130 3.746 -0.21 0.8456
 1 4 -3.3325 1.1879 5.326 -2.81 0.0352
 1 5 -3.3700 2.8966 3.343 -1.16 0.3209
 2 3 -0.8600 2.2132 4.918 -0.39 0.7138
 2 4 -3.7725 1.5023 5.864 -2.51 0.0467
 2 5 -3.8100 3.0391 3.958 -1.25 0.2789
 3 4 -2.9125 2.1340 4.49 -1.36 0.2367
 3 5 -2.9500 3.3961 5.256 -0.87 0.4229
 4 5 -0.03750 2.9820 3.713 -0.01 0.9906
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Table J2. Difference of least squares means for pulp cell responses by treatment 
Study/Factor Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
Study A 
 
       
CD45+ AlumIgG IOmIgG -7.0014 2.0504 14 -3.41 0.0042
 AlumIgG mIgG 0.6082 2.1505 14 0.28 0.7814
 IOmIgG mIgG 7.6097 2.1505 14 3.54 0.0033
CD4+ CD8- AlumIgG IOmIgG -1.7921 0.6739 14 -2.66 0.0187
 AlumIgG mIgG 0.08333 0.7068 14 0.12 0.9078
 IOmIgG mIgG 1.8755 0.7068 14 2.65 0.0189
 T cell+ AlumIgG IOmIgG -1.5483 0.5370 14 -2.88 0.0120
 AlumIgG mIgG 0.09343 0.5633 14 0.17 0.8706
 IOmIgG mIgG 1.6418 0.5633 14 2.91 0.0113
B cells AlumIgG IOmIgG -2.5900 0.9154 14 -2.83 0.0134
 AlumIgG mIgG -0.9621 0.9601 14 -1.00 0.3333
 IOmIgG mIgG 1.6279 0.9601 14 1.70 0.1121
Study B 
 
       
 T cell+ CD8- AlummIgG IOmIgG 1.0971 0.4098 9 2.68 0.0253
 AlummIgG mIgG 1.1918 0.4098 9 2.91 0.0174
 IOmIgG mIgG 0.09464 0.4098 9 0.23 0.8225
 
 
 
 
 
 
 
 
 
 
 
 
344 
 
 
 
Table J3. Simple effect comparisons of treatment*day least squares means by treatment for 
MHCII+ Macrophages+, Study B 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 0 0.25 -5.9175 2.0039 9 -2.95 0.0161
Alum-mIgG 0 1 -3.6900 0.8162 9 -4.52 0.0014
Alum-mIgG 0 2 -1.2225 0.1749 9 -6.99 <.0001
Alum-mIgG 0 3 -1.5275 0.4000 9 -3.82 0.0041
Alum-mIgG 0 4 -1.1425 0.7372 9 -1.55 0.1556
Alum-mIgG 0 5 -2.0350 0.6880 9 -2.96 0.0160
Alum-mIgG 0.25 1 2.2275 2.1347 9 1.04 0.3239
Alum-mIgG 0.25 2 4.6950 2.0032 9 2.34 0.0437
Alum-mIgG 0.25 3 4.3900 2.0467 9 2.14 0.0605
Alum-mIgG 0.25 4 4.7750 1.6066 9 2.97 0.0156
Alum-mIgG 0.25 5 3.8825 1.9913 9 1.95 0.0830
Alum-mIgG 1 2 2.4675 0.6780 9 3.64 0.0054
Alum-mIgG 1 3 2.1625 0.9872 9 2.19 0.0562
Alum-mIgG 1 4 2.5475 1.0412 9 2.45 0.0370
Alum-mIgG 1 5 1.6550 1.2472 9 1.33 0.2172
Alum-mIgG 2 3 -0.3050 0.5129 9 -0.59 0.5667
Alum-mIgG 2 4 0.08000 0.7712 9 0.10 0.9197
Alum-mIgG 2 5 -0.8125 0.7684 9 -1.06 0.3179
Alum-mIgG 3 4 0.3850 0.8077 9 0.48 0.6450
Alum-mIgG 3 5 -0.5075 0.6716 9 -0.76 0.4692
Alum-mIgG 4 5 -0.8925 0.8804 9 -1.01 0.3372
IO-mIgG 0 0.25 -4.1300 2.0039 9 -2.06 0.0694
IO-mIgG 0 1 -1.0450 0.8162 9 -1.28 0.2324
IO-mIgG 0 2 0.4050 0.1749 9 2.32 0.0458
IO-mIgG 0 3 -0.6275 0.4000 9 -1.57 0.1511
IO-mIgG 0 4 -1.5775 0.7372 9 -2.14 0.0610
IO-mIgG 0 5 -1.0025 0.6880 9 -1.46 0.1791
IO-mIgG 0.25 1 3.0850 2.1347 9 1.45 0.1823
IO-mIgG 0.25 2 4.5350 2.0032 9 2.26 0.0499
IO-mIgG 0.25 3 3.5025 2.0467 9 1.71 0.1212
IO-mIgG 0.25 4 2.5525 1.6066 9 1.59 0.1466
IO-mIgG 0.25 5 3.1275 1.9913 9 1.57 0.1507
IO-mIgG 1 2 1.4500 0.6780 9 2.14 0.0612
IO-mIgG 1 3 0.4175 0.9872 9 0.42 0.6823
IO-mIgG 1 4 -0.5325 1.0412 9 -0.51 0.6214
IO-mIgG 1 5 0.04250 1.2472 9 0.03 0.9736
IO-mIgG 2 3 -1.0325 0.5129 9 -2.01 0.0749
IO-mIgG 2 4 -1.9825 0.7712 9 -2.57 0.0301
IO-mIgG 2 5 -1.4075 0.7684 9 -1.83 0.1002
IO-mIgG 3 4 -0.9500 0.8077 9 -1.18 0.2697
IO-mIgG 3 5 -0.3750 0.6716 9 -0.56 0.5902
IO-mIgG 4 5 0.5750 0.8804 9 0.65 0.5300
mIgG 0 0.25 -1.9725 2.0039 9 -0.98 0.3507
mIgG 0 1 -0.6925 0.8162 9 -0.85 0.4182
mIgG 0 2 0.09250 0.1749 9 0.53 0.6096
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Table J3. Simple effect comparisons of treatment*day least squares means by treatment 
for MHCII+ Macrophages+, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 3 -0.4450 0.4000 9 -1.11 0.2947
mIgG 0 4 -0.5125 0.7372 9 -0.70 0.5045
mIgG 0 5 -1.1250 0.6880 9 -1.64 0.1364
mIgG 0.25 1 1.2800 2.1347 9 0.60 0.5636
mIgG 0.25 2 2.0650 2.0032 9 1.03 0.3295
mIgG 0.25 3 1.5275 2.0467 9 0.75 0.4745
mIgG 0.25 4 1.4600 1.6066 9 0.91 0.3872
mIgG 0.25 5 0.8475 1.9913 9 0.43 0.6804
mIgG 1 2 0.7850 0.6780 9 1.16 0.2768
mIgG 1 3 0.2475 0.9872 9 0.25 0.8077
mIgG 1 4 0.1800 1.0412 9 0.17 0.8666
mIgG 1 5 -0.4325 1.2472 9 -0.35 0.7367
mIgG 2 3 -0.5375 0.5129 9 -1.05 0.3219
mIgG 2 4 -0.6050 0.7712 9 -0.78 0.4529
mIgG 2 5 -1.2175 0.7684 9 -1.58 0.1476
mIgG 3 4 -0.06750 0.8077 9 -0.08 0.9352
mIgG 3 5 -0.6800 0.6716 9 -1.01 0.3377
mIgG 4 5 -0.6125 0.8804 9 -0.70 0.5042
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Table J4. Simple effect comparisons of treatment*day least squares means by day for MHCII+ 
Macrophages+, Study B 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 AlummIgG IOmIgG -0.4500 0.1990 9 -2.26 0.0501
day 0 AlummIgG mIgG -0.3825 0.1990 9 -1.92 0.0868
day 0 IOmIgG mIgG 0.06750 0.1990 9 0.34 0.7423
day 0.25 AlummIgG IOmIgG 1.3375 2.8703 9 0.47 0.6523
day 0.25 AlummIgG mIgG 3.5625 2.8703 9 1.24 0.2459
day 0.25 IOmIgG mIgG 2.2250 2.8703 9 0.78 0.4581
day 1 AlummIgG IOmIgG 2.1950 1.1972 9 1.83 0.0999
day 1 AlummIgG mIgG 2.6150 1.1972 9 2.18 0.0568
day 1 IOmIgG mIgG 0.4200 1.1972 9 0.35 0.7338
day 2 AlummIgG IOmIgG 1.1775 0.3642 9 3.23 0.0103
day 2 AlummIgG mIgG 0.9325 0.3642 9 2.56 0.0307
day 2 IOmIgG mIgG -0.2450 0.3642 9 -0.67 0.5180
day 3 AlummIgG IOmIgG 0.4500 0.5148 9 0.87 0.4047
day 3 AlummIgG mIgG 0.7000 0.5148 9 1.36 0.2070
day 3 IOmIgG mIgG 0.2500 0.5148 9 0.49 0.6388
day 4 AlummIgG IOmIgG -0.8850 1.0431 9 -0.85 0.4182
day 4 AlummIgG mIgG 0.2475 1.0431 9 0.24 0.8177
day 4 IOmIgG mIgG 1.1325 1.0431 9 1.09 0.3058
day 5 AlummIgG IOmIgG 0.5825 0.9621 9 0.61 0.5598
day 5 AlummIgG mIgG 0.5275 0.9621 9 0.55 0.5968
day 5 IOmIgG mIgG -0.05500 0.9621 9 -0.06 0.9557
 
 
Table J5. Simple effect comparisons of treatment*day least squares means by treatment for 
CD4+ CD8+, Study B 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 0 0.25 -0.3500 0.1584 9 -2.21 0.0545
Alum-mIgG 0 1 -0.8025 0.3252 9 -2.47 0.0357
Alum-mIgG 0 2 -1.3050 0.3512 9 -3.72 0.0048
Alum-mIgG 0 3 -0.6000 0.2498 9 -2.40 0.0398
Alum-mIgG 0 4 -0.3800 0.1059 9 -3.59 0.0059
Alum-mIgG 0 5 -0.2475 0.09574 9 -2.59 0.0294
Alum-mIgG 0.25 1 -0.4525 0.2711 9 -1.67 0.1294
Alum-mIgG 0.25 2 -0.9550 0.3329 9 -2.87 0.0185
Alum-mIgG 0.25 3 -0.2500 0.1880 9 -1.33 0.2163
Alum-mIgG 0.25 4 -0.03000 0.1591 9 -0.19 0.8546
Alum-mIgG 0.25 5 0.1025 0.1229 9 0.83 0.4259
Alum-mIgG 1 2 -0.5025 0.2370 9 -2.12 0.0630
Alum-mIgG 1 3 0.2025 0.1804 9 1.12 0.2907
Alum-mIgG 1 4 0.4225 0.3255 9 1.30 0.2266
Alum-mIgG 1 5 0.5550 0.3446 9 1.61 0.1417
Alum-mIgG 2 3 0.7050 0.2082 9 3.39 0.0080
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Table J5. Simple effect comparisons of treatment*day least squares means by treatment 
for CD4+ CD8+, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 2 4 0.9250 0.3412 9 2.71 0.0240
Alum-mIgG 2 5 1.0575 0.3977 9 2.66 0.0261
Alum-mIgG 3 4 0.2200 0.2474 9 0.89 0.3971
Alum-mIgG 3 5 0.3525 0.2558 9 1.38 0.2014
Alum-mIgG 4 5 0.1325 0.1147 9 1.15 0.2779
IO-mIgG 0 0.25 -0.1500 0.1584 9 -0.95 0.3685
IO-mIgG 0 1 -0.5975 0.3252 9 -1.84 0.0993
IO-mIgG 0 2 -0.4300 0.3512 9 -1.22 0.2519
IO-mIgG 0 3 -0.5150 0.2498 9 -2.06 0.0693
IO-mIgG 0 4 -0.1850 0.1059 9 -1.75 0.1147
IO-mIgG 0 5 -0.09250 0.09574 9 -0.97 0.3592
IO-mIgG 0.25 1 -0.4475 0.2711 9 -1.65 0.1331
IO-mIgG 0.25 2 -0.2800 0.3329 9 -0.84 0.4221
IO-mIgG 0.25 3 -0.3650 0.1880 9 -1.94 0.0841
IO-mIgG 0.25 4 -0.03500 0.1591 9 -0.22 0.8307
IO-mIgG 0.25 5 0.05750 0.1229 9 0.47 0.6510
IO-mIgG 1 2 0.1675 0.2370 9 0.71 0.4976
IO-mIgG 1 3 0.08250 0.1804 9 0.46 0.6583
IO-mIgG 1 4 0.4125 0.3255 9 1.27 0.2369
IO-mIgG 1 5 0.5050 0.3446 9 1.47 0.1768
IO-mIgG 2 3 -0.08500 0.2082 9 -0.41 0.6926
IO-mIgG 2 4 0.2450 0.3412 9 0.72 0.4909
IO-mIgG 2 5 0.3375 0.3977 9 0.85 0.4180
IO-mIgG 3 4 0.3300 0.2474 9 1.33 0.2150
IO-mIgG 3 5 0.4225 0.2558 9 1.65 0.1330
IO-mIgG 4 5 0.09250 0.1147 9 0.81 0.4409
mIgG 0 0.25 -0.4500 0.1584 9 -2.84 0.0194
mIgG 0 1 -0.6350 0.3252 9 -1.95 0.0826
mIgG 0 2 -0.6075 0.3512 9 -1.73 0.1177
mIgG 0 3 -0.5475 0.2498 9 -2.19 0.0561
mIgG 0 4 -0.06750 0.1059 9 -0.64 0.5399
mIgG 0 5 -0.06000 0.09574 9 -0.63 0.5464
mIgG 0.25 1 -0.1850 0.2711 9 -0.68 0.5121
mIgG 0.25 2 -0.1575 0.3329 9 -0.47 0.6474
mIgG 0.25 3 -0.09750 0.1880 9 -0.52 0.6165
mIgG 0.25 4 0.3825 0.1591 9 2.40 0.0396
mIgG 0.25 5 0.3900 0.1229 9 3.17 0.0113
mIgG 1 2 0.02750 0.2370 9 0.12 0.9102
mIgG 1 3 0.08750 0.1804 9 0.48 0.6393
mIgG 1 4 0.5675 0.3255 9 1.74 0.1152
mIgG 1 5 0.5750 0.3446 9 1.67 0.1295
mIgG 2 3 0.06000 0.2082 9 0.29 0.7797
mIgG 2 4 0.5400 0.3412 9 1.58 0.1480
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Table J5. Simple effect comparisons of treatment*day least squares means by treatment 
for CD4+ CD8+, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 2 5 0.5475 0.3977 9 1.38 0.2019
mIgG 3 4 0.4800 0.2474 9 1.94 0.0843
mIgG 3 5 0.4875 0.2558 9 1.91 0.0890
mIgG 4 5 0.007500 0.1147 9 0.07 0.9493
  
 
Table J6. Simple effect comparisons of treatment*day least squares means by day for CD4+ 
CD8+, Study B 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 AlummIgG IOmIgG 0.005000 0.01736 9 0.29 0.7799
day 0 AlummIgG mIgG 0.01500 0.01736 9 0.86 0.4100
day 0 IOmIgG mIgG 0.01000 0.01736 9 0.58 0.5787
day 0.25 AlummIgG IOmIgG 0.2050 0.2317 9 0.88 0.3994
day 0.25 AlummIgG mIgG -0.08500 0.2317 9 -0.37 0.7222
day 0.25 IOmIgG mIgG -0.2900 0.2317 9 -1.25 0.2423
day 1 AlummIgG IOmIgG 0.2100 0.4711 9 0.45 0.6663
day 1 AlummIgG mIgG 0.1825 0.4711 9 0.39 0.7075
day 1 IOmIgG mIgG -0.02750 0.4711 9 -0.06 0.9547
day 2 AlummIgG IOmIgG 0.8800 0.5025 9 1.75 0.1138
day 2 AlummIgG mIgG 0.7125 0.5025 9 1.42 0.1899
day 2 IOmIgG mIgG -0.1675 0.5025 9 -0.33 0.7465
day 3 AlummIgG IOmIgG 0.09000 0.3623 9 0.25 0.8094
day 3 AlummIgG mIgG 0.06750 0.3623 9 0.19 0.8563
day 3 IOmIgG mIgG -0.02250 0.3623 9 -0.06 0.9518
day 4 AlummIgG IOmIgG 0.2000 0.1517 9 1.32 0.2200
day 4 AlummIgG mIgG 0.3275 0.1517 9 2.16 0.0592
day 4 IOmIgG mIgG 0.1275 0.1517 9 0.84 0.4225
day 5 AlummIgG IOmIgG 0.1600 0.1385 9 1.16 0.2776
day 5 AlummIgG mIgG 0.2025 0.1385 9 1.46 0.1776
day 5 IOmIgG mIgG 0.04250 0.1385 9 0.31 0.7659
 
 
 
 
 
 
349 
 
 
 
Table J7. Simple effect comparisons of treatment*day least squares means by treatment for  T 
cell+ CD8+, Study B 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 0 0.25 -0.5175 0.1034 9 -5.00 0.0007
Alum-mIgG 0 1 -0.9475 0.2565 9 -3.69 0.0050
Alum-mIgG 0 2 -0.8000 0.1693 9 -4.73 0.0011
Alum-mIgG 0 3 -0.7750 0.2023 9 -3.83 0.0040
Alum-mIgG 0 4 -0.3300 0.07643 9 -4.32 0.0019
Alum-mIgG 0 5 -0.1975 0.1101 9 -1.79 0.1065
Alum-mIgG 0.25 1 -0.4300 0.2931 9 -1.47 0.1764
Alum-mIgG 0.25 2 -0.2825 0.2471 9 -1.14 0.2824
Alum-mIgG 0.25 3 -0.2575 0.2274 9 -1.13 0.2867
Alum-mIgG 0.25 4 0.1875 0.1341 9 1.40 0.1955
Alum-mIgG 0.25 5 0.3200 0.1703 9 1.88 0.0930
Alum-mIgG 1 2 0.1475 0.2155 9 0.68 0.5109
Alum-mIgG 1 3 0.1725 0.1703 9 1.01 0.3375
Alum-mIgG 1 4 0.6175 0.2791 9 2.21 0.0542
Alum-mIgG 1 5 0.7500 0.3015 9 2.49 0.0346
Alum-mIgG 2 3 0.02500 0.1894 9 0.13 0.8979
Alum-mIgG 2 4 0.4700 0.2205 9 2.13 0.0618
Alum-mIgG 2 5 0.6025 0.2009 9 3.00 0.0150
Alum-mIgG 3 4 0.4450 0.2391 9 1.86 0.0957
Alum-mIgG 3 5 0.5775 0.2383 9 2.42 0.0384
Alum-mIgG 4 5 0.1325 0.1482 9 0.89 0.3947
IO-mIgG 0 0.25 -0.1700 0.1034 9 -1.64 0.1347
IO-mIgG 0 1 -1.5600 0.2565 9 -6.08 0.0002
IO-mIgG 0 2 -0.7275 0.1693 9 -4.30 0.0020
IO-mIgG 0 3 -1.0475 0.2023 9 -5.18 0.0006
IO-mIgG 0 4 -0.2150 0.07643 9 -2.81 0.0203
IO-mIgG 0 5 -0.1800 0.1101 9 -1.63 0.1366
IO-mIgG 0.25 1 -1.3900 0.2931 9 -4.74 0.0011
IO-mIgG 0.25 2 -0.5575 0.2471 9 -2.26 0.0505
IO-mIgG 0.25 3 -0.8775 0.2274 9 -3.86 0.0039
IO-mIgG 0.25 4 -0.04500 0.1341 9 -0.34 0.7449
IO-mIgG 0.25 5 -0.01000 0.1703 9 -0.06 0.9545
IO-mIgG 1 2 0.8325 0.2155 9 3.86 0.0038
IO-mIgG 1 3 0.5125 0.1703 9 3.01 0.0147
IO-mIgG 1 4 1.3450 0.2791 9 4.82 0.0009
IO-mIgG 1 5 1.3800 0.3015 9 4.58 0.0013
IO-mIgG 2 3 -0.3200 0.1894 9 -1.69 0.1254
IO-mIgG 2 4 0.5125 0.2205 9 2.32 0.0452
IO-mIgG 2 5 0.5475 0.2009 9 2.73 0.0234
IO-mIgG 3 4 0.8325 0.2391 9 3.48 0.0069
IO-mIgG 3 5 0.8675 0.2383 9 3.64 0.0054
IO-mIgG 4 5 0.03500 0.1482 9 0.24 0.8186
mIgG 0 0.25 -0.7550 0.1034 9 -7.30 <.0001
mIgG 0 1 -1.0950 0.2565 9 -4.27 0.0021
mIgG 0 2 -0.6150 0.1693 9 -3.63 0.0055
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Table J7. Simple effect comparisons of treatment*day least squares means by treatment 
for  T cell+ CD8+, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 3 -0.9500 0.2023 9 -4.70 0.0011
mIgG 0 4 -0.3200 0.07643 9 -4.19 0.0024
mIgG 0 5 -0.2275 0.1101 9 -2.07 0.0689
mIgG 0.25 1 -0.3400 0.2931 9 -1.16 0.2759
mIgG 0.25 2 0.1400 0.2471 9 0.57 0.5848
mIgG 0.25 3 -0.1950 0.2274 9 -0.86 0.4134
mIgG 0.25 4 0.4350 0.1341 9 3.24 0.0101
mIgG 0.25 5 0.5275 0.1703 9 3.10 0.0128
mIgG 1 2 0.4800 0.2155 9 2.23 0.0529
mIgG 1 3 0.1450 0.1703 9 0.85 0.4165
mIgG 1 4 0.7750 0.2791 9 2.78 0.0215
mIgG 1 5 0.8675 0.3015 9 2.88 0.0183
mIgG 2 3 -0.3350 0.1894 9 -1.77 0.1108
mIgG 2 4 0.2950 0.2205 9 1.34 0.2137
mIgG 2 5 0.3875 0.2009 9 1.93 0.0858
mIgG 3 4 0.6300 0.2391 9 2.63 0.0272
mIgG 3 5 0.7225 0.2383 9 3.03 0.0142
mIgG 4 5 0.09250 0.1482 9 0.62 0.5481
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Table J8. Simple effect comparisons of treatment*day least squares means by day for  T cell+ 
CD8+, Study B 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 AlummIgG IOmIgG -0.1675 0.08977 9 -1.87 0.0949
day 0 AlummIgG mIgG 0.08250 0.08977 9 0.92 0.3820
day 0 IOmIgG mIgG 0.2500 0.08977 9 2.78 0.0212
day 0.25 AlummIgG IOmIgG 0.1800 0.1927 9 0.93 0.3746
day 0.25 AlummIgG mIgG -0.1550 0.1927 9 -0.80 0.4419
day 0.25 IOmIgG mIgG -0.3350 0.1927 9 -1.74 0.1161
day 1 AlummIgG IOmIgG -0.7800 0.3857 9 -2.02 0.0739
day 1 AlummIgG mIgG -0.06500 0.3857 9 -0.17 0.8699
day 1 IOmIgG mIgG 0.7150 0.3857 9 1.85 0.0968
day 2 AlummIgG IOmIgG -0.09500 0.2083 9 -0.46 0.6591
day 2 AlummIgG mIgG 0.2675 0.2083 9 1.28 0.2311
day 2 IOmIgG mIgG 0.3625 0.2083 9 1.74 0.1158
day 3 AlummIgG IOmIgG -0.4400 0.3060 9 -1.44 0.1843
day 3 AlummIgG mIgG -0.09250 0.3060 9 -0.30 0.7693
day 3 IOmIgG mIgG 0.3475 0.3060 9 1.14 0.2855
day 4 AlummIgG IOmIgG -0.05250 0.1819 9 -0.29 0.7795
day 4 AlummIgG mIgG 0.09250 0.1819 9 0.51 0.6234
day 4 IOmIgG mIgG 0.1450 0.1819 9 0.80 0.4460
day 5 AlummIgG IOmIgG -0.1500 0.1193 9 -1.26 0.2404
day 5 AlummIgG mIgG 0.05250 0.1193 9 0.44 0.6704
day 5 IOmIgG mIgG 0.2025 0.1193 9 1.70 0.1240
 
 
Table J9. Simple effect comparisons of treatment*day least squares means by treatment for  
T cell+ CD4- CD8-, Study B 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 0 0.25 -0.01500 0.06622 9 -0.23 0.8259
Alum-mIgG 0 1 -0.2900 0.1265 9 -2.29 0.0476
Alum-mIgG 0 2 -0.2900 0.09354 9 -3.10 0.0127
Alum-mIgG 0 3 -0.6800 0.1387 9 -4.90 0.0008
Alum-mIgG 0 4 -0.4000 0.2202 9 -1.82 0.1026
Alum-mIgG 0 5 -0.6750 0.1761 9 -3.83 0.0040
Alum-mIgG 0.25 1 -0.2750 0.1609 9 -1.71 0.1216
Alum-mIgG 0.25 2 -0.2750 0.1104 9 -2.49 0.0344
Alum-mIgG 0.25 3 -0.6650 0.1589 9 -4.18 0.0024
Alum-mIgG 0.25 4 -0.3850 0.2454 9 -1.57 0.1511
Alum-mIgG 0.25 5 -0.6600 0.1682 9 -3.93 0.0035
Alum-mIgG 1 2 -333E-18 0.1435 9 -0.00 1.0000
Alum-mIgG 1 3 -0.3900 0.2342 9 -1.67 0.1302
Alum-mIgG 1 4 -0.1100 0.2130 9 -0.52 0.6180
Alum-mIgG 1 5 -0.3850 0.2294 9 -1.68 0.1275
Alum-mIgG 2 3 -0.3900 0.1722 9 -2.27 0.0498
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Table J9. Simple effect comparisons of treatment*day least squares means by treatment 
for  T cell+ CD4- CD8-, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 2 4 -0.1100 0.1634 9 -0.67 0.5177
Alum-mIgG 2 5 -0.3850 0.2340 9 -1.64 0.1344
Alum-mIgG 3 4 0.2800 0.2271 9 1.23 0.2488
Alum-mIgG 3 5 0.005000 0.2533 9 0.02 0.9847
Alum-mIgG 4 5 -0.2750 0.3729 9 -0.74 0.4796
IO-mIgG 0 0.25 0.2825 0.06622 9 4.27 0.0021
IO-mIgG 0 1 0.04750 0.1265 9 0.38 0.7161
IO-mIgG 0 2 0.06500 0.09354 9 0.69 0.5047
IO-mIgG 0 3 -0.1750 0.1387 9 -1.26 0.2388
IO-mIgG 0 4 -0.4400 0.2202 9 -2.00 0.0768
IO-mIgG 0 5 -0.3225 0.1761 9 -1.83 0.1003
IO-mIgG 0.25 1 -0.2350 0.1609 9 -1.46 0.1781
IO-mIgG 0.25 2 -0.2175 0.1104 9 -1.97 0.0804
IO-mIgG 0.25 3 -0.4575 0.1589 9 -2.88 0.0182
IO-mIgG 0.25 4 -0.7225 0.2454 9 -2.94 0.0164
IO-mIgG 0.25 5 -0.6050 0.1682 9 -3.60 0.0058
IO-mIgG 1 2 0.01750 0.1435 9 0.12 0.9056
IO-mIgG 1 3 -0.2225 0.2342 9 -0.95 0.3669
IO-mIgG 1 4 -0.4875 0.2130 9 -2.29 0.0479
IO-mIgG 1 5 -0.3700 0.2294 9 -1.61 0.1412
IO-mIgG 2 3 -0.2400 0.1722 9 -1.39 0.1968
IO-mIgG 2 4 -0.5050 0.1634 9 -3.09 0.0129
IO-mIgG 2 5 -0.3875 0.2340 9 -1.66 0.1322
IO-mIgG 3 4 -0.2650 0.2271 9 -1.17 0.2732
IO-mIgG 3 5 -0.1475 0.2533 9 -0.58 0.5747
IO-mIgG 4 5 0.1175 0.3729 9 0.32 0.7599
mIgG 0 0.25 0.02500 0.06622 9 0.38 0.7145
mIgG 0 1 -0.06250 0.1265 9 -0.49 0.6332
mIgG 0 2 -0.06250 0.09354 9 -0.67 0.5208
mIgG 0 3 -0.2325 0.1387 9 -1.68 0.1280
mIgG 0 4 -0.2925 0.2202 9 -1.33 0.2167
mIgG 0 5 -0.3750 0.1761 9 -2.13 0.0621
mIgG 0.25 1 -0.08750 0.1609 9 -0.54 0.5998
mIgG 0.25 2 -0.08750 0.1104 9 -0.79 0.4485
mIgG 0.25 3 -0.2575 0.1589 9 -1.62 0.1397
mIgG 0.25 4 -0.3175 0.2454 9 -1.29 0.2280
mIgG 0.25 5 -0.4000 0.1682 9 -2.38 0.0413
mIgG 1 2 -477E-17 0.1435 9 -0.00 1.0000
mIgG 1 3 -0.1700 0.2342 9 -0.73 0.4863
mIgG 1 4 -0.2300 0.2130 9 -1.08 0.3083
mIgG 1 5 -0.3125 0.2294 9 -1.36 0.2062
mIgG 2 3 -0.1700 0.1722 9 -0.99 0.3493
mIgG 2 4 -0.2300 0.1634 9 -1.41 0.1928
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Table J9. Simple effect comparisons of treatment*day least squares means by treatment 
for  T cell+ CD4- CD8-, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 2 5 -0.3125 0.2340 9 -1.34 0.2146
mIgG 3 4 -0.06000 0.2271 9 -0.26 0.7975
mIgG 3 5 -0.1425 0.2533 9 -0.56 0.5875
mIgG 4 5 -0.08250 0.3729 9 -0.22 0.8298
  
 
Table J10. Simple effect comparisons of treatment*day least squares means by day for  T 
cell+ CD4- CD8-, Study B 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 AlummIgG IOmIgG -0.1825 0.06590 9 -2.77 0.0218
day 0 AlummIgG mIgG -0.06500 0.06590 9 -0.99 0.3498
day 0 IOmIgG mIgG 0.1175 0.06590 9 1.78 0.1083
day 0.25 AlummIgG IOmIgG 0.1150 0.06523 9 1.76 0.1118
day 0.25 AlummIgG mIgG -0.02500 0.06523 9 -0.38 0.7104
day 0.25 IOmIgG mIgG -0.1400 0.06523 9 -2.15 0.0604
day 1 AlummIgG IOmIgG 0.1550 0.2099 9 0.74 0.4791
day 1 AlummIgG mIgG 0.1625 0.2099 9 0.77 0.4587
day 1 IOmIgG mIgG 0.007500 0.2099 9 0.04 0.9723
day 2 AlummIgG IOmIgG 0.1725 0.1562 9 1.10 0.2980
day 2 AlummIgG mIgG 0.1625 0.1562 9 1.04 0.3253
day 2 IOmIgG mIgG -0.01000 0.1562 9 -0.06 0.9503
day 3 AlummIgG IOmIgG 0.3225 0.1820 9 1.77 0.1101
day 3 AlummIgG mIgG 0.3825 0.1820 9 2.10 0.0649
day 3 IOmIgG mIgG 0.06000 0.1820 9 0.33 0.7492
day 4 AlummIgG IOmIgG -0.2225 0.3219 9 -0.69 0.5069
day 4 AlummIgG mIgG 0.04250 0.3219 9 0.13 0.8979
day 4 IOmIgG mIgG 0.2650 0.3219 9 0.82 0.4317
day 5 AlummIgG IOmIgG 0.1700 0.2511 9 0.68 0.5154
day 5 AlummIgG mIgG 0.2350 0.2511 9 0.94 0.3738
day 5 IOmIgG mIgG 0.06500 0.2511 9 0.26 0.8016
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Table J11. Simple effect comparisons of treatment*day least squares means by treatment for B 
cell+ IgM+, Study B 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
Alum-mIgG 0 0.25 -0.7700 0.1879 9 -4.10 0.0027
Alum-mIgG 0 1 -11.8350 4.9403 9 -2.40 0.0402
Alum-mIgG 0 2 -9.5775 2.5620 9 -3.74 0.0046
Alum-mIgG 0 3 -6.3625 2.0573 9 -3.09 0.0129
Alum-mIgG 0 4 -2.6475 0.9962 9 -2.66 0.0261
Alum-mIgG 0 5 -1.2525 0.7824 9 -1.60 0.1439
Alum-mIgG 0.25 1 -11.0650 4.8665 9 -2.27 0.0491
Alum-mIgG 0.25 2 -8.8075 2.5914 9 -3.40 0.0079
Alum-mIgG 0.25 3 -5.5925 2.0790 9 -2.69 0.0248
Alum-mIgG 0.25 4 -1.8775 0.9620 9 -1.95 0.0827
Alum-mIgG 0.25 5 -0.4825 0.7042 9 -0.69 0.5105
Alum-mIgG 1 2 2.2575 3.7367 9 0.60 0.5607
Alum-mIgG 1 3 5.4725 4.3647 9 1.25 0.2415
Alum-mIgG 1 4 9.1875 5.3753 9 1.71 0.1216
Alum-mIgG 1 5 10.5825 4.9993 9 2.12 0.0634
Alum-mIgG 2 3 3.2150 1.9120 9 1.68 0.1270
Alum-mIgG 2 4 6.9300 2.9425 9 2.36 0.0429
Alum-mIgG 2 5 8.3250 2.9172 9 2.85 0.0190
Alum-mIgG 3 4 3.7150 2.0114 9 1.85 0.0978
Alum-mIgG 3 5 5.1100 2.1563 9 2.37 0.0419
Alum-mIgG 4 5 1.3950 0.9855 9 1.42 0.1906
IO-mIgG 0 0.25 -0.8275 0.1879 9 -4.41 0.0017
IO-mIgG 0 1 -12.7725 4.9403 9 -2.59 0.0294
IO-mIgG 0 2 -12.8425 2.5620 9 -5.01 0.0007
IO-mIgG 0 3 -15.4575 2.0573 9 -7.51 <.0001
IO-mIgG 0 4 -2.9625 0.9962 9 -2.97 0.0156
IO-mIgG 0 5 -3.0075 0.7824 9 -3.84 0.0039
IO-mIgG 0.25 1 -11.9450 4.8665 9 -2.45 0.0365
IO-mIgG 0.25 2 -12.0150 2.5914 9 -4.64 0.0012
IO-mIgG 0.25 3 -14.6300 2.0790 9 -7.04 <.0001
IO-mIgG 0.25 4 -2.1350 0.9620 9 -2.22 0.0536
IO-mIgG 0.25 5 -2.1800 0.7042 9 -3.10 0.0128
IO-mIgG 1 2 -0.07000 3.7367 9 -0.02 0.9855
IO-mIgG 1 3 -2.6850 4.3647 9 -0.62 0.5537
IO-mIgG 1 4 9.8100 5.3753 9 1.83 0.1013
IO-mIgG 1 5 9.7650 4.9993 9 1.95 0.0825
IO-mIgG 2 3 -2.6150 1.9120 9 -1.37 0.2046
IO-mIgG 2 4 9.8800 2.9425 9 3.36 0.0084
IO-mIgG 2 5 9.8350 2.9172 9 3.37 0.0082
IO-mIgG 3 4 12.4950 2.0114 9 6.21 0.0002
IO-mIgG 3 5 12.4500 2.1563 9 5.77 0.0003
IO-mIgG 4 5 -0.04500 0.9855 9 -0.05 0.9646
mIgG 0 0.25 -1.2450 0.1879 9 -6.63 <.0001
mIgG 0 1 -8.0925 4.9403 9 -1.64 0.1358
mIgG 0 2 -10.1550 2.5620 9 -3.96 0.0033
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Table J11. Simple effect comparisons of treatment*day least squares means by 
treatment for B cell+ IgM+, Study B (Cont.) 
Simple Effect Level Day Day Estimate Std. Error DF t Value Pr > |t|
mIgG 0 3 -10.9950 2.0573 9 -5.34 0.0005
mIgG 0 4 -0.9200 0.9962 9 -0.92 0.3798
mIgG 0 5 -1.8200 0.7824 9 -2.33 0.0450
mIgG 0.25 1 -6.8475 4.8665 9 -1.41 0.1930
mIgG 0.25 2 -8.9100 2.5914 9 -3.44 0.0074
mIgG 0.25 3 -9.7500 2.0790 9 -4.69 0.0011
mIgG 0.25 4 0.3250 0.9620 9 0.34 0.7432
mIgG 0.25 5 -0.5750 0.7042 9 -0.82 0.4353
mIgG 1 2 -2.0625 3.7367 9 -0.55 0.5944
mIgG 1 3 -2.9025 4.3647 9 -0.66 0.5227
mIgG 1 4 7.1725 5.3753 9 1.33 0.2149
mIgG 1 5 6.2725 4.9993 9 1.25 0.2412
mIgG 2 3 -0.8400 1.9120 9 -0.44 0.6708
mIgG 2 4 9.2350 2.9425 9 3.14 0.0120
mIgG 2 5 8.3350 2.9172 9 2.86 0.0189
mIgG 3 4 10.0750 2.0114 9 5.01 0.0007
mIgG 3 5 9.1750 2.1563 9 4.26 0.0021
mIgG 4 5 -0.9000 0.9855 9 -0.91 0.3849
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Table J12. Simple effect comparisons of treatment*day least squares means by day forB cell+ 
IgM+, Study B 
Simple Effect Level Treatment Treatment Estimate Std. Error DF t Value Pr > |t|
day 0 AlummIgG IOmIgG -0.1825 0.1428 9 -1.28 0.2334
day 0 AlummIgG mIgG 0.1000 0.1428 9 0.70 0.5016
day 0 IOmIgG mIgG 0.2825 0.1428 9 1.98 0.0794
day 0.25 AlummIgG IOmIgG -0.2400 0.3599 9 -0.67 0.5216
day 0.25 AlummIgG mIgG -0.3750 0.3599 9 -1.04 0.3246
day 0.25 IOmIgG mIgG -0.1350 0.3599 9 -0.38 0.7163
day 1 AlummIgG IOmIgG -1.1200 7.0164 9 -0.16 0.8767
day 1 AlummIgG mIgG 3.8425 7.0164 9 0.55 0.5973
day 1 IOmIgG mIgG 4.9625 7.0164 9 0.71 0.4973
day 2 AlummIgG IOmIgG -3.4475 3.5682 9 -0.97 0.3592
day 2 AlummIgG mIgG -0.4775 3.5682 9 -0.13 0.8965
day 2 IOmIgG mIgG 2.9700 3.5682 9 0.83 0.4267
day 3 AlummIgG IOmIgG -9.2775 2.8602 9 -3.24 0.0101
day 3 AlummIgG mIgG -4.5325 2.8602 9 -1.58 0.1475
day 3 IOmIgG mIgG 4.7450 2.8602 9 1.66 0.1315
day 4 AlummIgG IOmIgG -0.4975 1.3960 9 -0.36 0.7298
day 4 AlummIgG mIgG 1.8275 1.3960 9 1.31 0.2229
day 4 IOmIgG mIgG 2.3250 1.3960 9 1.67 0.1302
day 5 AlummIgG IOmIgG -1.9375 1.1490 9 -1.69 0.1260
day 5 AlummIgG mIgG -0.4675 1.1490 9 -0.41 0.6936
day 5 IOmIgG mIgG 1.4700 1.1490 9 1.28 0.2328
 
